<SEC-DOCUMENT>0001654954-21-005361.txt : 20210510
<SEC-HEADER>0001654954-21-005361.hdr.sgml : 20210510
<ACCEPTANCE-DATETIME>20210510171734
ACCESSION NUMBER:		0001654954-21-005361
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		55
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210510
DATE AS OF CHANGE:		20210510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celcuity Inc.
		CENTRAL INDEX KEY:			0001603454
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38207
		FILM NUMBER:		21908489

	BUSINESS ADDRESS:	
		STREET 1:		16305 36TH AVENUE N
		STREET 2:		SUITE 100
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55446
		BUSINESS PHONE:		763-392-0767

	MAIL ADDRESS:	
		STREET 1:		16305 36TH AVENUE N
		STREET 2:		SUITE 100
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Celcuity LLC
		DATE OF NAME CHANGE:	20140324
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>celc_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:celc="http://celcuity.com/20210331"><head><title>celc_10q.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html" /></head><body style="text-align:left;font:10pt times new roman"><div style='display:none;text-align:left;font:10pt times new roman;' id='XBRLDIV'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2021-01-01to2021-03-31">0001603454</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2021-01-01to2021-03-31" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2021-01-01to2021-03-31">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2021-01-01to2021-03-31">Q1</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2021-01-01to2021-03-31">2020</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">0.001</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-12-31" unitRef="Shares" decimals="0">2500000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-12-31" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-12-31" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-03-31" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">0.001</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" unitRef="Shares" decimals="0">25000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" unitRef="Shares" decimals="0">10299822</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-03-31" unitRef="Shares" decimals="0">12287896</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type='simple' xlink:href='celc-20210331.xsd'></link:schemaRef></ix:references><ix:resources><xbrli:context id="From2021-01-01to2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_ThirdTrancheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celc:ThirdTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_SecondTrancheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celc:SecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-04-08_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_TrancheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celc:TrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-03-09to2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_LicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celc:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseAxis">celc:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-09</xbrli:startDate><xbrli:endDate>2021-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-03-09to2021-04-08_us-gaap_SubsequentEventMember_celc_ThirdTrancheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celc:ThirdTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-09</xbrli:startDate><xbrli:endDate>2021-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_EquityGrantAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celc:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseAxis">celc:EquityGrantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_LicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celc:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseAxis">celc:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-03-09to2021-04-08_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-09</xbrli:startDate><xbrli:endDate>2021-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2017-10-25_celc_StockIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celc:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-05-14_celc_StockIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celc:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_celc_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_celc_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2017-10-25_celc_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_celc_StockIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celc:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_celc_ExpenseStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:ExpenseStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_celc_ExpenseStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:ExpenseStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-05-01to2020-05-14_celc_StockIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celc:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_celc_StockIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celc:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_celc_StockIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celc:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31_celc_ExpenseStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:ExpenseStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember_srt_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember_srt_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_celc_EmployeeStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_celc_PlacementSharesMember_celc_AtmAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">celc:PlacementSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">celc:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_celc_PlacementSharesMember_celc_AtmAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">celc:PlacementSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">celc:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-02-01to2021-02-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-02-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-05_celc_PlacementSharesMember_celc_AtmAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">celc:PlacementSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">celc:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_celc_MarchTwoThousandTwentyOneMember_celc_AgreementWithBiopharmaceuticalCompanyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">celc:MarchTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celc:AgreementWithBiopharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_celc_AgreementWithBiopharmaceuticalCompanyTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celc:AgreementWithBiopharmaceuticalCompanyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_celc_AgreementWithBiopharmaceuticalCompanyOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celc:AgreementWithBiopharmaceuticalCompanyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_celc_JanuaryTwoThousandTwentyOneMember_celc_AgreementWithBiopharmaceuticalCompanyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">celc:JanuaryTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celc:AgreementWithBiopharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2017-05-01to2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_celc_AgreementWithBiopharmaceuticalCompanyOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celc:AgreementWithBiopharmaceuticalCompanyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_celc_FinanceLeasesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">celc:FinanceLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_celc_OperatingLeasesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">celc:OperatingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">celc:SupplementalBalanceSheetInformationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_celc_RestrictedStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:RestrictedStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_celc_RestrictedStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:RestrictedStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_celc_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">celc:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_celc_StockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">celc:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_celc_StockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">celc:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_celc_WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">celc:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-05-03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160; &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;<strong><span style="font-size:18pt">FORM <ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>(Mark One)</strong> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric> QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>For the quarterly period ended <ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen">March 31, 2021</ix:nonNumeric></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>OR</strong> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</strong> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Commission File No. <ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntityFileNumber">001-38207</ix:nonNumeric></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntityRegistrantName">CELCUITY INC.</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Exact name of registrant as specified in its charter)</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>No. <ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntityTaxIdentificationNumber">82-2863566</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(State of incorporation)</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(IRS Employer Identification No.)</strong></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntityAddressAddressLine1">16305 36th Avenue North;</ix:nonNumeric> <ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntityAddressAddressLine2">Suite 100</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntityAddressCityOrTown">Minneapolis</ix:nonNumeric>, <ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen">Minnesota</ix:nonNumeric> <ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntityAddressPostalZipCode">55446</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Address of principal executive offices, including zip code)</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:CityAreaCode">763</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:LocalPhoneNumber">392-0767</ix:nonNumeric></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:33%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Title of each class</p></td><td style="width:34%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Trading Symbol(s)</p></td><td style="width:33%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Name of each exchange on which registered</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:Security12bTitle">Common Stock, $0.001 par value per share</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:TradingSymbol">CELC</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;<ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;NO &#9744;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;NO&#160;&#9744;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. &#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Large&#160;accelerated&#160;filer</p></td><td style="width:20%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#9744;</p></td><td style="width:30%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Accelerated&#160;filer</p></td><td style="width:20%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#9744;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Emerging growth company</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;YES&#160;<ix:nonNumeric contextRef="From2021-01-01to2021-03-31" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160;NO&#160;&#9746;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On May 3, 2021 there were <ix:nonFraction contextRef="AsOf2021-05-03" name="dei:EntityCommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,647,037</ix:nonFraction> shares of the registrant&#8217;s common stock, $0.001 par value per share, outstanding.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Celcuity Inc.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="TOC">Table of Contents</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PAGE</strong></p></td></tr><tr style="height:15px"><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a href="#p1">PART I. FINANCIAL INFORMATION</a></strong></p></td></tr><tr style="height:15px"><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i1"><strong>ITEM&#160;1.</strong> </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i1">Financial Statements (unaudited)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#BS">Condensed Balance Sheets as of March 31, 2021 and December 31, 2020</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#SO">Condensed Statements of Operations for the three months ended March 31, 2021 and 2020</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">4</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#EQ">Condensed Statements of Stockholders&#8217; Equity for the three months ended March 31, 2021</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#EQ2">Condensed Statements of Stockholders&#8217; Equity for the three months ended March 31, 2020</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#CF">Condensed Statements of Cash Flows for the three months ended March 31, 2021 and 2020</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#NOTES">Notes to Unaudited Condensed Financial Statements</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i2"><strong>ITEM&#160;2.</strong> </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i2">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">15</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i3"><strong>ITEM&#160;3.</strong> </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i3">Quantitative and Qualitative Disclosures About Market Risk</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">33</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i4"><strong>ITEM&#160;4.</strong> </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i4">Controls and Procedures</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">33</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a href="#p2">PART II. OTHER INFORMATION</a></strong></p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#it1"><strong>ITEM&#160;1.</strong> </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#it1">Legal Proceedings</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">34</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#it1a"><strong>ITEM&#160;1A.</strong> </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#it1a">Risk Factors</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">34</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#it2"><strong>ITEM&#160;2.</strong> </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#it2">Unregistered Sales of Equity Securities and Use of Proceeds</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">34</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#it3"><strong>ITEM&#160;3.</strong> </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#it3">Defaults Upon Senior Securities</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">34</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#it4"><strong>ITEM&#160;4</strong>. </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#it4">Mine Safety Disclosures</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">34</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#it5"><strong>ITEM&#160;5</strong>. </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#it5">Other Information</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">34</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#it6"><strong>ITEM&#160;6.</strong> </a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#it6">Exhibits</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">35</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><a href="#SIGNATURES">Signatures</a></strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">36</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">As used in this report, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Celcuity,&#8221; and the &#8220;Company&#8221; mean Celcuity Inc., unless the context indicates another meaning.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="p1">PART I.&#160;&#160;FINANCIAL INFORMATION</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="i1">ITEM&#160;1.&#160;&#160;Financial Statements</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Celcuity Inc. </strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160; <span class="atag" style="display: inline" id="BS">Condensed Balance Sheets </span></strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;(unaudited) </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Assets </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Current Assets: </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Cash and cash equivalents </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1307" contextRef="AsOf2021-03-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,936,902</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1308" contextRef="AsOf2020-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,637,911</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Deposits </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1309" contextRef="AsOf2021-03-31" name="us-gaap:DepositsAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,009</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1310" contextRef="AsOf2020-12-31" name="us-gaap:DepositsAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,009</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Deferred transaction costs </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1311" contextRef="AsOf2021-03-31" name="us-gaap:DeferredCostsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,719</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1312" contextRef="AsOf2020-12-31" name="us-gaap:DeferredCostsCurrent" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Payroll tax receivable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1313" contextRef="AsOf2021-03-31" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1314" contextRef="AsOf2020-12-31" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Prepaid assets </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1315" contextRef="AsOf2021-03-31" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">551,345</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1316" contextRef="AsOf2020-12-31" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">317,040</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Total current assets </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1317" contextRef="AsOf2021-03-31" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,713,975</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1318" contextRef="AsOf2020-12-31" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,166,960</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment, net </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1319" contextRef="AsOf2021-03-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">466,484</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1320" contextRef="AsOf2020-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">558,876</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease right-of-use assets </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1321" contextRef="AsOf2021-03-31" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,602</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1322" contextRef="AsOf2020-12-31" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,911</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Total Assets </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1323" contextRef="AsOf2021-03-31" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,367,061</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1324" contextRef="AsOf2020-12-31" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,956,747</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Liabilities and Stockholders' Equity: </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Current Liabilities: </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Accounts payable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1327" contextRef="AsOf2021-03-31" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318,213</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1328" contextRef="AsOf2020-12-31" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,377</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Finance lease liabilities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1329" contextRef="AsOf2021-03-31" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,819</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1330" contextRef="AsOf2020-12-31" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,810</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Operating lease liabilities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1331" contextRef="AsOf2021-03-31" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,656</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1332" contextRef="AsOf2020-12-31" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">187,518</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Accrued expenses </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1333" contextRef="AsOf2021-03-31" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">660,849</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1334" contextRef="AsOf2020-12-31" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">774,612</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Total current liabilities </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1335" contextRef="AsOf2021-03-31" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,170,537</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1336" contextRef="AsOf2020-12-31" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,185,317</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease liabilities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1337" contextRef="AsOf2021-03-31" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,841</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1338" contextRef="AsOf2020-12-31" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,299</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease liabilities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1339" contextRef="AsOf2021-03-31" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,139</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1340" contextRef="AsOf2020-12-31" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,861</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Total Liabilities </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1341" contextRef="AsOf2021-03-31" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,192,517</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1342" contextRef="AsOf2020-12-31" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,254,477</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Stockholders' Equity: </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Preferred stock, $<ix:nonFraction id="fid_1162" contextRef="AsOf2021-03-31" name="us-gaap:PreferredStockParOrStatedValuePerShare" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> par value: <ix:nonFraction id="fid_1163" contextRef="AsOf2021-03-31" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,500,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_1145" contextRef="AsOf2021-03-31" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">0</ix:nonFraction> shares issued and outstanding as of March 31, 2021 and December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1344" contextRef="AsOf2021-03-31" name="us-gaap:PreferredStockValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1345" contextRef="AsOf2020-12-31" name="us-gaap:PreferredStockValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common stock, $<ix:nonFraction id="fid_1149" contextRef="AsOf2021-03-31" name="us-gaap:CommonStockParOrStatedValuePerShare" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> par value: <ix:nonFraction id="fid_1153" contextRef="AsOf2021-03-31" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">25,000,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_1157" contextRef="AsOf2021-03-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">12,287,896</ix:nonFraction> and <ix:nonFraction id="fid_1156" contextRef="AsOf2020-12-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,299,822</ix:nonFraction> shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1346" contextRef="AsOf2021-03-31" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,288</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1347" contextRef="AsOf2020-12-31" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,300</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Additional paid-in capital </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1348" contextRef="AsOf2021-03-31" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,275,505</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1349" contextRef="AsOf2020-12-31" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,013,551</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated deficit </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1350" contextRef="AsOf2021-03-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">29,113,249</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1351" contextRef="AsOf2020-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">26,321,581</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Total Stockholders' Equity </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1352" contextRef="AsOf2021-03-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,174,544</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1353" contextRef="AsOf2020-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,702,270</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Total Liabilities and Stockholders' Equity </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1354" contextRef="AsOf2021-03-31" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,367,061</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1355" contextRef="AsOf2020-12-31" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,956,747</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>&#160;See accompanying notes to the financial statements </em></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Celcuity Inc. </strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<span class="atag" style="display: inline" id="SO">Condensed Statements of Operations </span></strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;(unaudited) </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Operating expenses: </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Research and development </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1165" contextRef="From2021-01-01to2021-03-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,236,342</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1166" contextRef="From2020-01-01to2020-03-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,847,414</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">General and administrative </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1167" contextRef="From2021-01-01to2021-03-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">555,428</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1168" contextRef="From2020-01-01to2020-03-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">463,399</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total operating expenses </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1169" contextRef="From2021-01-01to2021-03-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,791,770</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1170" contextRef="From2020-01-01to2020-03-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,310,813</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Loss from operations </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1171" contextRef="From2021-01-01to2021-03-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,791,770</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1172" contextRef="From2020-01-01to2020-03-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,310,813</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other income (expense) </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Interest expense </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1174" contextRef="From2021-01-01to2021-03-31" name="us-gaap:InterestExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1175" contextRef="From2020-01-01to2020-03-31" name="us-gaap:InterestExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Interest income </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1176" contextRef="From2021-01-01to2021-03-31" name="us-gaap:InvestmentIncomeInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD">388</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1177" contextRef="From2020-01-01to2020-03-31" name="us-gaap:InvestmentIncomeInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,851</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Loss on sale of fixed assets </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1178" contextRef="From2021-01-01to2021-03-31" name="celc:LossOnSaleOfFixedAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1179" contextRef="From2020-01-01to2020-03-31" name="celc:LossOnSaleOfFixedAssets" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other income, net </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1180" contextRef="From2021-01-01to2021-03-31" name="us-gaap:NonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1181" contextRef="From2020-01-01to2020-03-31" name="us-gaap:NonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,818</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Net loss before income taxes </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1182" contextRef="From2021-01-01to2021-03-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,791,668</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1183" contextRef="From2020-01-01to2020-03-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,246,995</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Income tax benefits </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1184" contextRef="From2021-01-01to2021-03-31" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1185" contextRef="From2020-01-01to2020-03-31" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Net loss </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1186" contextRef="From2021-01-01to2021-03-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,791,668</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1187" contextRef="From2020-01-01to2020-03-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,246,995</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per share, basic and diluted </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1188" contextRef="From2021-01-01to2021-03-31" name="us-gaap:EarningsPerShareBasicAndDiluted" decimals="INF" unitRef="USDPShares" sign="-">0.25</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1189" contextRef="From2020-01-01to2020-03-31" name="us-gaap:EarningsPerShareBasicAndDiluted" decimals="INF" unitRef="USDPShares" sign="-">0.22</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding, basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1190" contextRef="From2021-01-01to2021-03-31" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,072,097</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1191" contextRef="From2020-01-01to2020-03-31" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,253,988</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>&#160;See accompanying notes to the financial statements </em></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="21" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Celcuity Inc. </strong></p></td></tr><tr style="height:15px"><td colspan="21" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<span class="atag" style="display: inline" id="EQ">Condensed Statements of Changes in Stockholders' Equity </span></strong></p></td></tr><tr style="height:15px"><td colspan="21" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Three Months Ended March 31, 2021 </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Additional Paid-In </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Accumulated </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;Shares </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;Amount </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Capital</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Deficit</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balance at December 31, 2020</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1192" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,299,822</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1193" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,300</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1194" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,013,551</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1195" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">26,321,581</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1196" contextRef="AsOf2020-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,702,270</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1197" contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1198" contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">449,098</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1199" contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1200" contextRef="From2021-01-01to2021-03-31" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">449,098</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercise of common stock warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1201" contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" name="celc:ExerciseOfCommonStockWarrantsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,185</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1202" contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" name="celc:ExerciseOfCommonStockWarrantsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1203" contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" name="celc:ExerciseOfCommonStockWarrantsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,256</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1204" contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" name="celc:ExerciseOfCommonStockWarrantsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1205" contextRef="From2021-01-01to2021-03-31" name="celc:ExerciseOfCommonStockWarrantsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,257</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercise of common stock options, net of shares withheld for exercise price</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1206" contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">12,707</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1207" contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1208" contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1209" contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1210" contextRef="From2021-01-01to2021-03-31" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1211" contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,971,100</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1212" contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,971</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1213" contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,766,522</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1214" contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1215" contextRef="From2021-01-01to2021-03-31" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,768,493</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of common stock in an at-the-market ("ATM") offering</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1216" contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,082</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1217" contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1218" contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,959</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1219" contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1220" contextRef="From2021-01-01to2021-03-31" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,962</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance costs associated with ATM offering</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1221" contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" name="celc:IssuanceCostsAssociatedWithAtmOffering" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1222" contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" name="celc:IssuanceCostsAssociatedWithAtmOffering" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,868</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1223" contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" name="celc:IssuanceCostsAssociatedWithAtmOffering" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1224" contextRef="From2021-01-01to2021-03-31" name="celc:IssuanceCostsAssociatedWithAtmOffering" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,868</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1225" contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1226" contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1227" contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,791,668</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1228" contextRef="From2021-01-01to2021-03-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,791,668</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balance at March 31, 2021 </strong><em>(unaudited)</em></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1229" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">12,287,896</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1230" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,288</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1231" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,275,505</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1232" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">29,113,249</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1233" contextRef="AsOf2021-03-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,174,544</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="21" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>&#160;See accompanying notes to the financial statements </em></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="21" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Celcuity Inc. </strong></p></td></tr><tr style="height:15px"><td colspan="21" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<span class="atag" style="display: inline" id="EQ2">Condensed Statements of Changes in Stockholders' Equity </span></strong></p></td></tr><tr style="height:15px"><td colspan="21" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Three Months Ended March 31, 2020 </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Additional Paid-In </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Accumulated </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;Shares </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;Amount </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Capital</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Deficit</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balance at December 31, 2019</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1234" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,253,988</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1235" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,254</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1236" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,134,723</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1237" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">16,847,406</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1238" contextRef="AsOf2019-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,297,571</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1239" contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1240" contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">464,649</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1241" contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1242" contextRef="From2020-01-01to2020-03-31" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">464,649</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1243" contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1244" contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1245" contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,246,995</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1246" contextRef="From2020-01-01to2020-03-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,246,995</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balance at March 31, 2020 </strong><em>(unaudited)</em></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1247" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,253,988</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1248" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,254</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1249" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,599,372</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1250" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">19,094,401</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1251" contextRef="AsOf2020-03-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,515,225</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="21" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>&#160;See accompanying notes to the financial statements </em></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Celcuity Inc. </strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;<span class="atag" style="display: inline" id="CF">Condensed Statements of Cash Flows </span></strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;(unaudited) </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Cash flows from operating activities: </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1253" contextRef="From2021-01-01to2021-03-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,791,668</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1254" contextRef="From2020-01-01to2020-03-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,246,995</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Adjustments to reconcile net loss to net cash used for operations: </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:40pt">Depreciation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1256" contextRef="From2021-01-01to2021-03-31" name="us-gaap:Depreciation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,222</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1257" contextRef="From2020-01-01to2020-03-31" name="us-gaap:Depreciation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,792</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:40pt">Stock-based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1258" contextRef="From2021-01-01to2021-03-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">449,098</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1259" contextRef="From2020-01-01to2020-03-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">464,649</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:40pt">Loss on sale of fixed assets </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1260" contextRef="From2021-01-01to2021-03-31" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1261" contextRef="From2020-01-01to2020-03-31" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Changes in operating assets and liabilities: </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:40pt">Prepaid assets and deposits </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1263" contextRef="From2021-01-01to2021-03-31" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">234,305</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1264" contextRef="From2020-01-01to2020-03-31" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">62,651</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:40pt">Accounts payable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1265" contextRef="From2021-01-01to2021-03-31" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,924</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1266" contextRef="From2020-01-01to2020-03-31" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">92,197</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:40pt">Accrued expenses </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1267" contextRef="From2021-01-01to2021-03-31" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">113,763</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1268" contextRef="From2020-01-01to2020-03-31" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,143</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:40pt">Non-cash operating lease, net </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1269" contextRef="From2021-01-01to2021-03-31" name="celc:IncreaseDecreaseInNonCashOperatingLeaseExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,276</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1270" contextRef="From2020-01-01to2020-03-31" name="celc:IncreaseDecreaseInNonCashOperatingLeaseExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">21,342</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:50pt">Net cash used for operating activities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1271" contextRef="From2021-01-01to2021-03-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,521,505</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1272" contextRef="From2020-01-01to2020-03-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,833,601</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Cash flows from investing activities: </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Purchases of property and equipment </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1274" contextRef="From2021-01-01to2021-03-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,925</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1275" contextRef="From2020-01-01to2020-03-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,604</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from sale of property and equipment </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1276" contextRef="From2021-01-01to2021-03-31" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1277" contextRef="From2020-01-01to2020-03-31" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:50pt">Net cash used for investing activities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1278" contextRef="From2021-01-01to2021-03-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,425</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1279" contextRef="From2020-01-01to2020-03-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">45,604</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Cash flows from financing activities: </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from exercise of common stock warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1281" contextRef="From2021-01-01to2021-03-31" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,257</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1282" contextRef="From2020-01-01to2020-03-31" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from follow-on offering, net of underwriting discounts and offering costs </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1283" contextRef="From2021-01-01to2021-03-31" name="celc:ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,814,167</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1284" contextRef="From2020-01-01to2020-03-31" name="celc:ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Gross proceeds from an ATM offering </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1285" contextRef="From2021-01-01to2021-03-31" name="celc:GrossProceedsFromAnAtmOffering" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,962</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1286" contextRef="From2020-01-01to2020-03-31" name="celc:GrossProceedsFromAnAtmOffering" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payments for secondary registration statement costs </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1287" contextRef="From2021-01-01to2021-03-31" name="celc:PaymentsForRegistrationStatementCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,016</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1288" contextRef="From2020-01-01to2020-03-31" name="celc:PaymentsForRegistrationStatementCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payments for finance leases </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1289" contextRef="From2021-01-01to2021-03-31" name="celc:PaymentsForFinanceLeases" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,449</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1290" contextRef="From2020-01-01to2020-03-31" name="celc:PaymentsForFinanceLeases" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,438</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:50pt">Net cash provided by (used for) financing activities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1356" contextRef="From2021-01-01to2021-03-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,850,921</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1357" contextRef="From2020-01-01to2020-03-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,438</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net change in cash and cash equivalents </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1293" contextRef="From2021-01-01to2021-03-31" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,298,991</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1294" contextRef="From2020-01-01to2020-03-31" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,880,643</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Cash and cash equivalents: </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Beginning of period </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1296" contextRef="AsOf2020-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,637,911</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1297" contextRef="AsOf2019-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,735,002</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">End of period </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1298" contextRef="AsOf2021-03-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,936,902</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1299" contextRef="AsOf2020-03-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,854,359</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Supplemental disclosures of non-cash investing and financing activities: </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment included in accounts payable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1301" contextRef="From2021-01-01to2021-03-31" name="us-gaap:LiabilitiesAssumed1" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1302" contextRef="From2020-01-01to2020-03-31" name="us-gaap:LiabilitiesAssumed1" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,101</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Offering and registration statement costs included in accounts payable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1303" contextRef="From2021-01-01to2021-03-31" name="celc:OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,245</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1304" contextRef="From2020-01-01to2020-03-31" name="celc:OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,127</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>&#160;See accompanying notes to the financial statements </em></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CELCUITY INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="NOTES">NOTES TO CONDENSED FINANCIAL STATEMENTS (unaudited)</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(For the Three Months Ended March 31, 2021 and 2020)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:nonNumeric id="fid_1574" contextRef="From2021-01-01to2021-03-31" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>1.&#160;Organization</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong><span style="text-decoration:underline">Nature of Business</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Celcuity Inc., a Delaware corporation (the &#8220;Company&#8221;), is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated companion diagnostic (CDx) and therapeutic (Rx) strategy. Our CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from targeted therapies. This enables a CELsignia CDx to support advancement of new indications for already approved targeted therapies. Our therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver our companion diagnostics can identify. By pursuing an integrated companion diagnostic and therapeutic strategy, we believe we are uniquely positioned to achieve our goal of helping cancer patients receive the therapeutic best suited to treat their cancer driver. The Company was co-founded in 2012 by Brian F. Sullivan and Dr. Lance G. Laing and is based in Minnesota. The Company has not generated any revenues to date.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1575" contextRef="From2021-01-01to2021-03-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="cont_8573f0"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>2. Summary of Significant Accounting Policies</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Basis of Presentation</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1581" contextRef="From2021-01-01to2021-03-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px">The accompanying unaudited financial statements include the accounts of the Company and have been prepared in accordance with Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, as permitted by Article 10, the unaudited financial statements do not include all of the information required by accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). The balance sheet at December&#160;31, 2020 was derived from the audited financial statements at that date and does not include all the disclosures required by U.S. GAAP. In the opinion of management, all adjustments which are of a normal recurring nature and necessary for a fair presentation have been reflected in the financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&#160;31, 2020 and the related footnotes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Follow-on Offering</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1586" contextRef="From2021-01-01to2021-03-31" name="celc:FollowOnOfferingPolicyTextBlock" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px">On February 26, 2021, the Company completed a follow-on offering whereby it sold <ix:nonFraction id="fid_1402" contextRef="From2021-01-01to2021-03-31" name="celc:IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,971,100</ix:nonFraction> shares of common stock (including <ix:nonFraction id="fid_1403" contextRef="From2021-01-01to2021-03-31" name="celc:IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">257,100</ix:nonFraction> shares of common stock in connection with the full exercise of the underwriters&#8217; option to purchase additional shares) at a public offering price of $<ix:nonFraction id="fid_1404" contextRef="From2021-01-01to2021-03-31" name="us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare" decimals="INF" unitRef="USDPShares">14.00</ix:nonFraction> per share. The aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, was approximately $<ix:nonFraction id="fid_1405" contextRef="From2021-01-01to2021-03-31" name="celc:NetOfUnderwritingDiscountsAndOfferingCosts" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">27.6</ix:nonFraction> million before deducting underwriting discounts of approximately $<ix:nonFraction id="fid_1406" contextRef="From2021-01-01to2021-03-31" name="us-gaap:SalesCommissionsAndFees" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.6</ix:nonFraction> million and offering expenses of approximately $<ix:nonFraction id="fid_1407" contextRef="From2021-01-01to2021-03-31" name="celc:OfferingExpenses" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><strong>Accounting Estimates</strong></span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1582" contextRef="From2021-01-01to2021-03-31" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Management uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Risks and Uncertainties</span></strong><span style="text-decoration:underline"> </span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1583" contextRef="From2021-01-01to2021-03-31" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval of its diagnostic tests, the clinical and commercial success of its initial drug product, gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Clinical Trial Costs</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1584" contextRef="From2021-01-01to2021-03-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company records prepaid assets or accrued expenses for prepaid or estimated clinical trial costs conducted by third-party service providers, which includes the conduct of preclinical studies and clinical trials.&#160; These costs can be a significant component of the Company&#8217;s research and development expenses.&#160; The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with service agreements with its third-party service providers.&#160; The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period.&#160; As actual costs become known, the Company adjusts its prepaid assets or accrued expenses.&#160; The Company has not experienced any material differences between accrued costs and actual costs incurred.&#160; However, the status and timing of actual services performed, number of patients enrolled, and the rate of patient enrollments may vary from the Company&#8217;s estimates, resulting in an adjustment to expense in future periods.&#160; Changes in these estimates that result in material changes to the Company&#8217;s prepaid assets or accrued expenses could materially affect the Company&#8217;s results of operations.</p></ix:nonNumeric></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_8573f0"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Application of New or Revised Accounting Standards</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1585" contextRef="From2021-01-01to2021-03-31" name="celc:ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pursuant to the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), a company constituting an &#8220;emerging growth company&#8221; is, among other things, entitled to rely upon certain reduced reporting requirements. The Company is an emerging growth company but has irrevocably elected not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. As a result, the Company will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for public companies that are not emerging growth companies. </p></ix:nonNumeric></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1576" contextRef="From2021-01-01to2021-03-31" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>3. Net Loss Per Common Share</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per common share are the same.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">For the three months ended March 31, 2021 and 2020, potentially dilutive securities excluded from the computations of diluted weighted-average shares outstanding were options to purchase <ix:nonFraction id="fid_1409" contextRef="From2021-01-01to2021-03-31_celc_StockOptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">855,072</ix:nonFraction> and <ix:nonFraction id="fid_1410" contextRef="From2020-01-01to2020-03-31_celc_StockOptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">630,889</ix:nonFraction> shares of common stock, respectively, warrants to purchase <ix:nonFraction id="fid_1411" contextRef="From2021-01-01to2021-03-31_celc_WarrantsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">352,400</ix:nonFraction> and <ix:nonFraction id="fid_1408" contextRef="From2020-01-01to2020-03-31_celc_WarrantsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">353,585</ix:nonFraction> shares of common stock, respectively, and <ix:nonFraction id="fid_1412" contextRef="From2021-01-01to2021-03-31_celc_RestrictedStocksMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,686</ix:nonFraction> and <ix:nonFraction id="fid_1413" contextRef="From2020-01-01to2020-03-31_celc_RestrictedStocksMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">0</ix:nonFraction> shares of restricted common stock, respectively.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1577" contextRef="From2021-01-01to2021-03-31" name="us-gaap:CommitmentsDisclosureTextBlock" escape="true" continuedAt="cont_3d390e"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>4. Commitments</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><strong>Operating and Finance Leases</strong></span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Company leases its corporate space in Minneapolis, Minnesota. In September 2017, the Company entered into a non-cancelable operating lease agreement for building space. The new lease commenced, and the Company moved to the facility in May 2018, in conjunction with the termination of its then existing lease. Rent expense is recorded on a straight-line basis over the lease term. In July 2020 the Company signed an amendment to extend this lease through April 30, 2022. The lease amendment provides for monthly rent, real estate taxes and operating expenses. As a result of the lease amendment, the Company recorded an incremental $<ix:nonFraction id="fid_1461" contextRef="From2021-01-01to2021-03-31" name="us-gaap:IncreaseDecreaseInOperatingCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,211</ix:nonFraction> in the operating right-of-use (&#8220;ROU&#8221;) asset and lease liability. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The lease agreement, as amended, includes the option to extend the term for one additional year. The option to extend is at the Company&#8217;s discretion and because the Company has not determined if the option to extend will be exercised, the extended lease term is not included in the ROU assets and lease liabilities. The Company regularly evaluates the renewal options and when it is reasonably certain of exercise, the Company will include the renewal period in its lease term.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">In May 2018, the Company entered into a non-cancelable finance lease agreement for office equipment with a five-year term. The underlying assets are included in furniture and equipment. The lease contains a bargain purchase option at the end of the lease.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">When an implicit rate is not provided, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1587" contextRef="From2021-01-01to2021-03-31" name="celc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplemental balance sheet information consisted of the following at March 31, 2021:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating Lease</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1430" contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,602</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1416" contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember" name="us-gaap:OperatingLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,795</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Less: short term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1417" contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">185,656</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Long term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1427" contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember" name="celc:LongTermOperatingLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,139</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance Lease</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Furniture and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1420" contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember" name="us-gaap:CapitalLeasedAssetsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,932</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Less: Accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1421" contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember" name="us-gaap:CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">16,395</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;Net book value of property and equipment under finance lease </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1422" contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember" name="us-gaap:CapitalLeasesBalanceSheetAssetsByMajorClassNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,537</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1423" contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember" name="celc:FinanceLeaseLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,660</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Less: short term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1428" contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember" name="us-gaap:ShortTermBorrowings" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">5,819</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Long term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1597" contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,841</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_3d390e" continuedAt="cont_c2dfb8"><p style="font-size:10pt;font-family:times new roman;margin:0px">Maturity analysis under lease agreements consisted of the following as of March 31, 2021:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1588" contextRef="From2021-01-01to2021-03-31" name="us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Operating Leases</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Finance Leases</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1432" contextRef="AsOf2021-03-31_celc_OperatingLeasesMember" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,116</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1439" contextRef="AsOf2021-03-31_celc_FinanceLeasesMember" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,441</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1433" contextRef="AsOf2021-03-31_celc_OperatingLeasesMember" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,940</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1440" contextRef="AsOf2021-03-31_celc_FinanceLeasesMember" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,255</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1434" contextRef="AsOf2021-03-31_celc_OperatingLeasesMember" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1441" contextRef="AsOf2021-03-31_celc_FinanceLeasesMember" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,023</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Total minimum lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1435" contextRef="AsOf2021-03-31_celc_OperatingLeasesMember" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,056</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1442" contextRef="AsOf2021-03-31_celc_FinanceLeasesMember" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,719</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Less: Present value discount</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1436" contextRef="AsOf2021-03-31_celc_OperatingLeasesMember" name="celc:LessPresentValueDiscount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">10,261</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1443" contextRef="AsOf2021-03-31_celc_FinanceLeasesMember" name="celc:LessPresentValueDiscount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">99</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Less: Amount representing services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1437" contextRef="AsOf2021-03-31_celc_OperatingLeasesMember" name="celc:LesseeOperatingLeaseLiabilityAmountRepresentingServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1444" contextRef="AsOf2021-03-31_celc_FinanceLeasesMember" name="celc:LessAmountRepresentingServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,960</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Present value of net minimum lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1438" contextRef="AsOf2021-03-31_celc_OperatingLeasesMember" name="us-gaap:OperatingLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,795</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1445" contextRef="AsOf2021-03-31_celc_FinanceLeasesMember" name="us-gaap:FinanceLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,660</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><ix:nonNumeric id="fid_1589" contextRef="From2021-01-01to2021-03-31" name="celc:ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Weighted Average&#160; </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Remaining Lease Term </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Discount Rate</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; Operating lease </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonNumeric id="fid_1446" contextRef="From2021-01-01to2021-03-31" name="celc:OperatingLeaseWeightedAverageRemainingLeasesTerm1" format="ixt-sec:duryear">1.1</ix:nonNumeric> years </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1447" contextRef="AsOf2021-03-31" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" decimals="INF" unitRef="Pure" scale="-2">4.0</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; Finance lease </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonNumeric id="fid_1448" contextRef="From2021-01-01to2021-03-31" name="celc:FinanceLeaseWeightedAverageRemainingLeasesTerm1" format="ixt-sec:duryear">2.1</ix:nonNumeric> years </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1449" contextRef="AsOf2021-03-31" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" decimals="INF" unitRef="Pure" scale="-2">1.0</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Lease costs for the period ended March 31, 2021:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:nonNumeric id="fid_1590" contextRef="From2021-01-01to2021-03-31" name="us-gaap:LeaseCostTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Three-month Period </strong></p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;Operating lease cost </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1450" contextRef="From2021-01-01to2021-03-31" name="us-gaap:OperatingLeaseCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,430</ix:nonFraction></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;Finance lease cost: </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;&#160;&#160; Amortization </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1452" contextRef="From2021-01-01to2021-03-31" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,447</ix:nonFraction></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;&#160;&#160; Interest </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1453" contextRef="From2021-01-01to2021-03-31" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24</ix:nonFraction></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;Variable lease cost </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1454" contextRef="From2021-01-01to2021-03-31" name="us-gaap:VariableLeaseCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,869</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1455" contextRef="From2021-01-01to2021-03-31" name="us-gaap:LeaseCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,770</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><ix:nonNumeric id="fid_1591" contextRef="From2021-01-01to2021-03-31" name="celc:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplemental cash flow information related to leases for the period ended March 31, 2021:</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Three-month Period </strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="5" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Cash paid for amounts included in operating and finance leases: </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;&#160;&#160; Operating cash outflow from operating leases </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1457" contextRef="From2021-01-01to2021-03-31" name="us-gaap:OperatingLeasePayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,574</ix:nonFraction></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;&#160;&#160; Operating cash outflow from finance leases </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1458" contextRef="From2021-01-01to2021-03-31" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24</ix:nonFraction></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;&#160;&#160; Financing cash outflow from finance leases </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1459" contextRef="From2021-01-01to2021-03-31" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,449</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1460" contextRef="From2021-01-01to2021-03-31" name="celc:CashPaidForOperatingAndFinanceLeases" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,047</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Clinical Research Studies</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">In May 2017, the Company entered into an agreement with a clinical research organization to conduct a clinical research study.&#160; The Company made payments of approximately $<ix:nonFraction id="fid_1462" contextRef="From2021-01-01to2021-03-31" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,000</ix:nonFraction> and $<ix:nonFraction id="fid_1463" contextRef="From2020-01-01to2020-12-31" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction> in 2021 and 2020, respectively, and $<ix:nonFraction id="fid_1464" contextRef="From2017-05-01to2019-12-31" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction> prior to 2020.&#160; Additional payments will be due as certain milestones are met and clinical sites are added. The maximum amount of these additional payments is estimated to be approximately $<ix:nonFraction id="fid_1467" contextRef="AsOf2021-03-31" name="celc:EstimatedRemainingAmountOfPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,340,000</ix:nonFraction> over the course of the agreement. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In October 2018, the Company entered into an agreement with a biopharmaceutical company and a cancer research center to conduct a clinical research study. The Company made payments of approximately $<ix:nonFraction id="fid_1617" contextRef="AsOf2019-12-31_celc_AgreementWithBiopharmaceuticalCompanyOneMember" name="us-gaap:ContractualObligation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,000</ix:nonFraction> prior to 2020. Additional payments of approximately $<ix:nonFraction id="fid_1468" contextRef="AsOf2021-03-31_celc_AgreementWithBiopharmaceuticalCompanyOneMember" name="celc:FuturePaymentsRequiredUponCertainMilestonesBeingMet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,000</ix:nonFraction> will be due as certain milestones are met.</p></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_c2dfb8"><p style="font-size:10pt;font-family:times new roman;margin:0px">In December 2020, the Company entered into an agreement with a biopharmaceutical company and a cancer research center to conduct a clinical research study. The Company made zero payments in 2021&#160;and 2020. Future payments of approximately $<ix:nonFraction id="fid_1618" contextRef="AsOf2021-03-31_celc_AgreementWithBiopharmaceuticalCompanyTwoMember" name="celc:FuturePaymentsRequiredUponCertainMilestonesBeingMet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">740,000</ix:nonFraction> will be due as certain milestones are met.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">In January 2021, the Company entered into an agreement with a biopharmaceutical company and a cancer research center to conduct a clinical research study. The Company made zero payments in 2021. Future payments of approximately $<ix:nonFraction id="fid_1481" contextRef="AsOf2021-03-31_celc_JanuaryTwoThousandTwentyOneMember_celc_AgreementWithBiopharmaceuticalCompanyMember" name="celc:FuturePaymentsRequiredUponCertainMilestonesBeingMet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,210,600</ix:nonFraction> will be due as certain milestones are met.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">In March 2021, the Company entered into an agreement with two biopharmaceutical companies and a cancer research center to conduct a clinical research study. The Company made zero payments in 2021. Future payments of approximately $<ix:nonFraction id="fid_1482" contextRef="AsOf2021-03-31_celc_MarchTwoThousandTwentyOneMember_celc_AgreementWithBiopharmaceuticalCompanyMember" name="celc:FuturePaymentsRequiredUponCertainMilestonesBeingMet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,548,000</ix:nonFraction> will be due as certain milestones are met.</p></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1578" contextRef="From2021-01-01to2021-03-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>5. Stockholders&#8217; Equity</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">On February 26, 2021, the Company completed a follow-on offering whereby it sold <ix:nonFraction id="fid_1620" contextRef="From2021-02-01to2021-02-26" name="celc:IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,971,100</ix:nonFraction> shares of common stock (including <ix:nonFraction id="fid_1622" contextRef="From2021-02-01to2021-02-26" name="celc:IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">257,100</ix:nonFraction> shares of common stock in connection with the full exercise of the underwriters&#8217; option to purchase additional shares) at a public offering price of $<ix:nonFraction id="fid_1490" contextRef="AsOf2021-02-26" name="celc:PublicOfferingPrice" decimals="INF" unitRef="USDPShares">14.00</ix:nonFraction> per share. The aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, was approximately $<ix:nonFraction id="fid_1491" contextRef="From2021-02-01to2021-02-26" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">27.6</ix:nonFraction> million before deducting underwriting discounts of approximately $<ix:nonFraction id="fid_1492" contextRef="From2021-02-01to2021-02-26" name="us-gaap:SalesCommissionsAndFees" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.6</ix:nonFraction> million and offering expenses of approximately $<ix:nonFraction id="fid_1493" contextRef="From2021-02-01to2021-02-26" name="celc:OfferingExpenses" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">On June 5, 2020, the Company entered into an At Market Issuance Sales Agreement (the &#8220;ATM Agreement&#8221;) with B. Riley FBR, Inc. (the &#8220;Agent&#8221;). Pursuant to the ATM Agreement, the Company was able to offer and sell from time to time, at its option, shares of common stock having an aggregate offering price of up to $<ix:nonFraction id="fid_1483" contextRef="AsOf2020-06-05_celc_PlacementSharesMember_celc_AtmAgreementMember" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,000</ix:nonFraction>, par value $<ix:nonFraction id="fid_1486" contextRef="AsOf2020-06-05_celc_PlacementSharesMember_celc_AtmAgreementMember" name="us-gaap:CommonStockParOrStatedValuePerShare" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> per share (the &#8220;Placement Shares&#8221;), through the Agent.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Placement Shares were registered under the Securities Act of 1933, as amended, pursuant to the Registration Statement on Form S-3 (File No. 333-227466), which was originally filed with the SEC on September 21, 2018 and declared effective by the SEC on October 4, 2018, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed on June 5, 2020. Sales of the Company&#8217;s common stock, if any, under this prospectus supplement were able to be made by any method deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">During the three months ended March 31, 2021, the Company sold <ix:nonFraction id="fid_1487" contextRef="From2021-01-01to2021-03-31_celc_PlacementSharesMember_celc_AtmAgreementMember" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,082</ix:nonFraction> shares of common stock pursuant to the ATM Agreement, at an average selling price of $<ix:nonFraction id="fid_1488" contextRef="AsOf2021-03-31_celc_PlacementSharesMember_celc_AtmAgreementMember" name="celc:AverageSellingPricePerShare" decimals="INF" unitRef="USDPShares">12.64</ix:nonFraction>per share.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">On February 23, 2021, in conjunction with the Company&#8217;s follow-on offering, the ATM Agreement was terminated.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1579" contextRef="From2021-01-01to2021-03-31" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="cont_cbcf53"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>6. Stock-Based Compensation</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The following table summarizes the activity for all stock options outstanding for the three months ended March 31:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1592" contextRef="From2021-01-01to2021-03-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options outstanding at beginning of year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1497" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="celc:SharesOptionsOutstandingBeginning" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">849,949</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1503" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="celc:WeightedAverageExercisePriceBeginning" decimals="INF" unitRef="USDPShares">9.33</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1522" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember" name="celc:SharesOptionsOutstandingBeginning" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">585,215</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1516" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember" name="celc:WeightedAverageExercisePriceBeginning" decimals="INF" unitRef="USDPShares">14.37</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1498" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">38,391</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1504" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">15.20</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1521" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">57,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1515" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">10.17</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1499" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="celc:SharesExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">29,997</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1505" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">8.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1500" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,271</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1506" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">7.62</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1519" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,826</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1513" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">10.60</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Balance at March 31</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1501" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="celc:SharesOptionsOutstandingEnding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">855,072</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1507" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="celc:WeightedAverageExercisePriceEnding" decimals="INF" unitRef="USDPShares">9.65</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1518" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember" name="celc:SharesOptionsOutstandingEnding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">630,889</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1512" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember" name="celc:WeightedAverageExercisePriceEnding" decimals="INF" unitRef="USDPShares">14.06</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercisable at March 31:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1502" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="celc:SharesOptionsExercisables" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">406,332</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1508" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="celc:WeightedAverageExercisePriceOptionsExercisables" decimals="INF" unitRef="USDPShares">10.37</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1517" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember" name="celc:SharesOptionsExercisables" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">274,267</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1511" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember" name="celc:WeightedAverageExercisePriceOptionsExercisables" decimals="INF" unitRef="USDPShares">9.65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted Average Grant Date Fair Value for options granted during the period:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1509" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" decimals="INF" unitRef="USDPShares">10.07</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1510" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" decimals="INF" unitRef="USDPShares">6.59</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_cbcf53" continuedAt="cont_ee9300"><p style="font-size:10pt;font-family:times new roman;margin:0px">The following table summarizes additional information about stock options outstanding and exercisable at March 31, 2021:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1596" contextRef="From2021-01-01to2021-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="14"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options Outstanding</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="10"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options Exercisable</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options Outstanding</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Life</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"></td><td style="white-space: nowrap;"></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options Exercisable</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1523" contextRef="AsOf2021-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">855,072</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1524" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">7.81</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1525" contextRef="AsOf2021-03-31_celc_EmployeeStockOptionsMember" name="celc:OptionsOutstandingWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">9.65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1526" contextRef="AsOf2021-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,179,019</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1527" contextRef="AsOf2021-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">406,332</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1528" contextRef="AsOf2021-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" decimals="INF" unitRef="USDPShares">10.37</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1529" contextRef="AsOf2021-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,325,179</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company recognized stock-based compensation expense for stock options of $<ix:nonFraction id="fid_1555" contextRef="From2021-01-01to2021-03-31_celc_StockIncentivePlanMember" name="celc:StockBasedCompensationRelatedToRestrictedStockTotal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,192</ix:nonFraction> and $<ix:nonFraction id="fid_1554" contextRef="From2020-01-01to2020-03-31_celc_StockIncentivePlanMember" name="celc:StockBasedCompensationRelatedToRestrictedStockTotal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,664</ix:nonFraction> for the three months ended March 31, 2021 and 2020, respectively. In May 2020, the Company modified the exercise price on <ix:nonFraction id="fid_1624" contextRef="AsOf2020-05-14_celc_StockIncentivePlanMember" name="celc:StockOptionAwardsSharesModified" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">203,750</ix:nonFraction> stock option awards to $<ix:nonFraction id="fid_1557" contextRef="From2020-05-01to2020-05-14_celc_StockIncentivePlanMember" name="celc:ShareExercisePrice" decimals="INF" unitRef="USDPShares">5.10</ix:nonFraction>, the closing market price on the Nasdaq Capital Market on May 14, 2020. No director or officer awards were modified. The effect on stock-based compensation was $<ix:nonFraction id="fid_1558" contextRef="From2021-01-01to2021-03-31_celc_ExpenseStockOptionsMember" name="celc:StockBasedCompensationRelatedToRestrictedStockTotal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,449</ix:nonFraction> and $<ix:nonFraction id="fid_1559" contextRef="From2020-01-01to2020-03-31_celc_ExpenseStockOptionsMember" name="celc:StockBasedCompensationRelatedToRestrictedStockTotal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> for the three months ended March 31, 2021 and 2020, respectively. The effect on stock-based compensation over the remaining service period will be approximately $<ix:nonFraction id="fid_1625" contextRef="AsOf2020-03-31_celc_ExpenseStockOptionsMember" name="celc:FutureExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,000</ix:nonFraction>.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Black-Scholes option-pricing model was used to estimate the fair value of equity-based awards with the following weighted-average assumptions for the three months ended March 31:</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;</p><ix:nonNumeric id="fid_1593" contextRef="From2021-01-01to2021-03-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1534" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember_srt_MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">0.63</ix:nonFraction>% - <ix:nonFraction id="fid_1541" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember_srt_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">1.12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1535" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember_srt_MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">1.35</ix:nonFraction>% - <ix:nonFraction id="fid_1540" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember_srt_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">1.66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1533" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" decimals="INF" unitRef="Pure" scale="-2">76.6</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1532" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" decimals="INF" unitRef="Pure" scale="-2">73.3</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected life (years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1537" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember_srt_MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear">5.0</ix:nonNumeric> to <ix:nonNumeric id="fid_1538" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember_srt_MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear">6.07</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1536" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember_srt_MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear">5.5</ix:nonNumeric> to <ix:nonNumeric id="fid_1539" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember_srt_MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear">6.1</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected dividend yield </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1530" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" decimals="INF" unitRef="Pure" scale="-2">0</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1531" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" decimals="INF" unitRef="Pure" scale="-2">0</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The inputs for the Black-Scholes valuation model require management&#8217;s significant assumptions. Prior to the Company&#8217;s initial public offering, the price per share of common stock was determined by the Company&#8217;s board based on recent prices of common stock sold in private offerings. Subsequent to the initial public offering, the price per share of common stock is determined by using the closing market price on the Nasdaq Capital Market on the grant date. The risk-free interest rates are based on the rate for U.S. Treasury securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life is based on the simplified method in accordance with the SEC Staff Accounting Bulletin Nos. 107 and 110. The expected volatility is estimated based on historical volatility information of peer companies that are publicly available in combination with the Company&#8217;s calculated volatility since being publicly traded. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">All assumptions used to calculate the grant date fair value of non-employee options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options issued in connection with the agreements would also be cancelled. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">No restricted stock awards were granted during the three months ended March 31, 2021 and 2020. The Company had <ix:nonFraction id="fid_1562" contextRef="AsOf2021-03-31_us-gaap_RestrictedStockUnitsRSUMember" name="us-gaap:CapitalUnitsOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,686</ix:nonFraction> and <ix:nonFraction id="fid_1561" contextRef="AsOf2020-03-31_us-gaap_RestrictedStockUnitsRSUMember" name="us-gaap:CapitalUnitsOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">0</ix:nonFraction> shares of restricted stock outstanding as of March 31, 2021 and 2020, respectively, and <ix:nonFraction id="fid_1563" contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">0</ix:nonFraction> shares of restricted stock vested during the three months ended March 31, 2021 or 2020. The Company recognized stock-based compensation expense for restricted stock of $<ix:nonFraction id="fid_1564" contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember" name="celc:StockBasedCompensationRelatedToRestrictedStockTotal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,456</ix:nonFraction> and $<ix:nonFraction id="fid_1565" contextRef="From2020-01-01to2020-03-31_us-gaap_RestrictedStockUnitsRSUMember" name="celc:StockBasedCompensationRelatedToRestrictedStockTotal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> for the three months ended March 31, 2021 and 2020, respectively.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company initially reserved a maximum of <ix:nonFraction id="fid_1627" contextRef="AsOf2017-10-25_celc_StockIncentivePlanMember" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">750,000</ix:nonFraction> shares of common stock for issuance under the 2017 Amended and Restated Stock Incentive Plan (the &#8220;2017 Plan&#8221;). <ix:nonNumeric id="fid_1567" contextRef="From2021-01-01to2021-03-31_celc_StockIncentivePlanMember" name="celc:CommonStockSharesReservedDescription">The number of shares reserved for issuance was automatically increased by 102,540 shares on January 1, 2020 and by 102,998 shares on January 1, 2021 and will increase automatically on January 1 of each of 2022 through 2027 by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding December 31.</ix:nonNumeric> However, the Company&#8217;s board may reduce the amount of the increase in any particular year. The total remaining shares available for grant under the Company&#8217;s 2017 Plan as of March 31, 2021 was <ix:nonFraction id="fid_1568" contextRef="AsOf2021-03-31_celc_StockIncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">266,800</ix:nonFraction>.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Total unrecognized compensation cost related to stock options and restricted stock is estimated to be recognized as follows:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:nonNumeric id="fid_1594" contextRef="From2021-01-01to2021-03-31" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1542" contextRef="AsOf2021-03-31" name="celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,032,220</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1543" contextRef="AsOf2021-03-31" name="celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,147,153</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1544" contextRef="AsOf2021-03-31" name="celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" format="ixt:numdotdecimal" decimals="0" unitRef="USD">789,853</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1545" contextRef="AsOf2021-03-31" name="celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" format="ixt:numdotdecimal" decimals="0" unitRef="USD">291,273</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1546" contextRef="AsOf2021-03-31" name="celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,616</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10.05pt"><strong>Total estimated compensation cost to be recognized</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1547" contextRef="AsOf2021-03-31" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,272,115</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_ee9300"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Company recognized stock-based compensation expense related to its employee stock purchase plan of $<ix:nonFraction id="fid_1629" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember" name="celc:StockBasedCompensationExpenseRelatedToEspp" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,450</ix:nonFraction> and $<ix:nonFraction id="fid_1628" contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember" name="celc:StockBasedCompensationExpenseRelatedToEspp" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,985</ix:nonFraction> for the three months ended March 31, 2021 and 2020, respectively. The Company initially reserved a total of <ix:nonFraction id="fid_1630" contextRef="AsOf2017-10-25_celc_EmployeeStockPurchasePlanMember" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">100,000</ix:nonFraction> shares for issuance under the employee stock purchase plan. <ix:nonNumeric id="fid_1573" contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockPurchasePlanMember" name="celc:CommonStockSharesReservedDescription">The number of shares reserved for issuance was automatically increased by 51,270 shares on January 1, 2020 and 51,499 shares on January 1, 2021 and will increase automatically on each subsequent January 1 by the number of shares equal to 0.5% of the total outstanding number of shares of Company common stock as of the immediately preceding December 31.</ix:nonNumeric>&#160;&#160;However, the Company&#8217;s board may reduce the amount of the increase in any particular year. The total remaining shares available for issuance under the employee stock purchase plan as of March 31, 2021 was <ix:nonFraction id="fid_1572" contextRef="AsOf2021-03-31_celc_EmployeeStockPurchasePlanMember" name="celc:RemainingSharesAvailableForIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">163,710</ix:nonFraction>. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recognized total stock-based compensation expense as follows for the three months ended March 31:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1595" contextRef="From2021-01-01to2021-03-31" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation expense in operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1551" contextRef="From2021-01-01to2021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,181</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1550" contextRef="From2020-01-01to2020-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">293,116</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1552" contextRef="From2021-01-01to2021-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">193,917</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1553" contextRef="From2020-01-01to2020-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,533</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1548" contextRef="From2021-01-01to2021-03-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">449,098</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1549" contextRef="From2020-01-01to2020-03-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">464,649</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1580" contextRef="From2021-01-01to2021-03-31" name="us-gaap:SubsequentEventsTextBlock" escape="true" continuedAt="cont_98be28"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>7. Subsequent Events</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">On April 8, 2021, the Company entered into a license agreement (the &#8220;License Agreement&#8221;) with Pfizer, Inc. (&#8220;Pfizer&#8221;), pursuant to which the Company acquired exclusive (including as to Pfizer) worldwide sublicensable rights to research, develop, manufacture, and commercialize gedatolisib, a potent, well-tolerated, reversible dual inhibitor that targets PI3K and mTOR, for the treatment, diagnosis and prevention of all diseases. Pursuant to the License Agreement, the Company is obligated to use commercially reasonable efforts to develop and seek regulatory approval for at least one product in the United States and if regulatory approval is obtained, to commercialize such product in the United States and at least one international major market.&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company paid Pfizer a $<ix:nonFraction id="fid_1631" contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_LicenseAgreementMember" name="celc:UpfrontFee" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">5.0</ix:nonFraction> million upfront fee upon execution of the License Agreement and, pursuant to an Equity Grant Agreement, issued to Pfizer $<ix:nonFraction id="fid_1632" contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_EquityGrantAgreementMember" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">5.0</ix:nonFraction> million of shares of the Company&#8217;s common stock. The number of shares issued was <ix:nonFraction id="fid_1633" contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_LicenseAgreementMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">349,406</ix:nonFraction> and was calculated by dividing $5.0 million by $<ix:nonFraction id="fid_1603" contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_LicenseAgreementMember" name="celc:ClosingPricePerShare" decimals="INF" unitRef="USDPShares">14.31</ix:nonFraction>, the closing price of a share of the Company&#8217;s common stock on the Nasdaq Capital Market on April 8, 2021.<ix:nonNumeric id="fid_1614" contextRef="From2021-03-09to2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_LicenseAgreementMember" name="celc:DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents">The Company is also required to make milestone payments to Pfizer upon achievement of certain development and commercial milestone events, up to an aggregate of $330.0 million</ix:nonNumeric>. Additionally, the Company will pay Pfizer tiered royalties on sales of gedatolisib at percentages ranging from the low to mid-teens, which may be subject to deductions for expiration of valid claims, amounts due under third-party licenses and generic competition. Unless earlier terminated, the License Agreement will expire upon the expiration of all royalty obligations. The royalty period will expire on a country-by-country basis upon the later of (a) 12 years following the date of first commercial sale of such product in such country, (b) the expiration of all regulatory or data exclusivity in such country for such product or (c) the date upon which the manufacture, use, sale, offer for sale or importation of such product in such country would no longer infringe, but for the license granted in the License Agreement, a valid claim of a licensed patent right.&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company has the right to terminate the License Agreement for convenience upon 90 days&#8217; prior written notice. Pfizer may not terminate the agreement for convenience. Either the Company or Pfizer may terminate the License Agreement if the other party is in material breach and such breach is not cured within the specified cure period. In addition, either the Company or Pfizer may terminate the License Agreement in the event of specified insolvency events involving the other party.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Also, on April 8, 2021, the Company entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (&#8220;Innovatus&#8221;), as collateral agent and the Lenders listed on Schedule 1.1 thereto, pursuant to which Innovatus, as a Lender, has agreed to make certain term loans to the Company in the aggregate principal amount of up to $<ix:nonFraction id="fid_1607" contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember" name="us-gaap:LongTermLoansPayable" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">25.0</ix:nonFraction> million (the &#8220;Term Loans&#8221;). </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Funding of the first $<ix:nonFraction id="fid_1606" contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_TrancheMember" name="us-gaap:LongTermLoansPayable" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">15.0</ix:nonFraction> million tranche occurred on April 8, 2021. The Company will be eligible to draw on a second tranche of $<ix:nonFraction id="fid_1608" contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_SecondTrancheMember" name="us-gaap:LongTermLoansPayable" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">5.0</ix:nonFraction> million upon achievement of certain milestones, including meeting the primary end points of either the FACT-1 or FACT-2 clinical trials and receipt of unrestricted net cash proceeds of at least $<ix:nonFraction id="fid_1636" contextRef="From2021-03-09to2021-04-08_us-gaap_SubsequentEventMember" name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">50.0</ix:nonFraction> million from the issuance and sale of the Company&#8217;s equity securities. The Company will be eligible to draw on a third tranche of $<ix:nonFraction id="fid_1609" contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_ThirdTrancheMember" name="us-gaap:LongTermLoansPayable" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">5.0</ix:nonFraction> million upon the achievement of certain additional milestones, including commencement of certain Phase 3 clinical trials and the receipt of unrestricted net cash proceeds of at least $<ix:nonFraction id="fid_1637" contextRef="From2021-03-09to2021-04-08_us-gaap_SubsequentEventMember_celc_ThirdTrancheMember" name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">75.0</ix:nonFraction> million from the issuance and sale of the Company&#8217;s equity securities. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Innovatus has the right, at its election, after June 1, 2021 and until the third anniversary of the Loan Agreement, to convert up to 20% of the outstanding principal amount of all Terms Loans made under the Loan Agreement into shares of the Company&#8217;s common stock at a price per share equal to the volume weighted average closing price of the Company&#8217;s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement (the &#8220;Conversion Right&#8221;).</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_98be28"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_1615" contextRef="From2021-03-09to2021-04-08_us-gaap_SubsequentEventMember" name="us-gaap:LongTermDebtDescription">The Company is entitled to make interest-only payments for thirty-six months, or up to forty-eight months if certain conditions are met. The Term Loans will mature on the fifth anniversary of the initial funding date and will bear interest at a rate equal to sum of (a) the greater of (i) Prime Rate (as defined in the Loan Agreement) or (ii) 3.25%, plus (b) 5.70%. Additionally, the Company elected to make 2.7% of the interest rate as payable in-kind, which shall accrue as principal monthly. Other fees include a 1.0% facility fee on the funded loan amount, paid at closing and a final fee of 4.5% of the funded loan amount due at the maturity date or earlier if the Company prepays the loan. The Company has the option to prepay the loan at any time following the first anniversary of the loan closing, with tiered prepayment fees ranging from 0 &#8211; 2% based on when the prepayment would occur</ix:nonNumeric>.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Loan Agreement is secured by all assets of the Company. Proceeds will be used for working capital purposes and to fund the Company&#8217;s general business requirements. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months revenue.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the &#8220;Warrants&#8221;) to purchase a number of shares of the Company&#8217;s common stock equal to 2.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company&#8217;s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement. For the second and third tranches only the exercise price will be based on the lower of (i) the exercise price for the first tranche or (ii) the volume weighted average closing price of the Company&#8217;s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding. The Warrants may be exercised on a cashless basis and are exercisable through the 10<sup>th</sup> anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. </p></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="i2">ITEM&#160;2.&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed financial statements and the related notes appearing under Item&#160;1 of Part I of this Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and expected financial results, includes forward-looking statements that involve risks and uncertainties. You should review the &#8220;Risk Factors&#8221; discussed in our Annual Report on Form 10-K for the year ended December 31, 2020, in Exhibit 99.4 to our Current Report on Form 8-K, filed with the SEC on April 8, 2021 and elsewhere in this Quarterly Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. &#160;&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Overview </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">We are a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursing an integrated companion diagnostic (CDx) and therapeutic (Rx) strategy that leverages our CELsignia CDx platform. CELsignia is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from targeted therapies. This enables a CELsignia CDx to support advancement of new indications for already approved targeted therapies. Our therapeutic strategy aims to utilize CELsignia&#8217;s unique insights into tumor cell biology to identify, in-license, and develop potential first-in-class or best-in-class targeted therapies that treat the same cancer driver a CELsignia CDx can identify. We believe this integrated CDx and Rx strategy will maximize the impact our CELsignia platform has on the treatment landscape for cancer patients. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Our proprietary CELsignia diagnostic platform is the only commercially ready technology we are aware of that uses a patient&#8217;s living tumor cells to identify the specific abnormal cellular process driving a patient&#8217;s cancer and the targeted therapy that best treats it. This enables us to identify patients whose tumors may respond to a targeted therapy, even though they lack a previously associated molecular mutation. By identifying cancer patients whose tumors lack an associated genetic mutation but have abnormal cellular activity a matching targeted therapeutic is designed to inhibit, CELsignia CDx can expand the markets for a number of already approved targeted therapies. Our current CDx identifies breast and ovarian cancer patients whose tumors have cancer drivers potentially responsive to treatment with human epidermal growth factor receptor 2-negative (HER2), mesenchymal-epithelial transition factor (c-MET), or phosphatidylinositol 3-kinases (PI3K) targeted therapeutics. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Our CELsignia platform provides an important advantage over traditional molecular diagnostics. Current molecular diagnostics analyze fragmented cells to obtain a snapshot of the genetic mutations present in a patient&#8217;s tumor. Using cell fragments prevents molecular diagnostics from analyzing the dynamic cellular activities, known as cell signaling, that regulate cell proliferation or survival. Cancer can develop when critical cell signaling, regulating physiologic activity such as cell proliferation, becomes abnormal or dysregulated. Since genetic mutations are often only weakly correlated to the dysregulated cell signaling activity driving a patient&#8217;s cancer, a molecular diagnostic is prone to providing an incomplete diagnosis. CELsignia tests overcome this limitation by measuring dynamic cell signaling activity in a cancer patient&#8217;s living tumor cells. When a CELsignia test detects abnormal signaling activity, a more accurate diagnosis of the patient&#8217;s cancer driver is obtained. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">We are supporting the advancement of new potential indications for six different targeted therapies, controlled by other pharmaceutical companies, that would rely on a CELsignia CDx to select patients. Five Phase 2 trials are underway to evaluate the efficacy and safety of these therapies in CELsignia selected patients. These patients are not currently eligible to receive these drugs and are not identifiable with a molecular test. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">The first drug candidate we are developing internally is gedatolisib, a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class 1 isoforms of PI3K and mammalian target of rapamycin (mTOR). In April 2021, we obtained exclusive global development and commercialization rights to gedatolisib under a license agreement with Pfizer, Inc. Our interest in gedatolisib was prompted after we conducted a study of various PI3K targeted therapeutics while developing our CELsignia PI3K Activity test. Our CELsignia platform allows us to obtain proprietary insights about the relative effectiveness of PI3K targeted therapies. This study found that gedatolisib inhibited higher levels of PI3K-involved signaling activity than the other PI3K targeted therapeutics we evaluated and demonstrated superior drug synergy when combined with other targeted therapies. Gedatolisib&#8217;s initial clinical development program will focus on the treatment of patients with estrogen receptor positive (ER+), HER2-negative, advanced or metastatic breast cancer. Additional clinical development programs are expected to focus on other tumor types that involve a hormonal signaling pathway, such as endometrial, ovarian, or prostate cancer.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Supporting the development of a potential first-in-class targeted therapy for breast cancer, like gedatolisib, with our CELsignia platform is a natural extension of our strategy to use our CELsignia CDx to enable new indications for other companies&#8217; targeted therapies. By combining companion diagnostics designed to enable proprietary new drug indications with targeted therapies that treat signaling dysregulation our CDx identifies, we believe we are uniquely positioned to improve the standard-of-care for many early- and late-stage breast cancer patients. Our goal is to play a key role in the multiple treatment approaches required to treat breast cancer patients at various stages of their disease. With each program, we are:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Leveraging the proprietary insights CELsignia provides into live patient tumor cell function</td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Using a CELsignia CDx to identify new patients likely to respond to the paired targeted therapy</td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Developing a new targeted therapeutic option for breast cancer patients</td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Maximizing the probability of getting regulatory approval to market the targeted therapy indication</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>CELsignia Development and CDx Programs </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Our first analytically validated and commercially ready test using our CELsignia platform, the CELsignia HER2 Pathway Activity Test for breast cancer, diagnoses two new sub-types of HER2-negative breast cancer that traditional molecular diagnostics cannot detect. Our internal studies show that approximately 15-20% of HER2-negative breast cancer patients have abnormal HER2 signaling activity similar to levels found in HER2-positive breast cancer cells. As a result, these HER2-negative patients have undiagnosed HER2-driven breast cancer and would be likely to respond to the same anti-HER2 targeted therapies only HER2-positive patients receive today. We have three interventional clinical trials underway to evaluate the efficacy of HER2 targeted therapies in breast cancer patients selected with our CELsignia HER2 Pathway Activity Test.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.25in; text-align:left;">Our second CELsignia test for breast cancer evaluates independent c-Met signaling activity and its involvement with HER family signaling in HER2-negative breast cancer tumor cells. Our internal studies show that approximately 20%-25% of HER2-negative breast cancer patients have abnormal c-Met signaling activity that is co-activated with abnormal HER family signaling. These studies suggest that this sub-group of HER2-negative breast cancer patients may best respond to treatment with a combination of HER family and c-Met inhibitors.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Our third CELsignia test for breast cancer evaluates PI3K signaling in HER2-negative breast cancer tumor cells. Our internal studies demonstrate how measurement of PI3K-involved signaling may provide a more sensitive and specific method of identifying patients most likely to benefit from PI3K inhibitors than current genetic tests that measure PI3K mutations. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">We intend to combine these three tests to create the CELsignia Multi-Pathway Activity Test, or CELsignia MP Test. With this next generation CELsignia test, we plan to provide an analysis of EGFR/HER1, HER2, HER3, c-MET, and PI3K-node involved signaling activity for each patient tumor specimen received. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">We completed development of our first CELsignia test for ovarian cancer in 2020.&#160; This test identifies a new sub-group of ovarian cancer patients with tumors that have abnormal c-Met and HER2 signaling activity. &#160;&#160;These findings suggest that a significant sub-group of ovarian cancer patients may respond to treatment with a combination of ErbB and c-Met inhibitors. &#160;Nearly 15,000 women a year die from ovarian cancer, a disease that has less than a 50% five-year survival rate and a limited range of targeted therapy options.&#160; There is thus a significant unmet need for additional therapeutic options for ovarian cancer patients.&#160; As a companion diagnostic, our CELsignia test for ovarian cancer will be intended to help pharmaceutical companies obtain new drug indications and expand treatment options for this challenging tumor type.&#160; We initiated discussions with pharmaceutical companies about collaborating on clinical trials in late 2020.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">We also made significant progress in 2020 developing a new CELsignia test intended to diagnose cancers driven by dysregulated RAS signaling. &#160;Dysregulation of RAS signaling, which includes the RAF/MEK/ERK and PI3K/AKT/mTOR pathways, is estimated to drive 30%-40% of all cancers. Pharmaceutical companies have developed numerous drugs that target RAS-involved pathways.&#160; However, the number of interactions amongst RAS-regulated pathways has made it extremely difficult to use molecular tests to identify patients with dysregulated RAS signaling tumors.&#160; The challenge of diagnosing a cancer driven by a dysregulated RAS signaling network is magnified because two or more different pathways are typically involved.&#160; Recent research has also found that RAS mutations play a much less important role in dysregulated RAS signaling than previously thought.&#160; Our CELsignia platform is uniquely suited to untangle the complexity of dysregulated RAS signaling tumors and identify the targeted therapy combination capable of treating it. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Once development of the new RAS test is completed, we intend to add it to our current CELsignia MP Test for breast and ovarian cancer. This next generation CELsignia test would provide an analysis of EGFR/HER1, HER2, HER3, c-MET, PI3K, and RAS-involved signaling activity for each patient tumor specimen received. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">In addition to our CELsignia tests for HER2-negative breast cancer and ovarian cancer, we expect to develop CELsignia tests to diagnose eight new potential cancer sub-types we have discovered in lung, ovarian, kidney, and bladder cancers. Approved or investigational drugs are currently available to treat these new potential cancer sub-types. We expect to launch these additional tests on a staggered basis over the next few years while continuing our research to identify additional new cancer sub-types.&#160; Our overall commercialization strategy is to develop diagnostics that expand the patient population eligible for targeted therapies. We are collaborating with Genentech, Pfizer, Novartis, and Puma to conduct five Phase 2 clinical trials to evaluate the efficacy of our collaboration partners&#8217; targeted therapies in patients selected with one of our CELsignia tests. The goal of these trials is to support the development of five potential new drug indications to treat patient groups found responsive by our CELsignia test to their approved targeted therapies. Our CELsignia MP Test analyzes HER2, c-MET, and PI3K signaling activity using a patient&#8217;s live tumor cells. These tests have the potential to diagnose oncogenic signaling activity undetectable by molecular tests in up to one in three HER2-negative breast cancer patients and one in five ovarian cancer patients. We intend to use this test to identify HER2-negative breast cancer patients whose tumors have either abnormal HER2 signaling, abnormal c-Met and HER2 signaling, or abnormal PI3K signaling. Our overall commercialization strategy for our CELsignia CDx is to collaborate with pharmaceutical companies to advance the clinical development of their targeted therapies with the eventual goal of obtaining FDA approval of a new drug indication. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Our current programs include: </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Herceptin<sup>&#174;</sup> and Perjeta<sup>&#174;</sup> for HER2-negative early-stage breast cancer patients. Each drug targets the HER2 receptor and is owned by Genentech, Inc. These drugs are only currently approved to treat cancer patients who are HER2+.</td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Vizimpro<sup>&#174;</sup> and Xalkori<sup>&#174;</sup> for HER2-negative late-stage breast cancer patients. Vizimpro, a pan-HER inhibitor, and Xalkori, a c-Met inhibitor, are owned by Pfizer, Inc. These drugs are currently only approved to treat patients with non-small cell lung cancer who have specific molecular mutations.</td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Tabrecta<sup>&#174;</sup> and Nerlynx<sup>&#174;</sup> for HER2-negative late-stage breast cancer patients. Tabrecta, a c-Met inhibitor, is owned by Novartis AG and Nerlynx is owned by Puma Biotechnology, Inc. Tabrecta is currently only approved to treat patients with non-small cell lung cancer who have specific molecular mutations. Nerlynx is currently only approved to treat HER2+ breast cancer patients.</td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Nerlynx and Faslodex for ER+/HER2-negative late-stage breast cancer patients. Faslodex, a selective estrogen receptor degrader, is owned by AstraZeneca.</td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Nerlynx for ER-/HER2- early-stage breast cancer patients.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em><strong>Interventional Clinical Trials in Process using a CELsignia Test to Select Patients for Treatment</strong></em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>FACT-1 Clinical Trial to Evaluate Efficacy of Genentech&#8217;s HER2 Targeted Therapies</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt">We are collaborating with NSABP and Genentech to evaluate the efficacy and safety of Genentech&#8217;s drugs, Herceptin (trastuzumab) and Perjeta (pertuzumab), and chemotherapy in breast cancer patients selected with our CELsignia test. NSABP serves as the sponsor and principal investigator of the trial and is responsible for, among other things, setting up clinical sites, enrolling patients, and managing clinical data. NSABP contracted separately with Genentech to provide Herceptin and Perjeta for the study at no cost. We are performing the CELsignia HER2 Pathway Activity Test to select patients for the trial and are providing the funding for the trial&#8217;s patient-related costs. Completing this trial will require, among other things, successful enrollment of patients, meeting trial endpoint goals, and completing the trial in a timely manner. As of February 2021, there were 27 activated sites participating in the FACT-1 trial. The enrollment rate of patients has fallen short of the expectations NSABP originally provided. Based on NSABP&#8217;s updated estimates of patient enrollment rates to reflect the impact of COVID-19, we expect to obtain interim results&#160;late 2021 or&#160;early 2022 and final results approximately nine months later. The goal is to demonstrate that patients who have an abnormal HER2 signaling pathway, as identified by our CELsignia test, respond to treatment with a matching targeted therapy.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt">&#160;A synopsis of the trial protocol is provided below.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FACT-1 Clinical Trial Synopsis</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;border-top:#000000 1px solid;border-right:#000000 1px solid;border-bottom:#000000 1px solid;border-left:#000000 1px solid;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-RIGHT: #000000 1px solid;width:16%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;"><strong>Primary Objective</strong></p></td><td style="width:56%;vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">To evaluate the efficacy of neoadjuvant HER2 drug treatment in early-stage HER2-negative breast cancer patients with abnormal HER2 signaling</p></td></tr><tr style="height:15px"><td style="BORDER-RIGHT: #000000 1px solid;width:16%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;"><strong>Sites/Sponsor</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Subjects</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Endpoint </strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Investigational Arm</strong></p></td><td style="width:56%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;">Multi-center in collaboration with NSABP and Genentech</p><p style="MARGIN: 0px; text-align:justify;">54 HER2-negative early-stage breast cancer (26 ER+/28ER-) </p><p style="MARGIN: 0px; text-align:justify;">Pathological complete response (ypT0/Tis ypN0) </p><p style="MARGIN: 0px; text-align:justify;">AC-T + Trastuzumab + Pertuzumab</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>FACT-2 Clinical Trial to Evaluate Efficacy of Puma&#8217;s HER2 Targeted Therapy</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt">We are collaborating with Puma and West Cancer Center to conduct a Phase II single-arm interventional trial to evaluate the efficacy and safety of Puma&#8217;s drug, Nerlynx (neratinib), and chemotherapy in breast cancer patients selected with our CELsignia test. West Cancer Center serves as the sponsor and principal investigator of the trial and is responsible for enrolling patients and managing clinical data. Puma supplies Nerlynx, its pan-HER inhibitor currently approved by the FDA for extended adjuvant treatment of early-stage HER2-positive breast cancer. We provide the CELsignia HER2 Pathway Activity Test to select triple-negative breast cancer patients who have hyperactive HER2-driven signaling pathways for the trial and will initially fund the patient-related trial costs. Based on West Cancer Center estimates to reflect the impact of COVID-19, we expect interim results from this trial in late&#160;2021 or&#160;early 2022 and final results approximately nine months later. The goal of the trial is to demonstrate that triple-negative breast cancer patients who have a hyperactive HER2 signaling tumor, as identified by the CELsignia test, respond to treatment with Nerlynx, a matching HER2 therapy. We believe there is significant clinical interest in finding new diagnostic tests and targeted therapies for triple-negative breast cancer patients because fewer drug treatment options are available to them relative to other breast cancer sub-types. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt">A synopsis of the trial protocol is provided below.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FACT-2 Clinical Trial Synopsis</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;border-top:#000000 1px solid;border-right:#000000 1px solid;border-bottom:#000000 1px solid;border-left:#000000 1px solid;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-RIGHT: #000000 1px solid;width:16%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;"><strong>Primary Objective</strong></p></td><td style="width:56%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;">To evaluate the efficacy of neoadjuvant HER2 drug treatment in early-stage triple-negative breast cancer patients with abnormal HER2 signaling</p></td></tr><tr style="height:15px"><td style="BORDER-RIGHT: #000000 1px solid;width:16%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;"><strong>Sites/Sponsor</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Subjects</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Endpoint </strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Investigational</strong> <strong>Arm</strong></p></td><td style="width:56%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;">Multi-center in collaboration with West Cancer Center and Puma</p><p style="MARGIN: 0px; text-align:justify;">27 early-stage triple-negative breast cancer with abnormal HER2 signaling</p><p style="MARGIN: 0px; text-align:justify;">Pathological complete response (ypT0/Tis ypN0) </p><p style="MARGIN: 0px; text-align:justify;">Neratinib then Paclitaxel + Carboplatin + Neratinib</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>FACT-3 Clinical Trial to Evaluate Efficacy of Pfizer&#8217;s pan-HER and c-Met Targeted Therapies</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt">In January 2021, we announced a clinical trial collaboration with Sarah Cannon Research Institute, a global leader in cancer research, and Pfizer Inc., a global biopharmaceutical company, to conduct a Phase II clinical trial. This open-label Phase II trial will evaluate the efficacy and safety of two Pfizer targeted therapies, Vizimpro (dacomitinib), a pan-HER inhibitor, and Xalkori (crizotinib), a c-Met inhibitor, in previously treated metastatic HER2-negative breast cancer patients selected with our CELsignia Multi-Pathway Activity Test. Under the agreement, Sarah Cannon will serve as the sponsor and principal investigator of the trial and will be responsible for enrolling patients and managing clinical data. Pfizer will supply Vizimpro and Xalkori, targeted therapies currently approved by the FDA to treat metastatic non-small cell lung cancer. We will provide our CELsignia Multi-Pathway Activity Test to select HER2- metastatic breast cancer patients who have hyperactive HER2 and c-Met signaling pathways for the trial and will fund the patient-related trial costs. Based on the Sarah Cannon Research Institute&#8217;s estimates of patient enrollment rates, we expect to obtain interim results 12 to 15 months after the protocol is activated and final results 12-15 months later. We expect enrollment to begin in the second or third&#160;quarter of 2021. The goal of the trial is to demonstrate that previously treated HER2-negative metastatic breast cancer patients who have hyperactive HER2 and c-Met signaling tumors, as identified by the CELsignia test, respond to treatment with Vizimpro in combination with Xalkori. We believe there is significant clinical interest in finding new diagnostic tests and targeted therapies for metastatic HER2-negative breast cancer patients whose disease progressed on prior therapies. The anti-tumor effect of blockading EGFR/HER1, HER2, HER3 and c-Met pathways when the HER2 and c-Met pathways are hyperactive has been demonstrated in animal models. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt">A synopsis of the trial protocol is provided below.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FACT-3 Clinical Trial Synopsis</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;border-top:#000000 1px solid;border-right:#000000 1px solid;border-bottom:#000000 1px solid;border-left:#000000 1px solid;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-RIGHT: 1px solid;width:16%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;"><strong>Primary Objective</strong></p></td><td style="width:56%;vertical-align:top;"><p style="MARGIN: 0px; text-align:left;">To assess the efficacy of combined Vizimpro plus Xalkori in previously treated HER2-negative metastatic breast cancer subjects with hyperactive HER2 and c-Met signaling tumors</p></td></tr><tr style="height:15px"><td style="BORDER-RIGHT: 1px solid;width:16%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;"><strong>Sites/Sponsor</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Subjects</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Endpoint </strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Investigational</strong> <strong>Arm</strong></p></td><td style="width:56%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;">Multi-center in collaboration with Sarah Cannon Research Institute and Pfizer </p><p style="MARGIN: 0px; text-align:justify;">23 late-stage HER2-negative breast cancer with abnormal HER2/c-Met signaling</p><p style="MARGIN: 0px; text-align:justify;">Objective response using RECIST 1.1 criteria</p><p style="MARGIN: 0px; text-align:justify;">Vizimpro and Xalkori </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>FACT-4 Clinical Trial to Evaluate Efficacy of Puma&#8217;s HER2 Targeted Therapy </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt">In December 2020, we announced a clinical trial collaboration with Massachusetts General Hospital and Puma Biotechnology, a biopharmaceutical company, to conduct a Phase II clinical trial. This open-label Phase II trial will evaluate the efficacy and safety of Puma&#8217;s drug, Nerlynx (neratinib), and Faslodex (fulvestrant), an AstraZeneca drug, in previously treated metastatic HR-positive (HR+), HER2-negative breast cancer patients selected with our CELsignia HER2 Pathway Activity Test. Under the agreement, Massachusetts General Hospital will serve as the sponsor and the principal investigator of this study, while the UCLA Jonsson Comprehensive Cancer Center and the Vanderbilt-Ingram Cancer Center will serve as co-sponsors. Each of these institutions is amongst the United States&#8217; 51 NCI-Designated Comprehensive Cancer Centers tasked with developing new approaches to diagnosing and treating cancer. Puma will supply Nerlynx, its HER2 inhibitor currently approved by the FDA for early and late-stage HER2-positive breast cancer. We will provide our CELsignia HER2 Pathway Activity Test to select HR+, HER2-negative metastatic breast cancer patients who have hyperactive HER2-driven signaling pathways for the trial and will fund the patient-related trial costs. Based on Massachusetts General Hospital&#8217;s estimates of patient enrollment rates, we expect to obtain interim results 12 to 15 months after the protocol is activated and final results 12 to 15 months later. We expect enrollment to begin in the second quarter of 2021. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt">The goal of the trial is to demonstrate that previously treated HR+, HER2-negative metastatic breast cancer patients who have hyperactive HER2 signaling tumors, as identified by the CELsignia test, respond to treatment with Nerlynx in combination with Faslodex, a hormonal therapy that targets the estrogen receptor. We believe there is significant clinical interest in finding new diagnostic tests and targeted therapies for metastatic HR+, HER2-negative breast cancer patients whose disease progressed on prior therapies. Of particular interest are new therapeutic combinations that can overcome resistance to anti-estrogen therapies like Faslodex. The blockade of estrogen receptor and HER2 pathways when the HER2 pathway is hyperactive using a combination of Neratinib and Faslodex has been demonstrated in animal models. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt">A synopsis of the trial protocol is provided below.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FACT-4 Clinical Trial Synopsis</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;border-top:#000000 1px solid;border-right:#000000 1px solid;border-bottom:#000000 1px solid;border-left:#000000 1px solid;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-RIGHT: 1px solid;width:16%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;"><strong>Primary Objective</strong></p></td><td style="width:56%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;">To assess the efficacy of combining Nerlynx plus Faslodex in previously treated metastatic HR-positive, HER2-negative patients with hyperactive HER2 signaling tumors</p></td></tr><tr style="height:15px"><td style="BORDER-RIGHT: 1px solid;width:16%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;"><strong>Sites/Sponsor</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Subjects</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Endpoint </strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Investigational</strong> <strong>Arm</strong></p></td><td style="width:56%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;">Multi-center in collaboration with Mass General and Puma </p><p style="MARGIN: 0px; text-align:justify;">23 late-stage HR+/HER2-negative breast cancer with abnormal HER2 signaling</p><p style="MARGIN: 0px; text-align:justify;">Objective response using RECIST 1.1 criteria</p><p style="MARGIN: 0px; text-align:justify;">Nerlynx and Faslodex</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>FACT-6 Clinical Trial to Evaluate Efficacy of Novartis&#8217;s c-Met Inhibitor and Puma&#8217;s pan-HER inhibitor</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt">In March 2021, we announced a clinical trial collaboration with MD Anderson, a global leader in cancer research, Novartis AG, a global biopharmaceutical company, and Puma Biotechnology, to conduct a Phase I/II clinical trial. This open-label Phase I/II trial will evaluate the efficacy and safety of Novartis&#8217; c-Met inhibitor, Tabrecta (capmatinib), and Puma&#8217;s pan-HER inhibitor, Nerlynx (neratinib), in previously treated metastatic HER2-negative breast cancer patients selected with our CELsignia Multi-Pathway Activity Test. Under the agreement, MD Anderson will serve as the sponsor of the trial and will be responsible for enrolling patients and managing clinical data. Novartis will supply Tabrecta, a targeted therapy currently approved by the FDA to treat metastatic non-small cell lung cancer. Puma will supply Nerlynx, a targeted therapy currently approved by the FDA to treat HER2+ metastatic breast cancer. We will provide our CELsignia Multi-Pathway Activity Test to select HER2- metastatic breast cancer patients who have hyperactive HER2 and c-Met signaling pathways for the trial and will fund the patient-related trial costs. Based on MD Anderson&#8217;s estimates of patient enrollment rates, we expect to obtain interim results 12 to 15 months after the protocol is activated and final results 12-15 months later. We expect enrollment to begin in the second or third quarter of 2021. The goal of the trial is to demonstrate that previously treated HER2-negative metastatic breast cancer patients who have hyperactive HER2 and c-Met signaling tumors, as identified by the CELsignia test, respond to treatment with Tabrecta in combination with Nerlynx. We believe there is significant clinical interest in finding new diagnostic tests and targeted therapies for metastatic HER2-negative breast cancer patients whose disease progressed on prior therapies. The anti-tumor effect of blockading EGFR/HER1, HER2, HER3 and c-Met pathways when the HER2 and c-Met pathways are hyperactive has been demonstrated in animal models. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:33.75pt">A synopsis of the trial protocol is provided below.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FACT-6 Clinical Trial Synopsis</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;border-top:#000000 1px solid;border-right:#000000 1px solid;border-bottom:#000000 1px solid;border-left:#000000 1px solid;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-RIGHT: 1px solid;width:16%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;"><strong>Primary Objective</strong></p></td><td style="width:56%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;">To assess the efficacy of combined Tabrecta plus Nerlynx in previously treated HER2-negative metastatic breast cancer subjects with hyperactive HER2 and c-Met signaling tumors</p></td></tr><tr style="height:15px"><td style="BORDER-RIGHT: 1px solid;width:16%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;"><strong>Sites/Sponsor</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Subjects</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Endpoint </strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Investigational</strong> <strong>Arm</strong></p></td><td style="width:56%;vertical-align:top;"><p style="MARGIN: 0px; text-align:justify;">Multi-center in collaboration with MD Anderson, Novartis, and Puma</p><p style="MARGIN: 0px; text-align:justify;">Up to 48 late-stage HER2-negative breast cancer with abnormal HER2/c-Met signaling</p><p style="MARGIN: 0px; text-align:justify;">Objective response using RECIST 1.1 criteria</p><p style="MARGIN: 0px; text-align:justify;">Tabrecta and Nerlynx</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">In conjunction with the development of our CELsignia tests, we will seek collaborations with pharmaceutical companies to field clinical trials to advance the clinical development of their targeted therapies with the eventual goal of obtaining U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of a new drug indication.&#160; Collaborations are expected to involve initially Phase I or Phase II interventional clinical trials to evaluate the efficacy of our collaboration partners&#8217; targeted therapies patients selected with one of our CELsignia tests.&#160; We are currently evaluating, or expect to evaluate, a variety of targeted therapies in combination with other targeted therapies, hormonal therapies, of chemotherapies, including: i) pan-HER and c-Met inhibitors; ii) pan-HER inhibitors and endocrine therapy; iii) pan-HER inhibitors and chemotherapies; and iv) PI3K inhibitors and endocrine therapy.&#160; The FDA has approved three c-Met inhibitors, six HER-family inhibitors, and four PI3K inhibitors for cancer treatment. Additional c-Met, HER-family, and PI3K inhibitors are being evaluated in on-going clinical trials. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Gedatolisib &#8211; An Internal Drug Candidate</em> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Overview</em> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Gedatolisib (PF-05212384) is a potent, reversible dual inhibitor that selectively targets PI3K and mTOR. Gedatolisib was originally developed by Wyeth and clinical development was continued by Pfizer after it acquired Wyeth. We exclusively licensed global rights to gedatolisib from Pfizer in April 2021. An on-going Phase 1b trial evaluating patients with ER+/HER2- metastatic breast cancer was initiated in 2016 and subsequently enrolled 138 patients. Patient enrollment for the four expansion arms of the trial is complete. Based on the favorable preliminary results reported to date from the Phase 1b trial, we intend to initiate, subject to feedback from the FDA, a Phase 2/3 clinical trial evaluating gedatolisib in combination with palbociclib and an endocrine therapy in patients with ER+/HER2- advanced or metastatic breast cancer in the first half of 2022. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Background on Breast Cancer and Current Treatments </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Breast cancer is the most prevalent cancer in women, accounting for 30% of all female cancers and 13% of cancer-related deaths in the United States. The National Cancer Institute estimated that approximately 270,000 new cases of breast cancer would be diagnosed in the United States in 2019, and approximately 42,000 breast cancer patients would die of the disease. Approximately 190,000, or 70%, of these new cases are for ER+/HER2- breast cancer. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Four different breast cancer subtypes are currently identified using molecular tests that determine the level of ER and HER2 expression. About 70% of breast cancers are ER+/HER2-, which is indicative of hormone dependency. Despite progress in treatment strategies, metastatic ER+/HER2- breast cancer (mBC) remains an incurable disease, with a median overall survival (OS) of three years and a five-year survival rate of 25%. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Four different classes of targeted therapies are currently used to treat ER+/HER2- tumors. These drugs generated revenues of nearly $10 billion globally in 2019.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in"><strong><em>Endocrine-based therapies</em></strong><em>. </em>Selective ER modulators (tamoxifen), selective ER degrader (fulvestrant), and aromatase inhibitors (AIs) are established standards of care in women with HR+/HER2- mBC. The choice between these regimens when treating mBC depends on the type and duration of prior endocrine therapy treatment as well as the time elapsed from the end of prior endocrine therapy. Besides the well-known efficacy of these treatments as first-line therapies in women without visceral crisis, most patients develop endocrine resistance leading to therapeutic failure. Primary endocrine resistance is defined as relapse during the first two years of prior endocrine therapy or progressive disease within the first six months of first-line endocrine therapy for mBC. Secondary resistance is present (1) when a relapse occurs after the first two years of adjuvant endocrine therapy; (2) when a relapse occurs within 12 months of completing adjuvant endocrine therapy; or (3) when a progressive disease occurs after more than six months from the beginning of endocrine therapy for mBC. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Several mechanisms are responsible for endocrine resistance, including the dysregulation of multiple components of the ER pathway (aberration in ER expression, over-expression of ER co-activators, and down-regulation of co-repressors), altered regulation of signaling molecules involved in cell cycle or cell survival, and the activation of escape pathways that can provide cell replication. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in"><strong><em>CDK4/6 inhibitors</em></strong>. One common mechanism of resistance to endocrine therapies is the activation of the cyclin-dependent kinases 4 and 6 (CDK4/6) pathway. These kinases drive cell cycle progression and division. Inhibiting activation of the CDK4/6 prevents estrogen from activating the cyclin D1-CDK4/6-Rb complex, thus blockading an important mechanism of resistance to endocrine therapies. The resulting cell cycle arrest induces a significant delay in tumor progression. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">CDK 4/6 inhibitors were first introduced in 2015. Endocrine therapies administered in combination with oral CDK4/6 inhibitors lead to improved clinical efficacy when compared with endocrine therapies as monotherapy. In two randomized, double-blind clinical trials, treatment of HR+/HER2- advanced breast cancer patients with a combination of palbociclib and either letrozole or fulvestrant demonstrated a significant increase in the median progression free survival (PFS) period for patients who received palbociclib in combination with either letrozole or fulvestrant compared to patients who received letrozole or fulvestrant as single agents. These patients had previously progressed on or after prior endocrine therapy. Worldwide sales of currently marketed CDK4/6 inhibitors, which are indicated for the treatment of breast cancer, were $6.0 billion in 2019, and are expected to grow to $14.4 billion in 2026. Worldwide sales of Pfizer&#8217;s leading CDK4/6 inhibitor, palbocicib, or Ibrance&#174;, were $5.4 billion in 2020.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in"><strong><em>PI3K inhibitors</em></strong>. Another common mechanism of resistance to endocrine inhibitors is the activation of the PI3K pathway, an important intracellular pathway that regulates cell growth and metabolism. Approximately one third of HR+ breast cancer tumors resistant to endocrine therapy harbor activating mutations of the catalytic subunit of PI3K, referred to as PIK3CA. Fulvestrant used in combination with alpelisib, an oral PI3K-&#945; inhibitor marketed as Piqray&#174; by Novartis approved by the FDA in May 2019, has demonstrated improved clinical efficacy in patients whose tumors had a PIK3CA mutation and had not yet received treatment with a CDK4/6 inhibitor. These patients had previously progressed on or after prior endocrine therapy. Worldwide sales of Piqray&#174;, currently the only FDA-approved for the treatment of breast cancer, limited to patients with PIK3CA mutations, were approximately $320.0 million in 2020. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in"><strong><em>mTOR inhibitors</em></strong>. Similar to CDK4/6 and PI3K, the mTOR pathway has also been identified as a mechanism of resistance to endocrine therapy. Everolimus is an mTOR inhibitor that is currently approved by the FDA for the treatment of HR+/HER2- advanced breast cancer in combination with exemestane, an AI. Everolimus has also shown clinical benefit in combination with fulvestrant. These patients had previously progressed on or after prior AI therapy. Worldwide sales in breast cancer of everolimus, marketed as Afinitor&#174; by Novartis and a leading mTOR inhibitor, were approximately $831.0 million in 2019. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>The Importance of Targeting PI3K and mTOR in Cancer</em> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Activation of the PI3K/mTOR pathway has been implicated in a wide variety of human cancers, involving either activating mutations, or other unknown drivers of pathway amplification. These include cancers of the breast, prostate, endometrial, colon, rectum, and lung, among others. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">PI3K constitutes a lipid kinase family involved in the regulation of diverse cellular processes, including cell proliferation, survival, cytoskeletal organization, and glucose transport. Class I PI3Ks are of particular therapeutic interest. They are heterodimers, comprising a catalytic (p110&#945;, p110&#946;, p110&#948;, or p110&#947;) and a regulatory (p85&#945;, p55&#945;, p50&#945;, p85&#946;, p55&#947;, or p101) subunit. Oncogenic PI3K signaling is activated by cell-surface receptors such as receptor tyrosine kinases, G-protein-coupled receptors, and also by well-known oncogenic proteins such as Ras. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Activities associated with PI3K involve complex essential cell regulatory mechanisms including feedforward and feedback signaling loops. Overactivation of the pathway is frequently present in human malignancies and plays a key role in cancer progression. Each of the four catalytic isoforms of class I PI3K preferentially mediate signal transduction and tumor cell survival based on the type of malignancy and the genetic or epigenetic alterations an individual patient harbors. For example, studies have demonstrated the p110&#945; catalytic isoform is necessary for the growth of tumors driven by PIK3CA mutations and/or oncogenic RAS and receptor tyrosine kinases; the p110&#946; catalytic isoform mediates tumorigenesis arising from the loss of the dephosphorylase activity of PTEN; and the p110&#948; catalytic isoform is highly expressed in leukocytes, making it a desirable target for inhibition in the treatment of hematologic malignancies. Due to the multiple subcellular locations, activities, and importance of the different PI3K complexes in regulating many types of cancer cell proliferation, control of PI3K activity is an important target in cancer therapy. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">mTOR is as a critical effector in cell-signaling pathways commonly dysregulated in human cancers. The mTOR signaling pathway integrates both intracellular and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation, and survival. mTOR is a serine/threonine protein kinase, a downstream effector of PI3K, and regulated by hormones, growth factors, and nutrients, that is contained in two functionally distinct protein assemblies: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 belongs to a complex network of regulatory feedback loops, and once certain levels of activation are reached, is normally responsible for limiting the proliferative signals transmitted by upstream effectors such as PI3K/AKT activity. Equally complex mTORC2 regulates AKT phosphorylation, GSK3&#946;, and control over glycolysis, and participates in organizing the cellular actin cytoskeleton. In addition, mTORC1 activation leads to the direct reduction of mTORC2 activity and mTOR can activate the functional domain of the ER, leading to ligand-independent hormone receptor activation. In cancer, dysfunctional signaling leads to various constitutive activities of mTOR complexes, making mTOR a good therapeutic target.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">The illustration below depicts the PI3K/AKT/mTOR pathway and various pathway activation mechanisms.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="celc_10qimg7.jpg" alt="celc_10qimg7.jpg" /></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>PI3K/mTOR as Resistance Mechanism to Endocrine and CDK4/6 Inhibitors </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">The upregulation of the PI3K/AKT/mTOR pathway promotes hormone dependent and independent ER transcriptional activity, which contributes to endocrine resistance, leading to tumor cell growth, survival, motility, and metabolism. It has also been demonstrated in vivo that PI3K and mTOR inhibition can restore sensitivity to endocrine therapy, providing a strong rationale for the combination of the two therapies. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">In addition, the PI3K/AKT/mTOR pathway, like other mitogenic pathways, can also promote the activities of cyclin D and CDK4/6 to drive proliferative cell cycling. Internal preclinical studies conducted by Pfizer provided evidence in cell-line xenograft models that the combination of PI3K and CDK4/6 inhibitors may overcome both intrinsic and adaptive resistance to endocrine therapy, leading to tumor regressions. In an MCF7 xenograft model (ER+/HER2-/PIK3CA mutant) the combination of gedatolisib with palbociclib and fulvestrant led to durable tumor regressions. Importantly, tumors regressed to minimal volumes within 20 days of triplet therapy, and continued to remain dormant, without further therapy, for up to 90 days. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="celc_10qimg8.jpg" alt="celc_10qimg8.jpg" /></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Advantages of Gedatolisib over other PI3K and mTOR inhibitors</em> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">The important role the PI3K/AKT/mTOR pathway plays in cancer has led to significant investment in the development of many different PI3K and mTOR inhibitors for solid tumors. However, developing efficacious and well-tolerated therapies that target this pathway has been challenging. This reflects the inherent adaptability and complexity of the PI3K pathway, where numerous feedforward and feedback loops, crosstalk with other pathways, and compensatory pathways enable resistance to PI3K inhibition. Another major hurdle for the development of PI3K pathway inhibitors has been the inability to achieve optimal drug-target blockade in tumors while avoiding undue toxicities in patients. These challenges may explain why PI3K and mTOR inhibitors have not yielded the outstanding clinical activity many researchers expected. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">We believe there is significant potential for gedatolisib to address previously treated breast cancer tumors and has the potential to be used in other tumor types where the PI3K/AKT/mTOR pathway is either: i) driving tumorigenesis directly; ii) cooperating with other dysregulated signaling pathways; or iii) a mechanism of resistance to other drug therapies. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">As a result, we believe gedatolisib&#8217;s unique mechanism of action and intravenous formulation offer distinct advantages over currently approved and investigational therapies that target PI3K or mTOR alone or together. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:2%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Overcomes drug resistance that can occur with isoform-specific PI3K inhibitors. </strong></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Gedatolisib is a pan-class I isoform PI3K inhibitor with low nanomolar potency for the p110&#945;, p110&#946;, p110&#947;, and p110&#948; isoforms. Each isoform is known to preferentially affect different signal transduction events that involve tumor cell survival, depending upon the aberrations associated with the linked pathway. A pan-PI3K inhibitor can thus treat tumors harboring abnormalities that signal through different PI3K isoforms, which would potentially induce anti-tumor activity in a broader population of patients than an isoform-specific PI3K inhibitor. In addition, it has been reported that inhibition of one PI3K isoform may be offset by the increased activity of the other isoforms through different adaptive mechanisms. Inhibiting all four PI3K isoforms, as gedatolisib does, can thus prevent the confounding effect of isoform interaction that may occur with isoform-specific PI3K inhibitors.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:2%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Overcomes paradoxical activation of PI3K induced by mTOR inhibition.</strong> </td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">As a potent inhibitor of mTOR, in addition to PI3K, gedatolisib, inhibits the PI3K/AKT/mTOR pathway both upstream and downstream of AKT. Furthermore, it has been demonstrated that the PI3K pathway is activated following selective mTOR inhibition by relief of normal feedback regulatory mechanisms, thus providing a compelling rationale for simultaneous inhibition of PI3K and mTOR. </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:2%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Better tolerated by patients than oral PI3K and mTOR drugs.</strong> </td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Gedatolisib is administered intravenously (IV) once weekly or on a four-week cycle of three weeks-on, one week-off, in contrast to the orally administered pan-PI3K or dual PI3K/mTOR inhibitors that are no longer being clinically developed. Oral pan-PI3K or PI3K/mTOR inhibitors have repeatably been found to induce significant side effects that were not well tolerated by patients. This typically leads to a high proportion of patients requiring dose reductions or treatment discontinuation. The challenging toxicity profile of these drug candidates ultimately played a significant role in the decisions to halt their development, despite showing promising efficacy. By contrast, gedatolisib stabilizes at lower concentration levels in plasma compared to orally administered PI3K inhibitors, resulting in less toxicity, while maintaining concentrations sufficient to inhibit PI3K/AKT/mTOR signaling. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Isoform-specific PI3K inhibitors administered orally were developed to reduce toxicities in patients. While the range of toxicities associated with isoform-specific inhibitors is narrower than oral pan-PI3K or PI3K/mTOR inhibitors, administering them orally on a continuous basis still leads to challenging toxicities. The experience with an FDA approved oral p110-&#945; specific inhibitor, Piqray, illustrates the challenge. In its Phase 3 pivotal trial Piqray was found to induce a Grade 3 or 4 adverse event related to hyperglycemia in 39% of patients evaluated. In addition, 26% of patients discontinued treatment. By contrast, in the 103-patient dose expansion portion of the Phase 1b clinical trial with gedatolisib, only 7% of patients experienced Grade 3 or 4 hyperglycemia and less than 10% discontinued treatment. </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Clinical Experience with Gedatolisib</em> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">As of January 11, 2021, 457 patients with solid tumors have received gedatolisib in eight clinical trials sponsored by Pfizer. Of the 457 patients, 129 were treated with gedatolisib as a single agent in three clinical trials. The remaining 328 patients received gedatolisib in combination with other anti-cancer agents in five clinical trials. Additional patients received gedatolisib in combination with other anti-cancer agents in nine investigator sponsored clinical trials. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in"><span style="text-decoration:underline">Phase 1 First-in-Human Study </span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Pfizer conducted a Phase 1, open-label, dose-escalation first-in human study of single-agent gedatolisib in patients with advanced solid tumors. The primary objective of Part 1 of the study was to determine the safety, tolerability, and maximum tolerated dose (MTD) of single-agent gedatolisib administered once weekly as an intravenous (IV) infusion. Seventy-seven patients with advanced solid tumors received doses of gedatolisib and the MTD was determined to be 154 mg IV once weekly (n = 42). Subsequent analysis determined that the recommended Phase 2 dose could be increased to 180 mg IV once weekly. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">At the MTD, the majority of patients enrolled in the MTD group experienced only grade 1 treatment-related adverse events (AEs). Grade 3 treatment-related adverse events were noted in 23.8% of patients, and the most frequently reported included mucosal inflammation and stomatitis (7.1%), increased ALT (7.1%), and increased AST (4.8%). No treatment-related AEs of grade 4 or 5 severity were reported at any dose level. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in"><span style="text-decoration:underline">Phase 1b ER+/HER2- mBC Clinical Trial Results (preliminary)</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">In 2016, Pfizer initiated a Phase 1b trial dose-finding trial with an expansion portion for safety and efficacy to evaluate gedatolisib when added to either the standard doses of palbociclib plus letrozole or palbociclib plus fulvestrant in patients with ER+/HER2- metastatic breast cancer. PI3K mutation status was not used as an eligibility criterion. Patient enrollment for the trial is complete. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The illustration below depicts how the combination of gedatolisib, palbociclib, and fulvestrant is intended to simultaneously block interdependent ER, PI3K, mTOR &amp; CDK signaling pathways in ER+ breast cancer to address ER and CDKi resistance mechanisms. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="celc_10qimg9.jpg" alt="celc_10qimg9.jpg" /></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">A total of 138 patients with ER+/HER2- metastatic breast cancer were dosed in the clinical trial. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:2%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183; </span></p></td><td style="vertical-align:top;">35 patients were enrolled in two dose escalation arms to evaluate the safety and tolerability and determine the MTD of gedatolisib when used in combination with the standard doses of palbociclib and endocrine therapies. The MTD was determined to be 180 mg administered intravenously once weekly.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">103 patients were enrolled in one of four expansion arms (A, B, C, D) to determine if the triplet combination of gedatolisib plus palbociclib and letrozole or gedatolisib plus palbociclib and fulvestrant produced a superior objective response (OR), compared to historical control data of the doublet combination (palbociclib plus endocrine therapy). All patients received gedatolisib in combination with standard doses of palbociclib and endocrine therapy (either letrozole or fulvestrant). In Arms A, B, and C, patients received an intravenous dose of 180 mg of gedatolisib once weekly. In Arm D, patients received an intravenous dose of 180 mg of gedatolisib on a four-week cycle of three weeks-on, one week-off. Objective response was determined using Response Evaluation Criteria in Solid Tumors v1.0, or RECIST v1.0. </td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:2%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#9675;&#160;&#160;&#160; </strong></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Arm A: </strong>mBC with progression and no prior endocrine-based systemic therapy or a CDK4/6 inhibitor in the metastatic setting. First-line endocrine-based therapy for metastatic disease (CDK4/6 treatment naive). </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#9675;&#160;&#160;&#160; </strong></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Arm B: </strong>mBC with progression during one or two prior endocrine-based systemic therapy in the metastatic setting, with no prior therapy with any CDK inhibitor. Second- or third-line endocrine-based therapy for metastatic disease. </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#9675;&#160;&#160;&#160; </strong></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Arm C: </strong>mBC with progression during one or two prior endocrine-based systemic therapies in the metastatic setting and following prior therapy with a CDK inhibitor. Second- or third-line endocrine-based therapy for metastatic disease. </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#9675;&#160;&#160;&#160; </strong></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Arm D: </strong>mBC having progressed on a CDK inhibitor in combination with endocrine therapy as the most recent regimen for metastatic disease. Second- or third-line endocrine-based therapy for metastatic disease. </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">A preliminary analysis for the 103 patients enrolled in the expansion portion of the Phase 1b clinical trial, as of the database cutoff date of January 11, 2021, showed:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:2%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183; </span></p></td><td style="vertical-align:top;">Efficacy analysis for all arms in aggregate:</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:2%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9675;&#160;&#160;&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">60% objective response rate (ORR): 53 of the 88 evaluable patients had either a confirmed or unconfirmed partial response, or PR (48 confirmed, 5 unconfirmed).</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9675;&#160;&#160;&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">75% clinical benefit rate (CBR): 66 of the 88 evaluable patients had either a confirmed PR or had stable disease for 24 weeks.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:2%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183; </span></p></td><td style="vertical-align:top;">Best responses, as measured by RECIST v1.0, are shown in the following chart. The dotted line represents the cutoff for PR (defined as a 30% reduction from baseline). </td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="celc_10qimg10.jpg" alt="celc_10qimg10.jpg" /></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160; </p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:2%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Preliminary safety analysis:</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:2%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9675;&#160;&#160;&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">For all arms in aggregate, all patients experienced at least one Grade 1 or Grade 2 treatment-emergent adverse event. The most commonly reported adverse events regardless of grade and occurring in at least 30% of patients included stomatitis (81%), neutropenia (80%), nausea (75%), fatigue (68%), dysegeusia (46%), vomiting (45%), anemia (40%), diarrhea (34%), decreased appetite (32%), leukopenia (32%).</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9675;&#160;&#160;&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">For all arms in aggregate, the Grade 3 and 4 treatment-emergent adverse events occurring in at least 20% of patients were neutropenia (67%), stomatitis (27%) and rash (20%). Neutropenia is a known class effect of CDK4/6 inhibitors. Stomatitis was reversible in most patients with a steroidal mouth rinse. All grades of treatment-related adverse events related to hyperglycemia was reported in 22% of patients; Grade 3 or 4 hyperglycemia was reported in 7% of patients. Gedatolisib was discontinued in 10% of patients.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:2%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9675;&#160;&#160;&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">For the patients in Arm D, who received the recommended phase two dose, Grade 3 and 4 treatment-emergent adverse events occurring in at least 20% of patients were neutropenia (67%) stomatitis and (22%). All grades of treatment-related adverse events related to hyperglycemia was reported in 22% of patients; Grade 3 or 4 hyperglycemia was reported in 7% of patients.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9675;&#160;&#160;&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Gedatolisib was discontinued in 7% of patients.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9675;&#160;&#160;&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">22 patients were continuing to receive gedatolisib in combination with the other study drugs, 17 of whom have been on study treatment for more than two years.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:2%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Preliminary best overall response data for each arm is presented in the table below:</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:92%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="BORDER-TOP: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Arm</strong> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>(evaluable patients)</strong> </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid;width:15%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>A<br />(N=24)</strong> </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid;width:15%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>B<br />(N=12)</strong> </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid;width:15%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>C<br />(N=27)</strong> </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid;width:15%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>D<br />(N=25)</strong> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Patients</strong> </p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1L:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CDKi-Na&#239;ve</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2L+:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CDKi-na&#239;ve</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2L/3L:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CDKi-pretreated</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2L/3L:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Immediately </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">prior CDKi</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Overall Response Rate </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>(evaluable patients) </strong></p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">84%</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">75%<sup><span style="position:relative;top:-3.5pt">1</span></sup> </p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">33%<sup><span style="position:relative;top:-3.5pt">2</span></sup> </p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">60%<sup><span style="position:relative;top:-3.5pt">3</span></sup> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Clinical Benefit Rate </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>(evaluable patients)</strong> </p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">92%</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">92%</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">48% </p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">76%</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;margin-left:auto;line-height:normal;margin-right:auto;width:92%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;">1.<span style="font:7pt times new roman"> Arm A: 20 of the 24 evaluable patients had a confirmed PR. </span></td></tr><tr style="height:15px"><td style="vertical-align:top;">2.<span style="font:7pt times new roman"> Arm B: 9 of the 12 evaluable patients had either a confirmed PR or unconfirmed PR (7 confirmed PR, 2 unconfirmed PR). </span></td></tr><tr style="height:15px"><td style="vertical-align:top;">3.<span style="font:7pt times new roman"> Arm C: 9 of the 27 evaluable patients had either a confirmed PR or unconfirmed PR (7 confirmed PR, 2 unconfirmed PR).</span></td></tr><tr style="height:15px"><td style="vertical-align:top;">4.<span style="font:7pt times new roman"> Arm D: 15 of the 25 evaluable patients had either a confirmed PR or unconfirmed PR (14 confirmed PR, 1 unconfirmed PR). </span></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:2%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Preliminary progression free survival (PFS) data for each arm is presented in the table below:</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:92%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="BORDER-TOP: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Arm</strong> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>(enrolled patients)</strong> </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid;width:15%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>A<br />(N=31)</strong> </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid;width:15%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>B<br />(N=13)</strong> </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid;width:15%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>C<br />(N=32)</strong> </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid;width:15%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>D<br />(N=27)</strong> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Median PFS </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>(months) (95% CI)</strong> </p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&gt;29</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Not Yet Reached)</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11.9</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(3.7, NR)</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5.1</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(3.4, 7.5)</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">13.2</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(9.0, 16.7)</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">In light of the preliminary results reported to date from the Phase 1b trial, we intend to initiate, subject to feedback from the FDA, a Phase 2/3 clinical trial evaluating gedatolisib in combination with palbociclib and an endocrine therapy in patients with ER+/HER2- advanced or metastatic breast cancer in the first half of 2022. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">We expect to use the CELsignia PI3K activity test to help support development of gedatolisib for breast cancer indications. Our internal studies demonstrate how measurement of PI3K-involved signaling may provide a sensitive and specific method of identifying patients most likely to benefit from PI3K inhibitors. We believe CELsignia tests uniquely enable us to pursue indications simultaneously for unselected patient populations and CELsignia selected patient sub-groups. This approach can greatly reduce the risk of pursing an indication for a large, but unselected patient population, as we plan to do for the initial gedatolisib indication. By combining the capabilities of CELsignia PI3K Activity test with a potent pan-PI3K/mTOR inhibitor like gedatolisib, we believe we are uniquely suited to maximize the probability of obtaining regulatory approval to market gedatolisib.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.25in"><span style="text-decoration:underline">Phase 2 Pilot Clinical Trial for HER2+/PIK3CA+ Patients</span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">The Korean Cancer Study Group sponsored a Phase 2 pilot clinical trial to evaluate gedatolisib combined with a trastuzumab biosimilar (Herzuma&#174;), in patients with HER2+/PIK3CA+ metastatic breast cancers whose disease had progressed after treatment with three or more prior HER2 targeted therapy regimens. The clinical trial commenced in December 2019 and interim efficacy data from the first 16 patients enrolled was presented at the San Antonio Breast Cancer Symposium in December 2020. Patients received a trastuzumab biosimilar (8 mg/kg IV for 1st cycle loading dose, and then 6 mg/kg IV every 3 weeks) plus gedatolisib (180 mg, weekly IV). The primary endpoint was objective response, a reduction of at least 30% in tumor volume by RECIST v1.1.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">As of a data cutoff date of October 30, 2020, nine of 16 patients achieved a partial response, an ORR of 56%, and four patients had stable disease. Thirteen of 16 patients thus received either a partial response or stable disease, resulting in a clinical benefit rate of 81%. Best responses are shown in the following chart. The dotted lines represent the cutoff for progressive disease (&gt;20% tumor growth) and for partial response (&gt;30% tumor regression). </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Best Response</strong> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="celc_10qimg11.jpg" alt="celc_10qimg11.jpg" /></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in">* Patient whose target lesion decreased by 63% but a new leptomeningeal seeding occurred. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0.25in">The duration of treatment for the 16 patients evaluated is shown in the chart below. As of the October 30, 2020 data cutoff, 16 patients (80%) remained on therapy. Four patients discontinued treatment, one due to disease progression, one due to an adverse event of Grade 1 diarrhea, one participant decision, and one patient being unable to undergo the required MRI imaging due to a titanium rod implant from non-treatment related worsening of scoliosis. At the time of data cut-off, the median time on treatment for these 20 patients was 10.1 cycles (approximately 10 months) and all 10 patients who had achieved an objective response remained on therapy assessment. At the time of the analysis, nine patients had a continuing response. The dashed lines show the response at 3 months and 6 months.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Duration of Treatment</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="celc_10qimg12.jpg" alt="celc_10qimg12.jpg" /></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Impact of COVID-19 on our Business</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in"><em>Health and Safety </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">To help protect the health and safety of our employees, suppliers and collaborators, we took proactive, aggressive action from the earliest signs of the outbreak. We enacted rigorous safety measures in our laboratory and administrative offices, including implementing social distancing protocols, allowing working from home for those employees that do not need to be physically present in a lab to perform their work, suspending travel, implementing temperature checks at the entrances to our facilities, extensively and frequently disinfecting our workspaces and providing masks to those employees who must be physically present. We expect to continue with these measures until the COVID-19 pandemic is contained and we may take further actions as government authorities require or recommend or as we determine to be in the best interests of our employees, suppliers, and collaborators. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in"><em>Clinical Trials and Collaborations</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">As a result of the COVID-19 pandemic, governmental authorities implemented numerous and constantly evolving measures to try to contain the virus, such as travel bans and restrictions, limits on gatherings, quarantines, shelter-in-place orders, and business shutdowns.&#160; As we continue to advance our clinical trial collaborations, we are in close contact with our current clinical sponsors, and principal investigators, as well as prospective pharmaceutical company and clinical collaborators, to assess the impact of COVID-19 on our trial enrollment timelines and collaboration discussions. Based on delays in the enrollment of patients in our ongoing clinical trials due to the pandemic, we now expect interim results from the FACT-1 and FACT-2 trials to be delayed until late 2021 or early 2022 and final results approximately nine months later. &#160;As the impact of COVID-19 on our industry becomes clearer, we may need to reassess the timing of our anticipated clinical milestones. &#160;Prospective clinical trial collaborations with pharmaceutical companies and sponsors may also be delayed but the impact on the timing of finalizing agreements is not yet known.&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in"><em>Research and Development </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">While our facility currently remains operational, the evolving measures to try to contain the virus have impacted and may further impact our workforce and operations, as well as those of our vendors and suppliers. Our laboratory remains operational as of this date, but, in response to the COVID-19 pandemic, we have implemented protective policies that reduce the number of research and development staff operating in our laboratory at any one time. However, in light of the focus of healthcare providers and hospitals on fighting the virus, several of the clinical sites that provide us tumor tissue for research have halted this service, reducing the number of new tumor tissue specimens we would typically expect to receive. These various constraints may slow or diminish our research and development activities.&#160; In addition, cancer research-related industry meetings, such as the American Association for Cancer Research (AACR), were delayed for several months.&#160; Our submissions to present research results at these meetings were accepted, but the release of the results were postponed in conjunction with the delayed meeting schedules.&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in"><em>Liquidity</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Although there is uncertainty related to the anticipated impact of the recent COVID-19 outbreak on our future results, we believe our existing balance of cash and cash equivalents will be sufficient to meet our cash needs arising in the ordinary course of business for at least the next twelve months.&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Results of Operations</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">We have not generated any revenue from sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not and have never been profitable and have incurred losses in each period since our inception in 2012. For the three months ended March 31, 2021 and 2020, we reported a net loss of approximately $2.8 million and $2.2 million, respectively. &#160;As of March 31, 2021, we had an accumulated deficit of approximately $12.6 million under Celcuity LLC and $29.1 million under Celcuity Inc. As of March 31, 2021, we had cash and cash equivalents of approximately $34.9 million.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Components of Operating Results</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Revenue </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">To date, we have not generated any revenue. Initially, our ability to generate revenue will depend primarily upon our ability to obtain partnership agreements with pharmaceutical companies to provide companion diagnostics for such pharmaceutical partners&#8217; existing or investigational targeted therapies. We expect these partnerships to generate significant revenue from the sale of tests to identify patients eligible for clinical trials, from milestone payments, and, potentially, from royalties on the incremental drug revenues our tests enable. Once a new drug indication is received that requires use of our companion diagnostic to identify eligible patients, we expect to generate revenues from sales of tests to treating physicians. With the execution of the Pfizer license agreement in April 2021, whereby we acquired exclusive world-wide licensing rights to develop and commercialize gedatolisib, we expect to conduct clinical trials to support potential regulatory approval to market gedatolisib.&#160; If we obtain regulatory approvals to market gedatolisib, we expect to generate revenue from sales of the drug for the treatment of breast cancer patients. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Research and Development</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in"><em>&#160;</em>Since our inception, we have primarily focused on research and development of our CELsignia platform, development and validation of our CELsignia tests, and research related to the discovery of new cancer sub-types. Beginning in April 2021, we are also focusing on development of gedatolisib, a PI3K/mTOR targeted therapy. Research and development expenses primarily include: </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">employee-related expenses related to our research and development activities, including salaries, benefits, recruiting, travel and stock-based compensation expenses;</td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">laboratory supplies;</td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">consulting fees paid to third parties;</td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">clinical trial costs;</td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">facilities expenses; and</td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">legal costs associated with patent applications.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Internal and external research and development costs are expensed as they are incurred. As we initiate clinical trials to evaluate efficacy of targeted therapies in cancer patients selected with one of our CELsignia tests and to develop gedatolisib, the proportion of research and development expenses allocated to external spending will grow at a faster rate than expenses allocated to internal expenses.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>General and Administrative </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">General and administrative expenses consist primarily of salaries, benefits and stock-based compensation related to our executive, finance and support functions. Other general and administrative expenses include professional fees for auditing, tax, and legal services associated with being a public company, director and officer insurance and travel expenses for our general and administrative personnel. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Sales and Marketing </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Sales and marketing expenses consist primarily of professional and consulting fees related to these functions. To date, we have incurred immaterial sales and marketing expenses as we continue to focus primarily on the development of our CELsignia platform and corresponding CELsignia tests.&#160; We would expect to begin to incur increased sales and marketing expenses in anticipation of the commercialization of our first CELsignia tests and the commercialization of our first drug, gedatolisib. These increased expenses are expected to include payroll-related costs as we add employees in the commercial departments, costs related to the initiation and operation of our sales and distribution network and marketing related costs.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Interest Expense</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Interest expense is the result of finance lease obligations.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Interest Income </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Interest income consists of interest income earned on our cash, cash equivalents, and investment balances.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Results of Operations</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Increase (Decrease)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="margin:0px"><strong>$</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Percent Change</strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Statements of Operations Data: </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td colspan="4" style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating expenses: </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Research and development </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,236,342</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,847,414</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">388,928</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">General and administrative </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">555,428</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">463,399</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">92,029</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">20</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total operating expenses </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,791,770</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,310,813</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">480,957</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Loss from operations </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,791,770</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,310,813</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(480,957</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other income (expense) </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Interest expense </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(24</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(33</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">n/a</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Interest income </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">388</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">63,851</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(63,463</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(99</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Loss on sale of fixed assets </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(263</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(263</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">n/a</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other income, net </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">101</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">63,818</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(63,716</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(100</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Net loss before income taxes </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,791,668</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,246,995</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(544,673</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">24</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Income tax benefits </p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Net loss </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2,791,668</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2,246,995</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(544,673</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">24</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Research and Development</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Our research and development expenses for the three months ended March 31, 2021 were approximately $2.24 million, representing an increase of approximately $0.39 million, or 21%, compared to the same period in 2020.&#160;&#160;The increase primarily resulted from a $0.06 million increase in compensation related expenses, which included a decrease of approximately $0.04 million of non-cash stock-based compensation, to support development of our CELsignia platform. In addition, other research and development expenses increased $0.33 million due to clinical validation and laboratory studies, and operational and business development activities. &#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Conducting a significant amount of research and development is central to our business model. We plan to increase our research and development expenses for the foreseeable future as we seek to discover new cancer sub-types, develop and validate additional CELsignia tests to diagnose such sub-types and develop gedatolisib. We also expect to incur increased expenses to support companion diagnostic business development activities with pharmaceutical companies as we develop additional CELsignia tests. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>General and Administrative</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Our general and administrative expenses for the three months ended March 31, 2021 were approximately $0.56 million, representing an increase of approximately $0.09 million, or 20%, compared to the same period in 2020. The increase primarily resulted from a $0.08 million increase in professional fees associated with being a public company and director and officer insurance.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">We anticipate that our general and administrative expenses will increase in future periods, reflecting both increased costs in connection with the potential future commercialization of CELsignia tests, an expanding infrastructure, and increased professional fees associated with being a public company.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Interest Expense</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.25in; text-align:justify;">Interest expense for the three months ended March 31, 2021 is related to finance lease liabilities. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Interest Income </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Interest income for the three months ended March 31, 2021 was minimal and represents a decrease of approximately $0.06 million or 99% compared to the same period in 2020. This decrease was primarily the result of lower market interest rates.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Liquidity and Capital Resources </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Since our inception, we have incurred losses and cumulative negative cash flows from operations. Through March 31, 2021, we have raised capital of approximately $13.7 million and $7.5 million through private placements of common equity and unsecured convertible notes, respectively.&#160;&#160;On September 22, 2017, we closed on the initial public offering of our common stock, which generated approximately $23.3 million of additional cash after taking into account underwriting discounts and commissions and offering expenses. &#160;On June 5, 2020, we entered into an At Market Issuance Sales Agreement with B. Riley, FBR, Inc (the &#8220;ATM Agreement&#8221;). The ATM Agreement allowed us to sell shares of common stock up to an aggregate offering price of $10.0 million. Through March 31, 2021, we generated approximately $0.09 million of additional cash through sales pursuant to the ATM Agreement, after taking into account commissions and offering expenses. On February 26, 2021, we completed a follow-on offering of our common stock, which generated approximately $25.8 million of additional cash after taking into account underwriting discounts and offering expenses. In conjunction with the follow-on offering, the ATM Agreement was terminated.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Cash from these capital raising activities has been our primary source of funds for our operations since inception.&#160;&#160;As of March 31, 2021, our cash and cash equivalents were approximately $34.9 million, and we had an accumulated deficit of approximately $12.6 million under Celcuity LLC and approximately $29.1 million under Celcuity Inc. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">We expect that our research and development and general and administrative expenses will increase as we continue to develop our CELsignia platform and additional CELsignia tests, conduct research related to the discovery of new cancer sub-types, conduct clinical trials, develop gedatolisib and pursue other business development activities. We would also expect to incur sales and marketing expenses as we commercialize our CELsignia tests and gedatolisib. We expect to use cash on hand to fund our research and development expenses, capital expenditures, working capital, sales and marketing expenses, and general corporate expenses, as well as for the increased costs associated with being a public company. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Based on our current business plan, we believe that our current cash on hand will provide sufficient cash to finance operations and pay obligations when due for at least the next twelve months. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">We may seek to raise additional capital to expand our business, pursue strategic investments, and take advantage of financing or other opportunities that we believe to be in the best interests of the Company and our stockholders. Additional capital may be raised through the sale of common or preferred equity or convertible debt securities, entry into debt facilities or other third-party funding arrangements. The sale of equity and convertible debt securities may result in dilution to our stockholders and those securities may have rights senior to those of our common shares. Agreements entered into in connection with such capital raising activities could contain covenants that would restrict our operations or require us to relinquish certain rights. Additional capital may not be available on reasonable terms, or at all. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Cash Flows</em></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>&#160;</em></strong></p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(unaudited)</strong></p></td><td style="white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net cash provided by (used in):</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,521,505</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,833,601</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(30,425</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(45,604</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">25,850,921</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,438</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net increase (decrease) in cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">23,298,991</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(1,880,643</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>&#160;</em></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Operating Activities </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Net cash used in operating activities was approximately $2.52 million for the three months ended March 31, 2021 and consisted primarily of a net loss of approximately $2.79 million and working capital changes of approximately $0.28 million, adjusted for non-cash expense items of approximately $0.55 million. The approximately $0.28 million of working capital changes was primarily due to an increase in prepaid assets and a decrease in accrued expenses. Non-cash expense items of approximately $0.55 million primarily consisted of depreciation expense of $0.10 million and $0.45 million of stock-based compensation expense. The net cash used in operating activities was approximately $1.83 million for the three months ended March 31, 2020 and consisted primarily of a net loss of approximately $2.25 million and working capital changes of approximately $0.14 million, offset by non-cash expense items of approximately $0.56 million. The approximately $0.14 million of working capital changes was primarily due to an increase in prepaid assets and decreases in accounts payable. Non-cash expense items of approximately $0.56 million primarily consisted of depreciation expense of $0.10 million and stock-based compensation expense of approximately $0.46 million.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Investing Activities </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Net cash used in investing activities for the three months ended March 31, 2021 was approximately $0.03 million and consisted of purchases of property and equipment. Net cash used in investing activities for the three months ended March 31, 2020 was approximately $0.05 million and consisted of purchases of property and equipment. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Financing Activities </em></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Net cash provided by financing activities for the three months ended March 31, 2021 was approximately $25.85 million and primarily reflects net proceeds from the sale of shares of our common stock through a follow-on offering. The net cash used by financing activities for the three months ended March 31, 2020 was minimal and primarily reflects payments for finance leases.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Off-Balance Sheet Arrangements</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">We do not currently have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Recent Accounting Pronouncements</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed in Note 2 to our unaudited condensed financial statements included in Item 1 of Part I of this Quarterly Report, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Critical Accounting Policies and Use of Estimates</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our unaudited condensed financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during the reporting periods. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Our significant accounting policies are more fully described in Note 2 to our unaudited condensed financial statements included in Item 1 of Part I of this Quarterly Report.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Private Securities Litigation Reform Act</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">The Private Securities Litigation Reform Act of 1995 provides a &#8220;safe harbor&#8221; for forward-looking statements. Such forward-looking information is included in this Quarterly Report and in other materials filed or to be filed by us with the SEC (as well as information included in oral statements or other written statements made or to be made by us). Forward-looking statements include all statements based on future expectations. This Quarterly Report contains forward-looking statements that involve risks and uncertainties including, but not limited to, (i) our clinical trial plans and the estimated costs for such trials, including the timing of launching a Phase 2/3 clinical trial for gedatolisib; (ii) our expectations with respect to costs and timelines to develop, validate and launch CELsignia tests and to continue to develop gedatolisib; (iii) our beliefs related to the perceived advantages of our CELsignia tests compared to traditional molecular or other diagnostic tests; (iv) the expected benefits of gedatolisib; (v) our expectations regarding the timeline of patient enrollment and results from clinical trials, including the existing clinical trial for gedatolisib; (vi) the future payments that may be owned to Pfizer under the License Agreement; (vii) our expectations regarding partnering with pharmaceutical companies and other third parties; (viii) our expectations regarding revenue from sales of CELsignia tests and revenue from milestone or other payment sources; (ix) our plans with respect to research and development and related expenses for the foreseeable future; (x) our expectations regarding business development activities, including companion diagnostic related activities with pharmaceutical companies, expanding our sales and marketing functions and the costs associated with such activities; (xi) our expectations with respect to the CELsignia tests and the analytical capabilities of such tests; (xii) our beliefs regarding the ability of our cash on hand to fund our research and development expenses, capital expenditures, working capital, sales and marketing expenses, and general corporate expenses, as well as the increased costs associated with being a public company; and (xiii) our expectations regarding the impact that the COVID-19 pandemic and related economic effects will have on our business and results of operations.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">In some cases, you can identify forward-looking statements by the following words: &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are only predictions and are not guarantees of performance. These statements are based on our management&#8217;s beliefs and assumptions, which in turn are based on their interpretation of currently available information.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">These statements involve known and unknown risks, uncertainties and other factors that may cause our results or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. &#160;Certain risks, uncertainties and other factors include, but are not limited to, our limited operating history; the unknown impact of the COVID-19 pandemic on our business; our initial success being heavily dependent on the success of our CELsignia HER2 Pathway Activity Test; our inability to develop and commercialize gedatolisib; our inability to determine whether our CELsignia tests are currently commercially viable; challenges we may face in developing and maintaining relationships with pharmaceutical company partners; the complexity and timeline for development of CELsignia tests and gedatolisib; the uncertainty and costs associated with clinical trials; the uncertainty regarding market acceptance by physicians, patients, third-party payors and others in the medical community, and with the size of market opportunities available to us; the pricing of molecular and other diagnostic products and services that compete with us; uncertainty with insurance coverage and reimbursement for our &#160;CELsignia tests; difficulties we may face in managing growth, such as hiring and retaining a qualified sales force and attracting and retaining key personnel; changes in government regulations; and obtaining and maintaining intellectual property protection for our technology and time and expense associated with defending third-party claims of intellectual property infringement, investigations or litigation threatened or initiated against us. These and additional risks, uncertainties and other factors are described more fully in our Annual Report on Form 10-K for the year ended December 31, 2020 and in Exhibit 99.4 to our Current Report on Form 8-K, filed with the SEC on April 8, 2021 and elsewhere in this Quarterly Report. Copies of filings made with the SEC are available through the SEC&#8217;s electronic data gathering analysis and retrieval system (EDGAR) at www.sec.gov.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.25in; text-align:justify;">You should read the cautionary statements made in this Quarterly Report as being applicable to all related forward-looking statements wherever they appear in this Quarterly Report. We cannot assure you that the forward-looking statements in this Quarterly Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should read this Quarterly Report completely. Other than as required by law, we undertake no obligation to update these forward-looking statements, even though our situation may change in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="i3">ITEM&#160;3.&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">As a smaller reporting company, we are not required to provide disclosure pursuant to this item.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="i4">ITEM&#160;4.&#160;&#160;Controls and Procedures</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Evaluation of Disclosure Controls and Procedures</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Our Chief Executive Officer and Chief Financial Officer, referred to collectively herein as the Certifying Officers, are responsible for establishing and maintaining our disclosure controls and procedures. The Certifying Officers have reviewed and evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) as of March 31, 2021. Based on that review and evaluation, the Certifying Officers have concluded that, as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures, as designed and implemented, are effective and provide reasonable assurance that information required to be disclosed by us in the periodic and current reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the periods specified by the SEC&#8217;s rules and forms.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;<strong>Changes in Internal Control Over Financial Reporting</strong>.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.25in; text-align:justify;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="p2">PART II. &#8212; OTHER INFORMATION</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="it1">ITEM&#160;1.&#160;&#160;Legal Proceedings</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">From time to time we may be involved in disputes or litigation relating to claims arising out of our operations. We are not currently a party to any legal proceedings that could reasonably be expected to have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="it1a">ITEM&#160;1A.&#160;&#160;Risk Factors</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">As a smaller reporting company, we are not required to provide disclosure pursuant to this item.&#160;&#160;However, in addition to other information set forth in this Quarterly Report, including the important information in the section entitled &#8220;Private Securities Litigation Reform Act,&#8221; you should carefully consider the &#8220;Risk Factors&#8221; discussed in our Annual Report on Form 10-K for the year ended December 31, 2020 and in Exhibit 99.4 to our Current Report on Form 8-K, filed with the SEC on April 8, 2021 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in this Quarterly Report.&#160;&#160;Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial might materially adversely affect our actual business, financial condition and/or operating results. You should also consider the following risk factor: </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="it2">ITEM&#160;2.&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Use of Proceeds from Initial Public Offering of Common Stock</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">On September 22, 2017, we completed our initial public offering of 2,760,000 shares of our common stock at a price to the public of $9.50 per share.&#160;&#160;The total number of shares of common stock sold in the offering includes the exercise of an overallotment we granted to Craig-Hallum Capital Group LLC, the sole managing underwriter of the offering, to purchase 360,000 shares of common stock.&#160;&#160;The shares of common stock were registered for sale pursuant to Registration Statements on Form S-1 (Registration Nos. 333-220128 and 333-220527), filed with the SEC and declared effective on September 19, 2017 (the &#8220;Effective Date&#8221;).&#160;&#160;The aggregate offering price for the registered shares of common stock was approximately $26.2 million. The offering commenced on September 20, 2017 and did not terminate before all of the shares of common stock that were registered were sold.&#160;&#160;&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">The aggregate offering price for the shares of common stock sold in the offering was approximately $26.2 million.&#160;&#160;We received net proceeds of approximately $23.3 million from the offering, after deducting underwriting discounts and commissions of approximately $1.8 million and offering expenses of approximately $1.1 million. No payments for the foregoing expenses were made by us to any of our officers, directors or persons owning ten percent or more of our common stock, or to the associates of any of the foregoing, or to its affiliates, other than payments in the ordinary course of business to our officers for salaries and bonuses.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">There has been no material change in the planned use of proceeds as described in our Prospectus filed with the SEC on September 20, 2017.&#160;&#160;From the Effective Date through March 31, 2021, we have used approximately $14.8 million in furtherance of our planned use of proceeds, which includes funding additional research and development for discovery of new cancer sub-types and development and validation of new CELsignia tests; clinical trials to support clinical claims; development of operational processes and capital expenditures; and working capital and other general corporate purposes.&#160;&#160;&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Recent Unregistered Sales of Equity Securities</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">None</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="it3">ITEM&#160;3.&#160;&#160;Defaults Upon Senior Securities</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">None.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="it4">ITEM&#160;4.&#160;&#160;Mine Safety Disclosures</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">Not applicable.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="it5">ITEM&#160;5.&#160;&#160;Other Information</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.25in">None.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">34</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="it6">ITEM&#160;6.&#160;&#160;Exhibits</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBIT INDEX</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Exhibit&#160;No.</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Description</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000114420418043344/tv499834_ex3-1.htm">3.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000114420418043344/tv499834_ex3-1.htm">Certificate of Incorporation filed September 15, 2017, as amended by the Certificate of Amendment of Certificate of Incorporation, filed May 11, 2018, incorporated by reference from Exhibit 3.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2018.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000114420417058480/tv478251_ex3-2.htm">3.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000114420417058480/tv478251_ex3-2.htm">Bylaws, incorporated by reference from Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on November 13, 2017.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex4-1.htm">4.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex4-1.htm">Specimen Certificate representing shares of common stock of Celcuity Inc., incorporated by reference from Exhibit 4.1 to the Company&#8217;s Registration Statement&#160;on&#160;Form S-1/A&#160;filed September 12, 2017.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000165495421003990/celc_ex42.htm">4.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000165495421003990/celc_ex42.htm">Form of Warrant, incorporated by reference from Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on April 8, 2021. </a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000165495421003990/celc_ex41.htm">4.3</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000165495421003990/celc_ex41.htm">Equity Grant Agreement, dated April 8, 2021, between the Company and Pfizer, Inc., incorporated by reference from Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on April 8, 2021. </a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000165495421002061/celc_ex11.htm">10.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1603454/000165495421002061/celc_ex11.htm">Purchase Agreement, dated February 23, 2021, between Craig-Hallum Capital Group LLC and Celcuity Inc., incorporated by reference from Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on February 24, 2021.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="celc_ex311.htm">31.1*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="celc_ex311.htm">Certification of Chairman and Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="celc_ex312.htm">31.2*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="celc_ex312.htm">Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="celc_ex321.htm">32.1**</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="celc_ex321.htm">Certification of Chairman and Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="celc_ex322.htm">32.2**</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><a href="celc_ex322.htm">Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">101*</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Financial statements from the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2021, formatted in Inline XBRL: (i) the Condensed Balance Sheets, (ii) the Condensed Statements of Operations, (iii) the Condensed Statements of Changes in Stockholders&#8217; Equity, (iv) the Condensed Statements of Cash Flows, and (v) the Notes to Condensed Financial Statements.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">104*</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">_________</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;vertical-align:top;"><p style="margin:0px">*</p></td><td style="vertical-align:top;"><p style="margin:0px">Filed herewith.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="margin:0px">**</p></td><td style="vertical-align:top;"><p style="margin:0px">Furnished herewith.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">35</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="SIGNATURES">SIGNATURES</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.25in; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:50%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dated: May 10, 2021</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CELCUITY INC.</p></td><td style="width:12%;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">By</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">/s/ Brian F. Sullivan</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Brian F. Sullivan</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Chairman and Chief Executive Officer</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(Principal Executive Officer)</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">By</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">/s/ Vicky Hahne</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Vicky Hahne</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Chief Financial Officer</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">(Principal Financial and Accounting Officer)</p></td><td><p style="margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">36</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>celc_ex311.htm
<DESCRIPTION>CERTIFICATION UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<html><head><title>celc_ex311.htm</title><!--Document created using EDGARMaster--></head><body style="text-align:left;font-size:10pt;font-family: Times New Roman"><P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN: 0px 0px 0px 23pt"><STRONG>Exhibit 31.1</STRONG></P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN: 0px">&nbsp;</P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; MARGIN: 0px"><STRONG>CERTIFICATION UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</STRONG></P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; MARGIN: 0px">&nbsp;</P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN: 0px">I, Brian F. Sullivan, certify that: &nbsp;</P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left; BORDER-SPACING: 0; LINE-HEIGHT: normal" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 3%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">I have reviewed this Quarterly Report on Form 10-Q of Celcuity Inc.;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">2.</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">3.</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</P></TD></TR></TABLE>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left; BORDER-SPACING: 0; LINE-HEIGHT: normal" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 6%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(a)&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(b)&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(c)&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(d)&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</P></TD></TR></TABLE>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left; BORDER-SPACING: 0; LINE-HEIGHT: normal" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 3%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">5.</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</P></TD></TR></TABLE>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left; BORDER-SPACING: 0; LINE-HEIGHT: normal" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 6%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(a)&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(b)&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</P></TD></TR></TABLE>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; WIDTH: 100%; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 50%">
<P style="MARGIN: 0px">Dated: May 10, 2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px 0px 0px 0in">By</P></TD>
<TD style="WIDTH: 35%; VERTICAL-ALIGN: top; BORDER-BOTTOM: 1px solid">
<P style="MARGIN: 0px 0px 0px 0in">/s/ Brian F. Sullivan</P></TD>
<TD style="WIDTH: 12%">
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: bottom">
<P style="MARGIN: 0px 0px 0px 0in">Brian F. Sullivan</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: bottom">
<P style="MARGIN: 0px 0px 0px 0in">Chairman and Chief Executive Officer</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR></TABLE>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>celc_ex312.htm
<DESCRIPTION>CERTIFICATION UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<html><head><title>celc_ex312.htm</title><!--Document created using EDGARMaster--></head><body style="text-align:left;font-size:10pt;font-family: Times New Roman"><P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN: 0px 0px 0px 23pt"><STRONG>Exhibit 31.2</STRONG></P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN: 0px">&nbsp;</P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; MARGIN: 0px"><STRONG>CERTIFICATION UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</STRONG></P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; MARGIN: 0px">&nbsp;</P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: justify; MARGIN: 0px">I, Vicky Hahne, certify that: </P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left; BORDER-SPACING: 0; LINE-HEIGHT: normal" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 3%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">I have reviewed this Quarterly Report on Form 10-Q of Celcuity Inc.;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">2.</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">3.</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</P></TD></TR></TABLE>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left; BORDER-SPACING: 0; LINE-HEIGHT: normal" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 6%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(a)&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(b)&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(c)&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(d)&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</P></TD></TR></TABLE>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left; BORDER-SPACING: 0; LINE-HEIGHT: normal" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 3%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">5.</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</P></TD></TR></TABLE>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left; BORDER-SPACING: 0; LINE-HEIGHT: normal" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 6%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(a)&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(b)&nbsp;&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</P></TD></TR></TABLE>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; WIDTH: 100%; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 50%">
<P style="MARGIN: 0px">Dated: May 10, 2021&nbsp;&nbsp;</P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px 0px 0px 0in">By</P></TD>
<TD style="WIDTH: 35%; VERTICAL-ALIGN: top; BORDER-BOTTOM: 1px solid">
<P style="MARGIN: 0px 0px 0px 0in">/s/ Vicky Hahne</P></TD>
<TD style="WIDTH: 12%">
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: bottom">
<P style="MARGIN: 0px 0px 0px 0in">Vicky Hahne</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: bottom">
<P style="MARGIN: 0px 0px 0px 0in">Chief Financial Officer</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR></TABLE>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in">&nbsp;</P></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>celc_ex321.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
<TEXT>
<html><head><title>celc_ex321.htm</title><!--Document created using EDGARMaster--></head><body style="text-align:left;font-size:10pt;font-family: Times New Roman"><P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN: 0px"><STRONG>Exhibit 32.1</STRONG></P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN: 0px">&nbsp;</P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; MARGIN: 0px"><STRONG>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</STRONG></P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; MARGIN: 0px"><STRONG>PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</STRONG></P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; MARGIN: 0px">&nbsp;</P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px">In connection with the filing of the Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the &#8220;Report&#8221;) by Celcuity Inc. (&#8220;Registrant&#8221;), I, Brian F. Sullivan, the Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to the best of my knowledge:</P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left; BORDER-SPACING: 0; LINE-HEIGHT: normal" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 3%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">1.</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">2.</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</P></TD></TR></TABLE>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; WIDTH: 100%; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 50%">
<P style="MARGIN: 0px">Dated: May 10, 2021</P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px 0px 0px 0in">By</P></TD>
<TD style="WIDTH: 35%; VERTICAL-ALIGN: top; BORDER-BOTTOM: 1px solid">
<P style="MARGIN: 0px 0px 0px 0in">/s/ Brian F. Sullivan</P></TD>
<TD style="WIDTH: 12%">
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: bottom">
<P style="MARGIN: 0px 0px 0px 0in">Brian F. Sullivan</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: bottom">
<P style="MARGIN: 0px 0px 0px 0in">Chairman and Chief Executive Officer</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR></TABLE>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px">&nbsp;</P></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>celc_ex322.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
<TEXT>
<html><head><title>celc_ex322.htm</title><!--Document created using EDGARMaster--></head><body style="text-align:left;font-size:10pt;font-family: Times New Roman"><P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN: 0px"><STRONG>Exhibit 32.2</STRONG></P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: right; MARGIN: 0px">&nbsp;</P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; MARGIN: 0px"><STRONG>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</STRONG></P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; MARGIN: 0px"><STRONG>PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</STRONG></P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-ALIGN: center; MARGIN: 0px">&nbsp;</P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px">In connection with the filing of the Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the &#8220;Report&#8221;) by Celcuity Inc. (&#8220;Registrant&#8221;), I, Vicky Hahne, the Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to the best of my knowledge:</P>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left; BORDER-SPACING: 0; LINE-HEIGHT: normal" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 3%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">1.</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">2.</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</P></TD></TR></TABLE>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; WIDTH: 100%; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 50%">
<P style="MARGIN: 0px">Dated: May 10, 2021</P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px 0px 0px 0in">By</P></TD>
<TD style="WIDTH: 35%; VERTICAL-ALIGN: top; BORDER-BOTTOM: 1px solid">
<P style="MARGIN: 0px 0px 0px 0in">/s/ Vicky Hahne</P></TD>
<TD style="WIDTH: 12%">
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: bottom">
<P style="MARGIN: 0px 0px 0px 0in">Vicky Hahne</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: bottom">
<P style="MARGIN: 0px 0px 0px 0in">Chief Financial Officer</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR></TABLE>
<P style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px">&nbsp;</P></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>celc_10qimg7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 celc_10qimg7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $2 1 # 2(  A$! Q$!_\0
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MME##(Q,$4;(SB4']VI8E@OS$=*Y[Q)XE\::7/XJO8/'EQ(FG^%(=<ACA@MS
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MJ)0N[D.-R+39OB ^LH]]:S1V)U/_ %+-"2+<ISN<=E;D #+9QQUK5\=R0_\
M".I:?>OKBYA6S0??,HD5@P_W0"2?0&L2PTI)H[DRZEJS%+F6-?\ B8S\*KD
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MW.9M?J7[76+.\NS9[9[:["[_ +/=0M#(5_O ,!N'N,U?H\<+;_8-/FX%^E_
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MTA0QG:I=5=6!#'AMIX(YYYQ6O:MY>I0$]'#1_B>1_*K>K6<EYI<L=OQ<IB6
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MJHUM#8TB4KW3;:^:&61I8;B DPW-O(8Y8L]<,.Q[@Y!]*:+'4,C_ (JC5_\
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M+>Z@N!8/*9X)XXFD2/?RZ-MR5P^X\C&&]JEO[ZSUJYL-/L;J*Z@9_M5P8G#
M)&054XZ9?;^1JQ%JD7 N5:W?U/*GZ$?UQ4T;V/F//$]N'DQND4J&;'3)[UEU
MN05Y-'MC<275K+<6%Q(VYY+64IO;U93E6/U%/L;&2UDNKBYO&O+FX8%YG0)A
M5&%7 XP.3]233Y-0LX^//#M_=C^8_I6;)>2:@A&TPV^2IC_B;!Z-Z#VIJ['N
M+//]KNO.7F% 5C_VO5OZ"DHHK5*Q:T*NAV\-WXWO[BZP\]C#"EJK<^6C@EW7
MW9@5)]$Q2>*-:U#3_&&@V,%Y':V=S'-)+OV#S65HPJ L#G(9OE7!/KQ3;K3U
MN+F&\M[J>QOX05CN;<C=M/)1@00RY .".O(Q2[?$G_0U3?\ @%#_ (5$H7=R
M7&[.3T3QIXTENM,M]23R+>94>\N'MEWVRL("K%5.TAC(5!'W5.6&5-=EXZAA
M&B)JBJJWUE/$UK(!\V]I%78/4,"5(]_:JL/_  DTD0<^+)022.+*'L2/2D73
M9IKJ&ZU;5KC5);<[H$D5(XHFQC<$0 %L$C)SC/&*486=Q*+3N:3<,0.F:2BB
MM30*K>'889_%FM7UPHDO+3RH+<-R8H6C#97TW,6R>^T#M5FL^\TE;B\CU"UO
M)]/OXU\M;B#&63.=CJP*NN><$<=L4FKJPGJ9DWBKQ5<Z-)<+;QV,I@,D;Q(T
MC!O($P!5AC'\![YZ5)=>(O$5H]W"MT)KBW$L?D&W^;8L+.MP2/5@HQTYQUJ_
M,WB*&%I&\53''0"QAR3V'2G)_P )1Y:^9XKD#X^8+90X!_*N?V4NYOSQZ)?U
M\C,O)KFZ\-6.JZDHCUNRU)+>%BH21@TH1HVV\'<A)(7C@'M70GJ:SDTR:2_B
MU#5-2N-3N8,^3YJJD<.1@E44 ;L<;CDXSC&:T:VA'EBHMW,MY-I6N%%%%6(*
M*** "BBB@ I#TI:0]* .OC_U:_04^F1_ZM?H*?7(<X4444 9FM?\>:?]=!_(
MU@UO:U_QYI_UT'\C6#6\-C6.P4445H6%,,<9.3&I/NHI]% "  # &!Z"JX_<
MWQ7^"<;A_O#K^8_E5FH;F-I(#Y?^L0AT^H_SC\:"2:BF1R++$DJ?=89%.9E1
M&=V"(HW,S' 4>I/:@H6@ DX R?:O%_&_[1'A+PV\MCX?C_X2/44^4M$^RVC/
MO)_%_P !'XU\\^*OC1\0O%7F1W.N/IUF^1]DT[]PF/0D?,WXFNJGA:D]=CCJ
MXRG3TW9]FZAXN\*^';4?V[XBT_3F!;Y)KA0_WC_#][]*XG4/VA?A=8N5CU:[
MOR/^?6S<C\VVBOC76LMK$CL2S&.(ECR3^Z7O5'BNN&#C;WF<,\=.]HH^NI?V
MH/ RMB/1=:E'KLC7^;TZ']I_P([8FT?6H1Z^7&W\GKY"HK7ZI3,?KM0^W=._
M: ^%NH.$?7)[!C_S]VKH/S4$5WNC^)?#OB",/H6NV&I ]K>X5V_[YSG]*_.6
MM+1XE6Z?4I6>.WL@)'9&*,S?PH".06/Y $]JRG@XVNF;0QT[VDC]%1^_N]Q_
MU4!PO^T_<_AT^N:LU\/^&?CM\0_#DX#ZDFK66XDVE\N]5!.<*P^9?SQ[5]#^
M!OCUX,\7/%8W\G_"/ZJ^%$%VX\J1O1)>GX-@UQ3P]2&NYW4L53J:7LSUFBBB
MN<[ HHHH **** "BBB@ I#TI:0]* .OC_P!6OT%/ID?^K7Z"GUR'.%%%% &9
MK7_'FG_70?R-8-;VM?\ 'FG_ %T'\C6#6\-C6.P4445H6%%%% !117->-O&F
MC^ _"\VNZQ(2H^2"W0_/<R=D7^I[#FFDV[(3:BKL3Q-XMT/P)HUSJGB"Z\BT
M!W0(HW/,YZQH.YSSZ 'FOD#XC?&+Q-\0)I+,2-I6A;ODT^%_]8.QE;^,^W0>
MG>JM_P".F\=>+=0O_'5Y,EI=0,EO#!_JK5E^:-0.H&>"PY.3GKQYZ.@SUKU*
M&'4/BW/&Q%>4U:+T%I#TI:0]*] \LT=8_P"0J_\ USB_]%+6?6AK'_(5?_KG
M%_Z*6L^ICLBGNPHHHJB1R(\DBQQJ7=R%50,DD]!6EJCI;1QZ/ P9+9BTSKTD
MF/#'Z+]T?0GO3K'_ (EM@^K-Q<2$PV8]&_CD_P" @X'^T?:LGM4[LTV7J%)U
M%+15&9ZY\-?CEX@\$O#I>L-+K/A\?+Y+MF:V'K&Q[?[)X],5]?\ A_Q#HWBG
M0X-:T&^2]L9A\KKP5/=6'56'<&OSDKLOA[\1-<^'?B :AIKF:RF(%Y8NV$N%
M_HP[-_2N&OAE+WH[GIX;%N'NSU1]_45C^&?$FD>+O#EKK^AW'GV=RO&>&C8=
M48=F'<5L5Y+5M&>TFFKH****0PHHHH *0]*6D/2@#KX_]6OT%/ID?^K7Z"GU
MR'.%%%% &9K7_'FG_70?R-8-;VM?\>:?]=!_(U@UO#8UCL%%%%:%A1110!7O
M+RUT[3[C4+Z=;>TMHVFFE<X"(HR2:^#OB=\0+WXB>,)=2DWQ:;;YBL+8G_51
MY^\?]INI_ =J]N_:8\<-9Z=9^ ]/FVR7@%U?E3R(@?W<9^I&X^P'K7RU7JX2
ME9>T9X^+KW?LX]#U;X.>&]+U2?Q#X@U*UAOFT.T$UO:SKNC>1B<,R_Q 8Z>I
M%>Z>-_"GA_Q)X+OK+4])2TU6WLIKRVNUL1:F/R^<8!/'08)P<\5\R_#O5M:T
MWQC:6FB269EU0BQD@OSBWN%<X"2'L"<<]C7T7J'@OXL>)-1M?#MQX-TWPOI%
M\P@U'4K&\$[FWSN91EL@'L,=37GXKGCB.:^GKL=F'G1=%1:U5[Z;GR(OW12'
MI7NG[2'P]L_!?C33;_1;,6VCZC:+&B(/ECEB 4C\5VGZYKPMNE>S2J*I%274
M\2I!PFXLT=8_Y"K_ /7.+_T4M9]:&L?\A5_^N<7_ **6L^M8[(R>["K-A9M?
M7J6X<1IRTDAZ1H!EF/T%5JU9_P#B6Z2MF.+N]59+CU2/JD?X\,?^ T-]@BNK
M*VHWBWEWNA0QVT2B*",_P1CIGW/)/N35/M10*:5A-WU"CM6CHMA!JFMVMC=7
M@L;:1B9KDKN\F, LS8R,X /'>NLG^'L-JMT\FM+<_98=Y2T"2-<.'VND/S8;
M:,L3V&*3DEHRE!O8X*BN]D^'?EV]VQU!_.25XK:,HH\[9$'))SC!)P.>BEN1
M6%XCT.TT3[$+74#>BY1Y-^T(  Q4$#)."!D$\$$8[TE.+V!P:U9UWP;^)<WP
M_P#%@AOI&;P_J++'>1]1$>BS >H[^HSZ"ON!621%DC=71@&5E.0P/((/I7YH
M]J^P?V<_'+>(/!<OA?4)M^H:& (BQYDMC]W_ +Y/R_3;7#BZ6GM%\SU,'7_Y
M=R^1[?1117EGKA1110 4AZ4M(>E '7Q_ZM?H*?3(_P#5K]!3ZY#G"BBB@#,U
MK_CS3_KH/Y&L&M[6O^/-/^N@_D:P:WAL:QV"BBBM"PIKR1PQO-,X2*-2[L>B
MJ!DG\J=7"?&#66T+X.>)+V-RDLEO]EC(ZAI6"?R)JHKFDH]R92Y8N78^*O&G
MB2;Q=XZU?Q%,Q(O+AFC!_@C'"+^"@5S]'08HKZ%*RLCY:3<FVQ\<DD,J30N4
MEC8.C#JI!R#7WOI?Q U#Q)\//!'B#3[QK9-0E\G49$4'8Z1L&4GRY-N77^[S
MD#(S7P+7TC^S7\4M%\*P:IX7\5:O'IUC-(MS9S3DA!(?E=<]LX4\\<&O/QU)
MSAS):HZ\)4Y9.+ZG>_$/0?$GC_X1>(%UJ"9M0TR.+5M/$D2AB THD"E5& 47
M&PY8$9).X5\8_P -?HG\2_'6E>'_ (1:QXGTW4+:]W0&"U>&19%>63Y5Y&1Q
MDG\#7YV$D@D\DU& YN1I[7+QEN:/<OZQ_P A5_\ KG%_Z*6J'>K^L?\ (5?_
M *YQ?^BEJI'%)//'!"ADED8(BCJQ/ %>G'X4</VB]I<$.Z74;M ]K:88H>DK
MG[D?XD9/L#5&XGFNKF6YN'+RRL7=CW)J_JDL<0BTJU</!:$[W7I+*?OO].-H
M]A[UF@%B%4$D\ #O0M=1O3W4)17L>B_LX_%#6M)@U)=/M;&.=0Z1W=P$DVGH
M2O./QYK1_P"&6/BE_=TK_P "O_K5B\327VD:_5JG8\+IN%_NC\J]ONOV8?BE
M;VLDRVNG7#(N[RX[H;F]AD 9KQN^L;S3-0GT_4+:2UN[=S'+#(NUD8=015PJ
MPG\+N3*E.GK)%3"_W1^5+C'2EHK4P#O7>?"7Q0WA'XJ:-J3R;+2>7['=>ABD
M^4D_0[6_"N#I.>JG!['TJ)14DXLUA)QDI+H?IB1AB/2BL#P7K'_"0> - UIF
MW/=V,4CG_;V@-^H-;]?/-6=CZA.ZN%%%%(84AZ4M(>E '7Q_ZM?H*?3(_P#5
MK]!3ZY#G"BBB@#,UK_CS3_KH/Y&L&M[6O^/-/^N@_D:P:WAL:QV"BBBM"PKQ
M/]IJ[:#X3VULO'VG4HE/T57;_"O;*\'_ &HD9OASHSCHFIC/XQ/6]#^)$Y\3
MI1D?(]%%%>\?,A1110!?TN/[7.=-:614N 1&@?"^;CY,CH>>/QK/;H<C!I\;
MM'*DBL596#!AU!'>MOQ1#I$>KQ7&C7GVV"[@6YD)79LD8G>FWJ,$=/>L+VE8
MUW5^Q2UC_D*R?]<XO_12U+:?\2W3&U(\7-R&AM?55Z/)_P"RCW)]*T[Z7PKJ
M/C6R:(W%IHK)"+J1V+.N$&_'';&T>N/>LC6+JWO-6EDL?,%DF([990 RQKPH
M('Y_4FJ3NDK!M>5S.K=\)WUAIGCG0M1U1 ]C;7L4LZD9R@<$\=ZPJ*&KJPHR
MM)2['Z?7VKZ7=^&GF@U2T$-[;L+>9IE5)-R\$'/O7EEI9>5H&@Z:D>G02V<$
MPFO/[1@61)#&5"CR\ HQ.6/4@ '/4<[\![#3H?A-IUY;XEN)Y)/.D8[BK!B-
M@] !CCWK5U'5_$MO-=^69(XC<.L+&)2"JR,HQA#C@+]X'.1@BOEJO[N31]3A
MX*K\.^F^FYZ=X/CTG2?#5GHMKJEE<S01!I/):(<X^8X0 ?CCZU\2?'K6M%UW
MXRZQ>Z&\<MNJQPO-'@K+(J@,P(Z\\9[XKZMURQLM5\%7D6LQJ(WL6>5V78T1
M\O)8?W2#[^U? )QD[3N'8^M>CEL;RE)]/U/-Q]HQ275_D%%%%>Z>(%%%% 'W
M!\ KIKKX':)N;)@>>#Z 2MC^=>H5Y)^SJC+\$K%F& ]Y<D>XWX_I7K=?/UOX
MDO4^HH?PX^@4445D;!2'I2TAZ4 =?'_JU^@I],C_ -6OT%/KD.<**** ,S6O
M^/-/^N@_D:P:WM:_X\T_ZZ#^1K!K>&QK'8****T+"O(OVB]/:]^"]U.JY-E>
M07'T&2A_]#KUVL+QCH8\2^!=;T#&6OK.2)/]_&4_\> K2G+EFI&=6/-!Q/SL
MHIS(\;M'(I5U)5E/4$=13:^A1\J>D>!/A_:>*-'FU._OIH(EE,,<< &20 22
M3]:ZO_A3/A__ *"FH?\ CG^%6/A'_P B/+[7DG\EKI[VUNDFOKJ.W,LQ7=;7
M"-EXB%&(]OH2#G'4,<U\/C<;B(UIPC*R3T.5RDYN-[''_P#"G/#W&=6OQG_<
M_P */^%-^'_^@I?_ /CG^%=-<:7K$]H8II#--N$BR&;Y%_=L"H7L0S=?3%3Q
MZ?JWV*^AFN&E,]O(J!Y<A7+-MQZ#:17%]>Q/\P.Z7QG)?\*:T#_H):A_XY_A
M1_PIK0/^@EJ'_CG^%=2VE7SV\L$*+91-^\CA63Y48*%VY'3/S$XZ<42:7/)=
M^9!ID5FIC18V$JYMF$A9F&.N01TZ]#1]>Q/\Q7_;QS'_  IW0/\ H)7_ /XY
M_A2?\*9\/_\ 04U#_P <_P *WAH>LKIGV=9XBXE28EF)+@,"(\@C 7!QZYYY
MJ_!I^I+K,=](X9'^9U8@B/.XL .N>5 (XP.:3Q^*_F$]$[2.+U*'Q%\)=%.H
M^#O$]U';3S".>VN(T=2Q!PX!&,\8Z5DQ?''XF-I=U<_\) OF1R1JN+6+HP?/
M\/\ LBNH^+7_ "(J^]W'_)J\5L+A[;1;]XUB8F6$8EC60=).S BOI<N_VBCS
M5E>5]SOPV*K<EG+8Z/7OBOX^\2Z3)I6K:\[V<G^LCBC2(2#T;:!D>U<3QBKW
M]JW'_/"R_P# .+_XFKVE>)[[2+Q[J"STZ5VB:+;+9QE<,,'( &?H>*]N,%37
MN10YU)56N9E[P+X#UKQ_KCZ;I/EPI"GF3W,V=D*]!G'))/05ZA)^S;<PSK;S
M>.=,CF92RH\3*Q ZD GIP:S?@3X_T7PQK^K6?B":.Q@U0*R7.W;'&ZD_*<?=
M4Y^@Q7MFM:YX*U:^:Z7QUI$7[E(A&UPI4X+G+#O]_CT(KR*]7$1J-1T/9PU/
M#RBN?[]]>QY)_P ,UZG<6+7&F^,--O"0?+VQML<^FX$@5XEJFFWVBZO=:3J4
M)@O+20Q2QG^%A7V?I'C'P/X>T65;OQKI,H#F5O*N-Y'R@8&<LQ.,_CCM7RIX
MNU+_ (6#\5[RZTF!@-6O$@MD8?,02$4GW/6ML/6K2D_:;6,J]&BOX:ZZ>:]#
MZ^^"VGMIOP4\-0LNUIH&N2#_ --'9A^A%>@U5T^QATO2;/2[< 0V<"6Z >BJ
M%_I5JN.3YI.1Z$(\L5'L%%%%26%(>E+2'I0!U\?^K7Z"GTR/_5K]!3ZY#G"B
MBB@#,UK_ (\T_P"N@_D:P:WM:_X\T_ZZ#^1K!K>&QK'8****T+"@'!R.M%%
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MQ@L]IZL@ZM'[=5^G3P"O<IU(U%S1/G:M*5*7+(****T,0HHHH *,D'(X-%%
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81110 4AZ444 =?'_ *M?H*?117(<Y__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>celc_10qimg8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 celc_10qimg8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" #@ BH# 2(  A$! Q$!_\0
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M\*G^%O\ T33PK_X)K;_XBO.=-^)?CZXUG2M0NO[&.@W7BJX\-M;1P2"X(5Y
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M[-'GZ,V[ZK2 WO\ A4_PL_Z)IX5_\$UM_P#$4?\ "I_A9_T33PK_ .":V_\
MB*\K^&NCR:E\3?%6M7?A>2^%IXEU!8];?574VVW[L8MLX8#.,]/F]JXGX1K?
M-XF^'S0KJ&A7&H)J$UQJL]^\T>NJA=?)6(LRJZ$AOG"G"'&:%K8;TN?17_"I
M_A;_ -$T\*_^":V_^(H_X5/\+?\ HFGA7_P36W_Q%)INEZIHGP_U&SU36IM5
MNE2YD^T.JJ5#;F & .@/^'&*\#\.Z]XRN?A_\&;34-!>STG^V+ 1ZL-4$CWG
MRR85H@-P!&3R3TI7U ]]_P"%3_"S_HFGA7_P36W_ ,11_P *G^%O_1-/"O\
MX)K;_P"(KQ?X8Z5<7$/B#Q)<>'96ECNM86/7GU9RP(DD41_9\XX&0#[9K&^"
MZW#>*/!,++J'AX7GAV>ZO)I]2>5=?! 4/&NXK&T9.\YPP!'&.::U!Z'T!_PJ
M?X6_]$U\*_\ @FMO_B*7_A4_PM_Z)IX5_P#!-;?_ !%>9?#GPZLOQ,\2:O\
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MNSHH XS_ (5/\+/^B:>%?_!-;?\ Q%'_  J?X6?]$T\*_P#@FMO_ (BNSHH
MXS_A4_PL_P"B:>%?_!-;?_$4?\*G^%G_ $33PK_X)K;_ .(KLZ* .,_X5/\
M"S_HFGA7_P $UM_\11_PJ?X6?]$T\*_^":V_^(KLZ* .,_X5/\+/^B:>%?\
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M^%/_ "1#P'_V+]A_Z3)7:4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&Y&//8@5V%% '$6WPP\#V?BM_%%KHHAU=[AKMITN)@&E;.YRF_:2<GM5JW\
M>$;2RT2QM]%BCM-!N#=Z<BN^;:4EB64YR<[VR"2#GI76T4 030QW%O)!,H>*
M52CJ>X(P17.KX)\+PZ/H>CQZ3&+'0IH[C3H=[8MI$!",#G)QN/7/6NIHH X+
M3_A7X%TG6)=9T[1?LU[*TS.RW$VUC*")#L+[>=S=N]7E\ ^#ULM$LTT6)8="
MBDATY0[YMT=#&Z@YR05."#FNOHH X7PY\*? ?@_58]4\-Z"NGW44;0HR7$S!
M4;J K.5_2N@U;0])UI]/?5K%+MM.NDOK4L2/*F0$*XP>HR>O'-;5% &'J&@Z
M/JVI:7JFHV(GN]*D>:SE8D&%V0HQ&#@Y4D<YK$T7X7>!/#VHRZEI/A^&"\DA
M:W\UY))3'&WWD3>QV*?1<5V]% '(VO@3PC8G0#9Z'% _AY'CTQD=PULC##*#
MG)!'9LBNNHHH *XSQ=X3/BY-#LY+Q8+&QU2'4;J(Q[C<B++)&#G@;]A)YX7%
M=G10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5^37Q8_Y+?X\_[&"_\ _2EZ_66OR:^+'_);_'G_ &,%_P#^E+T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=NEPX#2?CTZ=JZJN4\*Z;]@M[F3_ (2B]\022R%))KEHPL;(2K(B1JJI@YR
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M'BQ[B/\ T.\@MO-$<[-;!VB@PF+A2$&YF8O\NW@ $J,'*&>A:A_QXO\ 5?\
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M73M/CT6]O%O9/+^T0-%Y<) R=^]U;@ GY0>GKQ6O=W=O8VDEU=2K%#&,LS'
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MJ3:+X7*7'DX'VFXB8[2<-\BL<G;G^(?CTI75FT;?5ZBDHRLKV:NTM&>@V?\
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M2DH#JPQ@A@"#75UY]\+4A7P%#-'>6]]))<3237<$TLHGD+G<[-*JL6]> !C
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MI"M'9,VT^OS2?THY>[#F\BQX8_Y%BP_ZY_U-;%<#X0T?6F\+VJZEXFN),[F
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MQ=1@RS,R@ GG XQ^ KL)"JVK[ERH0Y7VQ7$?$+P;X?\ &%MH\'B"SGN8X+U
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M&!QZ]L&[JWAG7-2\+?V='XFO+2ZFB59A(4F7I\R;E1&.>F[CZ<XI>S3WEO\
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M8B=@._< -V"2'QGJ.HKO:*'J!Q/A_P &R:'K"WQU 3A8V4A8BC2EDB3YSDY
M\G(_WC^/;444 %%%% !1110 4444 %%%% !1110 5^37Q8_Y+?X\_P"Q@O\
M_P!*7K]9:_)KXL?\EO\ 'G_8P7__ *4O0!^F/PI_Y(AX#_[%^P_])DKM*XOX
M4_\ )$/ ?_8OV'_I,E=I0 4444 96J3&UT>ZN MTQCC9@MI'YDIXZ(N#D^G%
M<1#J'CA5M%NOM$@RB7DT%I@)"5C)EC!3)?<9%*X/"YVCC/IE% 'A^K?"NZUS
MQ'%XZOKB"34Y[.W6:PO$;RHI47&04.<-D CMR1GI3EM8=!)7Q!X9GT51_P O
M,%S)<69_X&""@_WRM>Q7W_'DWU7_ -"%28Y[5$H*3;U7H[!S26TG^:^X\"UJ
MQFU#Q7HLNC^)KBPCA998?LES),/FX9B'=@<KN VG&&[UZG#_ &\RNMEJ]CK4
M.?FM]0A\F91Z%D&/SCK&U?X2^&=4\2)XDLC<:'J<>&)T\1I%,Z[MCRQE2LA&
MYASU!Y[8@N++7-%8?VE8-<VT?W;_ $F-G"#/5[;/F)_VQ9A_LBL(PK0;:ES+
MHGNO),J53F2C.-K=5U]487CCQ7?^&M5T7_0I-%EN)MFQAYT ^8;Y0T>3C:2I
M4J#R"!P:[Z'Q;I^[:NO:?,?^>=RWV67Z8;J?P%>>^)[AO$CZ'/!?K?VT,C!9
M;:U@NQG*90M)"QC? ^Z0K=?O8X],CUK2]0M7BO(@\9&&!42I^)7('XXJXXM3
MDX3BTX]U^HO8124HM7EK9/7YHY/P;XB\/A-4U+^UM1,3W+1%-3OFE\@KU0*S
M':02>F>,<T[Q%\1M+MGTZ'0O%&C+<75R(7%U%),,$<D;'7&/4YZ@50^&.B^"
M[6ZU:'1=+U+*R*6DU:V@49RP'E%%!Q_3%=3XQT?P'-;6M]XRCTV**V;RX+B\
MD$0B9N<*V1@\9'TK95J,_>W7DR/8U(MQ;=_-:F3XO^*&AZ+X>?4='UK2+JXC
MD4-%/(_S@\84("2W0_0&M'4/'NEZ;X-B\0^6VN(HC6==%9)]A8<M\S+A,\<\
M\CBH_%\W@VX\-6&K:U>/_9K3++!<6<;SK*61MN1&K;E()/(QG!ZXK%\1>"_!
MNN>"K*2:\M=/L (G%]>%D,D97Y0Q+(0QR#S^6>C4Z+TOK^@6J+>.G?\ 0[ZW
MU2.72;>^O$?31/&LAAO"L<D61G:XR0".AY-<Q_PL[01XTNO#;21D6\2S&\6Y
MB>-]PX555BY;.01CC@]"*GT'P3X531K*2.WL]3_<J/M:?.LQQ@LI+,<'_>/U
M-9ECH?A.T^)L_P!DUS28]1VLS:3%#"MPJ&->K ^9U^;/<,!T I)T^K8>_P!(
M_B5I/BA:K\1SX>AFMYK(0^>56"X^TM\OW0I0+GOUQM]ZQ=5\:0R?&'0A:V_B
MO+PE7T\3_9X'=@WE$PL0&SB3))'W0>U=3-%X)L_B/;1327D>ORLL\<*1S-$?
MW9098*4 P"<%L9&>M:=]XTTW3_%%MH<UC>R33*K"ZCB4P1@Y^\Y88Q@YX[TY
M8C#QUOY:M+7L7&G4?V?NN_F5M>\0:];^'M2N9?"=W:VT5K*\LW]H0Q21($)+
M*5+88#)!]:XWX<W_ (OUSX;W36=]',4DFC=M5E;49Y9-H(3.Y4"D%1@D]3ZU
MZC?:_IMK8SS1W$-PZ1LZPI*N9"!D*.<<]*QM&\;0W_AN;5)])DTV:+?MLVD5
MR^T9&&3*C/2L98FE'W9-)[[]BHTJDE[J=O0Y+X?^&/&FF^$;JWO+Z31;U9G:
M.*.RM56;(RI8C=GD[>3P  .E:'@OP;XNM=-NK?Q9XDU'+7!N(UM;E5&7^>0%
M@N[[Y/?'IBNCTOQ5'J^B2W<NEWEL<L@2/,A*@<L'7@'KWSQ6;X-N+BWL+I9-
M/UE]\Y96N[J:Y8*>0H,S9  P..N,]:GZU&32CKS:JR[>97)))W5K:/8S/&'P
MGA\5+8+9^(M0TW[*S2,TDDETTLG&QLO)QMPW3KN]JZY?!OAU2/+MKB,_],[V
M=/Y.*YWQMJ43'3U^V:SI\HESLM)OLYE7*[LY^]V ],^]=C]NU*7'D:24!'WI
MY57]%W&CZW%MQBVW'=)/2Y/L9)*4E9/;7L><^!?"?@R\U/7]NG>(+QX[K-P/
M$5O(L;2G.6CWJ!(< 9;GC;7J%KI6F:?&(['3[:U0?PPQ*@_05S&BZ?XJAN;U
MKZ\AB2>;S1L0.<]#Z8X"]0>E="VERR8^TZE=2CT5A&/_ !T _K2AB*E6/-RM
M>NA4Z<8RLY)^FIS&CIKD?Q!UB.ZU31I=-\L2106UBT=TI9B 'D,K!MH49P@R
M6!X[]C)<V\+?O)HT_P!Y@*PH?">BV^IS:EY<DLD@PRRN77MSSSGCN:UETG2X
M_N:? /I&/\*(3K23YDD_6^A,H4591;MZ):]3B;6:WA^)-[>-XPU.[@>$;=-(
MB>W5SG*KMBWG P0-YY8_0=#J>I:A-IES_8^ES2S^6=AF7RU/X$ALXZ<5>BT7
M2X]3;48K&-+IAM:51@D=/Z5I9^;M6:6(FI*I)+>UETZ?,;=&+3IQ;[W[_+H<
MOH/_  D7]BV\=U#;6CQKY?SJ68!> 2 <=!ZUFZQX%?6/%.F:]<7-M)<6.-DG
MD;9$ ;=\AR<=>]=]V]*J27=O%/';R7$:2R?<C9P&;Z#O1[#G@HRDW:VM[;#5
M5QDY125^ED0?V+9M@W'F7)'_ #VE9Q^1./TJ[#:V]O'L@MXXE]$4*/TJQ4,D
MBQHSR,%11EB3@ 5TQA%;)$.3>[)E55&%4*/0#%.JM;W5O=(7M;B*= <%HW#
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M_P"^A0!-14/VBW_Y[Q_]]"L77M0FM=-62QFY,T:RR1 .\418!W"X.2!['Z4
M:VH?\>+_ %7_ -"%6JP+6\FF\,6LVJ-%#>O%&TZ;@-K\9^E;/VBW_P">\?\
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MUS218I>+?0O#)Y15T.[/F,%0X'."2!FI;35--OK"WOK6]ADM[C;Y;[@-Q89
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ML@D1AO!W2C)4G++B,9('&>>M$/C:7[#KLL>E+:&QO8K>,7"/"JK*RCS9<J,
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MAB\UM[;1ZFJ)-BBBBI **** "BBB@ HHHH **** "BBB@ HHHH *_)KXL?\
M);_'G_8P7_\ Z4O7ZRU^37Q8_P"2W^//^Q@O_P#TI>@#],?A3_R1#P'_ -B_
M8?\ I,E=I7C?PY^)7PYL?A-X0T^_^('AVUN;;1;*&:"?5K=)(G6W0,K*7RK
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MI?A7_P '-M_\70!V=%<9_P +8^%G_12_"O\ X.;;_P"+H_X6Q\+/^BE^%?\
MP<VW_P 70!V=?DU\6/\ DM_CS_L8+_\ ]*7K],O^%L?"S_HI?A7_ ,'-M_\
I%U^:?Q#%UJ'Q4\6W]BQN;6YUB\FAFMIO,BD1IW*LC?Q*000>XH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>celc_10qimg9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 celc_10qimg9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $  7H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[+HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSGQ]\2+?P+J=E93:4]
MY]IM9KQV6YCB81Q-&K*BO_K9#Y@VH.3@UZ-7"^+/A[H'C*Y2YUG[1YL=C/8Q
M&)E'E"1HV\U<J=LBF)2K#ISUH YC4/BU=:/J?B#^V/",MK8Z"]L+J[:]C(5;
MAU6-MN,CY26;TQBNET#X@:3K4.F23-_9\^L&233K61M\MS;AL+.54'8K#!&>
MF0"<\4W4OASH>J3ZVU]=7DC:T]C)=#>F";5@T> 5QAB/F!SGG&*J6OPM\/V=
M_I%S;WNH(FCWDMY9P*Z*L/F.7,(8)O\ *!)_=[L8P#G H*/2:*;N7U%.H)"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O&?%'Q,U_1_&7BO1[+^QXXM(LX)X%O&6-G+["[$M,
MN[ 9L*% )P"ZDU[-4#PPN2S0HS$8)*@G% 'ANL?%#QAI]OJ-]9KI][:H;#[+
M&-,F$[+<Q-+ED\[.0%(QQC.>V#/>?%KQ!!<7/DZ3I\^U"/LJ&1GM5\J)A>2.
M.MN3(>0H.%&"3D#TVX\1:/;74D;/),T3;9&@@>54([$J",CTZBM6TNK6^M8[
MJSDCFA=1L=.01_GM2NBG&25VCPW4/C)KD;31Z/=:1J7E:5-<QR/:M MW<I-+
M'M4&?=Y>8QRH?(.<J"*]1\!^)KKQ=X9FU:_LA92)?7-KY&"#&(I6CPV>_P O
M/:NK\B#Y?W*?*,#Y1P*D  Z #OQ3)'4457DEC@B>25PD:*69F.  .I)H GXH
MXKYS\4_M&M!JLMIX1TBWNK6)BOVN\9L2X[JBX(7T)//I6EX+_:$T[5;Z/3O%
M=BFD22MM2\A<M!GL&!Y3Z\CUQ6GLIVO8ODE:Y[W5.ZN8;2VDN+F18XD4L[L<
M!0.]3JRLH92"I&01T->8_%359(TM-'B8JLN9IL=P#A1^>3^ KEKU/90<CEKU
M52@YOH3WGQ6LXKDQV.ERW,0./->01[O<#!_7%=!H/B[3/$@,=NS072C+6\HP
MV/4=B*\=L]+T^334U#4-8CLT>1HQ$D#2R9'L, <&J4-U)8ZDMUI]PP>"3=#+
MC:2 >"1[CJ*\J.,J1DI2U3]#QHXVM"2E4LT^FA]+]#7F'CGQK-9W#:/H\@CG
M7_7S]2F?X5]_4]J['3=<AOO"B:YT3R3(Z^A4'</S!KP1Y+C4M1:1LRW-U+GG
M^)F;_$UT8K$.,$H/XCJQF)<:<53?Q?D65U+7(;@7"W]^DY'F!S(^2/[W/4?I
M7J7@?Q=)KD3V-^5^VP+NW 8$J=-V/4=ZY;4KS4+6RU22\N-.GM;F-XK54GW/
M$W".D?&2!C!' XKG_"=\^G^+M-N%; :81-[JWRG^=<E*I*E52OH]SAI5)4:T
M5S-I[GT-VZ5E:KKVDZ+$)-2OHX-WW5)RS?0#DU2\4>((_#^BR7C /,QV0Q_W
MG/3\!U->*Q"]\1:S)+>7@$K*TLT\N2L:*,DX'8#H!7H8C%>R:A%7DST\5C/8
MM0@KR9[%8>//#NI7:VT-\8Y&.U1*A0,?0$\5U@_O"OG'6-!NM%=5N9;>9&D:
M,-#)NPRX.&'8X(./>O6OA[K,VK>&1'<R%Y[9_)9CR6& 03^!Q^%1AL5*<G"H
MK,SPF,E4FZ=169V]%%%>B>J%%%% !1110 4444 %%%% !1110 4444 %%%%
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MM\1F^%-7N-?\'Z/KEW8M8W%_9Q7,EL^<PLZABO/IFMZD%+61J@HHHH&%%%%
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MS! CF%^"L9 91((CR#W[5@ZLHRLD7"*FFY-*WWFGYFN1QC;X2O%11@*+BW.
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M-U'?F:+&XQ6$TJ\C/#*I!Z^M7F\/Z&TRR2:+8M*+A+D.;9"PE10J29Q]Y5
M;J  *VVZ5$I1=K*Q<5);L\M_X330_P"[J/\ X+YO_B:/^$TT/^[J/_@OF_\
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M= 4444 ;.B?ZN7_>'\JV*Q]$_P!7+_O#^5;%<T_B,9;A1114DA1110 4444
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M7MD^]"PRK#H5([@C(-?=UOK6L^)/!]O?>(K6PM(KFV6XFL! +A ,;_F+]2,
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MTHH/2@#CJ***ZSH"BBB@ KXO_:(\+-H/Q4EU:&/;9ZY&+I2!P)1\L@_/#?\
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MMG(!E;;AP$+*<YP-I)"G@8K0\5?L_P#P]U_PM/!IOA^WT74C"7@N;7<NQ\9
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M2\\,RMD-]Y[(G^"3_9]&_ \]?5PV(NN26YXV+PS3]I';J>04445Z!Y04444
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K#^5;%8^B?ZN7_>'\JV*YI_$8RW"BBBI)"BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>celc_10qimg10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 celc_10qimg10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $% IH# 2(  A$! Q$!_\0
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M50OE@%4Y &[/) J&S^'/C#3H!<MIMAJ.KS>&[;39KFXO7;]]%,Q=3TWAHF4
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MK56.UMX;F>YBA1)IR#*X'+X&!D^PHZ6 NT444@"BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^=Y9E1F*[D/53CN,X'-0:UXBUK2_$VH2^3))I6G:=%=21(J %G:0-O8DL,!
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MK:3[/+.UU+Y=O!:Q@O,[ N<#@= S$D@<$U@77CS3+-;Z:^L;^VM+1I(VGD5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP\;><8'R,'&T]3A@0"*ZYMNQB^-N.<],52@N;&27R;2X@>3RUDV1,I.P_=;
M['G!Z4 4]%D64ZE(%=<WC\.I4_=4=#7G<_\ R<7;_P#7O_[3:O2M*_X^-4_Z
M_&_] 2O-YO\ DXJW_P"O?_VFU<F(^SZH\[&_8_Q(\^\&_P#)]/C'_KQ?_P!
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MADDD<X5% R23V %>5^![*QN/B7J>K6\=R")KSRI4MX#%,'E!9FN$.^4<#:K
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M<[!D_*><G&:O>/O%.E:+J?@FQ\0>!6N&U:..UTT6VN2!(4#1@!QL']]03SD
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MX1A?$G]J,=+:Y-H)Q#)_K ">F,XP,YZ4:A\1_".EZ-INL7NHR16>I1M+;O\
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M-7+?&[_D.?!3_KM'_P"C+:NIL?\ DTSPC_UQ@_\ 0FKEOC=_R'/@I_UVC_\
M1EM7O4?X\O0\C_E\_1?F=UXV_P"3D_!O_7K)_P"@RU4\*_\ )UGB7_KU'_H,
M%6_&W_)R?@W_ *]9/_09:J>%?^3K?$G_ %Z_^RP5R/?_ +>/M*?\'_MUD/P2
M_P"2V?&C_L)#_P!&SUV>B_\ )+_$G^Y/_P"BA7&?!+_DMGQH_P"PD/\ T;/7
M9Z+_ ,DO\2?[D_\ Z*%<V-_B1]&>1_S#U/D9+?\ )NB_A_Z4U4\8_P#)&_"_
M_;+_ -%-5IO^3=E_#_TIJKXQ_P"2-^%_^V7_ **:LGM_VZOS/F_M/T7YG6^(
M/^1X\-_]<U_]"K)_YN)D_P"O;_VD*U?$'_([>'/^N:?^A5E?\W$R?]>W_M(5
MPX?^)+_$CU\7_!AZHD\"_P#)5O%_^\W_ *,->7_!'_DV;X@_]?=[_P"DR5ZA
MX%_Y*MXO_P!YO_1AKR_X(_\ )LWQ!_Z^[W_TF2OH:'\&?K^IGEW\2/J_S-_P
M;_R:U<_]?3?^CUK"^.G_ "03P#_V$;?_ -%/6[X-_P"36KG_ *^F_P#1ZU@_
M'/\ Y(+\/_\ L(V__HIZC#_Q?DC7%?[P_1_F=9\;?^2G?#O_ *^Q_P"CH:[6
M;_DJVF_]<!_Z"]<5\;/^2G?#S_K['_H^&NUF_P"2K:;_ -<!_P"@O7DYE]G_
M !(^B7^[P_PLR?!/_)6/%G^\_P#Z'6AX5_U?BC_>;_V>J'@K_DK'BW_>?_T.
MM#PO_J_%'^\W\WKBQ/Q0]7^1Y6!^"?JOS."^)7_)INO_ /76+_TICK'\3?\
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M(^!_]R/_ -"DKUY_Q)>J/+R_^-/T_0[VV_Y*Y/\ ]</_ &1:RO ?_)2?&/\
MUT?_ -&-6K;_ /)79_\ KA_[(M9/@/\ Y*7XQ_ZZ/_Z,:O&CM/\ Q,VQ7\:'
MHC,N/^2$_$+_ +!]S_Z(->30?\F!S_\ 81_]O!7K-Q_R0GXA?]@^Y_\ 1!KR
M:#_DP.?_ +"/_MX*]W _PH^I&)_B/T_R/4M/_P"3?_ /_7A!_P"B36;\5O\
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MXV_\C7\%/^PJO_H=M7H8+^(O\*_(VQGPO_$_T/3+[_DKUG_UQ_\ 9'J'2/\
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MT5Q&8QC?ED:0?NVZ9^G!]NM)]HC:T@"K)^\0%28V &,=<CY?QQ3 N3?\L_\
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ME63#1,HS&P(/[OKQP..IJYH<R?V]XI.V3_6,G$;==S^W3WZ5\MC?B7J_R.7
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M9!%58K:&!LPP11,$"?(@!"CH..PYP*;?V\UU:/#!>36,C XEA"EAQ_M C_\
M57.>&?",GAVX1FOENECA,*MY.QR"5P&.3E5V\#U9CWH W](_U^J?]?C?^@)5
M_P#Y>O\ @']:R]#C\O\ M*,.[XO'^9VW'[J]ZU/^7K_@']: %7_CXD_W5_K2
M0]'_ -]OYTJ_\?$G^ZO]:2'H_P#OM_.@!L?_ ![-_P "_F:&_P"/0?[HHC_X
M]F_X%_,T-_QYC_=% #I?^6?^^*4_\?"_[I_F*2;_ )9_[XI3_P ?"_[I_F*
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M?\E/^'O_ %^#_P!'PUV\W_)6-._ZX#_T%ZX?XV?\E/\ AY_U^C_T?#7<S?\
M)6-._P"N _\ 07KQ\S^S_B1](OX$/\+_ #,CP3_R5KQ;_O/_ .AUH^%?]5XI
M_P!]OYO6=X*_Y*SXN_WG_P#0ZT/"_P#JO%/^^W_L]<F(WAZO\CRL'_#GZK\S
M@OB5_P FFZ__ -=8O_2F.L?Q-_R9WX,_ZXVO_H+5L?$K_DTW7_\ KK%_Z4QU
MC^)O^3.O!G_7&U_]!:OI,+_!B:K^(O4B_:5_Y!_PR_Z^V_\ :-=1X@_Y.X\/
M?]>@_P#1<]<O^TI_R#_AC_U^'_VC74>(/^3N/#W_ %Z#_P!%SUKB/X<?7]32
MC_$GZ,Z;P]_R7?Q!_P!<&_\ :56M#_Y&'Q3_ +S?^A-5;P[_ ,EW\0_]<&_]
MI59T/_D8?%/^\W_H35\MC/BCZO\ (Y<%]KU_4A\-_P#).=7_ .VG_HM:\R^-
MW_)K]O\ ]A>/_P!"DKTSPW_R3K5O^VG_ *+6O,_C=_R:_;_]A>/_ -"DK? ?
MQH>C_,[<3_!EZG4>*/\ DGOPT_Z]+?\ ]$QU6^(O_)R'@?\ W(__ $.2K/BC
M_DGOPT_Z]+?_ -$QU6^(O_)R'@?_ '(__0Y*]>?Q3]4>7@?XLO3]#NK3_DK,
M_P#UP_\ 9%K-\!_\E)\8_P#71_\ T8U:5K_R5:;_ *X?^R+69X!_Y*5XQ_ZZ
M/_Z,:O$C]KU9MB_X\/1&9<?\D(^(7_8/N?\ T0:\E@_Y,$G_ .PC_P"W@KUJ
MX_Y(1\0O^P?<_P#H@UY+!_R8)/\ ]A'_ -O!7OX3^"O4RK?Q'Z'J>G?\D"\
M_P#7A!_Z)-9OQ5_Y*M\.O^OI?_1T5:6G?\D"\ _]>$'_ *)-9OQ5_P"2K?#K
M_KZ7_P!'15P2_C3^1[6#_AQ]'^1Z#/\ \E7L?^N/_LCTN@?\E(UO_KDW_LE)
M/_R5>Q_ZX_\ LCTN@?\ )2-;_P"N3?\ LE>&_P",O\3_ ")K_P -_P"%?F8/
MPK_Y%#Q)_P!=&_\ 18JYI?\ R2W4?^NC?S6J?PK_ .10\2?]=&_]%BKFE_\
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M?_:==>'^!>B_0^/QW\>7R_,O^./^2E>#O^NJ?^C%KUU>I^E>1>./^2F>#O\
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MO]:#_P ?:_[A_F*%_P"/F3Z+_6@ A_Y:?[YJ/_EQ?_=;^M20_P#+3_?-1_\
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M5E*/*KI-M^C6ASX*U&,XU'JW=??<YKPZI;X::S_VT_\ 1:UY?\;MQ_9BM_\
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M ,E)\9?]='_]&-7B0^UZLTQ?\:'HOR,NX_Y(1\0_^P?<_P#H@UY+!_R8)/\
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MN:7_ ,DMU'_KHW\UK?$[KT9QX3X5ZK\RQ?\ _)(H/^ ?^C*\]^-W_(V_!/\
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MYBA?^/F3Z+_6@_\ 'VO^X?YBA?\ CYD^B_UH (?^6G^^:C_Y<7_W6_K4D/\
MRT_WS4?_ "XO_NM_6@"2;_5'\/YTK_ZR+_>/\C23?ZH_A_.E?_61?[Q_D: $
M;_CYC^C?TH'_ !]M_N#^9H;_ (^8_HW]*!_Q]M_N#^9H 5/]9+_O#^0I(_\
M5G_>;^9I4_UDO^\/Y"DC_P!6?]YOYF@!H_X\/^V?]*)/]6G^\O\ .@?\>'_;
M/^E$G^K3_>7^= #F_P"/F/Z-_2@?\?;?[@_F:&_X^8_HW]*!_P ?;?[@_F:
M!/\ 72?A1#_RT_WS0G^ND_"B'_EI_OF@!O\ RX?]L_Z4Z;HO^^O\Z;_RX?\
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M3_T=%7IFJ>";!O#VG:#I+#3K#3]D<$6#(%0#:%R3GC/<FO,OBXNWXM?#Z/\
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M^\O\Q0W_ !\1_0T !_X^U_W#_,4)_P ?$OT7^M!_X^U_W#_,4)_Q\2_1?ZT
M$/\ RT_WS35_X\S_ +IIT/\ RT_WS35_X\S_ +IH &_X]X_JG\Q3G_UL7^\?
MY&FM_P >\?U3^8IS_P"MB_WC_(T !_X^U_W#_,4+_P ?,GT7^M!_X^U_W#_,
M4+_Q\R?1?ZT $/\ RT_WS4?_ "XO_NM_6I(?^6G^^:C_ .7%_P#=;^M $DW^
MJ/X?SI7_ -9%_O'^1I)O]4?P_G2O_K(O]X_R- "-_P ?,?T;^E _X^V_W!_,
MT-_Q\Q_1OZ4#_C[;_<'\S0 J?ZR7_>'\A21_ZL_[S?S-*G^LE_WA_(4D?^K/
M^\W\S0 T?\>'_;/^E$G^K3_>7^= _P"/#_MG_2B3_5I_O+_.@!S?\?,?T;^E
M _X^V_W!_,T-_P ?,?T;^E _X^V_W!_,T "?ZZ3\*(?^6G^^:$_UTGX40_\
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M_P#NM_6@"2;_ %1_#^=*_P#K(O\ >/\ (TDW^J/X?SI7_P!9%_O'^1H 1O\
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M\>#?[IJ2?_5GZC^8I@+)]Z+_ '_Z&AO^/B/_ '6_I1)]Z+_?_H:&_P"/B/\
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MZZO4&O//%'A?5M4\<>&]4M5B-K9.#,7?:P <,<#OP*] Z,/2O0HQ:E)M;O\
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+-2T44 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>celc_10qimg11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 celc_10qimg11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" #] <$# 2(  A$! Q$!_\0
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M-L#'3\>M'0#H:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .!\5:'XPU/6H;C0]=-E
M8B#9+ )C&7;=G((4[>W/<#'&<UNW,5U_:VA_:+HNPWHZA0%9_*;+>OX=*PO%
M6N>--/\ $%O:^']'6[L'@W27!MVE\N3<?1UR,#&/]K.>,5MSS7+ZQHGVBU,1
M8.[MN!"N8VRGKQZ]*%L'4Z.BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[,/,RRN8FRN,8P/7/X5!KOC#2O#NHV]EJ,=V9KB,R0B&W:028/*@C^(#)QZ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\O\ B=X7\:>(I+#_ (1O5H[2TA1Q<1/>2VV\EEY)C'S J&7!Z;LCFN@\!Z7J
M6B^"K'2]8N(Y[J#>,PRM*J(6)5 [?,VU2!D\\5C_ !<L[K4/AW+%:6[7.VZ@
MDD18_,_=AP6)0LH<8_A) -7OAK;K:^!K-5L_LH+NRQ_8Q:#!;J(P[@9]=W-$
M=F#Z&EK4'@^6]5O$/]E&Y2,,IO'0.J;L C<<@;CC/J<5H7@1=5T98\!!))@#
MH!Y35F:_X0T_Q)J$%Y?W5TOV="D<<93:I)Y;E2<D<?2I[_3;%=0TB!K>-TVR
M6YWKN+1^4PVGU'M0M@,OXG8_X0YN?^6\?\Z\2KUSXC:1I</@N18M/MER]O%\
ML0'R(WR+]%[#M7C@L;-7$@M8@XD,N=@SO(P6^I'>O Q]O;?(^9S*WMOD?0O@
M0C_A!-+Y_P"69_\ 0C5KQ9_R)^L?]>LG_H-8/@G0]'F\!:8DFEVKJUJ;<AHE
M(,6\G9T^[GG%7/%FCZ6?#&LW!TVV,K1FY9_*&3(BX5\_W@.A[5ZT?X"]/T/;
MC_NR_P /Z'A->R_"O'_"+W/_ %]M_P"@K7B(T^P"!!9PA=K+C8,8;EA^/>O6
M_AGI&EW'A:\\[3;:3S+M=^Z('=Y:J8\_[IZ>E>/@K>V/"RVWUCY,]3HK'71=
M(602+IML'$DDNX1+G?)Q(WU;N>](V@Z&T30MI%F8FA6V9#"N#$IRJ8Q]T'H.
ME?0GU!LT5E_V3I?V@S?V?;><9_M)?RADR[=N_/\ >V\9ZXJ :#HJQ>2NDV@C
M\E[;;Y"X\ICEDZ?=)Y(Z&@#;HK(_L31]YD_LVVWEXY"?*7):,8C/3JHZ>E*=
M#T<@ Z3:X'F@?N5X\W_6=OXN_KWH UJ*Q5T#0UC\E=)M!'Y4<&T0KCRXSF-.
MG13R!VI_]CZ6MR+C[#;>:LS7 ?RAD2,NUGS_ 'BO!/I0!K9'M2UAQ^'=!AM1
M:QZ)9) L!M1&L"A1#G=Y>,?=SSCIFIGT?2VF\XZ?;&3SEN-QB&?,4;5?_> X
M![4 :N1[4M8T/A_18;=88M)M$C59455A7 64YD XZ,>3Z]Z>VCZ.P(;2K4@^
M5D&%>?+YC[?P]O3M0!K4F1[5D+HVDB1)%TVU!22296$2Y#R??8<=6R<GO3#X
M?T-K8V[:3:&$PK;E#"NWRE.53&/N@\@4 ;=%97]D:;YOF_V;;>9]H^U[O*&?
M.V[?,_WL<9ZXJ(Z#HOE>2ND6?E>4\&SR5QY;G+IC'0GDCO0!M45BMH>CJ79M
M-MB7>.1B8EY:, 1L>.J@#![8J7^Q='W!O[-M<@R,#Y2\&3_6'I_%W]: -6BL
M8^']#>$PMH]F8S''"5,*X*1G,:].BGH.U2#2=-$_VA;&V\SSC<;_ "QGS"NT
MOG^\1QGTH U-P]12UB?\([H/D&W_ +%LO)\G[*8_(7:8MV[R\8^[GG'3-3MI
M.E^<9O[-MC(9$F+>4,[T&$;Z@< ]J -2BL9=!T94"C2;0*$ECP(5QMD.9%Z=
M&/)]>]/;1='?=NTNU;<(U;,2\B,YC'3^$]/2@#6HK(71='683?V;:B0222[Q
M$N=\@P[=.K#@GO3&T/16A\AM)M#%Y(MMAA7'E Y"8Q]T'G'2@#:HK)_LC2FN
M#<?V?;^:9Q=;_*&[S0NT29_O;>,]<5&NA:*(!"-)M!$L3P*GDK@1N<NF,=">
MH[T ;5%8S:'HS2&1M+M2Y:)]QA7.Z/B,].J]O2GKHNDJ4==,M@4:1EQ$ORF3
M_6$?[W?UH UJ*Q3H.AM'Y9TFS*>7'#M\E<;(SN1>G13R!V-2_P!DZ6LZS?V;
M;^:LS7(?RAD2D8+Y_O$<9ZT :F1[4M8A\/Z'Y7D?V/9F/R3;;/)7'E%MQ3&/
MND\XZ9J5M)TII3(VFVS2&5)RQB7)D085_J , ]J -:BL@Z#HI4*=)M" LJ@>
M2O E_P!8.G\7?U[TXZ+I!!!TNUP?*!_=+SY?^K[?P]O3M0!JT5CKH^E^<)_[
M-MA()7G#>4N0[KM=OJ1P3W%1CP_H?V?[/_9-IY/DK;;/)7;Y2G<J8Q]T'D"@
M#<HK);2=+><S-I]NTIG6Y+^4,^:HVA\_W@.,]<5&-!T58?)CTFT$0B> ((5P
M(W.73&.A/)'>@#:HK+;1=)D=FDTVV9F:-F)B4Y,?^K/3^'MZ4BZ+I*L&72[4
M$-*P(B7@R?ZP]/XN_KWH U:*Q6\/Z&\3QMI-FR/"ENRF%<&-#E$/'W5/0=JD
M72=-6?SETZV$WG&YWB(9\TKM+Y_O$<9ZXH U=P]12UA2>'/#\EL;5]$LF@,!
MM3&8%*F$G<8\8^[GG'3-;*JL:*B*%51@ = * )**** /.?BPU@W@OR+R0_\
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M_P#QND^U>+O^@3I?_@:__P ;H WJ;^M>13?%K68;B6%O"]J3&[(2+\\X./\
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MI7P]7#V]HK7.@IOZUP'B+Q=XD\/FV\_0[&8SE@/+OF&,8]8_>L8_%36@,_\
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M^_Y&:3_KW/\ Z$M<[JW_ "&[_P#Z^)?_ $,UT7P]_P"1FD_Z]S_Z$M?"TO\
M?/\ MX_1L5_N/R1ZT?\ 5"O%_&7_ ".=]_NQ_P#H KV@_P"J%>+^,_\ D<[[
M_=C_ /0!7O9S_N\?5'@Y3_&?H_S1F:3_ ,ARP_Z^8O\ T,5[U']Q*\%TC_D.
MV'_7S%_Z&*][C^ZE<V2_PY^J-\X_B1]#SOXF==-_WI/Y"O.7^XWTKT;XD_>T
MW_>D_D*\Y?[C?2N#&?[X_E^AMA?]U7S/H/3O^/"'_KFO\A5[^*J.G?\ 'A#_
M -<U_D*O?Q5][A_X<?0^9G\3'4445L9GE'Q2AT^^OO#^GZUXDN-#TRZF=S,1
M +<2Q@.F]I5(R3P!G!P:W/AOJ%K>>&)EM+U]1@M;R:V2]*1*MR%;[Z>4JJ5]
MP.U-^('B&QT'18FU33;+5+:X9D^S7#*69\?*5C8?.,]<<@'C-6_A]J=[JG@R
MVO+ZSLK,EF6.*Q(\M4!X^4?=/7*]JI;,'T(]9\"V&N7XO+J\O<H694+K(JLQ
MY(WJQ QQM!P.P%;$]E;6VLZ)Y40WQAX5<\ML$;8&:YCQ%X7\4ZQJT=U:>)#;
MP+N4Q(\T(9"<A"$;&5X._J<8Z&NBNK:==2T?=>2M*%>(M@;=WE-\^,=?QQ1T
M#J='5:/_ )"%S_NI_6JPM+S9M_M*3.U%SY:]5/S'I_%^G:H([6Z&I3,;Z0J)
M!(5V+@J00$^@/.>M &S169]COO("?VI+N\O9N\M<[LYW].N.,=*#:WGG,_\
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M/PKWE;6\^SJHU"13Y0CSL7[V<[^G4],=*X,H6D_D;YO\4?F<;\2_OZ9]9/\
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MA@!EOJ:X-X9LLWVIMNXMMVCIC[O]:\[%)?7'KV_0Z<(_]E6G<^B--_X\(?\
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M.3\/YBK55;[_ (\Y/P_F*M4 %%%% %:Q_P"/-?\ >;_T(U9JM8_\>:_[S?\
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MYXWW3]*\?'?[X_E^AZV#_P!S7S/H.Q_Y!\7^Z/Y5RGQ&_P"1:7_KNE=79?\
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MZY_ZZ_\ LJT 6**** *R_P#(2D_ZY+_,U9JLO_(2D_ZY+_,U9H *K77WK?\
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MUT'P_P#^1G;_ *XM_P"A+7PZ_P!Z7^(_0J_^YO\ PH]?KQ/QC_R.=]_NQ_\
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MM0Z7#6G*3-N.),XR2PP3GIT[5WU2!\\ZJ1_;E_S_ ,O$O_H9KH_AZW_%3/\
M]>[?^A+7HMUH>D,/-;3;<LTB[F,:Y.6&<\5-;Z7IMBYDL[&&!R,%DC"DCTX%
M?-?V94AB%6<DTG>UCV9YBIT72L]58T:\7\;?\CI??[J?^@"O:JXC6O \6K:Q
M-J#7TL+2A1L501P /Z5KFN#J8NBJ=-7::?8RRW$4\/5<ZCLK6_%'F^D_\AW3
M_P#KYB_]#%>]K]T5Y_IWP_CAN[2^_M"8^6R3;2JX)!!Q7H([+6.78"MA:<HU
M%:[[IFV9XJGB:D94W>R/.?B9TTWZR?R%>=/]QOI7H?Q._P"8=_O2?R%>>/\
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M_CUE_P!P_P J2V_X]8?]Q?Y4 34444 5[+_CV_X&_P#Z$:L57LO^/;_@;_\
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DB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>celc_10qimg12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 celc_10qimg12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" #N :P# 2(  A$! Q$!_\0
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M<O<,&07")@# '!&>E<V)]HXKV;L<6*]IRKV;L[E+_A;%]_T!8/\ O^?\*/\
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MP3X&_P"@\_\ X$1_X5M%8CK-?@>94]KS/EDK>J*7_"UKW_H"P?\ ?\_X4?\
M"UKW_H"P?]_S_A5O_A"_ _\ T'G_ / F/_"C_A"_ _\ T''_ / F/_"K_P!H
M_F7X&'^T?SK\"I_PM6^_Z L/_?\ /^%4IOB=?/?VDG]CQ?N]Y_UK\9&.O0?B
M#6M_PA?@?_H.O_X$Q_X55F\%^"_MMMMUAR/GR?.C../7M^1S2_VC^=?@3_M'
M\Z_ 7_A:U[_T!8/^_P"?\*C?XI7K_+_8L/4'(G;L<^E7?^$+\#_]!U__  )C
M_P *;)X-\%JF5UQR=P'_ !\Q]"0#VI_[1_.OP#_:/YU^!!_PM:^_Z!,/_?\
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M_E2_?_SK\!?[1_.OP(/^%K7O_0%@_P"_Y_PH_P"%K7O_ $!8/^_Y_P *M_\
M"%^!_P#H//\ ^!,?^%'_  A?@?\ Z#S_ /@3'_A3_P!H_F7X#_VC^=?@9EU\
M3KR:RFB;1DPT;*1YS<Y'L ?R(J2/XK:AY2;M%AW;1G]\P_3%6+CP7X*^S2[=
M<<G8V!]HC;/'ICGZ4^'P7X)\E-VNN#L&1]HC&./3'%+]_P#SK\ _VC^=?@0?
M\+6O?^@+!_W_ #_A1_PM>]_Z L'_ '_/^%6O^$+\$?\ 0>?_ ,"8_P#"E_X0
MGP1_T'G_ / F/_"C_:/YU^ ?[1_.OP*"_%2]5G;^Q83N.?\ 7MQP!Z>U2?\
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MOO\ H"Q?]_\ _P"M7J\;;T5^FX XKA?^%5Z#G_CZOO\ OZO_ ,37>*@5 @Z
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M4=E<XG_A$?$7_0!N/^^1_C1_PB/B+_H W'_?(_QKKO\ A:U[_P! :'_O^?\
MXFD_X6M>_P#0%A_\"#_\37F\M'^9_<>;R4?YV<C_ ,(CXB_Z 5Q_WR/\:/\
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MU?\ L>$A=_)E<D<>N,#\0:5J/\[^XE1H_P [^XYO_A$_$G_0%N/^^1_C3O\
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MTV[Z(X__ (1'Q%_T KC_ +Y'^-'_  B/B+_H!7'_ 'R/\:Z__A;%]_T!8?\
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M_A$_$/\ T!;C_OD?XU?,OY#+VO-KR?F=O_PA/@O_ *#C?^!,?^%'_"$^"_\
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M_H.-_P"!,?\ A7$?\(CXB_Z ,_\ WR/\:/\ A$?$7_0!G_[Y'^-'.OY"-/\
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M\U/K6%.,/A5C:G2A3^!6((O];<?]=!_Z"M3U7C_UMS_UT'_H*U8K0U"BBB@
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MP6S%O[><Y_Z>8_\ "N&C2Q$*DI3DFGMJCV<16HSP\(TU::WV[?YE/_A:<_\
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MBK_G^7_ORO\ A7F6I]Y'D?NN\OP,[_A$?$7_ $ [G_OV*/\ A$?$7_0#N?\
MOV*T?^$^\5?\_P O_?E?\*/^$^\5?\_R_P#?E?\ "BU/O(/W7>7X&=_PB/B+
M_H!W/_?L4?\ "(^(O^@'<_\ ?L5H_P#"?^*_^?Y?^_*_X4?\)_XK_P"?Y?\
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M Z_X4C>/O%6,&^C(R#_J%['/I6-##TL.FHRD[^AZ.-Q]/%N/.FN5=$NIG?\
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M]8O]P>I[>_/YTR[_ ./6;G'[MN<D=O4<_ES3[7_CUA_W%[D]O?G\Z +5%%%
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MV'0?7/X57T_2? ?B6YMVL]MH\>=UH#Y;.??U_"O1[.QLM/MA;V-K'!$/X47
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MN//]K6_E7W'7?\))\-_^>=M_X!-_\12?\)'\-_\ GG;?^ +?_$5R7_"M]?\
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MV2VDKRL8[F1<HP)XV_\ /,>V!65_PK'Q)C_667_?UO\ XFJ%CX%\07M_-;-
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MW*$)N(' SC-%@/6**\(U+5/C-8FS@87<K7?DQ"6UMK8%9#'(67:Q8=0I9F(
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M @<[>V:Z*:7XK-IFD%8FCO3I#F<0"W*?;\<"7<>$QTV?Q=>*@#U*C%>+3?\
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M- Y4H&";V(!"+N91EL?>% '<45S'AOQ=H?BZVFN-#NGF6!E#B2%XF 894X8
MD$<@]#73T %5Y?\ C\@^C?TJQ5>7_C\@^C?TH L4444 %%%% !1110!!>?\
M'E+_ +M3U!>?\>4O^[4] !1110 4444 %%%% &)XDU[3?#'A^YUS5V9;&VVF
M5E7=M!8#./J17$V_Q=\&RWMUI[6=]'<6N[[1$UH,QX>-?F )QS*A_/TKL?$W
MAW3_ !7X<N= U+>;*ZVB54(!8!@V.0>N*XFS^"?AFSU;4=5_M'4IKS4HA%<2
M22)E@'1L\+U^111'?4'MH=;X8\2:9XGTR74--AFBB69HV6:,(Q8 '=@$\$$$
M'WKF-0\1>%].UN_L]6TL3W2W#%G^S))D'!')YZ5U'A?PS8^%=*ETZQN+B>-Y
MFF+SD%LD  < # "@?AS7 Z]X;AU+Q+J=Y)X@TVQ9K@CR9GPZX '//>N;$<W*
MN179R8GVG)^[5W?\#3_X2[P#_P! /_R32F_\)=\/_P#H!_\ DFE<[_PA=G_T
M-VD_]_!_C3_^$,L_^ALTG_OX/\:\_P#??RK[CS?]H_E7W(Z'_A+/A_\ ] ,?
M^ B4?\)9\/\ _H!C_P !$KG?^$-L_P#H:])_[^#_ !H_X0NS_P"ANTG_ +^#
M_&C]]_(ON%_M'\J^Y'1_\)A\/\?\@$?^ B5IZ!J'A#Q%<RVUCHL2RQ()&\VU
M51@G'O7%?\(79_\ 0W:3_P!_!_C72>#=,TWPWJ%S=7/BC2YUEC$86.9000<]
MS6M+VSFE4@K?(VH^V=1*I!6]$=I'X?T4SS@Z39$!AC_1TX^4>U/7P_HJL&72
MK,,#D$6Z9!_*F0^(M ^TW)_MRPY9?^7A/[H]ZG_X2+P__P!!RP_\"$_QKTN2
M/8]7V<>QJT5E_P#"1^'_ /H.6'_@0G^-'_"1^'_^@Y8?^!"?XU19J5F7&1J5
MHOF%=V_Y=ZC=P.Q&3^'2D_X2/P__ -!RP_\  A/\:R[KQ)H(U.Q4>(+$>9Y@
M ^U1@'"YZ=3^!% '45#=?Z@?[Z?^A"J/_"1^'_\ H.6'_@0G^-0W/B+P^81_
MQ/+#[Z?\O"?WA[T ;5%9?_"1^'_^@Y8?^!"?XT?\)'X?_P"@Y8?^!"?XT :E
M%9?_  D?A_\ Z#EA_P"!"?XT?\)'X?\ ^@Y8?^!"?XT :E%9?_"1^'_^@Y8?
M^!"?XT?\)'X?_P"@Y8?^!"?XT :$O^K?_=--MO\ CUA_W%_E6=)XB\/^4_\
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# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>celc-20210331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05-10-2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:celc="http://celcuity.com/20210331" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://celcuity.com/20210331">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://celcuity.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/CondensedBalanceSheets" id="CondensedBalanceSheets">
        <link:definition>000002 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/CondensedBalanceSheetsParenthetical" id="CondensedBalanceSheetsParenthetical">
        <link:definition>000003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited" id="CondensedStatementsOfOperationsUnaudited">
        <link:definition>000004 - Statement - Condensed Statements of Operations (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity" id="CondensedStatementsOfChangesInStockholdersEquity">
        <link:definition>000005 - Statement - Condensed Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited" id="CondensedStatementsOfCashFlowsUnaudited">
        <link:definition>000006 - Statement - Condensed Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/Organization" id="Organization">
        <link:definition>000007 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/NetLossPerCommonShare" id="NetLossPerCommonShare">
        <link:definition>000009 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/Commitments" id="Commitments">
        <link:definition>000010 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>000011 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>000012 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>000013 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>000014 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/CommitmentsTables" id="CommitmentsTables">
        <link:definition>000015 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
        <link:definition>000016 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
        <link:definition>000017 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarative" id="NetLossPerCommonShareDetailsNarative">
        <link:definition>000018 - Disclosure - Net Loss Per Common Share (Details Narative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/CommitmentsDetails" id="CommitmentsDetails">
        <link:definition>000019 - Disclosure - Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/CommitmentsDetails1" id="CommitmentsDetails1">
        <link:definition>000020 - Disclosure - Commitments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/CommitmentsDetails2" id="CommitmentsDetails2">
        <link:definition>000021 - Disclosure - Commitments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/CommitmentsDetails3" id="CommitmentsDetails3">
        <link:definition>000022 - Disclosure - Commitments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/CommitmentsDetails4" id="CommitmentsDetails4">
        <link:definition>000023 - Disclosure - Commitments (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" id="CommitmentsDetailsNarrative">
        <link:definition>000024 - Disclosure - Commitments (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
        <link:definition>000025 - Disclosure - Stockholders Equity (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/StockbasedCompensationDetails" id="StockbasedCompensationDetails">
        <link:definition>000026 - Disclosure - StockBased Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/StockbasedCompensationDetails1" id="StockbasedCompensationDetails1">
        <link:definition>000027 - Disclosure - StockBased Compensation (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/StockbasedCompensationDetails2" id="StockbasedCompensationDetails2">
        <link:definition>000028 - Disclosure - StockBased Compensation (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/StockbasedCompensationDetails3" id="StockbasedCompensationDetails3">
        <link:definition>000029 - Disclosure - StockBased Compensation (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/StockbasedCompensationDetails4" id="StockbasedCompensationDetails4">
        <link:definition>000030 - Disclosure - StockBased Compensation (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/StockbasedCompensationDetailsNarrative" id="StockbasedCompensationDetailsNarrative">
        <link:definition>000031 - Disclosure - StockBased Compensation (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celcuity.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>000032 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="celc-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="celc-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="celc-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="celc-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <import namespace="http://fasb.org/srt-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" />
  <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <element id="celc_LossOnSaleOfFixedAssets" name="LossOnSaleOfFixedAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_ExerciseOfCommonStockWarrantsShares" name="ExerciseOfCommonStockWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="celc_ExerciseOfCommonStockWarrantsAmount" name="ExerciseOfCommonStockWarrantsAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_IssuanceCostsAssociatedWithAtmOffering" name="IssuanceCostsAssociatedWithAtmOffering" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_IncreaseDecreaseInNonCashOperatingLeaseExpense" name="IncreaseDecreaseInNonCashOperatingLeaseExpense" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" name="ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_GrossProceedsFromAnAtmOffering" name="GrossProceedsFromAnAtmOffering" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_PaymentsForRegistrationStatementCosts" name="PaymentsForRegistrationStatementCosts" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_PaymentsForFinanceLeases" name="PaymentsForFinanceLeases" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" name="OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_FollowOnOfferingPolicyTextBlock" name="FollowOnOfferingPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="celc_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" name="ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="celc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="celc_ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock" name="ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="celc_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares" name="IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock" name="IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="celc_NetOfUnderwritingDiscountsAndOfferingCosts" name="NetOfUnderwritingDiscountsAndOfferingCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_OfferingExpenses" name="OfferingExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_LongTermOperatingLeaseLiability" name="LongTermOperatingLeaseLiability" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_FinanceLeaseLiabilities" name="FinanceLeaseLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_LessPresentValueDiscount" name="LessPresentValueDiscount" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_LesseeOperatingLeaseLiabilityAmountRepresentingServices" name="LesseeOperatingLeaseLiabilityAmountRepresentingServices" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_LessAmountRepresentingServices" name="LessAmountRepresentingServices" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_OperatingLeaseWeightedAverageRemainingLeasesTerm1" name="OperatingLeaseWeightedAverageRemainingLeasesTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="celc_FinanceLeaseWeightedAverageRemainingLeasesTerm1" name="FinanceLeaseWeightedAverageRemainingLeasesTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="celc_FinanceLeaseCostsAbstract" name="FinanceLeaseCostsAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="celc_CashPaidForOperatingAndFinanceLeasesAbstract" name="CashPaidForOperatingAndFinanceLeasesAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="celc_CashPaidForOperatingAndFinanceLeases" name="CashPaidForOperatingAndFinanceLeases" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_FuturePaymentsRequiredUponCertainMilestonesBeingMet" name="FuturePaymentsRequiredUponCertainMilestonesBeingMet" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_EstimatedRemainingAmountOfPayments" name="EstimatedRemainingAmountOfPayments" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_PublicOfferingPrice" name="PublicOfferingPrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="celc_AverageSellingPricePerShare" name="AverageSellingPricePerShare" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="celc_SharesOptionsOutstandingBeginning" name="SharesOptionsOutstandingBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="celc_SharesExercised" name="SharesExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="celc_SharesOptionsOutstandingEnding" name="SharesOptionsOutstandingEnding" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="celc_SharesOptionsExercisables" name="SharesOptionsExercisables" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="celc_WeightedAverageExercisePriceBeginning" name="WeightedAverageExercisePriceBeginning" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="celc_WeightedAverageExercisePriceEnding" name="WeightedAverageExercisePriceEnding" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="celc_WeightedAverageExercisePriceOptionsExercisables" name="WeightedAverageExercisePriceOptionsExercisables" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="celc_OptionsOutstandingWeightedAverageExercisePrice" name="OptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" name="EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" name="EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" name="EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" name="EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears" name="EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_FutureExpenses" name="FutureExpenses" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_StockBasedCompensationRelatedToRestrictedStockTotal" name="StockBasedCompensationRelatedToRestrictedStockTotal" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_StockBasedCompensationExpenseRelatedToEspp" name="StockBasedCompensationExpenseRelatedToEspp" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_ShareExercisePrice" name="ShareExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="celc_CommonStockSharesReservedDescription" name="CommonStockSharesReservedDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="celc_RemainingSharesAvailableForIssuance" name="RemainingSharesAvailableForIssuance" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="celc_StockOptionAwardsSharesModified" name="StockOptionAwardsSharesModified" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="celc_ClosingPricePerShare" name="ClosingPricePerShare" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="celc_UpfrontFee" name="UpfrontFee" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="celc_DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents" name="DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantsMember" id="celc_WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SupplementalBalanceSheetInformationMember" id="celc_SupplementalBalanceSheetInformationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OperatingLeasesMember" id="celc_OperatingLeasesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsMember" id="celc_StockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RestrictedStocksMember" id="celc_RestrictedStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FinanceLeasesMember" id="celc_FinanceLeasesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PlacementSharesMember" id="celc_PlacementSharesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AtmAgreementMember" id="celc_AtmAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockIncentivePlanMember" id="celc_StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ExpenseStockOptionsMember" id="celc_ExpenseStockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EmployeeStockPurchasePlanMember" id="celc_EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PfizerIncMember" id="celc_PfizerIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="LicenseAgreementMember" id="celc_LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EquityGrantAgreementMember" id="celc_EquityGrantAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TrancheMember" id="celc_TrancheMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SecondTrancheMember" id="celc_SecondTrancheMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AgreementWithBiopharmaceuticalCompanyTwoMember" id="celc_AgreementWithBiopharmaceuticalCompanyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AgreementWithBiopharmaceuticalCompanyOneMember" id="celc_AgreementWithBiopharmaceuticalCompanyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JanuaryTwoThousandTwentyOneMember" id="celc_JanuaryTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AgreementWithBiopharmaceuticalCompanyMember" id="celc_AgreementWithBiopharmaceuticalCompanyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="MarchTwoThousandTwentyOneMember" id="celc_MarchTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EmployeeStockOptionsMember" id="celc_EmployeeStockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ThirdTrancheMember" id="celc_ThirdTrancheMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>celc-20210331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05-10-2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://celcuity.com/role/Cover" xlink:href="celc-20210331.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CondensedBalanceSheets" xlink:href="celc-20210331.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CondensedBalanceSheetsParenthetical" xlink:href="celc-20210331.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="celc-20210331.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity" xlink:href="celc-20210331.xsd#CondensedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="celc-20210331.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/Organization" xlink:href="celc-20210331.xsd#Organization" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="celc-20210331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShare" xlink:href="celc-20210331.xsd#NetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/Commitments" xlink:href="celc-20210331.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquity" xlink:href="celc-20210331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockBasedCompensation" xlink:href="celc-20210331.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/SubsequentEvents" xlink:href="celc-20210331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="celc-20210331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsTables" xlink:href="celc-20210331.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockBasedCompensationTables" xlink:href="celc-20210331.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="celc-20210331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarative" xlink:href="celc-20210331.xsd#NetLossPerCommonShareDetailsNarative" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetails" xlink:href="celc-20210331.xsd#CommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetails1" xlink:href="celc-20210331.xsd#CommitmentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetails2" xlink:href="celc-20210331.xsd#CommitmentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetails3" xlink:href="celc-20210331.xsd#CommitmentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetails4" xlink:href="celc-20210331.xsd#CommitmentsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:href="celc-20210331.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:href="celc-20210331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetails" xlink:href="celc-20210331.xsd#StockbasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetails1" xlink:href="celc-20210331.xsd#StockbasedCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetails2" xlink:href="celc-20210331.xsd#StockbasedCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetails3" xlink:href="celc-20210331.xsd#StockbasedCompensationDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetails4" xlink:href="celc-20210331.xsd#StockbasedCompensationDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetailsNarrative" xlink:href="celc-20210331.xsd#StockbasedCompensationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/SubsequentEventsDetailsNarrative" xlink:href="celc-20210331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - Condensed Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - Condensed Balance Sheets (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - Condensed Statements of Operations (unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LossOnSaleOfFixedAssets" xlink:label="loc_celcLossOnSaleOfFixedAssets" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_celcLossOnSaleOfFixedAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity" xlink:title="000005 - Statement - Condensed Statements of Changes in Stockholders' Equity" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - Condensed Statements of Cash Flows (unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:label="loc_celcIncreaseDecreaseInNonCashOperatingLeaseExpense" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_celcIncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="loc_celcProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_celcProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_GrossProceedsFromAnAtmOffering" xlink:label="loc_celcGrossProceedsFromAnAtmOffering" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_celcGrossProceedsFromAnAtmOffering" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_PaymentsForRegistrationStatementCosts" xlink:label="loc_celcPaymentsForRegistrationStatementCosts" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_celcPaymentsForRegistrationStatementCosts" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_PaymentsForFinanceLeases" xlink:label="loc_celcPaymentsForFinanceLeases" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_celcPaymentsForFinanceLeases" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Organization" xlink:title="000007 - Disclosure - Organization" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000008 - Disclosure - Summary of Significant Accounting Policies" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShare" xlink:title="000009 - Disclosure - Net Loss Per Common Share" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Commitments" xlink:title="000010 - Disclosure - Commitments" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquity" xlink:title="000011 - Disclosure - Stockholders' Equity" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockBasedCompensation" xlink:title="000012 - Disclosure - Stock-Based Compensation" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEvents" xlink:title="000013 - Disclosure - Subsequent Events" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000014 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsTables" xlink:title="000015 - Disclosure - Commitments (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockBasedCompensationTables" xlink:title="000016 - Disclosure - Stock-Based Compensation (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000017 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareDetailsNarative" xlink:title="000018 - Disclosure - Net Loss Per Common Share (Details Narative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetails" xlink:title="000019 - Disclosure - Commitments (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetails1" xlink:title="000020 - Disclosure - Commitments (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetails2" xlink:title="000021 - Disclosure - Commitments (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetails3" xlink:title="000022 - Disclosure - Commitments (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetails4" xlink:title="000023 - Disclosure - Commitments (Details 4)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:title="000024 - Disclosure - Commitments (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:title="000025 - Disclosure - Stockholders Equity (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetails" xlink:title="000026 - Disclosure - StockBased Compensation (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetails1" xlink:title="000027 - Disclosure - StockBased Compensation (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetails2" xlink:title="000028 - Disclosure - StockBased Compensation (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetails3" xlink:title="000029 - Disclosure - StockBased Compensation (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetails4" xlink:title="000030 - Disclosure - StockBased Compensation (Details 4)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetailsNarrative" xlink:title="000031 - Disclosure - StockBased Compensation (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEventsDetailsNarrative" xlink:title="000032 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>celc-20210331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05-10-2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://celcuity.com/role/Cover" xlink:href="celc-20210331.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CondensedBalanceSheets" xlink:href="celc-20210331.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CondensedBalanceSheetsParenthetical" xlink:href="celc-20210331.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="celc-20210331.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity" xlink:href="celc-20210331.xsd#CondensedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="celc-20210331.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/Organization" xlink:href="celc-20210331.xsd#Organization" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="celc-20210331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShare" xlink:href="celc-20210331.xsd#NetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/Commitments" xlink:href="celc-20210331.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquity" xlink:href="celc-20210331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockBasedCompensation" xlink:href="celc-20210331.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/SubsequentEvents" xlink:href="celc-20210331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="celc-20210331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsTables" xlink:href="celc-20210331.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockBasedCompensationTables" xlink:href="celc-20210331.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="celc-20210331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarative" xlink:href="celc-20210331.xsd#NetLossPerCommonShareDetailsNarative" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetails" xlink:href="celc-20210331.xsd#CommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetails1" xlink:href="celc-20210331.xsd#CommitmentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetails2" xlink:href="celc-20210331.xsd#CommitmentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetails3" xlink:href="celc-20210331.xsd#CommitmentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetails4" xlink:href="celc-20210331.xsd#CommitmentsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:href="celc-20210331.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:href="celc-20210331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetails" xlink:href="celc-20210331.xsd#StockbasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetails1" xlink:href="celc-20210331.xsd#StockbasedCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetails2" xlink:href="celc-20210331.xsd#StockbasedCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetails3" xlink:href="celc-20210331.xsd#StockbasedCompensationDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetails4" xlink:href="celc-20210331.xsd#StockbasedCompensationDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetailsNarrative" xlink:href="celc-20210331.xsd#StockbasedCompensationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/SubsequentEventsDetailsNarrative" xlink:href="celc-20210331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - Condensed Balance Sheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - Condensed Balance Sheets (Parenthetical)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - Condensed Statements of Operations (unaudited)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity" xlink:title="000005 - Statement - Condensed Statements of Changes in Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="4" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ExerciseOfCommonStockWarrantsShares" xlink:label="loc_celcExerciseOfCommonStockWarrantsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcExerciseOfCommonStockWarrantsShares" order="5" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ExerciseOfCommonStockWarrantsAmount" xlink:label="loc_celcExerciseOfCommonStockWarrantsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcExerciseOfCommonStockWarrantsAmount" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" order="12" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_IssuanceCostsAssociatedWithAtmOffering" xlink:label="loc_celcIssuanceCostsAssociatedWithAtmOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcIssuanceCostsAssociatedWithAtmOffering" order="13" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - Condensed Statements of Cash Flows (unaudited)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Organization" xlink:title="000007 - Disclosure - Organization" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000008 - Disclosure - Summary of Significant Accounting Policies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShare" xlink:title="000009 - Disclosure - Net Loss Per Common Share" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Commitments" xlink:title="000010 - Disclosure - Commitments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquity" xlink:title="000011 - Disclosure - Stockholders' Equity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockBasedCompensation" xlink:title="000012 - Disclosure - Stock-Based Compensation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEvents" xlink:title="000013 - Disclosure - Subsequent Events" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000014 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsTables" xlink:title="000015 - Disclosure - Commitments (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockBasedCompensationTables" xlink:title="000016 - Disclosure - Stock-Based Compensation (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000017 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareDetailsNarative" xlink:title="000018 - Disclosure - Net Loss Per Common Share (Details Narative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_WarrantsMember" xlink:label="loc_celcWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_celcWarrantsMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_StockOptionsMember" xlink:label="loc_celcStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_celcStockOptionsMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_RestrictedStocksMember" xlink:label="loc_celcRestrictedStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_celcRestrictedStocksMember" order="43" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetails" xlink:title="000019 - Disclosure - Commitments (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SupplementalBalanceSheetInformationMember" xlink:label="loc_celcSupplementalBalanceSheetInformationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_celcSupplementalBalanceSheetInformationMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" order="3" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LongTermOperatingLeaseLiability" xlink:label="loc_celcLongTermOperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcLongTermOperatingLeaseLiability" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasedAssetsGross" xlink:label="loc_us-gaapCapitalLeasedAssetsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalLeasedAssetsGross" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation" xlink:label="loc_us-gaapCapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet" xlink:label="loc_us-gaapCapitalLeasesBalanceSheetAssetsByMajorClassNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalLeasesBalanceSheetAssetsByMajorClassNet" order="7" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FinanceLeaseLiabilities" xlink:label="loc_celcFinanceLeaseLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcFinanceLeaseLiabilities" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermBorrowings" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" order="10" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetails1" xlink:title="000020 - Disclosure - Commitments (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealEstatePropertiesAxis" xlink:label="loc_us-gaapRealEstatePropertiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRealEstatePropertiesAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealEstatePropertiesDomain" xlink:label="loc_us-gaapRealEstatePropertiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRealEstatePropertiesAxis" xlink:to="loc_us-gaapRealEstatePropertiesDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealEstatePropertiesDomain" xlink:label="loc_us-gaapRealEstatePropertiesDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRealEstatePropertiesAxis" xlink:to="loc_us-gaapRealEstatePropertiesDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_OperatingLeasesMember" xlink:label="loc_celcOperatingLeasesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRealEstatePropertiesDomain" xlink:to="loc_celcOperatingLeasesMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FinanceLeasesMember" xlink:label="loc_celcFinanceLeasesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRealEstatePropertiesDomain" xlink:to="loc_celcFinanceLeasesMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" order="4" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LessPresentValueDiscount" xlink:label="loc_celcLessPresentValueDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcLessPresentValueDiscount" order="5" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LesseeOperatingLeaseLiabilityAmountRepresentingServices" xlink:label="loc_celcLesseeOperatingLeaseLiabilityAmountRepresentingServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcLesseeOperatingLeaseLiabilityAmountRepresentingServices" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" order="11" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LessAmountRepresentingServices" xlink:label="loc_celcLessAmountRepresentingServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcLessAmountRepresentingServices" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiability" order="13" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetails2" xlink:title="000021 - Disclosure - Commitments (Details 2)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetails3" xlink:title="000022 - Disclosure - Commitments (Details 3)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetails4" xlink:title="000023 - Disclosure - Commitments (Details 4)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:title="000024 - Disclosure - Commitments (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_AgreementWithBiopharmaceuticalCompanyOneMember" xlink:label="loc_celcAgreementWithBiopharmaceuticalCompanyOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_celcAgreementWithBiopharmaceuticalCompanyOneMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_JanuaryTwoThousandTwentyOneMember" xlink:label="loc_celcJanuaryTwoThousandTwentyOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_celcJanuaryTwoThousandTwentyOneMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_AgreementWithBiopharmaceuticalCompanyMember" xlink:label="loc_celcAgreementWithBiopharmaceuticalCompanyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_celcAgreementWithBiopharmaceuticalCompanyMember" order="43" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_AgreementWithBiopharmaceuticalCompanyTwoMember" xlink:label="loc_celcAgreementWithBiopharmaceuticalCompanyTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_celcAgreementWithBiopharmaceuticalCompanyTwoMember" order="44" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_MarchTwoThousandTwentyOneMember" xlink:label="loc_celcMarchTwoThousandTwentyOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_celcMarchTwoThousandTwentyOneMember" order="45" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapital" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" order="2" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EstimatedRemainingAmountOfPayments" xlink:label="loc_celcEstimatedRemainingAmountOfPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcEstimatedRemainingAmountOfPayments" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapContractualObligation" order="4" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FuturePaymentsRequiredUponCertainMilestonesBeingMet" xlink:label="loc_celcFuturePaymentsRequiredUponCertainMilestonesBeingMet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcFuturePaymentsRequiredUponCertainMilestonesBeingMet" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:title="000025 - Disclosure - Stockholders Equity (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:label="loc_us-gaapOtherInvestmentNotReadilyMarketableAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOtherInvestmentNotReadilyMarketableAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:label="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherInvestmentNotReadilyMarketableAxis" xlink:to="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:label="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapOtherInvestmentNotReadilyMarketableAxis" xlink:to="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_PlacementSharesMember" xlink:label="loc_celcPlacementSharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_celcPlacementSharesMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_AtmAgreementMember" xlink:label="loc_celcAtmAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain" xlink:to="loc_celcAtmAgreementMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_PublicOfferingPrice" xlink:label="loc_celcPublicOfferingPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcPublicOfferingPrice" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalesCommissionsAndFees" order="3" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_OfferingExpenses" xlink:label="loc_celcOfferingExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcOfferingExpenses" order="4" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock" xlink:label="loc_celcIssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcIssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock" order="5" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares" xlink:label="loc_celcIssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcIssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:label="loc_us-gaapEquityMethodInvestmentQuotedMarketValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentQuotedMarketValue" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" order="9" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_AverageSellingPricePerShare" xlink:label="loc_celcAverageSellingPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcAverageSellingPricePerShare" order="10" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetails" xlink:title="000026 - Disclosure - StockBased Compensation (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeStockOptionsMember" xlink:label="loc_celcEmployeeStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_celcEmployeeStockOptionsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SharesOptionsOutstandingBeginning" xlink:label="loc_celcSharesOptionsOutstandingBeginning" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcSharesOptionsOutstandingBeginning" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SharesExercised" xlink:label="loc_celcSharesExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcSharesExercised" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SharesOptionsOutstandingEnding" xlink:label="loc_celcSharesOptionsOutstandingEnding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcSharesOptionsOutstandingEnding" order="5" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SharesOptionsExercisables" xlink:label="loc_celcSharesOptionsExercisables" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcSharesOptionsExercisables" order="6" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_WeightedAverageExercisePriceBeginning" xlink:label="loc_celcWeightedAverageExercisePriceBeginning" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcWeightedAverageExercisePriceBeginning" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_WeightedAverageExercisePriceEnding" xlink:label="loc_celcWeightedAverageExercisePriceEnding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcWeightedAverageExercisePriceEnding" order="11" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_WeightedAverageExercisePriceOptionsExercisables" xlink:label="loc_celcWeightedAverageExercisePriceOptionsExercisables" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcWeightedAverageExercisePriceOptionsExercisables" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="13" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetails1" xlink:title="000027 - Disclosure - StockBased Compensation (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeStockOptionsMember" xlink:label="loc_celcEmployeeStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_celcEmployeeStockOptionsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_OptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_celcOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcOptionsOutstandingWeightedAverageExercisePrice" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetails2" xlink:title="000028 - Disclosure - StockBased Compensation (Details 2)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeStockOptionsMember" xlink:label="loc_celcEmployeeStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_celcEmployeeStockOptionsMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="33" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetails3" xlink:title="000029 - Disclosure - StockBased Compensation (Details 3)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetails4" xlink:title="000030 - Disclosure - StockBased Compensation (Details 4)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetailsNarrative" xlink:title="000031 - Disclosure - StockBased Compensation (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeStockOptionsMember" xlink:label="loc_celcEmployeeStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_celcEmployeeStockOptionsMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ExpenseStockOptionsMember" xlink:label="loc_celcExpenseStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_celcExpenseStockOptionsMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_StockIncentivePlanMember" xlink:label="loc_celcStockIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_celcStockIncentivePlanMember" order="33" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" order="34" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeStockPurchasePlanMember" xlink:label="loc_celcEmployeeStockPurchasePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_celcEmployeeStockPurchasePlanMember" order="35" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FutureExpenses" xlink:label="loc_celcFutureExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcFutureExpenses" order="1" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_StockBasedCompensationRelatedToRestrictedStockTotal" xlink:label="loc_celcStockBasedCompensationRelatedToRestrictedStockTotal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcStockBasedCompensationRelatedToRestrictedStockTotal" order="2" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ShareExercisePrice" xlink:label="loc_celcShareExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcShareExercisePrice" order="3" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_CommonStockSharesReservedDescription" xlink:label="loc_celcCommonStockSharesReservedDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcCommonStockSharesReservedDescription" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="5" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_StockOptionAwardsSharesModified" xlink:label="loc_celcStockOptionAwardsSharesModified" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcStockOptionAwardsSharesModified" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" order="7" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_StockBasedCompensationExpenseRelatedToEspp" xlink:label="loc_celcStockBasedCompensationExpenseRelatedToEspp" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcStockBasedCompensationExpenseRelatedToEspp" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalUnitsOutstanding" xlink:label="loc_us-gaapCapitalUnitsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalUnitsOutstanding" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_RemainingSharesAvailableForIssuance" xlink:label="loc_celcRemainingSharesAvailableForIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcRemainingSharesAvailableForIssuance" order="11" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEventsDetailsNarrative" xlink:title="000032 - Disclosure - Subsequent Events (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:label="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:label="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseAxis" xlink:to="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:label="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseAxis" xlink:to="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_PfizerIncMember" xlink:label="loc_celcPfizerIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_celcPfizerIncMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LicenseAgreementMember" xlink:label="loc_celcLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:to="loc_celcLicenseAgreementMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EquityGrantAgreementMember" xlink:label="loc_celcEquityGrantAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:to="loc_celcEquityGrantAgreementMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ThirdTrancheMember" xlink:label="loc_celcThirdTrancheMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_celcThirdTrancheMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_TrancheMember" xlink:label="loc_celcTrancheMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_celcTrancheMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SecondTrancheMember" xlink:label="loc_celcSecondTrancheMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_celcSecondTrancheMember" order="67" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermLoansPayable" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtDescription" xlink:label="loc_us-gaapLongTermDebtDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtDescription" order="3" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ClosingPricePerShare" xlink:label="loc_celcClosingPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcClosingPricePerShare" order="4" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_UpfrontFee" xlink:label="loc_celcUpfrontFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcUpfrontFee" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="6" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents" xlink:label="loc_celcDescriptionOfCertainDevelopmentAndCommercialMilestoneEvents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_celcDescriptionOfCertainDevelopmentAndCommercialMilestoneEvents" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue" order="8" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>celc-20210331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05-10-2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_243114" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_243114" xml:lang="en-US">Condensed Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl_9178ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl_9178ee" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_529219" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_529219" xml:lang="en-US">Current Assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_981601" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_981601" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl_1f434c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl_1f434c" xml:lang="en-US">Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl_17186e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl_17186e" xml:lang="en-US">Deferred transaction costs</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl_f23584" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl_f23584" xml:lang="en-US">Payroll tax receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl_be1f93" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl_be1f93" xml:lang="en-US">Prepaid assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_370440" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_370440" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_9" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_297e19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_297e19" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_864547" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_864547" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_43cdd2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_43cdd2" xml:lang="en-US">Total Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_12" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_797a59" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_797a59" xml:lang="en-US">Liabilities and Stockholders' Equity:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_8665c2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_8665c2" xml:lang="en-US">Current Liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_826a61" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_826a61" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_6d0efe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_6d0efe" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_e0d9d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_e0d9d7" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_890c32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_890c32" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_d85039" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_d85039" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_19" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_a711f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_a711f9" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_20" xml:lang="en-US">[Finance Lease, Liability, Noncurrent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_f7562f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_f7562f" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_21" xml:lang="en-US">[Operating Lease, Liability, Noncurrent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_2eb51c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_2eb51c" xml:lang="en-US">Total Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_22" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_223f49" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_223f49" xml:lang="en-US">Stockholders' Equity:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_81462f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_81462f" xml:lang="en-US">Preferred stock, $0.001 par value: 2,500,000 shares authorized; 0 shares issued and outstanding as of March 31, 2021 and December 31, 2020</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_6a3ea0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_6a3ea0" xml:lang="en-US">Common stock, $0.001 par value: 25,000,000 shares authorized; 12,287,896 and 10,299,822 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_4a8906" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_4a8906" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_f32bac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_f32bac" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_48c3a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_48c3a2" xml:lang="en-US">Total Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_28" xml:lang="en-US">[Stockholders' Equity Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_18e74f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_18e74f" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_29" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_29" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_200d18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_200d18" xml:lang="en-US">Preferred stock, par or stated value per share</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_37576e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_37576e" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_2667d4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_2667d4" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_53d381" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_53d381" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_4de57d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_4de57d" xml:lang="en-US">Common stock, par or stated value per share</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_b7bea2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_b7bea2" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_46dcc7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_46dcc7" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_13fe28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_13fe28" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_9f238e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_9f238e" xml:lang="en-US">Condensed Statements of Operations (unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_bf2cee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_bf2cee" xml:lang="en-US">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_343d51" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_343d51" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl_dd563a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl_dd563a" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_02c222" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_02c222" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_5" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_8d132e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_8d132e" xml:lang="en-US">Loss from operations</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_6" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl_c385b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl_c385b1" xml:lang="en-US">Other income (expense)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_d56d02" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl_d56d02" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl_8" xml:lang="en-US">[Interest Expense]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl_17fc55" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl_17fc55" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_LossOnSaleOfFixedAssets" xlink:to="celc_LossOnSaleOfFixedAssets_lbl_ad0376" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="celc_LossOnSaleOfFixedAssets_lbl_ad0376" xml:lang="en-US">Loss on sale of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LossOnSaleOfFixedAssets" xlink:label="celc_LossOnSaleOfFixedAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_LossOnSaleOfFixedAssets" xlink:to="celc_LossOnSaleOfFixedAssets_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_LossOnSaleOfFixedAssets_lbl_10" xml:lang="en-US">[Loss on sale of fixed assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl_c164b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl_c164b2" xml:lang="en-US">Other income, net</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl_11" xml:lang="en-US">[Nonoperating Income (Expense)]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_d3794c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_d3794c" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_12" xml:lang="en-US">[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl_e4f999" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl_e4f999" xml:lang="en-US">Income tax benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_6a6925" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_6a6925" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_14" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl_af63e4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl_af63e4" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_c71201" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_c71201" xml:lang="en-US">Weighted average common shares outstanding, basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_e4515e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_e4515e" xml:lang="en-US">Condensed Statements of Changes in Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_c594d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_c594d9" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_5d7f20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_5d7f20" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_64ea2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_64ea2f" xml:lang="en-US">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_0a1a2e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_0a1a2e" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_f765d4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_f765d4" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_bbec99" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_bbec99" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_05fa0e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_05fa0e" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_df0b94" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_df0b94" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_623345" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_623345" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_3a5d45" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_3a5d45" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ExerciseOfCommonStockWarrantsShares" xlink:label="celc_ExerciseOfCommonStockWarrantsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_ExerciseOfCommonStockWarrantsShares" xlink:to="celc_ExerciseOfCommonStockWarrantsShares_lbl_64098f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_ExerciseOfCommonStockWarrantsShares_lbl_64098f" xml:lang="en-US">Exercise of common stock warrants, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ExerciseOfCommonStockWarrantsAmount" xlink:label="celc_ExerciseOfCommonStockWarrantsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_ExerciseOfCommonStockWarrantsAmount" xlink:to="celc_ExerciseOfCommonStockWarrantsAmount_lbl_e5e1ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_ExerciseOfCommonStockWarrantsAmount_lbl_e5e1ad" xml:lang="en-US">Exercise of common stock warrants, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_2791f0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_2791f0" xml:lang="en-US">Exercise of common stock options, net of shares withheld for exercise price, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_e45546" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_e45546" xml:lang="en-US">Exercise of common stock options, net of shares withheld for exercise price, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_d0b0e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_d0b0e9" xml:lang="en-US">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl_b69558" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl_b69558" xml:lang="en-US">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_240d81" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_240d81" xml:lang="en-US">Issuance of common stock in an at-the-market ("ATM") offering, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_563863" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_563863" xml:lang="en-US">Issuance of common stock in an at-the-market ("ATM") offering, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_IssuanceCostsAssociatedWithAtmOffering" xlink:label="celc_IssuanceCostsAssociatedWithAtmOffering" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_IssuanceCostsAssociatedWithAtmOffering" xlink:to="celc_IssuanceCostsAssociatedWithAtmOffering_lbl_9f1ab7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_IssuanceCostsAssociatedWithAtmOffering_lbl_9f1ab7" xml:lang="en-US">Issuance costs associated with ATM offering</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_43f7b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_43f7b2" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_2a4d82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_2a4d82" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_8ff055" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_8ff055" xml:lang="en-US">Condensed Statements of Cash Flows (unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_504536" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_504536" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_468888" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_468888" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_d59345" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_d59345" xml:lang="en-US">Adjustments to reconcile net loss to net cash used for operations:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl_81452d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl_81452d" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_60b453" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl_60b453" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_6" xml:lang="en-US">[Share-based Payment Arrangement, Noncash Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl_25cea3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl_25cea3" xml:lang="en-US">Loss on sale of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl_7" xml:lang="en-US">[Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_3d8b54" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_3d8b54" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl_60f000" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl_60f000" xml:lang="en-US">Prepaid assets and deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_0cf064" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_0cf064" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_10" xml:lang="en-US">[Increase (Decrease) in Accounts Payable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_d96f0f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_d96f0f" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_11" xml:lang="en-US">[Increase (Decrease) in Accrued Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:label="celc_IncreaseDecreaseInNonCashOperatingLeaseExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:to="celc_IncreaseDecreaseInNonCashOperatingLeaseExpense_lbl_5d4c49" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_IncreaseDecreaseInNonCashOperatingLeaseExpense_lbl_5d4c49" xml:lang="en-US">Non-cash operating lease, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_c7f706" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_c7f706" xml:lang="en-US">Net cash used for operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_13" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_3d16d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_3d16d9" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_8cbd6f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_8cbd6f" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_15" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl_33f02b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl_33f02b" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_a3aa88" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_a3aa88" xml:lang="en-US">Net cash used for investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_17" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_9dc6d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_9dc6d6" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_5a42d5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_5a42d5" xml:lang="en-US">Proceeds from exercise of common stock warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="celc_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:to="celc_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts_lbl_3aee2b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts_lbl_3aee2b" xml:lang="en-US">Proceeds from follow-on offering, net of underwriting discounts and offering costs</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_GrossProceedsFromAnAtmOffering" xlink:label="celc_GrossProceedsFromAnAtmOffering" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_GrossProceedsFromAnAtmOffering" xlink:to="celc_GrossProceedsFromAnAtmOffering_lbl_f38967" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_GrossProceedsFromAnAtmOffering_lbl_f38967" xml:lang="en-US">Gross proceeds from an ATM offering</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_PaymentsForRegistrationStatementCosts" xlink:to="celc_PaymentsForRegistrationStatementCosts_lbl_c9c131" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="celc_PaymentsForRegistrationStatementCosts_lbl_c9c131" xml:lang="en-US">Payments for secondary registration statement costs</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_PaymentsForRegistrationStatementCosts" xlink:label="celc_PaymentsForRegistrationStatementCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_PaymentsForRegistrationStatementCosts" xlink:to="celc_PaymentsForRegistrationStatementCosts_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_PaymentsForRegistrationStatementCosts_lbl_22" xml:lang="en-US">[Payments for secondary registration statement costs]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_PaymentsForFinanceLeases" xlink:to="celc_PaymentsForFinanceLeases_lbl_1151b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="celc_PaymentsForFinanceLeases_lbl_1151b2" xml:lang="en-US">Payments for finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_PaymentsForFinanceLeases" xlink:label="celc_PaymentsForFinanceLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_PaymentsForFinanceLeases" xlink:to="celc_PaymentsForFinanceLeases_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_PaymentsForFinanceLeases_lbl_23" xml:lang="en-US">[Payments for finance leases]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_2c436f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_2c436f" xml:lang="en-US">Net cash provided by (used for) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_24" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_34c6a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_34c6a5" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_25" xml:lang="en-US">[Cash and Cash Equivalents, Period Increase (Decrease)]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl_587c12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl_587c12" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_e7765f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_e7765f" xml:lang="en-US">Beginning of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_599ae9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_599ae9" xml:lang="en-US">End of period</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl_777ea3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl_777ea3" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAssumed1" xlink:to="us-gaap_LiabilitiesAssumed1_lbl_beadb9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAssumed1_lbl_beadb9" xml:lang="en-US">Property and equipment included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:label="celc_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:to="celc_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable_lbl_348b8b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable_lbl_348b8b" xml:lang="en-US">Offering and registration statement costs included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_0f7495" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_0f7495" xml:lang="en-US">Organization</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_2a4bc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_2a4bc2" xml:lang="en-US">Note 1. Organization</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_8a2836" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_8a2836" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_0e55d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_0e55d6" xml:lang="en-US">Note 2. Summary of Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl_b1efdf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl_b1efdf" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_12ea6d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_12ea6d" xml:lang="en-US">Note 3. Net Loss Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_2a5744" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_2a5744" xml:lang="en-US">Commitments</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl_7ce8b7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl_7ce8b7" xml:lang="en-US">Note 4. Commitments</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl_5ab934" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl_5ab934" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_5107cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_5107cf" xml:lang="en-US">Note 5. Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl_3c508f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl_3c508f" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_e0a9c1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_e0a9c1" xml:lang="en-US">Note 6. Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_6826c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_6826c9" xml:lang="en-US">Subsequent Events</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_927740" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_927740" xml:lang="en-US">Note 7. Subsequent events</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl_6e7627" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl_6e7627" xml:lang="en-US">Basis of Presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FollowOnOfferingPolicyTextBlock" xlink:label="celc_FollowOnOfferingPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_FollowOnOfferingPolicyTextBlock" xlink:to="celc_FollowOnOfferingPolicyTextBlock_lbl_3aba5e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_FollowOnOfferingPolicyTextBlock_lbl_3aba5e" xml:lang="en-US">Follow-on Offering</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_0813af" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_0813af" xml:lang="en-US">Accounting Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl_608954" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl_608954" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_05ba95" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_05ba95" xml:lang="en-US">Clinical Trial Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" xlink:label="celc_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" xlink:to="celc_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock_lbl_714dde" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock_lbl_714dde" xml:lang="en-US">Application of New or Revised Accounting Standards</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="celc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="celc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl_a2f010" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl_a2f010" xml:lang="en-US">Schedule of supplemental balance sheet information related to leases</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl_804507" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl_804507" xml:lang="en-US">Schedule of maturity analysis under lease agreements</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock" xlink:label="celc_ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock" xlink:to="celc_ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock_lbl_074bef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock_lbl_074bef" xml:lang="en-US">Schedule of weighted average discount rate</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl_e730dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl_e730dc" xml:lang="en-US">Schedule of lease costs for the period</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="celc_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="celc_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl_3c6fc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl_3c6fc2" xml:lang="en-US">Schedule of supplemental cash flow information related to leases</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_ff0627" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_ff0627" xml:lang="en-US">Schedule of activity for all stock options outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl_8cafd8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl_8cafd8" xml:lang="en-US">Schedule of fair value of equity-based awards</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl_54f453" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl_54f453" xml:lang="en-US">Schedule of unrecognized compensation cost</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl_6487d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl_6487d7" xml:lang="en-US">Schedule of stock-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl_0f7fef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl_0f7fef" xml:lang="en-US">Schedule of stock options outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares" xlink:label="celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares" xlink:to="celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares_lbl_6645ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares_lbl_6645ed" xml:lang="en-US">Issuance of common stock upon closing of follow-on offering, net shares</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock" xlink:label="celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock" xlink:to="celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock_lbl_084733" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock_lbl_084733" xml:lang="en-US">Issuance of common stock upon closing of follow-on offering, including shares of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:to="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_lbl_5fb994" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_lbl_5fb994" xml:lang="en-US">Public offering price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_NetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="celc_NetOfUnderwritingDiscountsAndOfferingCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_NetOfUnderwritingDiscountsAndOfferingCosts" xlink:to="celc_NetOfUnderwritingDiscountsAndOfferingCosts_lbl_045230" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_NetOfUnderwritingDiscountsAndOfferingCosts_lbl_045230" xml:lang="en-US">Net of underwriting discounts and offering costs</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="us-gaap_SalesCommissionsAndFees" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_lbl_ee5472" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesCommissionsAndFees_lbl_ee5472" xml:lang="en-US">Deducting underwriting discounts</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_OfferingExpenses" xlink:label="celc_OfferingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_OfferingExpenses" xlink:to="celc_OfferingExpenses_lbl_ac4d35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_OfferingExpenses_lbl_ac4d35" xml:lang="en-US">Offering expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl_0f5537" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl_0f5537" xml:lang="en-US">Derivative Instrument Risk Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_d6bd76" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_d6bd76" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_WarrantsMember" xlink:label="celc_WarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_WarrantsMember" xlink:to="celc_WarrantsMember_lbl_c593f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_WarrantsMember_lbl_c593f7" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_StockOptionsMember" xlink:label="celc_StockOptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_StockOptionsMember" xlink:to="celc_StockOptionsMember_lbl_8b3a63" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_StockOptionsMember_lbl_8b3a63" xml:lang="en-US">Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_RestrictedStocksMember" xlink:label="celc_RestrictedStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_RestrictedStocksMember" xlink:to="celc_RestrictedStocksMember_lbl_6fd2e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_RestrictedStocksMember_lbl_6fd2e8" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_efb7c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_efb7c4" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl_7361f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl_7361f6" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SupplementalBalanceSheetInformationMember" xlink:label="celc_SupplementalBalanceSheetInformationMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_SupplementalBalanceSheetInformationMember" xlink:to="celc_SupplementalBalanceSheetInformationMember_lbl_b167b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_SupplementalBalanceSheetInformationMember_lbl_b167b0" xml:lang="en-US">Supplemental balance sheet information [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_ac0a4b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_ac0a4b" xml:lang="en-US">Right-of-use asset</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_e1c82b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl_e1c82b" xml:lang="en-US">Operating lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_e3af03" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_e3af03" xml:lang="en-US">Less: short term portion</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LongTermOperatingLeaseLiability" xlink:label="celc_LongTermOperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_LongTermOperatingLeaseLiability" xlink:to="celc_LongTermOperatingLeaseLiability_lbl_b3eca6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_LongTermOperatingLeaseLiability_lbl_b3eca6" xml:lang="en-US">Long term portion</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasedAssetsGross" xlink:label="us-gaap_CapitalLeasedAssetsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasedAssetsGross" xlink:to="us-gaap_CapitalLeasedAssetsGross_lbl_493d26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasedAssetsGross_lbl_493d26" xml:lang="en-US">Furniture and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation" xlink:label="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation" xlink:to="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation_lbl_694e1d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation_lbl_694e1d" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet" xlink:label="us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet" xlink:to="us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet_lbl_5a2336" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet_lbl_5a2336" xml:lang="en-US">Net book value of property and equipment under finance lease</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FinanceLeaseLiabilities" xlink:label="celc_FinanceLeaseLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_FinanceLeaseLiabilities" xlink:to="celc_FinanceLeaseLiabilities_lbl_f0183c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_FinanceLeaseLiabilities_lbl_f0183c" xml:lang="en-US">Finance lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl_6bb09e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl_6bb09e" xml:lang="en-US">Less: short term portions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_9a2562" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_9a2562" xml:lang="en-US">Long term portions</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealEstatePropertiesAxis" xlink:label="us-gaap_RealEstatePropertiesAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstatePropertiesAxis" xlink:to="us-gaap_RealEstatePropertiesAxis_lbl_f08054" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealEstatePropertiesAxis_lbl_f08054" xml:lang="en-US">Real Estate Property Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_OperatingLeasesMember" xlink:label="celc_OperatingLeasesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_OperatingLeasesMember" xlink:to="celc_OperatingLeasesMember_lbl_aea846" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_OperatingLeasesMember_lbl_aea846" xml:lang="en-US">Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FinanceLeasesMember" xlink:label="celc_FinanceLeasesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_FinanceLeasesMember" xlink:to="celc_FinanceLeasesMember_lbl_b9c2a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_FinanceLeasesMember_lbl_b9c2a8" xml:lang="en-US">Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_d1924b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_d1924b" xml:lang="en-US">2021</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_605652" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_605652" xml:lang="en-US">2022</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_49de9e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_49de9e" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_fb9824" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_fb9824" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LessPresentValueDiscount" xlink:label="celc_LessPresentValueDiscount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_LessPresentValueDiscount" xlink:to="celc_LessPresentValueDiscount_lbl_277bc4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_LessPresentValueDiscount_lbl_277bc4" xml:lang="en-US">Less: present value discount</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LesseeOperatingLeaseLiabilityAmountRepresentingServices" xlink:label="celc_LesseeOperatingLeaseLiabilityAmountRepresentingServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_LesseeOperatingLeaseLiabilityAmountRepresentingServices" xlink:to="celc_LesseeOperatingLeaseLiabilityAmountRepresentingServices_lbl_c0a194" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_LesseeOperatingLeaseLiabilityAmountRepresentingServices_lbl_c0a194" xml:lang="en-US">Less amount representing services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_2d545c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl_2d545c" xml:lang="en-US">Present value of net minimum lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_408b59" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_408b59" xml:lang="en-US">2021</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_9" xml:lang="en-US">[Finance Lease, Liability, Payments, Due Next Twelve Months]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_9c1684" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_9c1684" xml:lang="en-US">2022</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_10" xml:lang="en-US">[Finance Lease, Liability, Payments, Due Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_e3b389" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_e3b389" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_11" xml:lang="en-US">[Finance Lease, Liability, Payments, Due Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_873c02" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_873c02" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_12" xml:lang="en-US">[Finance Lease, Liability, Payment, Due]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_LessAmountRepresentingServices" xlink:to="celc_LessAmountRepresentingServices_lbl_8d972c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="celc_LessAmountRepresentingServices_lbl_8d972c" xml:lang="en-US">Less amount representing services</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LessAmountRepresentingServices" xlink:label="celc_LessAmountRepresentingServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_LessAmountRepresentingServices" xlink:to="celc_LessAmountRepresentingServices_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_LessAmountRepresentingServices_lbl_13" xml:lang="en-US">[Less amount representing services]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl_0a6212" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl_0a6212" xml:lang="en-US">Present value of net minimum lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl_14" xml:lang="en-US">[Finance Lease, Liability]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_OperatingLeaseWeightedAverageRemainingLeasesTerm1" xlink:label="celc_OperatingLeaseWeightedAverageRemainingLeasesTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_OperatingLeaseWeightedAverageRemainingLeasesTerm1" xlink:to="celc_OperatingLeaseWeightedAverageRemainingLeasesTerm1_lbl_59ec89" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_OperatingLeaseWeightedAverageRemainingLeasesTerm1_lbl_59ec89" xml:lang="en-US">Operating lease, weighted average remaining lease term</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_2266d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_2266d7" xml:lang="en-US">Operating lease, weighted average discount rate, percent</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FinanceLeaseWeightedAverageRemainingLeasesTerm1" xlink:label="celc_FinanceLeaseWeightedAverageRemainingLeasesTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_FinanceLeaseWeightedAverageRemainingLeasesTerm1" xlink:to="celc_FinanceLeaseWeightedAverageRemainingLeasesTerm1_lbl_093ec4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_FinanceLeaseWeightedAverageRemainingLeasesTerm1_lbl_093ec4" xml:lang="en-US">Finance lease, weighted average remaining lease term</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl_184ce5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl_184ce5" xml:lang="en-US">Finance lease, weighted average discount rate, percent</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl_984685" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl_984685" xml:lang="en-US">Operating lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FinanceLeaseCostsAbstract" xlink:label="celc_FinanceLeaseCostsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_FinanceLeaseCostsAbstract" xlink:to="celc_FinanceLeaseCostsAbstract_lbl_1a955a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_FinanceLeaseCostsAbstract_lbl_1a955a" xml:lang="en-US">Finance lease cost:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_2d9e7d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_2d9e7d" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl_5a0612" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl_5a0612" xml:lang="en-US">Interest</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl_98cfb0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl_98cfb0" xml:lang="en-US">Variable lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl_83ccf4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl_83ccf4" xml:lang="en-US">Total lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_CashPaidForOperatingAndFinanceLeasesAbstract" xlink:label="celc_CashPaidForOperatingAndFinanceLeasesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_CashPaidForOperatingAndFinanceLeasesAbstract" xlink:to="celc_CashPaidForOperatingAndFinanceLeasesAbstract_lbl_14b7c6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_CashPaidForOperatingAndFinanceLeasesAbstract_lbl_14b7c6" xml:lang="en-US">Cash paid for amounts included in operating and finance leases:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl_bfb2fe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl_bfb2fe" xml:lang="en-US">Operating cash outflow from operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl_a5ce95" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl_a5ce95" xml:lang="en-US">Operating cash outflow from finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_329bb4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_329bb4" xml:lang="en-US">Financing cash outflow from finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_CashPaidForOperatingAndFinanceLeases" xlink:label="celc_CashPaidForOperatingAndFinanceLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_CashPaidForOperatingAndFinanceLeases" xlink:to="celc_CashPaidForOperatingAndFinanceLeases_lbl_2019ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_CashPaidForOperatingAndFinanceLeases_lbl_2019ff" xml:lang="en-US">Total cash paid for amounts included in operating and finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_b60001" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_b60001" xml:lang="en-US">Plan Name Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl_c97d47" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl_c97d47" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_AgreementWithBiopharmaceuticalCompanyOneMember" xlink:label="celc_AgreementWithBiopharmaceuticalCompanyOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_AgreementWithBiopharmaceuticalCompanyOneMember" xlink:to="celc_AgreementWithBiopharmaceuticalCompanyOneMember_lbl_a57dea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_AgreementWithBiopharmaceuticalCompanyOneMember_lbl_a57dea" xml:lang="en-US">Agreement with biopharmaceutical company 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_JanuaryTwoThousandTwentyOneMember" xlink:label="celc_JanuaryTwoThousandTwentyOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_JanuaryTwoThousandTwentyOneMember" xlink:to="celc_JanuaryTwoThousandTwentyOneMember_lbl_684f18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_JanuaryTwoThousandTwentyOneMember_lbl_684f18" xml:lang="en-US">January 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_AgreementWithBiopharmaceuticalCompanyMember" xlink:label="celc_AgreementWithBiopharmaceuticalCompanyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_AgreementWithBiopharmaceuticalCompanyMember" xlink:to="celc_AgreementWithBiopharmaceuticalCompanyMember_lbl_f54ccd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_AgreementWithBiopharmaceuticalCompanyMember_lbl_f54ccd" xml:lang="en-US">Agreement with biopharmaceutical company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_AgreementWithBiopharmaceuticalCompanyTwoMember" xlink:label="celc_AgreementWithBiopharmaceuticalCompanyTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_AgreementWithBiopharmaceuticalCompanyTwoMember" xlink:to="celc_AgreementWithBiopharmaceuticalCompanyTwoMember_lbl_170426" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_AgreementWithBiopharmaceuticalCompanyTwoMember_lbl_170426" xml:lang="en-US">Agreement with biopharmaceutical company 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_MarchTwoThousandTwentyOneMember" xlink:label="celc_MarchTwoThousandTwentyOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_MarchTwoThousandTwentyOneMember" xlink:to="celc_MarchTwoThousandTwentyOneMember_lbl_37134f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_MarchTwoThousandTwentyOneMember_lbl_37134f" xml:lang="en-US">March 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapital_lbl_ba3061" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapital_lbl_ba3061" xml:lang="en-US">Increase in operating ROU asset and lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl_9e41ac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl_9e41ac" xml:lang="en-US">Payments to acquire in process research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EstimatedRemainingAmountOfPayments" xlink:label="celc_EstimatedRemainingAmountOfPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_EstimatedRemainingAmountOfPayments" xlink:to="celc_EstimatedRemainingAmountOfPayments_lbl_19bda3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_EstimatedRemainingAmountOfPayments_lbl_19bda3" xml:lang="en-US">Estimated remaining amount of payments</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl_aedcb4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl_aedcb4" xml:lang="en-US">Contractual obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FuturePaymentsRequiredUponCertainMilestonesBeingMet" xlink:label="celc_FuturePaymentsRequiredUponCertainMilestonesBeingMet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_FuturePaymentsRequiredUponCertainMilestonesBeingMet" xlink:to="celc_FuturePaymentsRequiredUponCertainMilestonesBeingMet_lbl_4baaab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_FuturePaymentsRequiredUponCertainMilestonesBeingMet_lbl_4baaab" xml:lang="en-US">Future payments required upon certain milestones being met</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl_8a5b7a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl_8a5b7a" xml:lang="en-US">Restatement Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:label="us-gaap_OtherInvestmentNotReadilyMarketableAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:to="us-gaap_OtherInvestmentNotReadilyMarketableAxis_lbl_620b04" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInvestmentNotReadilyMarketableAxis_lbl_620b04" xml:lang="en-US">Other Investment Not Readily Marketable Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_PlacementSharesMember" xlink:label="celc_PlacementSharesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_PlacementSharesMember" xlink:to="celc_PlacementSharesMember_lbl_4451a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_PlacementSharesMember_lbl_4451a3" xml:lang="en-US">Placement Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_AtmAgreementMember" xlink:label="celc_AtmAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_AtmAgreementMember" xlink:to="celc_AtmAgreementMember_lbl_742c91" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_AtmAgreementMember_lbl_742c91" xml:lang="en-US">ATM Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_PublicOfferingPrice" xlink:label="celc_PublicOfferingPrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_PublicOfferingPrice" xlink:to="celc_PublicOfferingPrice_lbl_510bba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_PublicOfferingPrice_lbl_510bba" xml:lang="en-US">Public offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl_f78b51" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl_f78b51" xml:lang="en-US">Net proceeds</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_lbl_520173" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesCommissionsAndFees_lbl_520173" xml:lang="en-US">Net of underwriting commissions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_OfferingExpenses" xlink:to="celc_OfferingExpenses_lbl_12dbba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="celc_OfferingExpenses_lbl_12dbba" xml:lang="en-US">Offering expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock" xlink:to="celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock_lbl_db2a63" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock_lbl_db2a63" xml:lang="en-US">Issuance of common stock upon closing of follow-on offering, including shares of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares" xlink:to="celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares_lbl_c69f70" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares_lbl_c69f70" xml:lang="en-US">Issuance of common stock upon closing of follow-on offering, net shares</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl_d75194" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl_d75194" xml:lang="en-US">Aggregate offering price, common stock shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_c5e02c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_c5e02c" xml:lang="en-US">Common stock par value</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_323c12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_323c12" xml:lang="en-US">Sale of stock number of shares issued in transaction</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_AverageSellingPricePerShare" xlink:label="celc_AverageSellingPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_AverageSellingPricePerShare" xlink:to="celc_AverageSellingPricePerShare_lbl_1b5c4c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_AverageSellingPricePerShare_lbl_1b5c4c" xml:lang="en-US">Average selling price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeStockOptionsMember" xlink:label="celc_EmployeeStockOptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_EmployeeStockOptionsMember" xlink:to="celc_EmployeeStockOptionsMember_lbl_6de274" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_EmployeeStockOptionsMember_lbl_6de274" xml:lang="en-US">Employee Stock Option</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SharesOptionsOutstandingBeginning" xlink:label="celc_SharesOptionsOutstandingBeginning" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_SharesOptionsOutstandingBeginning" xlink:to="celc_SharesOptionsOutstandingBeginning_lbl_d1b865" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_SharesOptionsOutstandingBeginning_lbl_d1b865" xml:lang="en-US">Shares options outstanding, beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_532833" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_532833" xml:lang="en-US">Shares, granted</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SharesExercised" xlink:label="celc_SharesExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_SharesExercised" xlink:to="celc_SharesExercised_lbl_bdde76" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_SharesExercised_lbl_bdde76" xml:lang="en-US">Shares, exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_dccf40" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_dccf40" xml:lang="en-US">shares, forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SharesOptionsOutstandingEnding" xlink:label="celc_SharesOptionsOutstandingEnding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_SharesOptionsOutstandingEnding" xlink:to="celc_SharesOptionsOutstandingEnding_lbl_3b4fe0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_SharesOptionsOutstandingEnding_lbl_3b4fe0" xml:lang="en-US">Shares options outstanding, ending</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SharesOptionsExercisables" xlink:label="celc_SharesOptionsExercisables" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_SharesOptionsExercisables" xlink:to="celc_SharesOptionsExercisables_lbl_7d97ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_SharesOptionsExercisables_lbl_7d97ad" xml:lang="en-US">Shares, options exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_WeightedAverageExercisePriceBeginning" xlink:label="celc_WeightedAverageExercisePriceBeginning" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_WeightedAverageExercisePriceBeginning" xlink:to="celc_WeightedAverageExercisePriceBeginning_lbl_1e86d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_WeightedAverageExercisePriceBeginning_lbl_1e86d6" xml:lang="en-US">Weighted average exercise price, beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_4430ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_4430ed" xml:lang="en-US">Weighted average exercise price, granted</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_91debd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_91debd" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_919c14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_919c14" xml:lang="en-US">Weighted average exercise price, forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_WeightedAverageExercisePriceEnding" xlink:label="celc_WeightedAverageExercisePriceEnding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_WeightedAverageExercisePriceEnding" xlink:to="celc_WeightedAverageExercisePriceEnding_lbl_2b783b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_WeightedAverageExercisePriceEnding_lbl_2b783b" xml:lang="en-US">Weighted average exercise price, ending</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_WeightedAverageExercisePriceOptionsExercisables" xlink:label="celc_WeightedAverageExercisePriceOptionsExercisables" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_WeightedAverageExercisePriceOptionsExercisables" xlink:to="celc_WeightedAverageExercisePriceOptionsExercisables_lbl_5faee8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_WeightedAverageExercisePriceOptionsExercisables_lbl_5faee8" xml:lang="en-US">Weighted average exercise price, options exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_fcabe1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_fcabe1" xml:lang="en-US">Weighted average grant date fair value for options granted during the period:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_b19f99" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_b19f99" xml:lang="en-US">Options Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_73397e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_73397e" xml:lang="en-US">Options outstanding, weighted average remaining contractual life</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_OptionsOutstandingWeightedAverageExercisePrice" xlink:label="celc_OptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_OptionsOutstandingWeightedAverageExercisePrice" xlink:to="celc_OptionsOutstandingWeightedAverageExercisePrice_lbl_a7fd7f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_OptionsOutstandingWeightedAverageExercisePrice_lbl_a7fd7f" xml:lang="en-US">Options outstanding, weighted average exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl_b7ccdf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl_b7ccdf" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl_ecb88b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl_ecb88b" xml:lang="en-US">Options exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl_338e65" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl_338e65" xml:lang="en-US">Options exercisable, weighted average exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl_cadd0e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl_cadd0e" xml:lang="en-US">Options exercisable, aggregate intrinsic value</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl_9001c2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl_9001c2" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl_331fe3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl_331fe3" xml:lang="en-US">Minimum Member</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl_4110ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl_4110ae" xml:lang="en-US">Maximum Member</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl_c27674" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl_c27674" xml:lang="en-US">Expected dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl_f2645f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl_f2645f" xml:lang="en-US">Expected volatility</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl_9f8891" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl_9f8891" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl_53dcda" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl_53dcda" xml:lang="en-US">Expected life (years)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" xlink:to="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears_lbl_4a0dcd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears_lbl_4a0dcd" xml:lang="en-US">2022</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" xlink:label="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" xlink:to="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears_lbl_2" xml:lang="en-US">[2022]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" xlink:to="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears_lbl_d6796a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears_lbl_d6796a" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" xlink:label="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" xlink:to="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears_lbl_3" xml:lang="en-US">[2023]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" xlink:label="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" xlink:to="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears_lbl_1fbf14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears_lbl_1fbf14" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl_2bf5f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl_2bf5f3" xml:lang="en-US">Total estimated compensation cost to be recognized</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" xlink:label="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" xlink:to="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear_lbl_7a9b3b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear_lbl_7a9b3b" xml:lang="en-US">2020</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears" xlink:to="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears_lbl_748507" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears_lbl_748507" xml:lang="en-US">2021</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears" xlink:label="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears" xlink:to="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears_lbl_7" xml:lang="en-US">[2021]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl_a9e1b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl_a9e1b2" xml:lang="en-US">Income Statement Location Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl_0ed645" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl_0ed645" xml:lang="en-US">Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl_9dd0e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl_9dd0e6" xml:lang="en-US">General And Administrative Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_a2715e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl_a2715e" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_f8b3c6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_f8b3c6" xml:lang="en-US">Award Type Axis</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_EmployeeStockOptionsMember" xlink:to="celc_EmployeeStockOptionsMember_lbl_e5ddb3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="celc_EmployeeStockOptionsMember_lbl_e5ddb3" xml:lang="en-US">Employee Stock Option</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ExpenseStockOptionsMember" xlink:label="celc_ExpenseStockOptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_ExpenseStockOptionsMember" xlink:to="celc_ExpenseStockOptionsMember_lbl_a8f78e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_ExpenseStockOptionsMember_lbl_a8f78e" xml:lang="en-US">Expense Stock Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_StockIncentivePlanMember" xlink:label="celc_StockIncentivePlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_StockIncentivePlanMember" xlink:to="celc_StockIncentivePlanMember_lbl_8a3a84" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_StockIncentivePlanMember_lbl_8a3a84" xml:lang="en-US">2017 Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl_5df3e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl_5df3e8" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeStockPurchasePlanMember" xlink:label="celc_EmployeeStockPurchasePlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_EmployeeStockPurchasePlanMember" xlink:to="celc_EmployeeStockPurchasePlanMember_lbl_d8fb5c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_EmployeeStockPurchasePlanMember_lbl_d8fb5c" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FutureExpenses" xlink:label="celc_FutureExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_FutureExpenses" xlink:to="celc_FutureExpenses_lbl_b1838e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_FutureExpenses_lbl_b1838e" xml:lang="en-US">Future expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_StockBasedCompensationRelatedToRestrictedStockTotal" xlink:to="celc_StockBasedCompensationRelatedToRestrictedStockTotal_lbl_4e4479" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="celc_StockBasedCompensationRelatedToRestrictedStockTotal_lbl_4e4479" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_StockBasedCompensationRelatedToRestrictedStockTotal" xlink:label="celc_StockBasedCompensationRelatedToRestrictedStockTotal" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_StockBasedCompensationRelatedToRestrictedStockTotal" xlink:to="celc_StockBasedCompensationRelatedToRestrictedStockTotal_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_StockBasedCompensationRelatedToRestrictedStockTotal_lbl_3" xml:lang="en-US">[Stock-based compensation]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ShareExercisePrice" xlink:label="celc_ShareExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_ShareExercisePrice" xlink:to="celc_ShareExercisePrice_lbl_dd6edc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_ShareExercisePrice_lbl_dd6edc" xml:lang="en-US">Share exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_CommonStockSharesReservedDescription" xlink:label="celc_CommonStockSharesReservedDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_CommonStockSharesReservedDescription" xlink:to="celc_CommonStockSharesReservedDescription_lbl_b4d5ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_CommonStockSharesReservedDescription_lbl_b4d5ee" xml:lang="en-US">Common stock shares reserved description</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_9ce666" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_9ce666" xml:lang="en-US">Shares available for grant under the 2017 Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_StockOptionAwardsSharesModified" xlink:label="celc_StockOptionAwardsSharesModified" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_StockOptionAwardsSharesModified" xlink:to="celc_StockOptionAwardsSharesModified_lbl_a1cd11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_StockOptionAwardsSharesModified_lbl_a1cd11" xml:lang="en-US">Stock option awards shares modified</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl_4f187d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl_4f187d" xml:lang="en-US">Common stock shares reserved for future issuance</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_StockBasedCompensationExpenseRelatedToEspp" xlink:label="celc_StockBasedCompensationExpenseRelatedToEspp" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_StockBasedCompensationExpenseRelatedToEspp" xlink:to="celc_StockBasedCompensationExpenseRelatedToEspp_lbl_318d70" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_StockBasedCompensationExpenseRelatedToEspp_lbl_318d70" xml:lang="en-US">Stock Based compensation expense related to ESPP</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalUnitsOutstanding" xlink:label="us-gaap_CapitalUnitsOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsOutstanding" xlink:to="us-gaap_CapitalUnitsOutstanding_lbl_62d7da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalUnitsOutstanding_lbl_62d7da" xml:lang="en-US">Restricted stock outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl_b3f139" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl_b3f139" xml:lang="en-US">Restricted stock vested</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_RemainingSharesAvailableForIssuance" xlink:label="celc_RemainingSharesAvailableForIssuance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_RemainingSharesAvailableForIssuance" xlink:to="celc_RemainingSharesAvailableForIssuance_lbl_7b0cdf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_RemainingSharesAvailableForIssuance_lbl_7b0cdf" xml:lang="en-US">Remaining shares available for issuance</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl_1d778d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl_1d778d" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_0e7739" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_0e7739" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis_lbl_05f0f8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis_lbl_05f0f8" xml:lang="en-US">Securities or Other Assets Sold under Agreements to Repurchase [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl_c05f20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl_c05f20" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_PfizerIncMember" xlink:label="celc_PfizerIncMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_PfizerIncMember" xlink:to="celc_PfizerIncMember_lbl_b20963" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_PfizerIncMember_lbl_b20963" xml:lang="en-US">Pfizer, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LicenseAgreementMember" xlink:label="celc_LicenseAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_LicenseAgreementMember" xlink:to="celc_LicenseAgreementMember_lbl_a1e6c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_LicenseAgreementMember_lbl_a1e6c8" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EquityGrantAgreementMember" xlink:label="celc_EquityGrantAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_EquityGrantAgreementMember" xlink:to="celc_EquityGrantAgreementMember_lbl_20c350" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_EquityGrantAgreementMember_lbl_20c350" xml:lang="en-US">Equity Grant Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ThirdTrancheMember" xlink:label="celc_ThirdTrancheMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_ThirdTrancheMember" xlink:to="celc_ThirdTrancheMember_lbl_7291a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_ThirdTrancheMember_lbl_7291a4" xml:lang="en-US">Tranche 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_TrancheMember" xlink:label="celc_TrancheMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_TrancheMember" xlink:to="celc_TrancheMember_lbl_4e295c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_TrancheMember_lbl_4e295c" xml:lang="en-US">Tranche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SecondTrancheMember" xlink:label="celc_SecondTrancheMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_SecondTrancheMember" xlink:to="celc_SecondTrancheMember_lbl_55989f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_SecondTrancheMember_lbl_55989f" xml:lang="en-US">Tranche 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl_b57ef2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl_b57ef2" xml:lang="en-US">Net cash proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl_03881a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl_03881a" xml:lang="en-US">Term loans</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtDescription" xlink:to="us-gaap_LongTermDebtDescription_lbl_8ee169" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtDescription_lbl_8ee169" xml:lang="en-US">Description of term Loan</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ClosingPricePerShare" xlink:label="celc_ClosingPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_ClosingPricePerShare" xlink:to="celc_ClosingPricePerShare_lbl_02ff92" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_ClosingPricePerShare_lbl_02ff92" xml:lang="en-US">Closing price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_UpfrontFee" xlink:label="celc_UpfrontFee" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_UpfrontFee" xlink:to="celc_UpfrontFee_lbl_171139" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_UpfrontFee_lbl_171139" xml:lang="en-US">Upfront fee</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_61e7c5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_61e7c5" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents" xlink:label="celc_DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celc_DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents" xlink:to="celc_DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents_lbl_d9da9c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="celc_DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents_lbl_d9da9c" xml:lang="en-US">Description of certain development and commercial milestone events</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_a61fcb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl_a61fcb" xml:lang="en-US">Common stock shares issued, value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_SharesOptionsExercisables" xlink:to="celc_SharesOptionsExercisables_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_SharesOptionsExercisables_d">The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_WeightedAverageExercisePriceOptionsExercisables" xlink:to="celc_WeightedAverageExercisePriceOptionsExercisables_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_WeightedAverageExercisePriceOptionsExercisables_d">The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_ClosingPricePerShare" xlink:to="celc_ClosingPricePerShare_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_ClosingPricePerShare_d">The price per share of the conversion feature embedded in the debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents" xlink:to="celc_DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents_d">Describes all significant commitments and obligations resulting from franchise agreements, including a description of the services that the franchisor has agreed to provide for agreements that have not yet been substantially performed.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_FinanceLeaseLiabilities" xlink:to="celc_FinanceLeaseLiabilities_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_FinanceLeaseLiabilities_d">Present value of lessee's discounted obligation for lease payments from finance lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_OptionsOutstandingWeightedAverageExercisePrice" xlink:to="celc_OptionsOutstandingWeightedAverageExercisePrice_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_OptionsOutstandingWeightedAverageExercisePrice_d">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_LongTermOperatingLeaseLiability" xlink:to="celc_LongTermOperatingLeaseLiability_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_LongTermOperatingLeaseLiability_d">Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_LessAmountRepresentingServices" xlink:to="celc_LessAmountRepresentingServices_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_LessAmountRepresentingServices_d">Amounts to be paid by lessee to lessor for maintenance, insurance, and tax expenses related to the leased asset.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_LessPresentValueDiscount" xlink:to="celc_LessPresentValueDiscount_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_LessPresentValueDiscount_d">Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_ShareExercisePrice" xlink:to="celc_ShareExercisePrice_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_ShareExercisePrice_d">The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_StockBasedCompensationRelatedToRestrictedStockTotal" xlink:to="celc_StockBasedCompensationRelatedToRestrictedStockTotal_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_StockBasedCompensationRelatedToRestrictedStockTotal_d">Amount of noncash expense for share-based payment arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_LossOnSaleOfFixedAssets" xlink:to="celc_LossOnSaleOfFixedAssets_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_LossOnSaleOfFixedAssets_d">Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_OperatingLeaseWeightedAverageRemainingLeasesTerm1" xlink:to="celc_OperatingLeaseWeightedAverageRemainingLeasesTerm1_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_OperatingLeaseWeightedAverageRemainingLeasesTerm1_d">Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_FinanceLeaseWeightedAverageRemainingLeasesTerm1" xlink:to="celc_FinanceLeaseWeightedAverageRemainingLeasesTerm1_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_FinanceLeaseWeightedAverageRemainingLeasesTerm1_d">Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_AverageSellingPricePerShare" xlink:to="celc_AverageSellingPricePerShare_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_AverageSellingPricePerShare_d">Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_FollowOnOfferingPolicyTextBlock" xlink:to="celc_FollowOnOfferingPolicyTextBlock_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_FollowOnOfferingPolicyTextBlock_d">Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation,</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_NetOfUnderwritingDiscountsAndOfferingCosts" xlink:to="celc_NetOfUnderwritingDiscountsAndOfferingCosts_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_NetOfUnderwritingDiscountsAndOfferingCosts_d">Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distribut</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="celc_OfferingExpenses" xlink:to="celc_OfferingExpenses_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="celc_OfferingExpenses_d">Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>celc-20210331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05-10-2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://celcuity.com/role/Cover" xlink:href="celc-20210331.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CondensedBalanceSheets" xlink:href="celc-20210331.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CondensedBalanceSheetsParenthetical" xlink:href="celc-20210331.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="celc-20210331.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity" xlink:href="celc-20210331.xsd#CondensedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="celc-20210331.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/Organization" xlink:href="celc-20210331.xsd#Organization" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="celc-20210331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShare" xlink:href="celc-20210331.xsd#NetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/Commitments" xlink:href="celc-20210331.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquity" xlink:href="celc-20210331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockBasedCompensation" xlink:href="celc-20210331.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/SubsequentEvents" xlink:href="celc-20210331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="celc-20210331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsTables" xlink:href="celc-20210331.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockBasedCompensationTables" xlink:href="celc-20210331.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="celc-20210331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarative" xlink:href="celc-20210331.xsd#NetLossPerCommonShareDetailsNarative" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetails" xlink:href="celc-20210331.xsd#CommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetails1" xlink:href="celc-20210331.xsd#CommitmentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetails2" xlink:href="celc-20210331.xsd#CommitmentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetails3" xlink:href="celc-20210331.xsd#CommitmentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetails4" xlink:href="celc-20210331.xsd#CommitmentsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:href="celc-20210331.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:href="celc-20210331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetails" xlink:href="celc-20210331.xsd#StockbasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetails1" xlink:href="celc-20210331.xsd#StockbasedCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetails2" xlink:href="celc-20210331.xsd#StockbasedCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetails3" xlink:href="celc-20210331.xsd#StockbasedCompensationDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetails4" xlink:href="celc-20210331.xsd#StockbasedCompensationDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/StockbasedCompensationDetailsNarrative" xlink:href="celc-20210331.xsd#StockbasedCompensationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://celcuity.com/role/SubsequentEventsDetailsNarrative" xlink:href="celc-20210331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - Condensed Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_d4e366" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_da9091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_d4e366" xlink:to="loc_us-gaapAssetsAbstract_da9091" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_53af15" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_da9091" xlink:to="loc_us-gaapAssetsCurrentAbstract_53af15" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_d5bbf3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_53af15" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_d5bbf3" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent_469370" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_53af15" xlink:to="loc_us-gaapDepositsAssetsCurrent_469370" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent_878d39" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_53af15" xlink:to="loc_us-gaapDeferredCostsCurrent_878d39" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_d6928f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_53af15" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_d6928f" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_8600a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_53af15" xlink:to="loc_us-gaapPrepaidExpenseCurrent_8600a2" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_b8f92c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_53af15" xlink:to="loc_us-gaapAssetsCurrent_b8f92c" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_4739af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_53af15" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_4739af" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_17d775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_53af15" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_17d775" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_b37ec3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_53af15" xlink:to="loc_us-gaapAssets_b37ec3" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_f5376f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_53af15" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_f5376f" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_8c30fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_f5376f" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_8c30fb" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_2124eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8c30fb" xlink:to="loc_us-gaapAccountsPayableCurrent_2124eb" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_7e132c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8c30fb" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_7e132c" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_ac2c31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8c30fb" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_ac2c31" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_422076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8c30fb" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_422076" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_b852fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8c30fb" xlink:to="loc_us-gaapLiabilitiesCurrent_b852fb" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_33636d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8c30fb" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_33636d" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_f09dc5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8c30fb" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_f09dc5" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_e1dd16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8c30fb" xlink:to="loc_us-gaapLiabilities_e1dd16" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_037cfb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8c30fb" xlink:to="loc_us-gaapStockholdersEquityAbstract_037cfb" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_7b60cd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_037cfb" xlink:to="loc_us-gaapPreferredStockValue_7b60cd" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_1b0c06" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_037cfb" xlink:to="loc_us-gaapCommonStockValue_1b0c06" order="24" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_8144e0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_037cfb" xlink:to="loc_us-gaapAdditionalPaidInCapital_8144e0" order="25" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_e762de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_037cfb" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_e762de" order="26" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_083473" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_037cfb" xlink:to="loc_us-gaapStockholdersEquity_083473" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_f15fbf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_037cfb" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_f15fbf" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - Condensed Balance Sheets (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_94d14a" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_a8174f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_94d14a" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_a8174f" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_9d456d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_94d14a" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_9d456d" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_355660" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_94d14a" xlink:to="loc_us-gaapPreferredStockSharesIssued_355660" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_33630d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_94d14a" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_33630d" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_c61a04" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_94d14a" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_c61a04" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_9ad409" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_94d14a" xlink:to="loc_us-gaapCommonStockSharesAuthorized_9ad409" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_a46621" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_94d14a" xlink:to="loc_us-gaapCommonStockSharesIssued_a46621" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_b986ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_94d14a" xlink:to="loc_us-gaapCommonStockSharesOutstanding_b986ae" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - Condensed Statements of Operations (unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_d67a94" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_d6d693" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_d67a94" xlink:to="loc_us-gaapOperatingExpensesAbstract_d6d693" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_61ee44" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_d6d693" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_61ee44" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_f54d13" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_d6d693" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_f54d13" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_633c9e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_d6d693" xlink:to="loc_us-gaapOperatingExpenses_633c9e" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_1ae496" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_d6d693" xlink:to="loc_us-gaapOperatingIncomeLoss_1ae496" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_f9d278" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_d6d693" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_f9d278" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_305438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_f9d278" xlink:to="loc_us-gaapInterestExpense_305438" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest_37e59a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_f9d278" xlink:to="loc_us-gaapInvestmentIncomeInterest_37e59a" order="8" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LossOnSaleOfFixedAssets" xlink:label="loc_celcLossOnSaleOfFixedAssets_55a4f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_f9d278" xlink:to="loc_celcLossOnSaleOfFixedAssets_55a4f0" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_6a44db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_f9d278" xlink:to="loc_us-gaapNonoperatingIncomeExpense_6a44db" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c611e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_f9d278" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c611e" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_59b3ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_f9d278" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_59b3ef" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_96377d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_f9d278" xlink:to="loc_us-gaapNetIncomeLoss_96377d" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_9bebf5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_f9d278" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_9bebf5" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_8d4f3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_f9d278" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_8d4f3f" order="15" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity" xlink:title="000005 - Statement - Condensed Statements of Changes in Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_a0316f" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_d20d76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_a0316f" xlink:to="loc_us-gaapStatementTable_d20d76" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_bebc27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d20d76" xlink:to="loc_us-gaapStatementLineItems_bebc27" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_10c7ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d20d76" xlink:to="loc_us-gaapStatementEquityComponentsAxis_10c7ac" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_d00bda" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_10c7ac" xlink:to="loc_us-gaapEquityComponentDomain_d00bda" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_a7be32" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_d00bda" xlink:to="loc_us-gaapCommonStockMember_a7be32" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_4a2fc2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_d00bda" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_4a2fc2" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_558ea9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_d00bda" xlink:to="loc_us-gaapRetainedEarningsMember_558ea9" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_6986c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bebc27" xlink:to="loc_us-gaapSharesIssued_6986c6" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_e241ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bebc27" xlink:to="loc_us-gaapStockholdersEquity_e241ec" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_0ed8bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bebc27" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_0ed8bc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_114f5b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bebc27" xlink:to="loc_us-gaapNetIncomeLoss_114f5b" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ExerciseOfCommonStockWarrantsShares" xlink:label="loc_celcExerciseOfCommonStockWarrantsShares_b56ac7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bebc27" xlink:to="loc_celcExerciseOfCommonStockWarrantsShares_b56ac7" order="5" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ExerciseOfCommonStockWarrantsAmount" xlink:label="loc_celcExerciseOfCommonStockWarrantsAmount_369de8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bebc27" xlink:to="loc_celcExerciseOfCommonStockWarrantsAmount_369de8" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_61b2ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bebc27" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_61b2ae" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_cb7b99" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bebc27" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_cb7b99" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_653d0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bebc27" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_653d0c" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_170402" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bebc27" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_170402" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_f16275" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bebc27" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_f16275" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_d64fc7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bebc27" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_d64fc7" order="12" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_IssuanceCostsAssociatedWithAtmOffering" xlink:label="loc_celcIssuanceCostsAssociatedWithAtmOffering_1e67e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bebc27" xlink:to="loc_celcIssuanceCostsAssociatedWithAtmOffering_1e67e9" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_a8306d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bebc27" xlink:to="loc_us-gaapSharesIssued_a8306d" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_38db5e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bebc27" xlink:to="loc_us-gaapStockholdersEquity_38db5e" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - Condensed Statements of Cash Flows (unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_9f00e9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_36ab6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_9f00e9" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_36ab6a" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_1aa49f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_36ab6a" xlink:to="loc_us-gaapNetIncomeLoss_1aa49f" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_58eab6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_36ab6a" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_58eab6" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_a741d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_58eab6" xlink:to="loc_us-gaapDepreciation_a741d5" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_34f63e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_58eab6" xlink:to="loc_us-gaapShareBasedCompensation_34f63e" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets_721792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_58eab6" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets_721792" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_ef199f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_58eab6" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_ef199f" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cdd996" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_ef199f" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cdd996" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_217e76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_ef199f" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_217e76" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_8b8920" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_ef199f" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_8b8920" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:label="loc_celcIncreaseDecreaseInNonCashOperatingLeaseExpense_25fc5e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_ef199f" xlink:to="loc_celcIncreaseDecreaseInNonCashOperatingLeaseExpense_25fc5e" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_4dc4c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_ef199f" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_4dc4c2" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_63c26c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_ef199f" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_63c26c" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_e61b44" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_63c26c" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_e61b44" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment_02d21f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_63c26c" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment_02d21f" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_35996e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_63c26c" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_35996e" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_e4e95e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_63c26c" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_e4e95e" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_ccec60" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_e4e95e" xlink:to="loc_us-gaapProceedsFromWarrantExercises_ccec60" order="18" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="loc_celcProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts_426e58" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_e4e95e" xlink:to="loc_celcProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts_426e58" order="19" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_GrossProceedsFromAnAtmOffering" xlink:label="loc_celcGrossProceedsFromAnAtmOffering_8923d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_e4e95e" xlink:to="loc_celcGrossProceedsFromAnAtmOffering_8923d1" order="20" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_PaymentsForRegistrationStatementCosts" xlink:label="loc_celcPaymentsForRegistrationStatementCosts_d1320a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_e4e95e" xlink:to="loc_celcPaymentsForRegistrationStatementCosts_d1320a" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_PaymentsForFinanceLeases" xlink:label="loc_celcPaymentsForFinanceLeases_f17665" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_e4e95e" xlink:to="loc_celcPaymentsForFinanceLeases_f17665" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_b98e88" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_e4e95e" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_b98e88" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease_363fec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_e4e95e" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease_363fec" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract_8821d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_e4e95e" xlink:to="loc_us-gaapCashAndCashEquivalentsAbstract_8821d9" order="25" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_9357bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract_8821d9" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_9357bd" order="26" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_6f0607" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract_8821d9" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_6f0607" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b2a37d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract_8821d9" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b2a37d" order="28" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaapLiabilitiesAssumed1_249e04" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b2a37d" xlink:to="loc_us-gaapLiabilitiesAssumed1_249e04" order="29" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:label="loc_celcOfferingAndRegistrationStatementCostsIncludedInAccountsPayable_92f73e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b2a37d" xlink:to="loc_celcOfferingAndRegistrationStatementCostsIncludedInAccountsPayable_92f73e" order="30" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Organization" xlink:title="000007 - Disclosure - Organization">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73fa97" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_aed67a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73fa97" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_aed67a" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000008 - Disclosure - Summary of Significant Accounting Policies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_98059a" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock_fd568e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_98059a" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock_fd568e" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShare" xlink:title="000009 - Disclosure - Net Loss Per Common Share">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_f35750" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock_95e974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_f35750" xlink:to="loc_us-gaapEarningsPerShareTextBlock_95e974" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Commitments" xlink:title="000010 - Disclosure - Commitments">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_2d72d2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock_f32637" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_2d72d2" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock_f32637" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquity" xlink:title="000011 - Disclosure - Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_385176" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_0178d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_385176" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_0178d1" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockBasedCompensation" xlink:title="000012 - Disclosure - Stock-Based Compensation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bca1aa" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_490c1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bca1aa" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_490c1d" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEvents" xlink:title="000013 - Disclosure - Subsequent Events">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_b2a9a3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_ed8e75" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_b2a9a3" xlink:to="loc_us-gaapSubsequentEventsTextBlock_ed8e75" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000014 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_1aca21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_3f33ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1aca21" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_3f33ee" order="1" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FollowOnOfferingPolicyTextBlock" xlink:label="loc_celcFollowOnOfferingPolicyTextBlock_303354" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1aca21" xlink:to="loc_celcFollowOnOfferingPolicyTextBlock_303354" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_5bf3a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1aca21" xlink:to="loc_us-gaapUseOfEstimates_5bf3a2" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk_f68417" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1aca21" xlink:to="loc_us-gaapConcentrationRiskCreditRisk_f68417" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_f45f06" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1aca21" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_f45f06" order="5" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" xlink:label="loc_celcApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock_572453" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1aca21" xlink:to="loc_celcApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock_572453" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsTables" xlink:title="000015 - Disclosure - Commitments (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_7799bb" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="loc_celcScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_298862" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_7799bb" xlink:to="loc_celcScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_298862" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_afe502" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_7799bb" xlink:to="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_afe502" order="2" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock" xlink:label="loc_celcScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock_0a5201" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_7799bb" xlink:to="loc_celcScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock_0a5201" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock_70e75c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_7799bb" xlink:to="loc_us-gaapLeaseCostTableTextBlock_70e75c" order="4" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="loc_celcScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_1a2858" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_7799bb" xlink:to="loc_celcScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_1a2858" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockBasedCompensationTables" xlink:title="000016 - Disclosure - Stock-Based Compensation (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9bcedb" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_934fbf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9bcedb" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_934fbf" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d732d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9bcedb" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d732d9" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_ee0d70" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9bcedb" xlink:to="loc_us-gaapScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_ee0d70" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e2fd1f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9bcedb" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e2fd1f" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_b39399" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9bcedb" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_b39399" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000017 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_5be4d3" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares" xlink:label="loc_celcIssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares_196e0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5be4d3" xlink:to="loc_celcIssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares_196e0c" order="1" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock" xlink:label="loc_celcIssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock_b7cdbb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5be4d3" xlink:to="loc_celcIssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock_b7cdbb" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:label="loc_us-gaapAcceleratedShareRepurchasesInitialPricePaidPerShare_050911" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5be4d3" xlink:to="loc_us-gaapAcceleratedShareRepurchasesInitialPricePaidPerShare_050911" order="3" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_NetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="loc_celcNetOfUnderwritingDiscountsAndOfferingCosts_dd0f4f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5be4d3" xlink:to="loc_celcNetOfUnderwritingDiscountsAndOfferingCosts_dd0f4f" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees_1698f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5be4d3" xlink:to="loc_us-gaapSalesCommissionsAndFees_1698f2" order="5" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_OfferingExpenses" xlink:label="loc_celcOfferingExpenses_117fcf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_5be4d3" xlink:to="loc_celcOfferingExpenses_117fcf" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareDetailsNarative" xlink:title="000018 - Disclosure - Net Loss Per Common Share (Details Narative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_2ba1a4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_a0737e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_2ba1a4" xlink:to="loc_us-gaapStatementTable_a0737e" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_399ec0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a0737e" xlink:to="loc_us-gaapStatementLineItems_399ec0" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_e57afd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a0737e" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_e57afd" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_edfdd8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_e57afd" xlink:to="loc_us-gaapDerivativeContractTypeDomain_edfdd8" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e7772d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a0737e" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e7772d" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_f7b09c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e7772d" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_f7b09c" order="40" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_WarrantsMember" xlink:label="loc_celcWarrantsMember_0734b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_edfdd8" xlink:to="loc_celcWarrantsMember_0734b7" order="41" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_StockOptionsMember" xlink:label="loc_celcStockOptionsMember_33a960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_edfdd8" xlink:to="loc_celcStockOptionsMember_33a960" order="42" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_RestrictedStocksMember" xlink:label="loc_celcRestrictedStocksMember_7f4978" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_f7b09c" xlink:to="loc_celcRestrictedStocksMember_7f4978" order="43" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cdb315" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_399ec0" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cdb315" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetails" xlink:title="000019 - Disclosure - Commitments (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_7c7077" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_8f9b04" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_7c7077" xlink:to="loc_us-gaapStatementTable_8f9b04" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_b48627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_8f9b04" xlink:to="loc_us-gaapStatementLineItems_b48627" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis_3f2540" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_8f9b04" xlink:to="loc_us-gaapBalanceSheetLocationAxis_3f2540" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_c34e64" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationAxis_3f2540" xlink:to="loc_us-gaapBalanceSheetLocationDomain_c34e64" order="20" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SupplementalBalanceSheetInformationMember" xlink:label="loc_celcSupplementalBalanceSheetInformationMember_5c3927" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain_c34e64" xlink:to="loc_celcSupplementalBalanceSheetInformationMember_5c3927" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_c6e0c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b48627" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_c6e0c6" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_1ce16b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b48627" xlink:to="loc_us-gaapOperatingLeaseLiability_1ce16b" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_c3d549" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b48627" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_c3d549" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LongTermOperatingLeaseLiability" xlink:label="loc_celcLongTermOperatingLeaseLiability_556f53" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b48627" xlink:to="loc_celcLongTermOperatingLeaseLiability_556f53" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasedAssetsGross" xlink:label="loc_us-gaapCapitalLeasedAssetsGross_a8aef6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b48627" xlink:to="loc_us-gaapCapitalLeasedAssetsGross_a8aef6" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation" xlink:label="loc_us-gaapCapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation_ffa1ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b48627" xlink:to="loc_us-gaapCapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation_ffa1ab" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet" xlink:label="loc_us-gaapCapitalLeasesBalanceSheetAssetsByMajorClassNet_aef2f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b48627" xlink:to="loc_us-gaapCapitalLeasesBalanceSheetAssetsByMajorClassNet_aef2f9" order="7" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FinanceLeaseLiabilities" xlink:label="loc_celcFinanceLeaseLiabilities_ee9355" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b48627" xlink:to="loc_celcFinanceLeaseLiabilities_ee9355" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_a7b394" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b48627" xlink:to="loc_us-gaapShortTermBorrowings_a7b394" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_e8f150" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b48627" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_e8f150" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetails1" xlink:title="000020 - Disclosure - Commitments (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_30634a" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_c4ae5a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_30634a" xlink:to="loc_us-gaapStatementTable_c4ae5a" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_524256" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c4ae5a" xlink:to="loc_us-gaapStatementLineItems_524256" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealEstatePropertiesAxis" xlink:label="loc_us-gaapRealEstatePropertiesAxis_86b45f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c4ae5a" xlink:to="loc_us-gaapRealEstatePropertiesAxis_86b45f" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealEstatePropertiesDomain" xlink:label="loc_us-gaapRealEstatePropertiesDomain_ba9930" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRealEstatePropertiesAxis_86b45f" xlink:to="loc_us-gaapRealEstatePropertiesDomain_ba9930" order="20" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_OperatingLeasesMember" xlink:label="loc_celcOperatingLeasesMember_906426" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRealEstatePropertiesDomain_ba9930" xlink:to="loc_celcOperatingLeasesMember_906426" order="21" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FinanceLeasesMember" xlink:label="loc_celcFinanceLeasesMember_d90e1f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRealEstatePropertiesDomain_ba9930" xlink:to="loc_celcFinanceLeasesMember_d90e1f" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_967689" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_524256" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_967689" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_083c30" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_524256" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_083c30" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_e50d1c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_524256" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_e50d1c" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_44191e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_524256" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_44191e" order="4" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LessPresentValueDiscount" xlink:label="loc_celcLessPresentValueDiscount_bb620d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_524256" xlink:to="loc_celcLessPresentValueDiscount_bb620d" order="5" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LesseeOperatingLeaseLiabilityAmountRepresentingServices" xlink:label="loc_celcLesseeOperatingLeaseLiabilityAmountRepresentingServices_782398" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_524256" xlink:to="loc_celcLesseeOperatingLeaseLiabilityAmountRepresentingServices_782398" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_c2db8d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_524256" xlink:to="loc_us-gaapOperatingLeaseLiability_c2db8d" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_013ea3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_524256" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_013ea3" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_7d7544" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_524256" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_7d7544" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_892d90" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_524256" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_892d90" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_f0bac6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_524256" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_f0bac6" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LessAmountRepresentingServices" xlink:label="loc_celcLessAmountRepresentingServices_c34576" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_524256" xlink:to="loc_celcLessAmountRepresentingServices_c34576" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_249b2b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_524256" xlink:to="loc_us-gaapFinanceLeaseLiability_249b2b" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetails2" xlink:title="000021 - Disclosure - Commitments (Details 2)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c7472b" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_OperatingLeaseWeightedAverageRemainingLeasesTerm1" xlink:label="loc_celcOperatingLeaseWeightedAverageRemainingLeasesTerm1_7328c8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c7472b" xlink:to="loc_celcOperatingLeaseWeightedAverageRemainingLeasesTerm1_7328c8" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_0b8be1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c7472b" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_0b8be1" order="2" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FinanceLeaseWeightedAverageRemainingLeasesTerm1" xlink:label="loc_celcFinanceLeaseWeightedAverageRemainingLeasesTerm1_05a4d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c7472b" xlink:to="loc_celcFinanceLeaseWeightedAverageRemainingLeasesTerm1_05a4d7" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_470c09" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c7472b" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_470c09" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetails3" xlink:title="000022 - Disclosure - Commitments (Details 3)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_6ceed2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost_f7c62c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_6ceed2" xlink:to="loc_us-gaapOperatingLeaseCost_f7c62c" order="1" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FinanceLeaseCostsAbstract" xlink:label="loc_celcFinanceLeaseCostsAbstract_fa5856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_6ceed2" xlink:to="loc_celcFinanceLeaseCostsAbstract_fa5856" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_3f000b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_celcFinanceLeaseCostsAbstract_fa5856" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_3f000b" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense_177915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_celcFinanceLeaseCostsAbstract_fa5856" xlink:to="loc_us-gaapFinanceLeaseInterestExpense_177915" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost_510647" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_celcFinanceLeaseCostsAbstract_fa5856" xlink:to="loc_us-gaapVariableLeaseCost_510647" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost_9137a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_celcFinanceLeaseCostsAbstract_fa5856" xlink:to="loc_us-gaapLeaseCost_9137a8" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetails4" xlink:title="000023 - Disclosure - Commitments (Details 4)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_5e2985" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_CashPaidForOperatingAndFinanceLeasesAbstract" xlink:label="loc_celcCashPaidForOperatingAndFinanceLeasesAbstract_49be7c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_5e2985" xlink:to="loc_celcCashPaidForOperatingAndFinanceLeasesAbstract_49be7c" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_88354f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_celcCashPaidForOperatingAndFinanceLeasesAbstract_49be7c" xlink:to="loc_us-gaapOperatingLeasePayments_88354f" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability_efcba6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_celcCashPaidForOperatingAndFinanceLeasesAbstract_49be7c" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability_efcba6" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments_0879f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_celcCashPaidForOperatingAndFinanceLeasesAbstract_49be7c" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments_0879f2" order="4" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_CashPaidForOperatingAndFinanceLeases" xlink:label="loc_celcCashPaidForOperatingAndFinanceLeases_581a1e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_celcCashPaidForOperatingAndFinanceLeasesAbstract_49be7c" xlink:to="loc_celcCashPaidForOperatingAndFinanceLeases_581a1e" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:title="000024 - Disclosure - Commitments (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_97810d" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_1bbc0d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_97810d" xlink:to="loc_us-gaapStatementTable_1bbc0d" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_469445" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1bbc0d" xlink:to="loc_us-gaapStatementLineItems_469445" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_100957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1bbc0d" xlink:to="loc_us-gaapPlanNameAxis_100957" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_cb0ff5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_100957" xlink:to="loc_us-gaapPlanNameDomain_cb0ff5" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_30004b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1bbc0d" xlink:to="loc_us-gaapAwardDateAxis_30004b" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_34673b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_30004b" xlink:to="loc_us-gaapAwardDateDomain_34673b" order="40" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_AgreementWithBiopharmaceuticalCompanyOneMember" xlink:label="loc_celcAgreementWithBiopharmaceuticalCompanyOneMember_37983a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_cb0ff5" xlink:to="loc_celcAgreementWithBiopharmaceuticalCompanyOneMember_37983a" order="41" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_JanuaryTwoThousandTwentyOneMember" xlink:label="loc_celcJanuaryTwoThousandTwentyOneMember_7dc009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_34673b" xlink:to="loc_celcJanuaryTwoThousandTwentyOneMember_7dc009" order="42" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_AgreementWithBiopharmaceuticalCompanyMember" xlink:label="loc_celcAgreementWithBiopharmaceuticalCompanyMember_a28e78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_cb0ff5" xlink:to="loc_celcAgreementWithBiopharmaceuticalCompanyMember_a28e78" order="43" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_AgreementWithBiopharmaceuticalCompanyTwoMember" xlink:label="loc_celcAgreementWithBiopharmaceuticalCompanyTwoMember_9f2f4e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_cb0ff5" xlink:to="loc_celcAgreementWithBiopharmaceuticalCompanyTwoMember_9f2f4e" order="44" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_MarchTwoThousandTwentyOneMember" xlink:label="loc_celcMarchTwoThousandTwentyOneMember_bebb32" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_34673b" xlink:to="loc_celcMarchTwoThousandTwentyOneMember_bebb32" order="45" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapital_387a89" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_469445" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapital_387a89" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment_cc74c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_469445" xlink:to="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment_cc74c2" order="2" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EstimatedRemainingAmountOfPayments" xlink:label="loc_celcEstimatedRemainingAmountOfPayments_07566f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_469445" xlink:to="loc_celcEstimatedRemainingAmountOfPayments_07566f" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_011cb9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_469445" xlink:to="loc_us-gaapContractualObligation_011cb9" order="4" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FuturePaymentsRequiredUponCertainMilestonesBeingMet" xlink:label="loc_celcFuturePaymentsRequiredUponCertainMilestonesBeingMet_d217fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_469445" xlink:to="loc_celcFuturePaymentsRequiredUponCertainMilestonesBeingMet_d217fa" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:title="000025 - Disclosure - Stockholders Equity (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_895634" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_49116f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_895634" xlink:to="loc_us-gaapStatementTable_49116f" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_57e231" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_49116f" xlink:to="loc_us-gaapStatementLineItems_57e231" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis_1d011d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_49116f" xlink:to="loc_srtRestatementAxis_1d011d" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_362ea4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis_1d011d" xlink:to="loc_srtRestatementDomain_362ea4" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:label="loc_us-gaapOtherInvestmentNotReadilyMarketableAxis_11450d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_49116f" xlink:to="loc_us-gaapOtherInvestmentNotReadilyMarketableAxis_11450d" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:label="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain_a0d209" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherInvestmentNotReadilyMarketableAxis_11450d" xlink:to="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain_a0d209" order="40" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_PlacementSharesMember" xlink:label="loc_celcPlacementSharesMember_96688f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain_362ea4" xlink:to="loc_celcPlacementSharesMember_96688f" order="41" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_AtmAgreementMember" xlink:label="loc_celcAtmAgreementMember_bc9187" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain_a0d209" xlink:to="loc_celcAtmAgreementMember_bc9187" order="42" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_PublicOfferingPrice" xlink:label="loc_celcPublicOfferingPrice_79f8d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57e231" xlink:to="loc_celcPublicOfferingPrice_79f8d2" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_b2e0ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57e231" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_b2e0ac" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees_3bdc28" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57e231" xlink:to="loc_us-gaapSalesCommissionsAndFees_3bdc28" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_OfferingExpenses" xlink:label="loc_celcOfferingExpenses_17b19a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57e231" xlink:to="loc_celcOfferingExpenses_17b19a" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock" xlink:label="loc_celcIssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock_e46bcf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57e231" xlink:to="loc_celcIssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock_e46bcf" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares" xlink:label="loc_celcIssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares_d8656b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57e231" xlink:to="loc_celcIssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares_d8656b" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:label="loc_us-gaapEquityMethodInvestmentQuotedMarketValue_358303" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57e231" xlink:to="loc_us-gaapEquityMethodInvestmentQuotedMarketValue_358303" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_ecd6d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57e231" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_ecd6d4" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_1549fd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57e231" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_1549fd" order="9" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_AverageSellingPricePerShare" xlink:label="loc_celcAverageSellingPricePerShare_ee8a01" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_57e231" xlink:to="loc_celcAverageSellingPricePerShare_ee8a01" order="10" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetails" xlink:title="000026 - Disclosure - StockBased Compensation (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ba977" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_3f31fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ba977" xlink:to="loc_us-gaapStatementTable_3f31fc" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_ab6ab3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3f31fc" xlink:to="loc_us-gaapStatementLineItems_ab6ab3" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0cb0d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3f31fc" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0cb0d7" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_2d5624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0cb0d7" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_2d5624" order="10" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeStockOptionsMember" xlink:label="loc_celcEmployeeStockOptionsMember_1705b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_2d5624" xlink:to="loc_celcEmployeeStockOptionsMember_1705b6" order="11" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SharesOptionsOutstandingBeginning" xlink:label="loc_celcSharesOptionsOutstandingBeginning_3db129" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ab6ab3" xlink:to="loc_celcSharesOptionsOutstandingBeginning_3db129" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8eff6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ab6ab3" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8eff6d" order="2" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SharesExercised" xlink:label="loc_celcSharesExercised_5369d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ab6ab3" xlink:to="loc_celcSharesExercised_5369d2" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8cbc7f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ab6ab3" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8cbc7f" order="4" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SharesOptionsOutstandingEnding" xlink:label="loc_celcSharesOptionsOutstandingEnding_772bb3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ab6ab3" xlink:to="loc_celcSharesOptionsOutstandingEnding_772bb3" order="5" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SharesOptionsExercisables" xlink:label="loc_celcSharesOptionsExercisables_d275de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ab6ab3" xlink:to="loc_celcSharesOptionsExercisables_d275de" order="6" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_WeightedAverageExercisePriceBeginning" xlink:label="loc_celcWeightedAverageExercisePriceBeginning_a205a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ab6ab3" xlink:to="loc_celcWeightedAverageExercisePriceBeginning_a205a8" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15117c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ab6ab3" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15117c" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a3a37c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ab6ab3" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a3a37c" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2cd1ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ab6ab3" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2cd1ce" order="10" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_WeightedAverageExercisePriceEnding" xlink:label="loc_celcWeightedAverageExercisePriceEnding_4e9771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ab6ab3" xlink:to="loc_celcWeightedAverageExercisePriceEnding_4e9771" order="11" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_WeightedAverageExercisePriceOptionsExercisables" xlink:label="loc_celcWeightedAverageExercisePriceOptionsExercisables_a1c7bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ab6ab3" xlink:to="loc_celcWeightedAverageExercisePriceOptionsExercisables_a1c7bb" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3829eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ab6ab3" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3829eb" order="13" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetails1" xlink:title="000027 - Disclosure - StockBased Compensation (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1a906" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_7d6667" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1a906" xlink:to="loc_us-gaapStatementTable_7d6667" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_e02fc2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7d6667" xlink:to="loc_us-gaapStatementLineItems_e02fc2" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b7a3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7d6667" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b7a3f" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_fcfb70" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8b7a3f" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_fcfb70" order="10" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeStockOptionsMember" xlink:label="loc_celcEmployeeStockOptionsMember_97223c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_fcfb70" xlink:to="loc_celcEmployeeStockOptionsMember_97223c" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f39c08" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e02fc2" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f39c08" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5381e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e02fc2" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5381e9" order="2" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_OptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_celcOptionsOutstandingWeightedAverageExercisePrice_9c5433" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e02fc2" xlink:to="loc_celcOptionsOutstandingWeightedAverageExercisePrice_9c5433" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56ac0a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e02fc2" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56ac0a" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9a86b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e02fc2" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9a86b7" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d6bcdd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e02fc2" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d6bcdd" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_90edf1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e02fc2" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_90edf1" order="7" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetails2" xlink:title="000028 - Disclosure - StockBased Compensation (Details 2)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fee3d1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_81c44e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fee3d1" xlink:to="loc_us-gaapStatementTable_81c44e" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_d3493e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_81c44e" xlink:to="loc_us-gaapStatementLineItems_d3493e" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9bb8bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_81c44e" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9bb8bb" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_2c3c54" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9bb8bb" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_2c3c54" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_a411ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_81c44e" xlink:to="loc_srtRangeAxis_a411ea" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_294d0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_a411ea" xlink:to="loc_srtRangeMember_294d0c" order="30" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeStockOptionsMember" xlink:label="loc_celcEmployeeStockOptionsMember_693fd8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_2c3c54" xlink:to="loc_celcEmployeeStockOptionsMember_693fd8" order="31" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_62f80d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_294d0c" xlink:to="loc_srtMinimumMember_62f80d" order="32" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_370f8f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_294d0c" xlink:to="loc_srtMaximumMember_370f8f" order="33" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6f85e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d3493e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6f85e9" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d6ff3e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d3493e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d6ff3e" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bad94d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d3493e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bad94d" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7d2ab0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d3493e" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7d2ab0" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetails3" xlink:title="000029 - Disclosure - StockBased Compensation (Details 3)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_460cc3" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" xlink:label="loc_celcEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears_3d1a13" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_460cc3" xlink:to="loc_celcEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears_3d1a13" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" xlink:label="loc_celcEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears_e7a9e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_460cc3" xlink:to="loc_celcEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears_e7a9e5" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" xlink:label="loc_celcEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears_4d2363" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_460cc3" xlink:to="loc_celcEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears_4d2363" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_06b3b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_460cc3" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_06b3b1" order="4" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" xlink:label="loc_celcEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear_6ad2a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_460cc3" xlink:to="loc_celcEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear_6ad2a6" order="5" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears" xlink:label="loc_celcEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears_ec6271" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_460cc3" xlink:to="loc_celcEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears_ec6271" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetails4" xlink:title="000030 - Disclosure - StockBased Compensation (Details 4)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e46a97" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_5f22df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e46a97" xlink:to="loc_us-gaapStatementTable_5f22df" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_ec49a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5f22df" xlink:to="loc_us-gaapStatementLineItems_ec49a3" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis_0308d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5f22df" xlink:to="loc_us-gaapIncomeStatementLocationAxis_0308d3" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_07f5d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis_0308d3" xlink:to="loc_us-gaapIncomeStatementLocationDomain_07f5d2" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_92bf7b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain_07f5d2" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_92bf7b" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_efcf67" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain_07f5d2" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_efcf67" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_3bbdf2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ec49a3" xlink:to="loc_us-gaapShareBasedCompensation_3bbdf2" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockbasedCompensationDetailsNarrative" xlink:title="000031 - Disclosure - StockBased Compensation (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bd301" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_00eb34" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bd301" xlink:to="loc_us-gaapStatementTable_00eb34" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_b43b8b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_00eb34" xlink:to="loc_us-gaapStatementLineItems_b43b8b" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e6a7dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_00eb34" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e6a7dd" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_803421" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e6a7dd" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_803421" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_f50adc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_00eb34" xlink:to="loc_us-gaapAwardTypeAxis_f50adc" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc77d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_f50adc" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc77d9" order="30" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeStockOptionsMember" xlink:label="loc_celcEmployeeStockOptionsMember_d61e1f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_803421" xlink:to="loc_celcEmployeeStockOptionsMember_d61e1f" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ExpenseStockOptionsMember" xlink:label="loc_celcExpenseStockOptionsMember_0f62f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_803421" xlink:to="loc_celcExpenseStockOptionsMember_0f62f4" order="32" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_StockIncentivePlanMember" xlink:label="loc_celcStockIncentivePlanMember_e8b062" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc77d9" xlink:to="loc_celcStockIncentivePlanMember_e8b062" order="33" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_161cf0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc77d9" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_161cf0" order="34" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EmployeeStockPurchasePlanMember" xlink:label="loc_celcEmployeeStockPurchasePlanMember_b9ce5a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_803421" xlink:to="loc_celcEmployeeStockPurchasePlanMember_b9ce5a" order="35" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_FutureExpenses" xlink:label="loc_celcFutureExpenses_474dcd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b43b8b" xlink:to="loc_celcFutureExpenses_474dcd" order="1" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_StockBasedCompensationRelatedToRestrictedStockTotal" xlink:label="loc_celcStockBasedCompensationRelatedToRestrictedStockTotal_314e26" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b43b8b" xlink:to="loc_celcStockBasedCompensationRelatedToRestrictedStockTotal_314e26" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ShareExercisePrice" xlink:label="loc_celcShareExercisePrice_7aa7d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b43b8b" xlink:to="loc_celcShareExercisePrice_7aa7d9" order="3" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_CommonStockSharesReservedDescription" xlink:label="loc_celcCommonStockSharesReservedDescription_ac47c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b43b8b" xlink:to="loc_celcCommonStockSharesReservedDescription_ac47c7" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_048035" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b43b8b" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_048035" order="5" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_StockOptionAwardsSharesModified" xlink:label="loc_celcStockOptionAwardsSharesModified_8eef1a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b43b8b" xlink:to="loc_celcStockOptionAwardsSharesModified_8eef1a" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_b41f6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b43b8b" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_b41f6d" order="7" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_StockBasedCompensationExpenseRelatedToEspp" xlink:label="loc_celcStockBasedCompensationExpenseRelatedToEspp_3ebcf5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b43b8b" xlink:to="loc_celcStockBasedCompensationExpenseRelatedToEspp_3ebcf5" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalUnitsOutstanding" xlink:label="loc_us-gaapCapitalUnitsOutstanding_2970af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b43b8b" xlink:to="loc_us-gaapCapitalUnitsOutstanding_2970af" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3a5a60" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b43b8b" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3a5a60" order="10" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_RemainingSharesAvailableForIssuance" xlink:label="loc_celcRemainingSharesAvailableForIssuance_5398b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b43b8b" xlink:to="loc_celcRemainingSharesAvailableForIssuance_5398b1" order="11" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/SubsequentEventsDetailsNarrative" xlink:title="000032 - Disclosure - Subsequent Events (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_48ad30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_fd5fae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_48ad30" xlink:to="loc_us-gaapStatementTable_fd5fae" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_1547d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fd5fae" xlink:to="loc_us-gaapStatementLineItems_1547d2" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis_e5d2ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fd5fae" xlink:to="loc_us-gaapSubsequentEventTypeAxis_e5d2ef" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_02d141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis_e5d2ef" xlink:to="loc_us-gaapSubsequentEventTypeDomain_02d141" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_aa8ddc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fd5fae" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_aa8ddc" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_0fa31a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_aa8ddc" xlink:to="loc_us-gaapRelatedPartyDomain_0fa31a" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis" xlink:label="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseAxis_58ca7c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fd5fae" xlink:to="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseAxis_58ca7c" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain" xlink:label="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain_aad57c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseAxis_58ca7c" xlink:to="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain_aad57c" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_d28bb6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain_02d141" xlink:to="loc_us-gaapSubsequentEventMember_d28bb6" order="61" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_PfizerIncMember" xlink:label="loc_celcPfizerIncMember_920156" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_0fa31a" xlink:to="loc_celcPfizerIncMember_920156" order="62" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_LicenseAgreementMember" xlink:label="loc_celcLicenseAgreementMember_9a16f8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain_aad57c" xlink:to="loc_celcLicenseAgreementMember_9a16f8" order="63" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_EquityGrantAgreementMember" xlink:label="loc_celcEquityGrantAgreementMember_799c9a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsSoldUnderAgreementsToRepurchaseTypeDomain_aad57c" xlink:to="loc_celcEquityGrantAgreementMember_799c9a" order="64" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ThirdTrancheMember" xlink:label="loc_celcThirdTrancheMember_c5ebf7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_0fa31a" xlink:to="loc_celcThirdTrancheMember_c5ebf7" order="65" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_TrancheMember" xlink:label="loc_celcTrancheMember_22ab59" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_0fa31a" xlink:to="loc_celcTrancheMember_22ab59" order="66" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_SecondTrancheMember" xlink:label="loc_celcSecondTrancheMember_9ca804" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_0fa31a" xlink:to="loc_celcSecondTrancheMember_9ca804" order="67" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized_3ee39f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1547d2" xlink:to="loc_us-gaapRevenueRecognitionMilestoneMethodRevenueRecognized_3ee39f" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable_bac78b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1547d2" xlink:to="loc_us-gaapLongTermLoansPayable_bac78b" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtDescription" xlink:label="loc_us-gaapLongTermDebtDescription_bb18d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1547d2" xlink:to="loc_us-gaapLongTermDebtDescription_bb18d9" order="3" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_ClosingPricePerShare" xlink:label="loc_celcClosingPricePerShare_307850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1547d2" xlink:to="loc_celcClosingPricePerShare_307850" order="4" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_UpfrontFee" xlink:label="loc_celcUpfrontFee_300a8b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1547d2" xlink:to="loc_celcUpfrontFee_300a8b" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_94ab62" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1547d2" xlink:to="loc_us-gaapCommonStockSharesIssued_94ab62" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="celc-20210331.xsd#celc_DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents" xlink:label="loc_celcDescriptionOfCertainDevelopmentAndCommercialMilestoneEvents_f7c5cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1547d2" xlink:to="loc_celcDescriptionOfCertainDevelopmentAndCommercialMilestoneEvents_f7c5cc" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_7da4df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1547d2" xlink:to="loc_us-gaapCommonStockValue_7da4df" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>celc_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:celc="http://celcuity.com/20210331"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="celc-20210331.xsd" xlink:type="simple"/>
    <context id="From2021-01-01to2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_ThirdTrancheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celc:ThirdTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-08</instant>
        </period>
    </context>
    <context id="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_SecondTrancheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celc:SecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-08</instant>
        </period>
    </context>
    <context id="AsOf2021-04-08_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-08</instant>
        </period>
    </context>
    <context id="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_TrancheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celc:TrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-08</instant>
        </period>
    </context>
    <context id="From2021-03-09to2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseAxis">celc:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celc:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-09</startDate>
            <endDate>2021-04-08</endDate>
        </period>
    </context>
    <context id="From2021-03-09to2021-04-08_us-gaap_SubsequentEventMember_celc_ThirdTrancheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celc:ThirdTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-09</startDate>
            <endDate>2021-04-08</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_EquityGrantAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseAxis">celc:EquityGrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celc:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-08</instant>
        </period>
    </context>
    <context id="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseAxis">celc:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celc:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-08</instant>
        </period>
    </context>
    <context id="From2021-03-09to2021-04-08_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-09</startDate>
            <endDate>2021-04-08</endDate>
        </period>
    </context>
    <context id="AsOf2017-10-25_celc_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celc:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-25</instant>
        </period>
    </context>
    <context id="AsOf2020-05-14_celc_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celc:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-14</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_celc_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_celc_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2017-10-25_celc_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-25</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_celc_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celc:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_celc_ExpenseStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:ExpenseStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_celc_ExpenseStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:ExpenseStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-05-01to2020-05-14_celc_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celc:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-14</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_celc_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celc:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_celc_StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celc:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_celc_ExpenseStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:ExpenseStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_celc_EmployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:EmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_celc_PlacementSharesMember_celc_AtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">celc:PlacementSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">celc:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_celc_PlacementSharesMember_celc_AtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">celc:PlacementSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">celc:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-02-01to2021-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-26</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2021-02-26</instant>
        </period>
    </context>
    <context id="AsOf2020-06-05_celc_PlacementSharesMember_celc_AtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">celc:PlacementSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">celc:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-05</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_celc_MarchTwoThousandTwentyOneMember_celc_AgreementWithBiopharmaceuticalCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">celc:MarchTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celc:AgreementWithBiopharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_celc_AgreementWithBiopharmaceuticalCompanyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celc:AgreementWithBiopharmaceuticalCompanyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_celc_AgreementWithBiopharmaceuticalCompanyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celc:AgreementWithBiopharmaceuticalCompanyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_celc_JanuaryTwoThousandTwentyOneMember_celc_AgreementWithBiopharmaceuticalCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">celc:JanuaryTwoThousandTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celc:AgreementWithBiopharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2017-05-01to2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_celc_AgreementWithBiopharmaceuticalCompanyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celc:AgreementWithBiopharmaceuticalCompanyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_celc_FinanceLeasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">celc:FinanceLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_celc_OperatingLeasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">celc:OperatingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">celc:SupplementalBalanceSheetInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_celc_RestrictedStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:RestrictedStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_celc_RestrictedStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">celc:RestrictedStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_celc_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">celc:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_celc_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">celc:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_celc_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">celc:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_celc_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">celc:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-05-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2021-05-03</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-03-31">0001603454</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-01-01to2021-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-01-01to2021-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-01-01to2021-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2021-01-01to2021-03-31">2020</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="0" unitRef="Shares">2500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-03-31" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="0" unitRef="Shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="0" unitRef="Shares">10299822</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-03-31" decimals="0" unitRef="Shares">12287896</us-gaap:CommonStockSharesOutstanding>
    <dei:DocumentType contextRef="From2021-01-01to2021-03-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2021-01-01to2021-03-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-01-01to2021-03-31">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2021-01-01to2021-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-01-01to2021-03-31">001-38207</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-01-01to2021-03-31">CELCUITY INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-01-01to2021-03-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-01-01to2021-03-31">82-2863566</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-01-01to2021-03-31">16305 36th Avenue North;</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-01-01to2021-03-31">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-01-01to2021-03-31">Minneapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-01-01to2021-03-31">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-01-01to2021-03-31">55446</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-01-01to2021-03-31">763</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-01-01to2021-03-31">392-0767</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-01-01to2021-03-31">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-01-01to2021-03-31">CELC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-01-01to2021-03-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2021-01-01to2021-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-01-01to2021-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-01-01to2021-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-01-01to2021-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-03-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2021-01-01to2021-03-31">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="From2021-01-01to2021-03-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-05-03" decimals="INF" unitRef="Shares">12647037</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1307"
      unitRef="USD">34936902</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1308"
      unitRef="USD">11637911</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1309"
      unitRef="USD">22009</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1310"
      unitRef="USD">22009</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DeferredCostsCurrent
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1311"
      unitRef="USD">13719</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCostsCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1312"
      unitRef="USD">0</us-gaap:DeferredCostsCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1313"
      unitRef="USD">190000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1314"
      unitRef="USD">190000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1315"
      unitRef="USD">551345</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1316"
      unitRef="USD">317040</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1317"
      unitRef="USD">35713975</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1318"
      unitRef="USD">12166960</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1319"
      unitRef="USD">466484</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1320"
      unitRef="USD">558876</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1321"
      unitRef="USD">186602</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1322"
      unitRef="USD">230911</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1323"
      unitRef="USD">36367061</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1324"
      unitRef="USD">12956747</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1327"
      unitRef="USD">318213</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1328"
      unitRef="USD">217377</us-gaap:AccountsPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1329"
      unitRef="USD">5819</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1330"
      unitRef="USD">5810</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1331"
      unitRef="USD">185656</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1332"
      unitRef="USD">187518</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1333"
      unitRef="USD">660849</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1334"
      unitRef="USD">774612</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1335"
      unitRef="USD">1170537</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1336"
      unitRef="USD">1185317</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1337"
      unitRef="USD">6841</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1338"
      unitRef="USD">8299</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1339"
      unitRef="USD">15139</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1340"
      unitRef="USD">60861</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1341"
      unitRef="USD">1192517</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1342"
      unitRef="USD">1254477</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-31"
      decimals="INF"
      id="fid_1162"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1163"
      unitRef="Shares">2500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1145"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1344"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1345"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-31"
      decimals="INF"
      id="fid_1149"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1153"
      unitRef="Shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1157"
      unitRef="Shares">12287896</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1156"
      unitRef="Shares">10299822</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1346"
      unitRef="USD">12288</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1347"
      unitRef="USD">10300</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1348"
      unitRef="USD">64275505</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1349"
      unitRef="USD">38013551</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1350"
      unitRef="USD">-29113249</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1351"
      unitRef="USD">-26321581</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1352"
      unitRef="USD">35174544</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1353"
      unitRef="USD">11702270</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1354"
      unitRef="USD">36367061</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1355"
      unitRef="USD">12956747</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1165"
      unitRef="USD">2236342</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1166"
      unitRef="USD">1847414</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1167"
      unitRef="USD">555428</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1168"
      unitRef="USD">463399</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1169"
      unitRef="USD">2791770</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1170"
      unitRef="USD">2310813</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1171"
      unitRef="USD">-2791770</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1172"
      unitRef="USD">-2310813</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1174"
      unitRef="USD">24</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1175"
      unitRef="USD">33</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1176"
      unitRef="USD">388</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1177"
      unitRef="USD">63851</us-gaap:InvestmentIncomeInterest>
    <celc:LossOnSaleOfFixedAssets
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1178"
      unitRef="USD">263</celc:LossOnSaleOfFixedAssets>
    <celc:LossOnSaleOfFixedAssets
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1179"
      unitRef="USD">0</celc:LossOnSaleOfFixedAssets>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1180"
      unitRef="USD">101</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1181"
      unitRef="USD">63818</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1182"
      unitRef="USD">-2791668</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1183"
      unitRef="USD">-2246995</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1184"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1185"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1186"
      unitRef="USD">-2791668</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1187"
      unitRef="USD">-2246995</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2021-01-01to2021-03-31"
      decimals="INF"
      id="fid_1188"
      unitRef="USDPShares">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-01-01to2020-03-31"
      decimals="INF"
      id="fid_1189"
      unitRef="USDPShares">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1190"
      unitRef="Shares">11072097</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1191"
      unitRef="Shares">10253988</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1192"
      unitRef="Shares">10299822</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1193"
      unitRef="USD">10300</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1194"
      unitRef="USD">38013551</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1195"
      unitRef="USD">-26321581</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1196"
      unitRef="USD">11702270</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1197"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1198"
      unitRef="USD">449098</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1199"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1200"
      unitRef="USD">449098</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <celc:ExerciseOfCommonStockWarrantsShares
      contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1201"
      unitRef="Shares">1185</celc:ExerciseOfCommonStockWarrantsShares>
    <celc:ExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1202"
      unitRef="USD">1</celc:ExerciseOfCommonStockWarrantsAmount>
    <celc:ExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1203"
      unitRef="USD">11256</celc:ExerciseOfCommonStockWarrantsAmount>
    <celc:ExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1204"
      unitRef="USD">0</celc:ExerciseOfCommonStockWarrantsAmount>
    <celc:ExerciseOfCommonStockWarrantsAmount
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1205"
      unitRef="USD">11257</celc:ExerciseOfCommonStockWarrantsAmount>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1206"
      unitRef="Shares">12707</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1207"
      unitRef="USD">13</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1208"
      unitRef="USD">-13</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1209"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1210"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1211"
      unitRef="Shares">1971100</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1212"
      unitRef="USD">1971</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1213"
      unitRef="USD">25766522</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1214"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1215"
      unitRef="USD">25768493</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1216"
      unitRef="Shares">3082</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1217"
      unitRef="USD">3</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1218"
      unitRef="USD">38959</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1219"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1220"
      unitRef="USD">38962</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <celc:IssuanceCostsAssociatedWithAtmOffering
      contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1221"
      unitRef="USD">0</celc:IssuanceCostsAssociatedWithAtmOffering>
    <celc:IssuanceCostsAssociatedWithAtmOffering
      contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1222"
      unitRef="USD">-3868</celc:IssuanceCostsAssociatedWithAtmOffering>
    <celc:IssuanceCostsAssociatedWithAtmOffering
      contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1223"
      unitRef="USD">0</celc:IssuanceCostsAssociatedWithAtmOffering>
    <celc:IssuanceCostsAssociatedWithAtmOffering
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1224"
      unitRef="USD">-3868</celc:IssuanceCostsAssociatedWithAtmOffering>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1225"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1226"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1227"
      unitRef="USD">-2791668</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1228"
      unitRef="USD">-2791668</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1229"
      unitRef="Shares">12287896</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1230"
      unitRef="USD">12288</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1231"
      unitRef="USD">64275505</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1232"
      unitRef="USD">-29113249</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1233"
      unitRef="USD">35174544</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1234"
      unitRef="Shares">10253988</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1235"
      unitRef="USD">10254</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1236"
      unitRef="USD">36134723</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1237"
      unitRef="USD">-16847406</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_1238"
      unitRef="USD">19297571</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1239"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1240"
      unitRef="USD">464649</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1241"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1242"
      unitRef="USD">464649</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1243"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1244"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1245"
      unitRef="USD">-2246995</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1246"
      unitRef="USD">-2246995</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1247"
      unitRef="Shares">10253988</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1248"
      unitRef="USD">10254</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1249"
      unitRef="USD">36599372</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1250"
      unitRef="USD">-19094401</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31"
      decimals="0"
      id="fid_1251"
      unitRef="USD">17515225</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1253"
      unitRef="USD">-2791668</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1254"
      unitRef="USD">-2246995</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1256"
      unitRef="USD">98222</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1257"
      unitRef="USD">94792</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1258"
      unitRef="USD">449098</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1259"
      unitRef="USD">464649</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1260"
      unitRef="USD">263</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1261"
      unitRef="USD">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1263"
      unitRef="USD">-234305</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1264"
      unitRef="USD">-62651</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1265"
      unitRef="USD">73924</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1266"
      unitRef="USD">-92197</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1267"
      unitRef="USD">-113763</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1268"
      unitRef="USD">30143</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <celc:IncreaseDecreaseInNonCashOperatingLeaseExpense
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1269"
      unitRef="USD">-3276</celc:IncreaseDecreaseInNonCashOperatingLeaseExpense>
    <celc:IncreaseDecreaseInNonCashOperatingLeaseExpense
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1270"
      unitRef="USD">-21342</celc:IncreaseDecreaseInNonCashOperatingLeaseExpense>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1271"
      unitRef="USD">-2521505</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1272"
      unitRef="USD">-1833601</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1274"
      unitRef="USD">30925</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1275"
      unitRef="USD">45604</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1276"
      unitRef="USD">500</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1277"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1278"
      unitRef="USD">-30425</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1279"
      unitRef="USD">-45604</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1281"
      unitRef="USD">11257</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1282"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <celc:ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1283"
      unitRef="USD">25814167</celc:ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts>
    <celc:ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1284"
      unitRef="USD">0</celc:ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts>
    <celc:GrossProceedsFromAnAtmOffering
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1285"
      unitRef="USD">38962</celc:GrossProceedsFromAnAtmOffering>
    <celc:GrossProceedsFromAnAtmOffering
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1286"
      unitRef="USD">0</celc:GrossProceedsFromAnAtmOffering>
    <celc:PaymentsForRegistrationStatementCosts
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1287"
      unitRef="USD">12016</celc:PaymentsForRegistrationStatementCosts>
    <celc:PaymentsForRegistrationStatementCosts
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1288"
      unitRef="USD">0</celc:PaymentsForRegistrationStatementCosts>
    <celc:PaymentsForFinanceLeases
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1289"
      unitRef="USD">1449</celc:PaymentsForFinanceLeases>
    <celc:PaymentsForFinanceLeases
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1290"
      unitRef="USD">1438</celc:PaymentsForFinanceLeases>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1356"
      unitRef="USD">25850921</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1357"
      unitRef="USD">-1438</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1293"
      unitRef="USD">23298991</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1294"
      unitRef="USD">-1880643</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1296"
      unitRef="USD">11637911</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_1297"
      unitRef="USD">18735002</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1298"
      unitRef="USD">34936902</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-03-31"
      decimals="0"
      id="fid_1299"
      unitRef="USD">16854359</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LiabilitiesAssumed1
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1301"
      unitRef="USD">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1302"
      unitRef="USD">14101</us-gaap:LiabilitiesAssumed1>
    <celc:OfferingAndRegistrationStatementCostsIncludedInAccountsPayable
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1303"
      unitRef="USD">51245</celc:OfferingAndRegistrationStatementCostsIncludedInAccountsPayable>
    <celc:OfferingAndRegistrationStatementCostsIncludedInAccountsPayable
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1304"
      unitRef="USD">6127</celc:OfferingAndRegistrationStatementCostsIncludedInAccountsPayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1574">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;1.&#160;Organization&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Nature of Business&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Celcuity Inc., a Delaware corporation (the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated companion diagnostic (CDx) and therapeutic (Rx) strategy. Our CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from targeted therapies. This enables a CELsignia CDx to support advancement of new indications for already approved targeted therapies. Our therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver our companion diagnostics can identify. By pursuing an integrated companion diagnostic and therapeutic strategy, we believe we are uniquely positioned to achieve our goal of helping cancer patients receive the therapeutic best suited to treat their cancer driver. The Company was co-founded in 2012 by Brian F. Sullivan and Dr. Lance G. Laing and is based in Minnesota. The Company has not generated any revenues to date.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1575">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;2. Summary of Significant Accounting Policies&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The accompanying unaudited financial statements include the accounts of the Company and have been prepared in accordance with Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, as permitted by Article 10, the unaudited financial statements do not include all of the information required by accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). The balance sheet at December&#160;31, 2020 was derived from the audited financial statements at that date and does not include all the disclosures required by U.S. GAAP. In the opinion of management, all adjustments which are of a normal recurring nature and necessary for a fair presentation have been reflected in the financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&#160;31, 2020 and the related footnotes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Follow-on Offering&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;On February 26, 2021, the Company completed a follow-on offering whereby it sold 1,971,100 shares of common stock (including 257,100 shares of common stock in connection with the full exercise of the underwriters&#x2019; option to purchase additional shares) at a public offering price of $14.00 per share. The aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, was approximately $27.6 million before deducting underwriting discounts of approximately $1.6 million and offering expenses of approximately $0.2 million.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="text-decoration:underline"&gt;&lt;strong&gt;Accounting Estimates&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Management uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/strong&gt;&lt;span style="text-decoration:underline"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval of its diagnostic tests, the clinical and commercial success of its initial drug product, gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Clinical Trial Costs&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Company records prepaid assets or accrued expenses for prepaid or estimated clinical trial costs conducted by third-party service providers, which includes the conduct of preclinical studies and clinical trials.&#160; These costs can be a significant component of the Company&#x2019;s research and development expenses.&#160; The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with service agreements with its third-party service providers.&#160; The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period.&#160; As actual costs become known, the Company adjusts its prepaid assets or accrued expenses.&#160; The Company has not experienced any material differences between accrued costs and actual costs incurred.&#160; However, the status and timing of actual services performed, number of patients enrolled, and the rate of patient enrollments may vary from the Company&#x2019;s estimates, resulting in an adjustment to expense in future periods.&#160; Changes in these estimates that result in material changes to the Company&#x2019;s prepaid assets or accrued expenses could materially affect the Company&#x2019;s results of operations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Application of New or Revised Accounting Standards&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Pursuant to the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), a company constituting an &#x201c;emerging growth company&#x201d; is, among other things, entitled to rely upon certain reduced reporting requirements. The Company is an emerging growth company but has irrevocably elected not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. As a result, the Company will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for public companies that are not emerging growth companies. &lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1581">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The accompanying unaudited financial statements include the accounts of the Company and have been prepared in accordance with Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, as permitted by Article 10, the unaudited financial statements do not include all of the information required by accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). The balance sheet at December&#160;31, 2020 was derived from the audited financial statements at that date and does not include all the disclosures required by U.S. GAAP. In the opinion of management, all adjustments which are of a normal recurring nature and necessary for a fair presentation have been reflected in the financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&#160;31, 2020 and the related footnotes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <celc:FollowOnOfferingPolicyTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1586">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;On February 26, 2021, the Company completed a follow-on offering whereby it sold 1,971,100 shares of common stock (including 257,100 shares of common stock in connection with the full exercise of the underwriters&#x2019; option to purchase additional shares) at a public offering price of $14.00 per share. The aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, was approximately $27.6 million before deducting underwriting discounts of approximately $1.6 million and offering expenses of approximately $0.2 million.&lt;/p&gt;</celc:FollowOnOfferingPolicyTextBlock>
    <celc:IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1402"
      unitRef="Shares">1971100</celc:IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares>
    <celc:IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1403"
      unitRef="Shares">257100</celc:IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock>
    <us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare
      contextRef="From2021-01-01to2021-03-31"
      decimals="INF"
      id="fid_1404"
      unitRef="USDPShares">14.00</us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare>
    <celc:NetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2021-01-01to2021-03-31"
      decimals="-5"
      id="fid_1405"
      unitRef="USD">27600000</celc:NetOfUnderwritingDiscountsAndOfferingCosts>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2021-01-01to2021-03-31"
      decimals="-5"
      id="fid_1406"
      unitRef="USD">1600000</us-gaap:SalesCommissionsAndFees>
    <celc:OfferingExpenses
      contextRef="From2021-01-01to2021-03-31"
      decimals="-5"
      id="fid_1407"
      unitRef="USD">200000</celc:OfferingExpenses>
    <us-gaap:UseOfEstimates contextRef="From2021-01-01to2021-03-31" id="fid_1582">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Management uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2021-01-01to2021-03-31" id="fid_1583">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval of its diagnostic tests, the clinical and commercial success of its initial drug product, gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2021-01-01to2021-03-31" id="fid_1584">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Company records prepaid assets or accrued expenses for prepaid or estimated clinical trial costs conducted by third-party service providers, which includes the conduct of preclinical studies and clinical trials.&#160; These costs can be a significant component of the Company&#x2019;s research and development expenses.&#160; The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with service agreements with its third-party service providers.&#160; The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period.&#160; As actual costs become known, the Company adjusts its prepaid assets or accrued expenses.&#160; The Company has not experienced any material differences between accrued costs and actual costs incurred.&#160; However, the status and timing of actual services performed, number of patients enrolled, and the rate of patient enrollments may vary from the Company&#x2019;s estimates, resulting in an adjustment to expense in future periods.&#160; Changes in these estimates that result in material changes to the Company&#x2019;s prepaid assets or accrued expenses could materially affect the Company&#x2019;s results of operations.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <celc:ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1585">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Pursuant to the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), a company constituting an &#x201c;emerging growth company&#x201d; is, among other things, entitled to rely upon certain reduced reporting requirements. The Company is an emerging growth company but has irrevocably elected not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. As a result, the Company will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for public companies that are not emerging growth companies. &lt;/p&gt;</celc:ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1576">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;3. Net Loss Per Common Share&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per common share are the same.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;For the three months ended March 31, 2021 and 2020, potentially dilutive securities excluded from the computations of diluted weighted-average shares outstanding were options to purchase 855,072 and 630,889 shares of common stock, respectively, warrants to purchase 352,400 and 353,585 shares of common stock, respectively, and 15,686 and 0 shares of restricted common stock, respectively.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-01to2021-03-31_celc_StockOptionsMember"
      decimals="0"
      id="fid_1409"
      unitRef="Shares">855072</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-01to2020-03-31_celc_StockOptionsMember"
      decimals="0"
      id="fid_1410"
      unitRef="Shares">630889</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-01to2021-03-31_celc_WarrantsMember"
      decimals="0"
      id="fid_1411"
      unitRef="Shares">352400</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-01to2020-03-31_celc_WarrantsMember"
      decimals="0"
      id="fid_1408"
      unitRef="Shares">353585</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-01to2021-03-31_celc_RestrictedStocksMember"
      decimals="0"
      id="fid_1412"
      unitRef="Shares">15686</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-01to2020-03-31_celc_RestrictedStocksMember"
      decimals="0"
      id="fid_1413"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1577">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;4. Commitments&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="text-decoration:underline"&gt;&lt;strong&gt;Operating and Finance Leases&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;The Company leases its corporate space in Minneapolis, Minnesota. In September 2017, the Company entered into a non-cancelable operating lease agreement for building space. The new lease commenced, and the Company moved to the facility in May 2018, in conjunction with the termination of its then existing lease. Rent expense is recorded on a straight-line basis over the lease term. In July 2020 the Company signed an amendment to extend this lease through April 30, 2022. The lease amendment provides for monthly rent, real estate taxes and operating expenses. As a result of the lease amendment, the Company recorded an incremental $197,211 in the operating right-of-use (&#x201c;ROU&#x201d;) asset and lease liability. &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;The lease agreement, as amended, includes the option to extend the term for one additional year. The option to extend is at the Company&#x2019;s discretion and because the Company has not determined if the option to extend will be exercised, the extended lease term is not included in the ROU assets and lease liabilities. The Company regularly evaluates the renewal options and when it is reasonably certain of exercise, the Company will include the renewal period in its lease term.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;In May 2018, the Company entered into a non-cancelable finance lease agreement for office equipment with a five-year term. The underlying assets are included in furniture and equipment. The lease contains a bargain purchase option at the end of the lease.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;When an implicit rate is not provided, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Supplemental balance sheet information consisted of the following at March 31, 2021:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Operating Lease&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;186,602&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Operating lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;200,795&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Less: short term portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(185,656&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Long term portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;15,139&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Finance Lease&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;28,932&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(16,395&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;Net book value of property and equipment under finance lease &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;12,537&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Finance lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,660&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Less: short term portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(5,819&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Long term portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6,841&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Maturity analysis under lease agreements consisted of the following as of March 31, 2021:&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Operating Leases&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Finance Leases&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;146,116&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,441&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;64,940&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,255&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,023&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;211,056&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;15,719&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Less: Present value discount&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(10,261&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(99&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Less: Amount representing services&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,960&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Present value of net minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;200,795&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;12,660&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;Weighted Average&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;Remaining Lease Term &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Discount Rate&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&#160; Operating lease &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;1.1 years &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.0&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&#160; Finance lease &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;2.1 years &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.0&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Lease costs for the period ended March 31, 2021:&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;Three-month Period &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;Operating lease cost &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;45,430&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;Finance lease cost: &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;&#160;&#160; Amortization &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,447&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;&#160;&#160; Interest &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;Variable lease cost &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;19,869&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;66,770&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Supplemental cash flow information related to leases for the period ended March 31, 2021:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;Three-month Period &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td colspan="5" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;Cash paid for amounts included in operating and finance leases: &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;&#160;&#160; Operating cash outflow from operating leases &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;68,574&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;&#160;&#160; Operating cash outflow from finance leases &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;&#160;&#160; Financing cash outflow from finance leases &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,449&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;70,047&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Clinical Research Studies&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;In May 2017, the Company entered into an agreement with a clinical research organization to conduct a clinical research study.&#160; The Company made payments of approximately $275,000 and $100,000 in 2021 and 2020, respectively, and $600,000 prior to 2020.&#160; Additional payments will be due as certain milestones are met and clinical sites are added. The maximum amount of these additional payments is estimated to be approximately $2,340,000 over the course of the agreement. &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;In October 2018, the Company entered into an agreement with a biopharmaceutical company and a cancer research center to conduct a clinical research study. The Company made payments of approximately $70,000 prior to 2020. Additional payments of approximately $112,000 will be due as certain milestones are met.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;In December 2020, the Company entered into an agreement with a biopharmaceutical company and a cancer research center to conduct a clinical research study. The Company made zero payments in 2021&#160;and 2020. Future payments of approximately $740,000 will be due as certain milestones are met.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;In January 2021, the Company entered into an agreement with a biopharmaceutical company and a cancer research center to conduct a clinical research study. The Company made zero payments in 2021. Future payments of approximately $1,210,600 will be due as certain milestones are met.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;In March 2021, the Company entered into an agreement with two biopharmaceutical companies and a cancer research center to conduct a clinical research study. The Company made zero payments in 2021. Future payments of approximately $1,548,000 will be due as certain milestones are met.&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1461"
      unitRef="USD">197211</us-gaap:IncreaseDecreaseInOperatingCapital>
    <celc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1587">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Supplemental balance sheet information consisted of the following at March 31, 2021:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Operating Lease&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;186,602&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Operating lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;200,795&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Less: short term portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(185,656&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Long term portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;15,139&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Finance Lease&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;28,932&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(16,395&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;Net book value of property and equipment under finance lease &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;12,537&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Finance lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,660&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Less: short term portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(5,819&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Long term portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6,841&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</celc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember"
      decimals="0"
      id="fid_1430"
      unitRef="USD">186602</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember"
      decimals="0"
      id="fid_1416"
      unitRef="USD">200795</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember"
      decimals="0"
      id="fid_1417"
      unitRef="USD">-185656</us-gaap:OperatingLeaseLiabilityCurrent>
    <celc:LongTermOperatingLeaseLiability
      contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember"
      decimals="0"
      id="fid_1427"
      unitRef="USD">15139</celc:LongTermOperatingLeaseLiability>
    <us-gaap:CapitalLeasedAssetsGross
      contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember"
      decimals="0"
      id="fid_1420"
      unitRef="USD">28932</us-gaap:CapitalLeasedAssetsGross>
    <us-gaap:CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
      contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember"
      decimals="0"
      id="fid_1421"
      unitRef="USD">-16395</us-gaap:CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation>
    <us-gaap:CapitalLeasesBalanceSheetAssetsByMajorClassNet
      contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember"
      decimals="0"
      id="fid_1422"
      unitRef="USD">12537</us-gaap:CapitalLeasesBalanceSheetAssetsByMajorClassNet>
    <celc:FinanceLeaseLiabilities
      contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember"
      decimals="0"
      id="fid_1423"
      unitRef="USD">12660</celc:FinanceLeaseLiabilities>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember"
      decimals="0"
      id="fid_1428"
      unitRef="USD">-5819</us-gaap:ShortTermBorrowings>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember"
      decimals="0"
      id="fid_1597"
      unitRef="USD">6841</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1588">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Operating Leases&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Finance Leases&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;146,116&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,441&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;64,940&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,255&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,023&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;211,056&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;15,719&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Less: Present value discount&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(10,261&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(99&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Less: Amount representing services&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,960&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Present value of net minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;200,795&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;12,660&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2021-03-31_celc_OperatingLeasesMember"
      decimals="0"
      id="fid_1432"
      unitRef="USD">146116</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2021-03-31_celc_FinanceLeasesMember"
      decimals="0"
      id="fid_1439"
      unitRef="USD">5441</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2021-03-31_celc_OperatingLeasesMember"
      decimals="0"
      id="fid_1433"
      unitRef="USD">64940</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2021-03-31_celc_FinanceLeasesMember"
      decimals="0"
      id="fid_1440"
      unitRef="USD">7255</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2021-03-31_celc_OperatingLeasesMember"
      decimals="0"
      id="fid_1434"
      unitRef="USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2021-03-31_celc_FinanceLeasesMember"
      decimals="0"
      id="fid_1441"
      unitRef="USD">3023</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2021-03-31_celc_OperatingLeasesMember"
      decimals="0"
      id="fid_1435"
      unitRef="USD">211056</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2021-03-31_celc_FinanceLeasesMember"
      decimals="0"
      id="fid_1442"
      unitRef="USD">15719</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <celc:LessPresentValueDiscount
      contextRef="AsOf2021-03-31_celc_OperatingLeasesMember"
      decimals="0"
      id="fid_1436"
      unitRef="USD">-10261</celc:LessPresentValueDiscount>
    <celc:LessPresentValueDiscount
      contextRef="AsOf2021-03-31_celc_FinanceLeasesMember"
      decimals="0"
      id="fid_1443"
      unitRef="USD">-99</celc:LessPresentValueDiscount>
    <celc:LesseeOperatingLeaseLiabilityAmountRepresentingServices
      contextRef="AsOf2021-03-31_celc_OperatingLeasesMember"
      decimals="0"
      id="fid_1437"
      unitRef="USD">0</celc:LesseeOperatingLeaseLiabilityAmountRepresentingServices>
    <celc:LessAmountRepresentingServices
      contextRef="AsOf2021-03-31_celc_FinanceLeasesMember"
      decimals="0"
      id="fid_1444"
      unitRef="USD">2960</celc:LessAmountRepresentingServices>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2021-03-31_celc_OperatingLeasesMember"
      decimals="0"
      id="fid_1438"
      unitRef="USD">200795</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2021-03-31_celc_FinanceLeasesMember"
      decimals="0"
      id="fid_1445"
      unitRef="USD">12660</us-gaap:FinanceLeaseLiability>
    <celc:ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1589">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;Weighted Average&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;Remaining Lease Term &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Discount Rate&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&#160; Operating lease &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;1.1 years &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.0&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&#160; Finance lease &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;2.1 years &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.0&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</celc:ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock>
    <celc:OperatingLeaseWeightedAverageRemainingLeasesTerm1 contextRef="From2021-01-01to2021-03-31" id="fid_1446">P1Y1M6D</celc:OperatingLeaseWeightedAverageRemainingLeasesTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2021-03-31"
      decimals="INF"
      id="fid_1447"
      unitRef="Pure">0.040</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <celc:FinanceLeaseWeightedAverageRemainingLeasesTerm1 contextRef="From2021-01-01to2021-03-31" id="fid_1448">P2Y1M6D</celc:FinanceLeaseWeightedAverageRemainingLeasesTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2021-03-31"
      decimals="INF"
      id="fid_1449"
      unitRef="Pure">0.010</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1590">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;Three-month Period &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;Operating lease cost &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;45,430&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;Finance lease cost: &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;&#160;&#160; Amortization &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,447&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;&#160;&#160; Interest &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;Variable lease cost &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;19,869&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;66,770&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1450"
      unitRef="USD">45430</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1452"
      unitRef="USD">1447</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1453"
      unitRef="USD">24</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:VariableLeaseCost
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1454"
      unitRef="USD">19869</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1455"
      unitRef="USD">66770</us-gaap:LeaseCost>
    <celc:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1591">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Supplemental cash flow information related to leases for the period ended March 31, 2021:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;Three-month Period &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td colspan="5" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;Cash paid for amounts included in operating and finance leases: &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;&#160;&#160; Operating cash outflow from operating leases &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;68,574&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;&#160;&#160; Operating cash outflow from finance leases &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;&#160;&#160;&#160; Financing cash outflow from finance leases &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,449&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;70,047&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</celc:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1457"
      unitRef="USD">68574</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1458"
      unitRef="USD">24</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1459"
      unitRef="USD">1449</us-gaap:FinanceLeasePrincipalPayments>
    <celc:CashPaidForOperatingAndFinanceLeases
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1460"
      unitRef="USD">70047</celc:CashPaidForOperatingAndFinanceLeases>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1462"
      unitRef="USD">275000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      id="fid_1463"
      unitRef="USD">100000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2017-05-01to2019-12-31"
      decimals="0"
      id="fid_1464"
      unitRef="USD">600000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <celc:EstimatedRemainingAmountOfPayments
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1467"
      unitRef="USD">2340000</celc:EstimatedRemainingAmountOfPayments>
    <us-gaap:ContractualObligation
      contextRef="AsOf2019-12-31_celc_AgreementWithBiopharmaceuticalCompanyOneMember"
      decimals="0"
      id="fid_1617"
      unitRef="USD">70000</us-gaap:ContractualObligation>
    <celc:FuturePaymentsRequiredUponCertainMilestonesBeingMet
      contextRef="AsOf2021-03-31_celc_AgreementWithBiopharmaceuticalCompanyOneMember"
      decimals="0"
      id="fid_1468"
      unitRef="USD">112000</celc:FuturePaymentsRequiredUponCertainMilestonesBeingMet>
    <celc:FuturePaymentsRequiredUponCertainMilestonesBeingMet
      contextRef="AsOf2021-03-31_celc_AgreementWithBiopharmaceuticalCompanyTwoMember"
      decimals="0"
      id="fid_1618"
      unitRef="USD">740000</celc:FuturePaymentsRequiredUponCertainMilestonesBeingMet>
    <celc:FuturePaymentsRequiredUponCertainMilestonesBeingMet
      contextRef="AsOf2021-03-31_celc_JanuaryTwoThousandTwentyOneMember_celc_AgreementWithBiopharmaceuticalCompanyMember"
      decimals="0"
      id="fid_1481"
      unitRef="USD">1210600</celc:FuturePaymentsRequiredUponCertainMilestonesBeingMet>
    <celc:FuturePaymentsRequiredUponCertainMilestonesBeingMet
      contextRef="AsOf2021-03-31_celc_MarchTwoThousandTwentyOneMember_celc_AgreementWithBiopharmaceuticalCompanyMember"
      decimals="0"
      id="fid_1482"
      unitRef="USD">1548000</celc:FuturePaymentsRequiredUponCertainMilestonesBeingMet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1578">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;5. Stockholders&#x2019; Equity&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;On February 26, 2021, the Company completed a follow-on offering whereby it sold 1,971,100 shares of common stock (including 257,100 shares of common stock in connection with the full exercise of the underwriters&#x2019; option to purchase additional shares) at a public offering price of $14.00 per share. The aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, was approximately $27.6 million before deducting underwriting discounts of approximately $1.6 million and offering expenses of approximately $0.2 million.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;On June 5, 2020, the Company entered into an At Market Issuance Sales Agreement (the &#x201c;ATM Agreement&#x201d;) with B. Riley FBR, Inc. (the &#x201c;Agent&#x201d;). Pursuant to the ATM Agreement, the Company was able to offer and sell from time to time, at its option, shares of common stock having an aggregate offering price of up to $10,000,000, par value $0.001 per share (the &#x201c;Placement Shares&#x201d;), through the Agent.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Placement Shares were registered under the Securities Act of 1933, as amended, pursuant to the Registration Statement on Form S-3 (File No. 333-227466), which was originally filed with the SEC on September 21, 2018 and declared effective by the SEC on October 4, 2018, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed on June 5, 2020. Sales of the Company&#x2019;s common stock, if any, under this prospectus supplement were able to be made by any method deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;During the three months ended March 31, 2021, the Company sold 3,082 shares of common stock pursuant to the ATM Agreement, at an average selling price of $12.64per share.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;On February 23, 2021, in conjunction with the Company&#x2019;s follow-on offering, the ATM Agreement was terminated.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <celc:IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares
      contextRef="From2021-02-01to2021-02-26"
      decimals="0"
      id="fid_1620"
      unitRef="Shares">1971100</celc:IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares>
    <celc:IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock
      contextRef="From2021-02-01to2021-02-26"
      decimals="0"
      id="fid_1622"
      unitRef="Shares">257100</celc:IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock>
    <celc:PublicOfferingPrice
      contextRef="AsOf2021-02-26"
      decimals="INF"
      id="fid_1490"
      unitRef="USDPShares">14.00</celc:PublicOfferingPrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2021-02-01to2021-02-26"
      decimals="-5"
      id="fid_1491"
      unitRef="USD">27600000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2021-02-01to2021-02-26"
      decimals="-5"
      id="fid_1492"
      unitRef="USD">1600000</us-gaap:SalesCommissionsAndFees>
    <celc:OfferingExpenses
      contextRef="From2021-02-01to2021-02-26"
      decimals="-5"
      id="fid_1493"
      unitRef="USD">200000</celc:OfferingExpenses>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="AsOf2020-06-05_celc_PlacementSharesMember_celc_AtmAgreementMember"
      decimals="0"
      id="fid_1483"
      unitRef="USD">10000000</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-06-05_celc_PlacementSharesMember_celc_AtmAgreementMember"
      decimals="INF"
      id="fid_1486"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-01-01to2021-03-31_celc_PlacementSharesMember_celc_AtmAgreementMember"
      decimals="0"
      id="fid_1487"
      unitRef="Shares">3082</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <celc:AverageSellingPricePerShare
      contextRef="AsOf2021-03-31_celc_PlacementSharesMember_celc_AtmAgreementMember"
      decimals="INF"
      id="fid_1488"
      unitRef="USDPShares">12.64</celc:AverageSellingPricePerShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1579">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;6. Stock-Based Compensation&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The following table summarizes the activity for all stock options outstanding for the three months ended March 31:&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;849,949&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9.33&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;585,215&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14.37&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&#160; Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;38,391&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15.20&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;57,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10.17&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&#160; Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,997&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&#160; Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(3,271&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;7.62&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(11,826&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;10.60&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;Balance at March 31&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;855,072&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;9.65&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;630,889&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;14.06&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercisable at March 31:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;406,332&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10.37&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;274,267&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Weighted Average Grant Date Fair Value for options granted during the period:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10.07&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6.59&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The following table summarizes additional information about stock options outstanding and exercisable at March 31, 2021:&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="14" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Options Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Options Exercisable&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Options Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Contractual Life&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"/&gt;&lt;td style="white-space: nowrap;"/&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Options Exercisable&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;855,072&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;7.81&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;9.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"&gt;5,179,019&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"&gt;406,332&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;10.37&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"&gt;2,325,179&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Company recognized stock-based compensation expense for stock options of $418,192 and $450,664 for the three months ended March 31, 2021 and 2020, respectively. In May 2020, the Company modified the exercise price on 203,750 stock option awards to $5.10, the closing market price on the Nasdaq Capital Market on May 14, 2020. No director or officer awards were modified. The effect on stock-based compensation was $13,449 and $0 for the three months ended March 31, 2021 and 2020, respectively. The effect on stock-based compensation over the remaining service period will be approximately $122,000.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;The Black-Scholes option-pricing model was used to estimate the fair value of equity-based awards with the following weighted-average assumptions for the three months ended March 31:&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;0.63% - 1.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1.35% - 1.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;76.6&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;73.3&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5.0 to 6.07&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5.5 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expected dividend yield &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;The inputs for the Black-Scholes valuation model require management&#x2019;s significant assumptions. Prior to the Company&#x2019;s initial public offering, the price per share of common stock was determined by the Company&#x2019;s board based on recent prices of common stock sold in private offerings. Subsequent to the initial public offering, the price per share of common stock is determined by using the closing market price on the Nasdaq Capital Market on the grant date. The risk-free interest rates are based on the rate for U.S. Treasury securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life is based on the simplified method in accordance with the SEC Staff Accounting Bulletin Nos. 107 and 110. The expected volatility is estimated based on historical volatility information of peer companies that are publicly available in combination with the Company&#x2019;s calculated volatility since being publicly traded. &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;All assumptions used to calculate the grant date fair value of non-employee options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options issued in connection with the agreements would also be cancelled. &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;No restricted stock awards were granted during the three months ended March 31, 2021 and 2020. The Company had 15,686 and 0 shares of restricted stock outstanding as of March 31, 2021 and 2020, respectively, and 0 shares of restricted stock vested during the three months ended March 31, 2021 or 2020. The Company recognized stock-based compensation expense for restricted stock of $20,456 and $0 for the three months ended March 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Company initially reserved a maximum of 750,000 shares of common stock for issuance under the 2017 Amended and Restated Stock Incentive Plan (the &#x201c;2017 Plan&#x201d;). The number of shares reserved for issuance was automatically increased by 102,540 shares on January 1, 2020 and by 102,998 shares on January 1, 2021 and will increase automatically on January 1 of each of 2022 through 2027 by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding December 31. However, the Company&#x2019;s board may reduce the amount of the increase in any particular year. The total remaining shares available for grant under the Company&#x2019;s 2017 Plan as of March 31, 2021 was 266,800.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total unrecognized compensation cost related to stock options and restricted stock is estimated to be recognized as follows:&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,032,220&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,147,153&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;789,853&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;291,273&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;11,616&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10.05pt"&gt;&lt;strong&gt;Total estimated compensation cost to be recognized&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,272,115&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;The Company recognized stock-based compensation expense related to its employee stock purchase plan of $10,450 and $13,985 for the three months ended March 31, 2021 and 2020, respectively. The Company initially reserved a total of 100,000 shares for issuance under the employee stock purchase plan. The number of shares reserved for issuance was automatically increased by 51,270 shares on January 1, 2020 and 51,499 shares on January 1, 2021 and will increase automatically on each subsequent January 1 by the number of shares equal to 0.5% of the total outstanding number of shares of Company common stock as of the immediately preceding December 31.&#160;&#160;However, the Company&#x2019;s board may reduce the amount of the increase in any particular year. The total remaining shares available for issuance under the employee stock purchase plan as of March 31, 2021 was 163,710. &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company recognized total stock-based compensation expense as follows for the three months ended March 31:&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock-based compensation expense in operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;255,181&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;293,116&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;193,917&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;171,533&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;449,098&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;464,649&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1592">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;849,949&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9.33&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;585,215&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14.37&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&#160; Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;38,391&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15.20&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;57,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10.17&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&#160; Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,997&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&#160;&#160; Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(3,271&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;7.62&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(11,826&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;10.60&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;Balance at March 31&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;855,072&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;9.65&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;630,889&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;14.06&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercisable at March 31:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;406,332&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10.37&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;274,267&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Weighted Average Grant Date Fair Value for options granted during the period:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10.07&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6.59&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <celc:SharesOptionsOutstandingBeginning
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1497"
      unitRef="Shares">849949</celc:SharesOptionsOutstandingBeginning>
    <celc:WeightedAverageExercisePriceBeginning
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1503"
      unitRef="USDPShares">9.33</celc:WeightedAverageExercisePriceBeginning>
    <celc:SharesOptionsOutstandingBeginning
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1522"
      unitRef="Shares">585215</celc:SharesOptionsOutstandingBeginning>
    <celc:WeightedAverageExercisePriceBeginning
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1516"
      unitRef="USDPShares">14.37</celc:WeightedAverageExercisePriceBeginning>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1498"
      unitRef="Shares">38391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1504"
      unitRef="USDPShares">15.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1521"
      unitRef="Shares">57500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1515"
      unitRef="USDPShares">10.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <celc:SharesExercised
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1499"
      unitRef="Shares">29997</celc:SharesExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1505"
      unitRef="USDPShares">8.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1500"
      unitRef="Shares">3271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1506"
      unitRef="USDPShares">7.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1519"
      unitRef="Shares">11826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1513"
      unitRef="USDPShares">10.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <celc:SharesOptionsOutstandingEnding
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1501"
      unitRef="Shares">855072</celc:SharesOptionsOutstandingEnding>
    <celc:WeightedAverageExercisePriceEnding
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1507"
      unitRef="USDPShares">9.65</celc:WeightedAverageExercisePriceEnding>
    <celc:SharesOptionsOutstandingEnding
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1518"
      unitRef="Shares">630889</celc:SharesOptionsOutstandingEnding>
    <celc:WeightedAverageExercisePriceEnding
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1512"
      unitRef="USDPShares">14.06</celc:WeightedAverageExercisePriceEnding>
    <celc:SharesOptionsExercisables
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1502"
      unitRef="Shares">406332</celc:SharesOptionsExercisables>
    <celc:WeightedAverageExercisePriceOptionsExercisables
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1508"
      unitRef="USDPShares">10.37</celc:WeightedAverageExercisePriceOptionsExercisables>
    <celc:SharesOptionsExercisables
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1517"
      unitRef="Shares">274267</celc:SharesOptionsExercisables>
    <celc:WeightedAverageExercisePriceOptionsExercisables
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1511"
      unitRef="USDPShares">9.65</celc:WeightedAverageExercisePriceOptionsExercisables>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1509"
      unitRef="USDPShares">10.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1510"
      unitRef="USDPShares">6.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1596">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="14" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Options Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Options Exercisable&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Options Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Contractual Life&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"/&gt;&lt;td style="white-space: nowrap;"/&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Options Exercisable&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;855,072&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;7.81&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;9.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"&gt;5,179,019&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"&gt;406,332&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;10.37&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"&gt;2,325,179&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1523"
      unitRef="Shares">855072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      id="fid_1524">P7Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <celc:OptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1525"
      unitRef="USDPShares">9.65</celc:OptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1526"
      unitRef="USD">5179019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1527"
      unitRef="Shares">406332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1528"
      unitRef="USDPShares">10.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1529"
      unitRef="USD">2325179</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <celc:StockBasedCompensationRelatedToRestrictedStockTotal
      contextRef="From2021-01-01to2021-03-31_celc_StockIncentivePlanMember"
      decimals="0"
      id="fid_1555"
      unitRef="USD">418192</celc:StockBasedCompensationRelatedToRestrictedStockTotal>
    <celc:StockBasedCompensationRelatedToRestrictedStockTotal
      contextRef="From2020-01-01to2020-03-31_celc_StockIncentivePlanMember"
      decimals="0"
      id="fid_1554"
      unitRef="USD">450664</celc:StockBasedCompensationRelatedToRestrictedStockTotal>
    <celc:StockOptionAwardsSharesModified
      contextRef="AsOf2020-05-14_celc_StockIncentivePlanMember"
      decimals="0"
      id="fid_1624"
      unitRef="Shares">203750</celc:StockOptionAwardsSharesModified>
    <celc:ShareExercisePrice
      contextRef="From2020-05-01to2020-05-14_celc_StockIncentivePlanMember"
      decimals="INF"
      id="fid_1557"
      unitRef="USDPShares">5.10</celc:ShareExercisePrice>
    <celc:StockBasedCompensationRelatedToRestrictedStockTotal
      contextRef="From2021-01-01to2021-03-31_celc_ExpenseStockOptionsMember"
      decimals="0"
      id="fid_1558"
      unitRef="USD">13449</celc:StockBasedCompensationRelatedToRestrictedStockTotal>
    <celc:StockBasedCompensationRelatedToRestrictedStockTotal
      contextRef="From2020-01-01to2020-03-31_celc_ExpenseStockOptionsMember"
      decimals="0"
      id="fid_1559"
      unitRef="USD">0</celc:StockBasedCompensationRelatedToRestrictedStockTotal>
    <celc:FutureExpenses
      contextRef="AsOf2020-03-31_celc_ExpenseStockOptionsMember"
      decimals="0"
      id="fid_1625"
      unitRef="USD">122000</celc:FutureExpenses>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1593">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;0.63% - 1.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1.35% - 1.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;76.6&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;73.3&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5.0 to 6.07&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5.5 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expected dividend yield &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="fid_1534"
      unitRef="Pure">0.0063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="fid_1541"
      unitRef="Pure">0.0112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="fid_1535"
      unitRef="Pure">0.0135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="fid_1540"
      unitRef="Pure">0.0166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1533"
      unitRef="Pure">0.766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1532"
      unitRef="Pure">0.733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember_srt_MinimumMember"
      id="fid_1537">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember_srt_MaximumMember"
      id="fid_1538">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember_srt_MinimumMember"
      id="fid_1536">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember_srt_MaximumMember"
      id="fid_1539">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1530"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember"
      decimals="INF"
      id="fid_1531"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CapitalUnitsOutstanding
      contextRef="AsOf2021-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="fid_1562"
      unitRef="Shares">15686</us-gaap:CapitalUnitsOutstanding>
    <us-gaap:CapitalUnitsOutstanding
      contextRef="AsOf2020-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="fid_1561"
      unitRef="Shares">0</us-gaap:CapitalUnitsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="fid_1563"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <celc:StockBasedCompensationRelatedToRestrictedStockTotal
      contextRef="From2021-01-01to2021-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="fid_1564"
      unitRef="USD">20456</celc:StockBasedCompensationRelatedToRestrictedStockTotal>
    <celc:StockBasedCompensationRelatedToRestrictedStockTotal
      contextRef="From2020-01-01to2020-03-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="fid_1565"
      unitRef="USD">0</celc:StockBasedCompensationRelatedToRestrictedStockTotal>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2017-10-25_celc_StockIncentivePlanMember"
      decimals="0"
      id="fid_1627"
      unitRef="Shares">750000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <celc:CommonStockSharesReservedDescription
      contextRef="From2021-01-01to2021-03-31_celc_StockIncentivePlanMember"
      id="fid_1567">The number of shares reserved for issuance was automatically increased by 102,540 shares on January 1, 2020 and by 102,998 shares on January 1, 2021 and will increase automatically on January 1 of each of 2022 through 2027 by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding December 31.</celc:CommonStockSharesReservedDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-03-31_celc_StockIncentivePlanMember"
      decimals="0"
      id="fid_1568"
      unitRef="Shares">266800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1594">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,032,220&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,147,153&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;789,853&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;291,273&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;11,616&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10.05pt"&gt;&lt;strong&gt;Total estimated compensation cost to be recognized&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,272,115&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1542"
      unitRef="USD">1032220</celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear>
    <celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1543"
      unitRef="USD">1147153</celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears>
    <celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1544"
      unitRef="USD">789853</celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears>
    <celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1545"
      unitRef="USD">291273</celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears>
    <celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1546"
      unitRef="USD">11616</celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2021-03-31"
      decimals="0"
      id="fid_1547"
      unitRef="USD">3272115</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <celc:StockBasedCompensationExpenseRelatedToEspp
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1629"
      unitRef="USD">10450</celc:StockBasedCompensationExpenseRelatedToEspp>
    <celc:StockBasedCompensationExpenseRelatedToEspp
      contextRef="From2020-01-01to2020-03-31_celc_EmployeeStockOptionsMember"
      decimals="0"
      id="fid_1628"
      unitRef="USD">13985</celc:StockBasedCompensationExpenseRelatedToEspp>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2017-10-25_celc_EmployeeStockPurchasePlanMember"
      decimals="0"
      id="fid_1630"
      unitRef="Shares">100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <celc:CommonStockSharesReservedDescription
      contextRef="From2021-01-01to2021-03-31_celc_EmployeeStockPurchasePlanMember"
      id="fid_1573">The number of shares reserved for issuance was automatically increased by 51,270 shares on January 1, 2020 and 51,499 shares on January 1, 2021 and will increase automatically on each subsequent January 1 by the number of shares equal to 0.5% of the total outstanding number of shares of Company common stock as of the immediately preceding December 31.</celc:CommonStockSharesReservedDescription>
    <celc:RemainingSharesAvailableForIssuance
      contextRef="AsOf2021-03-31_celc_EmployeeStockPurchasePlanMember"
      decimals="0"
      id="fid_1572"
      unitRef="Shares">163710</celc:RemainingSharesAvailableForIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1595">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock-based compensation expense in operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;255,181&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;293,116&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;193,917&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;171,533&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;449,098&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;464,649&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="fid_1551"
      unitRef="USD">255181</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="fid_1550"
      unitRef="USD">293116</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="fid_1552"
      unitRef="USD">193917</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="fid_1553"
      unitRef="USD">171533</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-03-31"
      decimals="0"
      id="fid_1548"
      unitRef="USD">449098</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_1549"
      unitRef="USD">464649</us-gaap:ShareBasedCompensation>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2021-01-01to2021-03-31" id="fid_1580">&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;7. Subsequent Events&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;On April 8, 2021, the Company entered into a license agreement (the &#x201c;License Agreement&#x201d;) with Pfizer, Inc. (&#x201c;Pfizer&#x201d;), pursuant to which the Company acquired exclusive (including as to Pfizer) worldwide sublicensable rights to research, develop, manufacture, and commercialize gedatolisib, a potent, well-tolerated, reversible dual inhibitor that targets PI3K and mTOR, for the treatment, diagnosis and prevention of all diseases. Pursuant to the License Agreement, the Company is obligated to use commercially reasonable efforts to develop and seek regulatory approval for at least one product in the United States and if regulatory approval is obtained, to commercialize such product in the United States and at least one international major market.&#160; &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Company paid Pfizer a $5.0 million upfront fee upon execution of the License Agreement and, pursuant to an Equity Grant Agreement, issued to Pfizer $5.0 million of shares of the Company&#x2019;s common stock. The number of shares issued was 349,406 and was calculated by dividing $5.0 million by $14.31, the closing price of a share of the Company&#x2019;s common stock on the Nasdaq Capital Market on April 8, 2021.The Company is also required to make milestone payments to Pfizer upon achievement of certain development and commercial milestone events, up to an aggregate of $330.0 million. Additionally, the Company will pay Pfizer tiered royalties on sales of gedatolisib at percentages ranging from the low to mid-teens, which may be subject to deductions for expiration of valid claims, amounts due under third-party licenses and generic competition. Unless earlier terminated, the License Agreement will expire upon the expiration of all royalty obligations. The royalty period will expire on a country-by-country basis upon the later of (a) 12 years following the date of first commercial sale of such product in such country, (b) the expiration of all regulatory or data exclusivity in such country for such product or (c) the date upon which the manufacture, use, sale, offer for sale or importation of such product in such country would no longer infringe, but for the license granted in the License Agreement, a valid claim of a licensed patent right.&#160; &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Company has the right to terminate the License Agreement for convenience upon 90 days&#x2019; prior written notice. Pfizer may not terminate the agreement for convenience. Either the Company or Pfizer may terminate the License Agreement if the other party is in material breach and such breach is not cured within the specified cure period. In addition, either the Company or Pfizer may terminate the License Agreement in the event of specified insolvency events involving the other party.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Also, on April 8, 2021, the Company entered into a loan and security agreement (the &#x201c;Loan Agreement&#x201d;) with Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (&#x201c;Innovatus&#x201d;), as collateral agent and the Lenders listed on Schedule 1.1 thereto, pursuant to which Innovatus, as a Lender, has agreed to make certain term loans to the Company in the aggregate principal amount of up to $25.0 million (the &#x201c;Term Loans&#x201d;). &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Funding of the first $15.0 million tranche occurred on April 8, 2021. The Company will be eligible to draw on a second tranche of $5.0 million upon achievement of certain milestones, including meeting the primary end points of either the FACT-1 or FACT-2 clinical trials and receipt of unrestricted net cash proceeds of at least $50.0 million from the issuance and sale of the Company&#x2019;s equity securities. The Company will be eligible to draw on a third tranche of $5.0 million upon the achievement of certain additional milestones, including commencement of certain Phase 3 clinical trials and the receipt of unrestricted net cash proceeds of at least $75.0 million from the issuance and sale of the Company&#x2019;s equity securities. &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Innovatus has the right, at its election, after June 1, 2021 and until the third anniversary of the Loan Agreement, to convert up to 20% of the outstanding principal amount of all Terms Loans made under the Loan Agreement into shares of the Company&#x2019;s common stock at a price per share equal to the volume weighted average closing price of the Company&#x2019;s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement (the &#x201c;Conversion Right&#x201d;).&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Company is entitled to make interest-only payments for thirty-six months, or up to forty-eight months if certain conditions are met. The Term Loans will mature on the fifth anniversary of the initial funding date and will bear interest at a rate equal to sum of (a) the greater of (i) Prime Rate (as defined in the Loan Agreement) or (ii) 3.25%, plus (b) 5.70%. Additionally, the Company elected to make 2.7% of the interest rate as payable in-kind, which shall accrue as principal monthly. Other fees include a 1.0% facility fee on the funded loan amount, paid at closing and a final fee of 4.5% of the funded loan amount due at the maturity date or earlier if the Company prepays the loan. The Company has the option to prepay the loan at any time following the first anniversary of the loan closing, with tiered prepayment fees ranging from 0 &#x2013; 2% based on when the prepayment would occur.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Loan Agreement is secured by all assets of the Company. Proceeds will be used for working capital purposes and to fund the Company&#x2019;s general business requirements. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months revenue.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the &#x201c;Warrants&#x201d;) to purchase a number of shares of the Company&#x2019;s common stock equal to 2.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company&#x2019;s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement. For the second and third tranches only the exercise price will be based on the lower of (i) the exercise price for the first tranche or (ii) the volume weighted average closing price of the Company&#x2019;s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding. The Warrants may be exercised on a cashless basis and are exercisable through the 10&lt;sup&gt;th&lt;/sup&gt; anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. &lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <celc:UpfrontFee
      contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_LicenseAgreementMember"
      decimals="-5"
      id="fid_1631"
      unitRef="USD">5000000.0</celc:UpfrontFee>
    <us-gaap:CommonStockValue
      contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_EquityGrantAgreementMember"
      decimals="-5"
      id="fid_1632"
      unitRef="USD">5000000.0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_LicenseAgreementMember"
      decimals="0"
      id="fid_1633"
      unitRef="Shares">349406</us-gaap:CommonStockSharesIssued>
    <celc:ClosingPricePerShare
      contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_LicenseAgreementMember"
      decimals="INF"
      id="fid_1603"
      unitRef="USDPShares">14.31</celc:ClosingPricePerShare>
    <celc:DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents
      contextRef="From2021-03-09to2021-04-08_us-gaap_SubsequentEventMember_celc_PfizerIncMember_celc_LicenseAgreementMember"
      id="fid_1614">The Company is also required to make milestone payments to Pfizer upon achievement of certain development and commercial milestone events, up to an aggregate of $330.0 million</celc:DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents>
    <us-gaap:LongTermLoansPayable
      contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="fid_1607"
      unitRef="USD">25000000.0</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLoansPayable
      contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_TrancheMember"
      decimals="-5"
      id="fid_1606"
      unitRef="USD">15000000.0</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLoansPayable
      contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_SecondTrancheMember"
      decimals="-5"
      id="fid_1608"
      unitRef="USD">5000000.0</us-gaap:LongTermLoansPayable>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="From2021-03-09to2021-04-08_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="fid_1636"
      unitRef="USD">50000000.0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:LongTermLoansPayable
      contextRef="AsOf2021-04-08_us-gaap_SubsequentEventMember_celc_ThirdTrancheMember"
      decimals="-5"
      id="fid_1609"
      unitRef="USD">5000000.0</us-gaap:LongTermLoansPayable>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="From2021-03-09to2021-04-08_us-gaap_SubsequentEventMember_celc_ThirdTrancheMember"
      decimals="-5"
      id="fid_1637"
      unitRef="USD">75000000.0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:LongTermDebtDescription
      contextRef="From2021-03-09to2021-04-08_us-gaap_SubsequentEventMember"
      id="fid_1615">The Company is entitled to make interest-only payments for thirty-six months, or up to forty-eight months if certain conditions are met. The Term Loans will mature on the fifth anniversary of the initial funding date and will bear interest at a rate equal to sum of (a) the greater of (i) Prime Rate (as defined in the Loan Agreement) or (ii) 3.25%, plus (b) 5.70%. Additionally, the Company elected to make 2.7% of the interest rate as payable in-kind, which shall accrue as principal monthly. Other fees include a 1.0% facility fee on the funded loan amount, paid at closing and a final fee of 4.5% of the funded loan amount due at the maturity date or earlier if the Company prepays the loan. The Company has the option to prepay the loan at any time following the first anniversary of the loan closing, with tiered prepayment fees ranging from 0 &#x2013; 2% based on when the prepayment would occur</us-gaap:LongTermDebtDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667808941688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CELCUITY INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001603454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,647,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2863566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">16305 36th Avenue North;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Minneapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">55446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">392-0767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CELC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667814172744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,936,902<span></span>
</td>
<td class="nump">$ 11,637,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">22,009<span></span>
</td>
<td class="nump">22,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred transaction costs</a></td>
<td class="nump">13,719<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Payroll tax receivable</a></td>
<td class="nump">190,000<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid assets</a></td>
<td class="nump">551,345<span></span>
</td>
<td class="nump">317,040<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">35,713,975<span></span>
</td>
<td class="nump">12,166,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">466,484<span></span>
</td>
<td class="nump">558,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">186,602<span></span>
</td>
<td class="nump">230,911<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">36,367,061<span></span>
</td>
<td class="nump">12,956,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">318,213<span></span>
</td>
<td class="nump">217,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">5,819<span></span>
</td>
<td class="nump">5,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">185,656<span></span>
</td>
<td class="nump">187,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">660,849<span></span>
</td>
<td class="nump">774,612<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,170,537<span></span>
</td>
<td class="nump">1,185,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">6,841<span></span>
</td>
<td class="nump">8,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">15,139<span></span>
</td>
<td class="nump">60,861<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">1,192,517<span></span>
</td>
<td class="nump">1,254,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value: 2,500,000 shares authorized; 0 shares issued and outstanding as of March 31, 2021 and December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 25,000,000 shares authorized; 12,287,896 and 10,299,822 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">12,288<span></span>
</td>
<td class="nump">10,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">64,275,505<span></span>
</td>
<td class="nump">38,013,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(29,113,249)<span></span>
</td>
<td class="num">(26,321,581)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">35,174,544<span></span>
</td>
<td class="nump">11,702,270<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 36,367,061<span></span>
</td>
<td class="nump">$ 12,956,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667818830584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">12,287,896<span></span>
</td>
<td class="nump">10,299,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">12,287,896<span></span>
</td>
<td class="nump">10,299,822<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667808854488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 2,236,342<span></span>
</td>
<td class="nump">$ 1,847,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">555,428<span></span>
</td>
<td class="nump">463,399<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,791,770<span></span>
</td>
<td class="nump">2,310,813<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,791,770)<span></span>
</td>
<td class="num">(2,310,813)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">63,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_LossOnSaleOfFixedAssets', window );">Loss on sale of fixed assets</a></td>
<td class="num">(263)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">63,818<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(2,791,668)<span></span>
</td>
<td class="num">(2,246,995)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,791,668)<span></span>
</td>
<td class="num">$ (2,246,995)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding, basic and diluted</a></td>
<td class="nump">11,072,097<span></span>
</td>
<td class="nump">10,253,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_LossOnSaleOfFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_LossOnSaleOfFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667809103096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,253,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2019</a></td>
<td class="nump">$ 19,297,571<span></span>
</td>
<td class="nump">$ 10,254<span></span>
</td>
<td class="nump">$ 36,134,723<span></span>
</td>
<td class="num">$ (16,847,406)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">464,649<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">464,649<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,246,995)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,246,995)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,253,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2020</a></td>
<td class="nump">17,515,225<span></span>
</td>
<td class="nump">$ 10,254<span></span>
</td>
<td class="nump">36,599,372<span></span>
</td>
<td class="num">(19,094,401)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,299,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2020</a></td>
<td class="nump">11,702,270<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="nump">38,013,551<span></span>
</td>
<td class="num">(26,321,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">449,098<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">449,098<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,791,668)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,791,668)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_ExerciseOfCommonStockWarrantsShares', window );">Exercise of common stock warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_ExerciseOfCommonStockWarrantsAmount', window );">Exercise of common stock warrants, amount</a></td>
<td class="nump">11,257<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">11,256<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,971,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, amount</a></td>
<td class="nump">25,768,493<span></span>
</td>
<td class="nump">$ 1,971<span></span>
</td>
<td class="nump">25,766,522<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in an at-the-market ("ATM") offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in an at-the-market ("ATM") offering, amount</a></td>
<td class="nump">38,962<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">38,959<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_IssuanceCostsAssociatedWithAtmOffering', window );">Issuance costs associated with ATM offering</a></td>
<td class="num">(3,868)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(3,868)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,287,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2021</a></td>
<td class="nump">$ 35,174,544<span></span>
</td>
<td class="nump">$ 12,288<span></span>
</td>
<td class="nump">$ 64,275,505<span></span>
</td>
<td class="num">$ (29,113,249)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_ExerciseOfCommonStockWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_ExerciseOfCommonStockWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_ExerciseOfCommonStockWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_ExerciseOfCommonStockWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_IssuanceCostsAssociatedWithAtmOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_IssuanceCostsAssociatedWithAtmOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667808826664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,791,668)<span></span>
</td>
<td class="num">$ (2,246,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used for operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">98,222<span></span>
</td>
<td class="nump">94,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">449,098<span></span>
</td>
<td class="nump">464,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on sale of fixed assets</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid assets and deposits</a></td>
<td class="num">(234,305)<span></span>
</td>
<td class="num">(62,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">73,924<span></span>
</td>
<td class="num">(92,197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(113,763)<span></span>
</td>
<td class="nump">30,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_IncreaseDecreaseInNonCashOperatingLeaseExpense', window );">Non-cash operating lease, net</a></td>
<td class="num">(3,276)<span></span>
</td>
<td class="num">(21,342)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used for operating activities</a></td>
<td class="num">(2,521,505)<span></span>
</td>
<td class="num">(1,833,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(30,925)<span></span>
</td>
<td class="num">(45,604)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
<td class="num">(30,425)<span></span>
</td>
<td class="num">(45,604)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants</a></td>
<td class="nump">11,257<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts', window );">Proceeds from follow-on offering, net of underwriting discounts and offering costs</a></td>
<td class="nump">25,814,167<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_GrossProceedsFromAnAtmOffering', window );">Gross proceeds from an ATM offering</a></td>
<td class="nump">38,962<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_PaymentsForRegistrationStatementCosts', window );">Payments for secondary registration statement costs</a></td>
<td class="num">(12,016)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_PaymentsForFinanceLeases', window );">Payments for finance leases</a></td>
<td class="num">(1,449)<span></span>
</td>
<td class="num">(1,438)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used for) financing activities</a></td>
<td class="nump">25,850,921<span></span>
</td>
<td class="num">(1,438)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">23,298,991<span></span>
</td>
<td class="num">(1,880,643)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Beginning of period</a></td>
<td class="nump">11,637,911<span></span>
</td>
<td class="nump">18,735,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">End of period</a></td>
<td class="nump">34,936,902<span></span>
</td>
<td class="nump">16,854,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Property and equipment included in accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable', window );">Offering and registration statement costs included in accounts payable</a></td>
<td class="nump">$ 51,245<span></span>
</td>
<td class="nump">$ 6,127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_GrossProceedsFromAnAtmOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_GrossProceedsFromAnAtmOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_IncreaseDecreaseInNonCashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_IncreaseDecreaseInNonCashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_PaymentsForFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_PaymentsForFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_PaymentsForRegistrationStatementCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_PaymentsForRegistrationStatementCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667810492376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Note 1. Organization</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>1.&#160;Organization</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong><span style="text-decoration:underline">Nature of Business</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Celcuity Inc., a Delaware corporation (the &#8220;Company&#8221;), is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated companion diagnostic (CDx) and therapeutic (Rx) strategy. Our CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from targeted therapies. This enables a CELsignia CDx to support advancement of new indications for already approved targeted therapies. Our therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver our companion diagnostics can identify. By pursuing an integrated companion diagnostic and therapeutic strategy, we believe we are uniquely positioned to achieve our goal of helping cancer patients receive the therapeutic best suited to treat their cancer driver. The Company was co-founded in 2012 by Brian F. Sullivan and Dr. Lance G. Laing and is based in Minnesota. The Company has not generated any revenues to date.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667813910488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Note 2. Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>2. Summary of Significant Accounting Policies</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Basis of Presentation</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The accompanying unaudited financial statements include the accounts of the Company and have been prepared in accordance with Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, as permitted by Article 10, the unaudited financial statements do not include all of the information required by accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). The balance sheet at December&#160;31, 2020 was derived from the audited financial statements at that date and does not include all the disclosures required by U.S. GAAP. In the opinion of management, all adjustments which are of a normal recurring nature and necessary for a fair presentation have been reflected in the financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&#160;31, 2020 and the related footnotes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Follow-on Offering</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">On February 26, 2021, the Company completed a follow-on offering whereby it sold 1,971,100 shares of common stock (including 257,100 shares of common stock in connection with the full exercise of the underwriters&#8217; option to purchase additional shares) at a public offering price of $14.00 per share. The aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, was approximately $27.6 million before deducting underwriting discounts of approximately $1.6 million and offering expenses of approximately $0.2 million.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><strong>Accounting Estimates</strong></span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Management uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Risks and Uncertainties</span></strong><span style="text-decoration:underline"> </span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval of its diagnostic tests, the clinical and commercial success of its initial drug product, gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Clinical Trial Costs</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company records prepaid assets or accrued expenses for prepaid or estimated clinical trial costs conducted by third-party service providers, which includes the conduct of preclinical studies and clinical trials.&#160; These costs can be a significant component of the Company&#8217;s research and development expenses.&#160; The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with service agreements with its third-party service providers.&#160; The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period.&#160; As actual costs become known, the Company adjusts its prepaid assets or accrued expenses.&#160; The Company has not experienced any material differences between accrued costs and actual costs incurred.&#160; However, the status and timing of actual services performed, number of patients enrolled, and the rate of patient enrollments may vary from the Company&#8217;s estimates, resulting in an adjustment to expense in future periods.&#160; Changes in these estimates that result in material changes to the Company&#8217;s prepaid assets or accrued expenses could materially affect the Company&#8217;s results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Application of New or Revised Accounting Standards</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Pursuant to the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), a company constituting an &#8220;emerging growth company&#8221; is, among other things, entitled to rely upon certain reduced reporting requirements. The Company is an emerging growth company but has irrevocably elected not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. As a result, the Company will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for public companies that are not emerging growth companies. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667818987096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Note 3. Net Loss Per Common Share</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>3. Net Loss Per Common Share</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per common share are the same.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">For the three months ended March 31, 2021 and 2020, potentially dilutive securities excluded from the computations of diluted weighted-average shares outstanding were options to purchase 855,072 and 630,889 shares of common stock, respectively, warrants to purchase 352,400 and 353,585 shares of common stock, respectively, and 15,686 and 0 shares of restricted common stock, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667818677128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Note 4. Commitments</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>4. Commitments</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline"><strong>Operating and Finance Leases</strong></span></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Company leases its corporate space in Minneapolis, Minnesota. In September 2017, the Company entered into a non-cancelable operating lease agreement for building space. The new lease commenced, and the Company moved to the facility in May 2018, in conjunction with the termination of its then existing lease. Rent expense is recorded on a straight-line basis over the lease term. In July 2020 the Company signed an amendment to extend this lease through April 30, 2022. The lease amendment provides for monthly rent, real estate taxes and operating expenses. As a result of the lease amendment, the Company recorded an incremental $197,211 in the operating right-of-use (&#8220;ROU&#8221;) asset and lease liability. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The lease agreement, as amended, includes the option to extend the term for one additional year. The option to extend is at the Company&#8217;s discretion and because the Company has not determined if the option to extend will be exercised, the extended lease term is not included in the ROU assets and lease liabilities. The Company regularly evaluates the renewal options and when it is reasonably certain of exercise, the Company will include the renewal period in its lease term.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">In May 2018, the Company entered into a non-cancelable finance lease agreement for office equipment with a five-year term. The underlying assets are included in furniture and equipment. The lease contains a bargain purchase option at the end of the lease.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">When an implicit rate is not provided, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplemental balance sheet information consisted of the following at March 31, 2021:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating Lease</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">186,602</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,795</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Less: short term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(185,656</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Long term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,139</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance Lease</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Furniture and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,932</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Less: Accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(16,395</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;Net book value of property and equipment under finance lease </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,537</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,660</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Less: short term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,819</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Long term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,841</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">Maturity analysis under lease agreements consisted of the following as of March 31, 2021:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Operating Leases</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Finance Leases</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">146,116</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,441</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,940</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,255</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,023</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Total minimum lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">211,056</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,719</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Less: Present value discount</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(10,261</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(99</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Less: Amount representing services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,960</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Present value of net minimum lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">200,795</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,660</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Weighted Average&#160; </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Remaining Lease Term </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Discount Rate</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; Operating lease </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;1.1 years </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; Finance lease </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;2.1 years </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Lease costs for the period ended March 31, 2021:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Three-month Period </strong></p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;Operating lease cost </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">45,430</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;Finance lease cost: </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;&#160;&#160; Amortization </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right;">1,447</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;&#160;&#160; Interest </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right;">24</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;Variable lease cost </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">19,869</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">66,770</td><td style="PADDING-BOTTOM: 3px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplemental cash flow information related to leases for the period ended March 31, 2021:</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Three-month Period </strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="5" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Cash paid for amounts included in operating and finance leases: </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;&#160;&#160; Operating cash outflow from operating leases </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">68,574</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;&#160;&#160; Operating cash outflow from finance leases </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right;">24</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;&#160;&#160; Financing cash outflow from finance leases </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,449</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">70,047</td><td style="PADDING-BOTTOM: 3px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span style="text-decoration:underline">Clinical Research Studies</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">In May 2017, the Company entered into an agreement with a clinical research organization to conduct a clinical research study.&#160; The Company made payments of approximately $275,000 and $100,000 in 2021 and 2020, respectively, and $600,000 prior to 2020.&#160; Additional payments will be due as certain milestones are met and clinical sites are added. The maximum amount of these additional payments is estimated to be approximately $2,340,000 over the course of the agreement. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In October 2018, the Company entered into an agreement with a biopharmaceutical company and a cancer research center to conduct a clinical research study. The Company made payments of approximately $70,000 prior to 2020. Additional payments of approximately $112,000 will be due as certain milestones are met.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In December 2020, the Company entered into an agreement with a biopharmaceutical company and a cancer research center to conduct a clinical research study. The Company made zero payments in 2021&#160;and 2020. Future payments of approximately $740,000 will be due as certain milestones are met.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">In January 2021, the Company entered into an agreement with a biopharmaceutical company and a cancer research center to conduct a clinical research study. The Company made zero payments in 2021. Future payments of approximately $1,210,600 will be due as certain milestones are met.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">In March 2021, the Company entered into an agreement with two biopharmaceutical companies and a cancer research center to conduct a clinical research study. The Company made zero payments in 2021. Future payments of approximately $1,548,000 will be due as certain milestones are met.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667810462648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Note 5. Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>5. Stockholders&#8217; Equity</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">On February 26, 2021, the Company completed a follow-on offering whereby it sold 1,971,100 shares of common stock (including 257,100 shares of common stock in connection with the full exercise of the underwriters&#8217; option to purchase additional shares) at a public offering price of $14.00 per share. The aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, was approximately $27.6 million before deducting underwriting discounts of approximately $1.6 million and offering expenses of approximately $0.2 million.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">On June 5, 2020, the Company entered into an At Market Issuance Sales Agreement (the &#8220;ATM Agreement&#8221;) with B. Riley FBR, Inc. (the &#8220;Agent&#8221;). Pursuant to the ATM Agreement, the Company was able to offer and sell from time to time, at its option, shares of common stock having an aggregate offering price of up to $10,000,000, par value $0.001 per share (the &#8220;Placement Shares&#8221;), through the Agent.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Placement Shares were registered under the Securities Act of 1933, as amended, pursuant to the Registration Statement on Form S-3 (File No. 333-227466), which was originally filed with the SEC on September 21, 2018 and declared effective by the SEC on October 4, 2018, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed on June 5, 2020. Sales of the Company&#8217;s common stock, if any, under this prospectus supplement were able to be made by any method deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">During the three months ended March 31, 2021, the Company sold 3,082 shares of common stock pursuant to the ATM Agreement, at an average selling price of $12.64per share.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">On February 23, 2021, in conjunction with the Company&#8217;s follow-on offering, the ATM Agreement was terminated.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667814519976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Note 6. Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>6. Stock-Based Compensation</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The following table summarizes the activity for all stock options outstanding for the three months ended March 31:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options outstanding at beginning of year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">849,949</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.33</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">585,215</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14.37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,391</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15.20</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,997</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,271</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7.62</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(11,826</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10.60</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Balance at March 31</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">855,072</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9.65</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">630,889</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">14.06</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercisable at March 31:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">406,332</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">274,267</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted Average Grant Date Fair Value for options granted during the period:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.07</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.59</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">The following table summarizes additional information about stock options outstanding and exercisable at March 31, 2021:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="14" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options Outstanding</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options Exercisable</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options Outstanding</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Life</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"/><td style="white-space: nowrap;"/><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options Exercisable</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">855,072</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">7.81</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">9.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">5,179,019</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">406,332</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">10.37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">2,325,179</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company recognized stock-based compensation expense for stock options of $418,192 and $450,664 for the three months ended March 31, 2021 and 2020, respectively. In May 2020, the Company modified the exercise price on 203,750 stock option awards to $5.10, the closing market price on the Nasdaq Capital Market on May 14, 2020. No director or officer awards were modified. The effect on stock-based compensation was $13,449 and $0 for the three months ended March 31, 2021 and 2020, respectively. The effect on stock-based compensation over the remaining service period will be approximately $122,000.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Black-Scholes option-pricing model was used to estimate the fair value of equity-based awards with the following weighted-average assumptions for the three months ended March 31:</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.63% - 1.12</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1.35% - 1.66</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76.6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected life (years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5.0 to 6.07</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5.5 to 6.1</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected dividend yield </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The inputs for the Black-Scholes valuation model require management&#8217;s significant assumptions. Prior to the Company&#8217;s initial public offering, the price per share of common stock was determined by the Company&#8217;s board based on recent prices of common stock sold in private offerings. Subsequent to the initial public offering, the price per share of common stock is determined by using the closing market price on the Nasdaq Capital Market on the grant date. The risk-free interest rates are based on the rate for U.S. Treasury securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life is based on the simplified method in accordance with the SEC Staff Accounting Bulletin Nos. 107 and 110. The expected volatility is estimated based on historical volatility information of peer companies that are publicly available in combination with the Company&#8217;s calculated volatility since being publicly traded. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">All assumptions used to calculate the grant date fair value of non-employee options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options issued in connection with the agreements would also be cancelled. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">No restricted stock awards were granted during the three months ended March 31, 2021 and 2020. The Company had 15,686 and 0 shares of restricted stock outstanding as of March 31, 2021 and 2020, respectively, and 0 shares of restricted stock vested during the three months ended March 31, 2021 or 2020. The Company recognized stock-based compensation expense for restricted stock of $20,456 and $0 for the three months ended March 31, 2021 and 2020, respectively.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company initially reserved a maximum of 750,000 shares of common stock for issuance under the 2017 Amended and Restated Stock Incentive Plan (the &#8220;2017 Plan&#8221;). The number of shares reserved for issuance was automatically increased by 102,540 shares on January 1, 2020 and by 102,998 shares on January 1, 2021 and will increase automatically on January 1 of each of 2022 through 2027 by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding December 31. However, the Company&#8217;s board may reduce the amount of the increase in any particular year. The total remaining shares available for grant under the Company&#8217;s 2017 Plan as of March 31, 2021 was 266,800.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Total unrecognized compensation cost related to stock options and restricted stock is estimated to be recognized as follows:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,032,220</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,147,153</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">789,853</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">291,273</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,616</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10.05pt"><strong>Total estimated compensation cost to be recognized</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,272,115</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The Company recognized stock-based compensation expense related to its employee stock purchase plan of $10,450 and $13,985 for the three months ended March 31, 2021 and 2020, respectively. The Company initially reserved a total of 100,000 shares for issuance under the employee stock purchase plan. The number of shares reserved for issuance was automatically increased by 51,270 shares on January 1, 2020 and 51,499 shares on January 1, 2021 and will increase automatically on each subsequent January 1 by the number of shares equal to 0.5% of the total outstanding number of shares of Company common stock as of the immediately preceding December 31.&#160;&#160;However, the Company&#8217;s board may reduce the amount of the increase in any particular year. The total remaining shares available for issuance under the employee stock purchase plan as of March 31, 2021 was 163,710. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recognized total stock-based compensation expense as follows for the three months ended March 31:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation expense in operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">255,181</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">293,116</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">193,917</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">171,533</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">449,098</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">464,649</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667814684280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Note 7. Subsequent events</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>7. Subsequent Events</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">On April 8, 2021, the Company entered into a license agreement (the &#8220;License Agreement&#8221;) with Pfizer, Inc. (&#8220;Pfizer&#8221;), pursuant to which the Company acquired exclusive (including as to Pfizer) worldwide sublicensable rights to research, develop, manufacture, and commercialize gedatolisib, a potent, well-tolerated, reversible dual inhibitor that targets PI3K and mTOR, for the treatment, diagnosis and prevention of all diseases. Pursuant to the License Agreement, the Company is obligated to use commercially reasonable efforts to develop and seek regulatory approval for at least one product in the United States and if regulatory approval is obtained, to commercialize such product in the United States and at least one international major market.&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company paid Pfizer a $5.0 million upfront fee upon execution of the License Agreement and, pursuant to an Equity Grant Agreement, issued to Pfizer $5.0 million of shares of the Company&#8217;s common stock. The number of shares issued was 349,406 and was calculated by dividing $5.0 million by $14.31, the closing price of a share of the Company&#8217;s common stock on the Nasdaq Capital Market on April 8, 2021.The Company is also required to make milestone payments to Pfizer upon achievement of certain development and commercial milestone events, up to an aggregate of $330.0 million. Additionally, the Company will pay Pfizer tiered royalties on sales of gedatolisib at percentages ranging from the low to mid-teens, which may be subject to deductions for expiration of valid claims, amounts due under third-party licenses and generic competition. Unless earlier terminated, the License Agreement will expire upon the expiration of all royalty obligations. The royalty period will expire on a country-by-country basis upon the later of (a) 12 years following the date of first commercial sale of such product in such country, (b) the expiration of all regulatory or data exclusivity in such country for such product or (c) the date upon which the manufacture, use, sale, offer for sale or importation of such product in such country would no longer infringe, but for the license granted in the License Agreement, a valid claim of a licensed patent right.&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company has the right to terminate the License Agreement for convenience upon 90 days&#8217; prior written notice. Pfizer may not terminate the agreement for convenience. Either the Company or Pfizer may terminate the License Agreement if the other party is in material breach and such breach is not cured within the specified cure period. In addition, either the Company or Pfizer may terminate the License Agreement in the event of specified insolvency events involving the other party.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Also, on April 8, 2021, the Company entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (&#8220;Innovatus&#8221;), as collateral agent and the Lenders listed on Schedule 1.1 thereto, pursuant to which Innovatus, as a Lender, has agreed to make certain term loans to the Company in the aggregate principal amount of up to $25.0 million (the &#8220;Term Loans&#8221;). </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Funding of the first $15.0 million tranche occurred on April 8, 2021. The Company will be eligible to draw on a second tranche of $5.0 million upon achievement of certain milestones, including meeting the primary end points of either the FACT-1 or FACT-2 clinical trials and receipt of unrestricted net cash proceeds of at least $50.0 million from the issuance and sale of the Company&#8217;s equity securities. The Company will be eligible to draw on a third tranche of $5.0 million upon the achievement of certain additional milestones, including commencement of certain Phase 3 clinical trials and the receipt of unrestricted net cash proceeds of at least $75.0 million from the issuance and sale of the Company&#8217;s equity securities. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Innovatus has the right, at its election, after June 1, 2021 and until the third anniversary of the Loan Agreement, to convert up to 20% of the outstanding principal amount of all Terms Loans made under the Loan Agreement into shares of the Company&#8217;s common stock at a price per share equal to the volume weighted average closing price of the Company&#8217;s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement (the &#8220;Conversion Right&#8221;).</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company is entitled to make interest-only payments for thirty-six months, or up to forty-eight months if certain conditions are met. The Term Loans will mature on the fifth anniversary of the initial funding date and will bear interest at a rate equal to sum of (a) the greater of (i) Prime Rate (as defined in the Loan Agreement) or (ii) 3.25%, plus (b) 5.70%. Additionally, the Company elected to make 2.7% of the interest rate as payable in-kind, which shall accrue as principal monthly. Other fees include a 1.0% facility fee on the funded loan amount, paid at closing and a final fee of 4.5% of the funded loan amount due at the maturity date or earlier if the Company prepays the loan. The Company has the option to prepay the loan at any time following the first anniversary of the loan closing, with tiered prepayment fees ranging from 0 &#8211; 2% based on when the prepayment would occur.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Loan Agreement is secured by all assets of the Company. Proceeds will be used for working capital purposes and to fund the Company&#8217;s general business requirements. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months revenue.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the &#8220;Warrants&#8221;) to purchase a number of shares of the Company&#8217;s common stock equal to 2.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company&#8217;s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement. For the second and third tranches only the exercise price will be based on the lower of (i) the exercise price for the first tranche or (ii) the volume weighted average closing price of the Company&#8217;s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding. The Warrants may be exercised on a cashless basis and are exercisable through the 10<sup>th</sup> anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667814607336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">The accompanying unaudited financial statements include the accounts of the Company and have been prepared in accordance with Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, as permitted by Article 10, the unaudited financial statements do not include all of the information required by accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). The balance sheet at December&#160;31, 2020 was derived from the audited financial statements at that date and does not include all the disclosures required by U.S. GAAP. In the opinion of management, all adjustments which are of a normal recurring nature and necessary for a fair presentation have been reflected in the financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&#160;31, 2020 and the related footnotes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_FollowOnOfferingPolicyTextBlock', window );">Follow-on Offering</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">On February 26, 2021, the Company completed a follow-on offering whereby it sold 1,971,100 shares of common stock (including 257,100 shares of common stock in connection with the full exercise of the underwriters&#8217; option to purchase additional shares) at a public offering price of $14.00 per share. The aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, was approximately $27.6 million before deducting underwriting discounts of approximately $1.6 million and offering expenses of approximately $0.2 million.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Management uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval of its diagnostic tests, the clinical and commercial success of its initial drug product, gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Clinical Trial Costs</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company records prepaid assets or accrued expenses for prepaid or estimated clinical trial costs conducted by third-party service providers, which includes the conduct of preclinical studies and clinical trials.&#160; These costs can be a significant component of the Company&#8217;s research and development expenses.&#160; The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with service agreements with its third-party service providers.&#160; The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period.&#160; As actual costs become known, the Company adjusts its prepaid assets or accrued expenses.&#160; The Company has not experienced any material differences between accrued costs and actual costs incurred.&#160; However, the status and timing of actual services performed, number of patients enrolled, and the rate of patient enrollments may vary from the Company&#8217;s estimates, resulting in an adjustment to expense in future periods.&#160; Changes in these estimates that result in material changes to the Company&#8217;s prepaid assets or accrued expenses could materially affect the Company&#8217;s results of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock', window );">Application of New or Revised Accounting Standards</a></td>
<td class="text"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pursuant to the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), a company constituting an &#8220;emerging growth company&#8221; is, among other things, entitled to rely upon certain reduced reporting requirements. The Company is an emerging growth company but has irrevocably elected not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. As a result, the Company will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for public companies that are not emerging growth companies. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_FollowOnOfferingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_FollowOnOfferingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667848730344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Schedule of supplemental balance sheet information related to leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplemental balance sheet information consisted of the following at March 31, 2021:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating Lease</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">186,602</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,795</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Less: short term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(185,656</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Long term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,139</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance Lease</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Furniture and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,932</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Less: Accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(16,395</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;Net book value of property and equipment under finance lease </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,537</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,660</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Less: short term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,819</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Long term portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,841</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Schedule of maturity analysis under lease agreements</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Operating Leases</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Finance Leases</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">146,116</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,441</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,940</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,255</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,023</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Total minimum lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">211,056</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,719</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Less: Present value discount</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(10,261</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(99</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Less: Amount representing services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,960</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Present value of net minimum lease payments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">200,795</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,660</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock', window );">Schedule of weighted average discount rate</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Weighted Average&#160; </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Remaining Lease Term </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Discount Rate</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; Operating lease </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;1.1 years </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; Finance lease </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;2.1 years </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease costs for the period</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Three-month Period </strong></p></td><td style="PADDING-BOTTOM: 1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;Operating lease cost </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">45,430</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;Finance lease cost: </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;&#160;&#160; Amortization </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right;">1,447</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;&#160;&#160; Interest </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right;">24</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;Variable lease cost </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">19,869</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">66,770</td><td style="PADDING-BOTTOM: 3px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock', window );">Schedule of supplemental cash flow information related to leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplemental cash flow information related to leases for the period ended March 31, 2021:</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Three-month Period </strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="5" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Cash paid for amounts included in operating and finance leases: </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;&#160;&#160; Operating cash outflow from operating leases </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">68,574</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;&#160;&#160; Operating cash outflow from finance leases </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right;">24</td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">&#160;&#160;&#160; Financing cash outflow from finance leases </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,449</td><td style="PADDING-BOTTOM: 1px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">70,047</td><td style="PADDING-BOTTOM: 3px;width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667822127736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of activity for all stock options outstanding</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options outstanding at beginning of year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">849,949</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.33</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">585,215</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14.37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,391</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15.20</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,997</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160; Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,271</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7.62</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(11,826</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10.60</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Balance at March 31</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">855,072</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9.65</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">630,889</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">14.06</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercisable at March 31:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">406,332</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">274,267</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted Average Grant Date Fair Value for options granted during the period:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.07</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.59</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of equity-based awards</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.63% - 1.12</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1.35% - 1.66</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">%</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76.6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected life (years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5.0 to 6.07</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5.5 to 6.1</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected dividend yield </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of unrecognized compensation cost</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,032,220</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,147,153</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">789,853</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">291,273</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,616</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10.05pt"><strong>Total estimated compensation cost to be recognized</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,272,115</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation expense in operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">255,181</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">293,116</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">193,917</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">171,533</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:10pt">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">449,098</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">464,649</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of stock options outstanding</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="14" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options Outstanding</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options Exercisable</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options Outstanding</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Life</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"/><td style="white-space: nowrap;"/><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options Exercisable</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:11%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">855,072</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">7.81</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">9.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">5,179,019</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">406,332</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">10.37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">2,325,179</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667819718328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 26, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares', window );">Issuance of common stock upon closing of follow-on offering, net shares</a></td>
<td class="nump">1,971,100<span></span>
</td>
<td class="nump">1,971,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock', window );">Issuance of common stock upon closing of follow-on offering, including shares of common stock</a></td>
<td class="nump">257,100<span></span>
</td>
<td class="nump">257,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare', window );">Public offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_NetOfUnderwritingDiscountsAndOfferingCosts', window );">Net of underwriting discounts and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Deducting underwriting discounts</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_OfferingExpenses', window );">Offering expenses</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_NetOfUnderwritingDiscountsAndOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distribut</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_NetOfUnderwritingDiscountsAndOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_OfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_OfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667810315960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details Narative) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_RestrictedStocksMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">15,686<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=celc_WarrantsMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">352,400<span></span>
</td>
<td class="nump">353,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=celc_StockOptionsMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">855,072<span></span>
</td>
<td class="nump">630,889<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_RestrictedStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_RestrictedStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=celc_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=celc_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=celc_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=celc_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667808632536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 186,602<span></span>
</td>
<td class="nump">$ 230,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: short term portion</a></td>
<td class="nump">185,656<span></span>
</td>
<td class="nump">187,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long term portions</a></td>
<td class="nump">15,139<span></span>
</td>
<td class="nump">$ 60,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=celc_SupplementalBalanceSheetInformationMember', window );">Supplemental balance sheet information [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">186,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">200,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: short term portion</a></td>
<td class="num">(185,656)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_LongTermOperatingLeaseLiability', window );">Long term portion</a></td>
<td class="nump">15,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasedAssetsGross', window );">Furniture and equipment</a></td>
<td class="nump">28,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation', window );">Less: Accumulated depreciation</a></td>
<td class="num">(16,395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet', window );">Net book value of property and equipment under finance lease</a></td>
<td class="nump">12,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_FinanceLeaseLiabilities', window );">Finance lease liability</a></td>
<td class="nump">12,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Less: short term portions</a></td>
<td class="num">(5,819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long term portions</a></td>
<td class="nump">$ 6,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_FinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_FinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_LongTermOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_LongTermOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasedAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of leased physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45014-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasedAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total gross amount less the charge for the use of the long-lived depreciable assets subject to a lease meeting the criteria for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total charge for the use of long-lived depreciable assets subject to a lease meeting the criteria for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45014-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=celc_SupplementalBalanceSheetInformationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=celc_SupplementalBalanceSheetInformationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667808833656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Details 1)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesAxis=celc_OperatingLeasesMember', window );">Operating Leases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 146,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">64,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">211,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_LessPresentValueDiscount', window );">Less: present value discount</a></td>
<td class="num">(10,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_LesseeOperatingLeaseLiabilityAmountRepresentingServices', window );">Less amount representing services</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of net minimum lease payments</a></td>
<td class="nump">200,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesAxis=celc_FinanceLeasesMember', window );">Finance Leases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_LessPresentValueDiscount', window );">Less: present value discount</a></td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">5,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">7,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">3,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">15,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_LessAmountRepresentingServices', window );">Less amount representing services</a></td>
<td class="num">(2,960)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of net minimum lease payments</a></td>
<td class="nump">$ 12,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_LessAmountRepresentingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts to be paid by lessee to lessor for maintenance, insurance, and tax expenses related to the leased asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_LessAmountRepresentingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_LessPresentValueDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_LessPresentValueDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_LesseeOperatingLeaseLiabilityAmountRepresentingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_LesseeOperatingLeaseLiabilityAmountRepresentingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstatePropertiesAxis=celc_OperatingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstatePropertiesAxis=celc_OperatingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstatePropertiesAxis=celc_FinanceLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstatePropertiesAxis=celc_FinanceLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667813916680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 2)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_OperatingLeaseWeightedAverageRemainingLeasesTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate, percent</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_FinanceLeaseWeightedAverageRemainingLeasesTerm1', window );">Finance lease, weighted average remaining lease term</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease, weighted average discount rate, percent</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_FinanceLeaseWeightedAverageRemainingLeasesTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_FinanceLeaseWeightedAverageRemainingLeasesTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_OperatingLeaseWeightedAverageRemainingLeasesTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_OperatingLeaseWeightedAverageRemainingLeasesTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667814250664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 3)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 45,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_FinanceLeaseCostsAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization</a></td>
<td class="nump">1,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest</a></td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">19,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 66,770<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_FinanceLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_FinanceLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667814062248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 4)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_CashPaidForOperatingAndFinanceLeasesAbstract', window );"><strong>Cash paid for amounts included in operating and finance leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflow from operating leases</a></td>
<td class="nump">$ 68,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash outflow from finance leases</a></td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash outflow from finance leases</a></td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_CashPaidForOperatingAndFinanceLeases', window );">Total cash paid for amounts included in operating and finance leases</a></td>
<td class="nump">$ 70,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_CashPaidForOperatingAndFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_CashPaidForOperatingAndFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_CashPaidForOperatingAndFinanceLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_CashPaidForOperatingAndFinanceLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667814161032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">32 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Increase in operating ROU asset and lease liability</a></td>
<td class="nump">$ 197,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to acquire in process research and development</a></td>
<td class="nump">275,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_EstimatedRemainingAmountOfPayments', window );">Estimated remaining amount of payments</a></td>
<td class="nump">2,340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=celc_AgreementWithBiopharmaceuticalCompanyOneMember', window );">Agreement with biopharmaceutical company 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_FuturePaymentsRequiredUponCertainMilestonesBeingMet', window );">Future payments required upon certain milestones being met</a></td>
<td class="nump">112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=celc_AgreementWithBiopharmaceuticalCompanyMember', window );">Agreement with biopharmaceutical company [Member] | January 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_FuturePaymentsRequiredUponCertainMilestonesBeingMet', window );">Future payments required upon certain milestones being met</a></td>
<td class="nump">1,210,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=celc_AgreementWithBiopharmaceuticalCompanyMember', window );">Agreement with biopharmaceutical company [Member] | March 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_FuturePaymentsRequiredUponCertainMilestonesBeingMet', window );">Future payments required upon certain milestones being met</a></td>
<td class="nump">1,548,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=celc_AgreementWithBiopharmaceuticalCompanyTwoMember', window );">Agreement with biopharmaceutical company 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_FuturePaymentsRequiredUponCertainMilestonesBeingMet', window );">Future payments required upon certain milestones being met</a></td>
<td class="nump">$ 740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_EstimatedRemainingAmountOfPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_EstimatedRemainingAmountOfPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_FuturePaymentsRequiredUponCertainMilestonesBeingMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_FuturePaymentsRequiredUponCertainMilestonesBeingMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=celc_AgreementWithBiopharmaceuticalCompanyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=celc_AgreementWithBiopharmaceuticalCompanyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=celc_AgreementWithBiopharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=celc_AgreementWithBiopharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=celc_JanuaryTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=celc_JanuaryTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=celc_MarchTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=celc_MarchTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=celc_AgreementWithBiopharmaceuticalCompanyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=celc_AgreementWithBiopharmaceuticalCompanyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667814197800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 26, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 05, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_PublicOfferingPrice', window );">Public offering price</a></td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds</a></td>
<td class="nump">$ 27,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Net of underwriting commissions</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_OfferingExpenses', window );">Offering expenses</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock', window );">Issuance of common stock upon closing of follow-on offering, including shares of common stock</a></td>
<td class="nump">257,100<span></span>
</td>
<td class="nump">257,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares', window );">Issuance of common stock upon closing of follow-on offering, net shares</a></td>
<td class="nump">1,971,100<span></span>
</td>
<td class="nump">1,971,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=celc_PlacementSharesMember', window );">Placement Shares [Member] | ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Aggregate offering price, common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_AverageSellingPricePerShare', window );">Average selling price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_AverageSellingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_AverageSellingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_OfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_OfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_PublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_PublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=celc_PlacementSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=celc_PlacementSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=celc_AtmAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=celc_AtmAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667809107192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details) - Employee Stock Option - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_SharesOptionsOutstandingBeginning', window );">Shares options outstanding, beginning</a></td>
<td class="nump">849,949<span></span>
</td>
<td class="nump">585,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, granted</a></td>
<td class="nump">38,391<span></span>
</td>
<td class="nump">57,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_SharesExercised', window );">Shares, exercised</a></td>
<td class="nump">29,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">shares, forfeited</a></td>
<td class="nump">3,271<span></span>
</td>
<td class="nump">11,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_SharesOptionsOutstandingEnding', window );">Shares options outstanding, ending</a></td>
<td class="nump">855,072<span></span>
</td>
<td class="nump">630,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_SharesOptionsExercisables', window );">Shares, options exercisable</a></td>
<td class="nump">406,332<span></span>
</td>
<td class="nump">274,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_WeightedAverageExercisePriceBeginning', window );">Weighted average exercise price, beginning</a></td>
<td class="nump">$ 9.33<span></span>
</td>
<td class="nump">$ 14.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">15.20<span></span>
</td>
<td class="nump">10.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="nump">8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited</a></td>
<td class="nump">7.62<span></span>
</td>
<td class="nump">10.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_WeightedAverageExercisePriceEnding', window );">Weighted average exercise price, ending</a></td>
<td class="nump">9.65<span></span>
</td>
<td class="nump">14.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_WeightedAverageExercisePriceOptionsExercisables', window );">Weighted average exercise price, options exercisable</a></td>
<td class="nump">10.37<span></span>
</td>
<td class="nump">9.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value for options granted during the period:</a></td>
<td class="nump">$ 10.07<span></span>
</td>
<td class="nump">$ 6.59<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_SharesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_SharesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_SharesOptionsExercisables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_SharesOptionsExercisables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_SharesOptionsOutstandingBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_SharesOptionsOutstandingBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_SharesOptionsOutstandingEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_SharesOptionsOutstandingEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_WeightedAverageExercisePriceBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_WeightedAverageExercisePriceBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_WeightedAverageExercisePriceEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_WeightedAverageExercisePriceEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_WeightedAverageExercisePriceOptionsExercisables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_WeightedAverageExercisePriceOptionsExercisables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_EmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_EmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667818552184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details 1) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding | shares</a></td>
<td class="nump">855,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life</a></td>
<td class="text">7 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_OptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 9.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 5,179,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable | shares</a></td>
<td class="nump">406,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 10.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 2,325,179<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_OptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_OptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_EmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_EmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667819784712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details 2) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">76.60%<span></span>
</td>
<td class="nump">73.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_EmployeeStockOptionsMember', window );">Minimum Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.63%<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_EmployeeStockOptionsMember', window );">Maximum Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.12%<span></span>
</td>
<td class="nump">1.66%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_EmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_EmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667814829704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>StockBased Compensation (Details 3)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears', window );">2022</a></td>
<td class="nump">$ 789,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears', window );">2023</a></td>
<td class="nump">291,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears', window );">2024</a></td>
<td class="nump">11,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total estimated compensation cost to be recognized</a></td>
<td class="nump">3,272,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">1,032,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears', window );">2021</a></td>
<td class="nump">$ 1,147,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667814637912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 449,098<span></span>
</td>
<td class="nump">$ 464,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research And Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">255,181<span></span>
</td>
<td class="nump">293,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General And Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 193,917<span></span>
</td>
<td class="nump">$ 171,533<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667806575848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>StockBased Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 14, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Oct. 25, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=celc_StockIncentivePlanMember', window );">2017 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_StockBasedCompensationRelatedToRestrictedStockTotal', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 418,192<span></span>
</td>
<td class="nump">$ 450,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_ShareExercisePrice', window );">Share exercise price</a></td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_CommonStockSharesReservedDescription', window );">Common stock shares reserved description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The number of shares reserved for issuance was automatically increased by 102,540 shares on January 1, 2020 and by 102,998 shares on January 1, 2021 and will increase automatically on January 1 of each of 2022 through 2027 by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding December 31.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant under the 2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_StockOptionAwardsSharesModified', window );">Stock option awards shares modified</a></td>
<td class="nump">203,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_StockBasedCompensationRelatedToRestrictedStockTotal', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,456<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsOutstanding', window );">Restricted stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,686<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_EmployeeStockOptionsMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_StockBasedCompensationExpenseRelatedToEspp', window );">Stock Based compensation expense related to ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,450<span></span>
</td>
<td class="nump">$ 13,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_ExpenseStockOptionsMember', window );">Expense Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_FutureExpenses', window );">Future expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_StockBasedCompensationRelatedToRestrictedStockTotal', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,449<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_CommonStockSharesReservedDescription', window );">Common stock shares reserved description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The number of shares reserved for issuance was automatically increased by 51,270 shares on January 1, 2020 and 51,499 shares on January 1, 2021 and will increase automatically on each subsequent January 1 by the number of shares equal to 0.5% of the total outstanding number of shares of Company common stock as of the immediately preceding December 31.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_RemainingSharesAvailableForIssuance', window );">Remaining shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_CommonStockSharesReservedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_CommonStockSharesReservedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_FutureExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_FutureExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_RemainingSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_RemainingSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_ShareExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_ShareExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_StockBasedCompensationExpenseRelatedToEspp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_StockBasedCompensationExpenseRelatedToEspp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_StockBasedCompensationRelatedToRestrictedStockTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_StockBasedCompensationRelatedToRestrictedStockTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_StockOptionAwardsSharesModified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_StockOptionAwardsSharesModified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of capital units or capital shares outstanding. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=celc_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=celc_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_EmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_EmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_ExpenseStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_ExpenseStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celc_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140667806479816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 08, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,287,896<span></span>
</td>
<td class="nump">10,299,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,288<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Net cash proceeds</a></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Term loans</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtDescription', window );">Description of term Loan</a></td>
<td class="text">The Company is entitled to make interest-only payments for thirty-six months, or up to forty-eight months if certain conditions are met. The Term Loans will mature on the fifth anniversary of the initial funding date and will bear interest at a rate equal to sum of (a) the greater of (i) Prime Rate (as defined in the Loan Agreement) or (ii) 3.25%, plus (b) 5.70%. Additionally, the Company elected to make 2.7% of the interest rate as payable in-kind, which shall accrue as principal monthly. Other fees include a 1.0% facility fee on the funded loan amount, paid at closing and a final fee of 4.5% of the funded loan amount due at the maturity date or earlier if the Company prepays the loan. The Company has the option to prepay the loan at any time following the first anniversary of the loan closing, with tiered prepayment fees ranging from 0 &#8211; 2% based on when the prepayment would occur<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Pfizer, Inc. [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_ClosingPricePerShare', window );">Closing price per share</a></td>
<td class="nump">$ 14.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_UpfrontFee', window );">Upfront fee</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Number of shares issued</a></td>
<td class="nump">349,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celc_DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents', window );">Description of certain development and commercial milestone events</a></td>
<td class="text">The Company is also required to make milestone payments to Pfizer upon achievement of certain development and commercial milestone events, up to an aggregate of $330.0 million<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Pfizer, Inc. [Member] | Equity Grant Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock shares issued, value</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Tranche 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Net cash proceeds</a></td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Term loans</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Term loans</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Tranche 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Term loans</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_ClosingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_ClosingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes all significant commitments and obligations resulting from franchise agreements, including a description of the services that the franchisor has agreed to provide for agreements that have not yet been substantially performed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celc_UpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celc_UpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celc_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celc_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis=celc_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis=celc_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis=celc_EquityGrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis=celc_EquityGrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celc_ThirdTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celc_ThirdTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celc_TrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celc_TrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celc_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celc_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>50
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MTL*171DE0.]1R5TD@N8@P2'O'S!F-C/03IGAR.Q10C*(R5]1>CYX<<#A<#!
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MMYR%7)D/X/U:2GT<F#^HF\[3_P!02P,$%     @ *XJJ4AX:9MYA!0  N!0
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MI?XJ]K^QSJ'8S)>+4MG_@WUG&RZ"O%%:5-U@0%#QNOU+GSLBC@; /.X!N!N
MQP.BF0&D&T"LHRTRZ]8GJNG5A13[0!IKF,T\6&[L:/"&UV8;[[6$7SF,TU>W
MHBY@4U@1W&NJ&6R05H'8!+=4;8,OL,DJ>-?4M"FX9L7[X"SX=O\I>/?+^XNE
MAM7-',N\6^FF70G/K$2".U'KK0H^PXK%Z_%+0-U#QP?H-]@[X1V5'P."/@0X
MQ,B!Y_;GAX<>.*1GDMCYR!R3AK&-96PC115 IDFJ>?W8ABK7G*ESSSI1OTYD
MUXEFUOD3<KL42KEVH!V9V)$F@9^NSO J0TF27BR?CJEQ&>(HR;*X-WP%+N[!
MQ5X2KHO_(&;;*-("\CP7=<Y+%M0=:O/5/.>&K<;$'92B U>B]C*4]" 2+T.?
M&%2TG-L)72RUH^,CY[,48SRBR&$5K3+LYF?50UMYH=UKD7\_,W6G"')103%6
MLS!7$P!1E(79>"L=9@G\R]Q TQYHZ@7ZA]DK*+.*PN9!/=CP9X!,E6+:&7GI
M! 5.R CIU"9T@\QZD)D_Y;:T?F0JX/5QMEF, :V+H.3T@9<G,P^%0[$,O:RL
M)=M17ARO4;"=4-Q-2C=;_"K-2$3">,2,RS#!28S<_*"CZHZ\@*_S7#0F&7?T
MA3Z4S(D2319?D0Q'8XQ3L[,,HVPU@Q$/&/$IC+*!X&+/)AV8FTD\71PALIK$
MF,.0A"@B,R"'XHZ(O^J*^LS6K"'02@9I_,%4,R=B,D5,\"H9XW68842BF3J#
M!I5 IV7"661?"9(3>>2 %&,43\/688E20I)P+G ''4%^(1FK*:^?F'J#FJ)!
M+)!?+=:-S+>PD[;MV4G#DGZQJ<U^-'QGM,S)TE0?SDB8X0E'#KLH3L)HAJ%!
M29!?2M92Y(P5'3^'.OT&!Z;"$8?A&/W4:*9FHT%9D%]:II'IVEPGY*F" .?1
ME'.'G8_S06_0"<$91>6&UQ3ZFY^.2CPH#3ZE-,>[RYZ9S+FR.PQM0V6$V702
MP9Y*26NW^N"IJ""$X]6(+(?9S!;C07:P7W9>H]^($B@[ ]!BLV$2Z+)5TSC3
MP%E [B6WFU]PU:F5"=Z#+3BL9AR<*A*.4Q2A9.+CU'+.QT&VL%^V?I6F1=J]
M\I36P?7?=SUT)VB'0*59,NX^'69SB <-PWX-6].7MC,W.:=,:U[ R1V:]$>N
M=-M_0UAUIT /[0[)0CA$8VESV,VY,*@:]JO:*Q?:[&.M$+NAN@0J.NJ-.Z1.
M,Y+.H!U$#,<_5^D@2IXXG'J#AQ<X3G=E[[VS?#C=B%V!'H/:H+$G4TN?)X-(
M8K](6D]LMVV:;>N3R5'[8%3F">1GK@Q-!1 3G*59-@'OD$J4IF$RU[[A02SQ
MZG3A=B'V5NM!TK!?TFX@A>K:;*218,A]43BIF.H20@F!$_J$"H=ENB(@T#.-
M(1XT#&=>K)]M;?6AS*85*LI(DH63(C6U1$D:1R2>.7V20?](Z-VP^V:W*VTA
MHJ45AE*H1K9-6GWHQ8_Z!G#JK6),!CDC)^7,T53!\GG9F*SFYCKR]$&+^%2H
M9=1A GHVUTZ30:R(7ZS^.HBI\<!7\-_N%)Y<)<4(1^.6S&&6(#P^.RZ/+C(K
M)A_M_:X*+(KV8K#_VM\A7]N;T]'W&W1^V]X$#].T%]-W5$*N*A"-#4P9?EP!
MU[*]ZVU?M-C9Z]('H;6H[..646A3C '\OA%"'U[, OV-^]7_4$L#!!0    (
M "N*JE(SK,H1X@,  )$(   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
ME59M;]LX#/XKA \X;$ ;)VYW5VQ)@"7=[@:LNZ*]E\^*3=M"9<F3J*;9KS]2
M3K*TE_:P+XTDDP^?AZ2H3M?.WX46D>"A,S;,LI:H?YOGH6RQ4V'D>K3\I7:^
M4\1;W^2A]ZBJY-29O!B/?\D[I6TVGZ:S:S^?NDA&6[SV$&+7*;]9H''K63;)
M=@<WNFE)#O+YM%<-WB+]U5][WN5[E$IW:(-V%CS6L^S]Y.WB7.R3P=\:U^%@
M#:)DY=R=;#Y5LVPLA-!@28*@^.<>EVB, #&-KUO,;!]2' _7._2/23MK6:F
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M^-W2=;VRF[2;O'M] CJP6\FQ=:G,:2"^8K#2+*!LK3.NV3!4<H& >*=M ^0
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M9U5[5:Z5!:G),A*^IQ00E%4Y-'@CI*A,=981@$*N"R5,AXT/%W)KE2+8 L5
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MM?D06"SB)ZR?1ZOD_!';%]%JEL WL%0S(%G<4S<,6$Y2T3WI8D?O_L3+[G3
M(2FR8;:(DF2!7_-H!D#4(\5B%IW/8H$N-)_3FZDX$].(_M\8BD0*X[(I3\)5
MH&=%,9P-MRYA=^#ETR#.J>J;!H_/DSA*%PG(>7[.% 6GEKQH59L=/.,H>XL2
MY(#A>1J=@_ 7)TIA?057/X+J&*:=Q[[PA0%<7F'TP/T'0PM=HHXI<4.^^N&
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MVS=6WZ+-%Y*FPUZ30=T=%:@KBK;1A$.),0OH0(!NVPSW?"<*M]84[%^B: 7
MWOK,,\IVA//Y[%%"ZUPSR/4"]N2.MY@Q3" T^,5FGV*GV]6:%M.^=1]8.'0/
M[GJOZ+XMU_XTLZ4?U\$V3GV$=^)ER\3T[SR7J;)]JJ2YP&S_"1>&;<!=]JO>
M (\JYXG)(A>4.&F;6" 5.36;043O&>I2T*04%;P#V*W,NP,;V$93*Q_-RM:
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M3W'Z,!:N17+\KNB!(IJRV4CR(,17\C=HB@YQI_Q8?.EYIY$ZCWF$*.^?C2=
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MWH<6$>Y"8\XZSC?#HVXG N>5Z3*QU% W9Z(=&!92FP*^4J#Y"9#X+K-5/&9
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M+W#R],77#?^J.:\]<)$_+A5HL*4%>%_4M4]?Z(#N9^[+?P-02P,$%     @
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M&6#^Y=\UTI=@&_XM86%#L#5_7"N)9D8+\)YNM-HO9*#[<>GBOU!+ P04
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M->UYH5I2TKF'_:>H?*+>XOY][DN!;:0, :2LUQ26@F,_LF8%1 -FNUP/Z;Z
MOULJT0X7/QFN8%OU3"S/.GPA2E$4RV\0%IF?!='.;AL9<$8>&6?Z&??@;/#S
M:8HX2ET@+R$U:"IK:/')$#L)B]3/T@Q.X9- B+U%])'Z83R%&];8P!R=FTXV
M3'<2N305T.\=:TT"C+O"G\91[^VR++NZ<VFO**:L9*3WF?DQDCJ%OS!-9F+
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M#'Y0B#0&L)\*H0\3$Z#^Y5G\ 5!+ P04    "  KBJI2:9O0P*0"  "/!P
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M5#U1U1LC2S>4;*3!$<<M#SB%@K(&^'XGI7G:V#FGG6M7OP!02P,$%     @
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M-#)YR;*U*2=:Y$4[<2^T:4Z*X=:T@U3:!>;]6@C]/+$=2MU@+GX#4$L#!!0
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MOFFZ_?K9)F'92LD+^..><^XQOI=\I_2+J0&0O DNS3RH$9O+,#1E#8*:"]6
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M4!;;CQ]VV.]!.P/<;Y6RVXD+,/R#5'\!4$L#!!0    ( "N*JE(6J3 4B0,
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MC0<]WC%]14;T9Q)',>VK:!B^@JR#1WWU7 RGUP/5C+K>C[R_Y(R_SS)#J3!
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M-+I*L3FZ&4";A565'\G6RN* YV\+'-I!.P-\OU'*[A<N0/<W8/$?4$L#!!0
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M]:T"O!90_^\8D^=![:#[^EG]!E!+ P04    "  KBJI2-8#YIM("   !"
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M]LUE(NN:7W>TJ%S9G EMBK!K+LT[":1=8.;G0NA]QV[0OKQ&+U!+ P04
M"  KBJI2RV:Y;40"   &!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6R%5%MOVC 4_BM6M(=.VIK8(9=6(=( 3=O#)%36[=DD![#JQ,PVI=NO[[%#
MHVB$\I+XV.>['%].<53ZR>P +'EI9&NFP<[:_7T8FFH'#3>W:@\MKFR4;KC%
M4&]#L]? :P]J9,BB* T;+MJ@+/S<4I>%.E@I6EAJ8@Y-P_7?&4AUG 8T>)MX
M$-N==1-A6>SY%E9@'_=+C5'8L]2B@=8(U1(-FVGPA=[/<I?O$WX).)K!F+A*
MUDH]N>![/0TB9P@D5-8Q</P]PQRD=$1HX\^),^@E'7 X?F/_ZFO'6M;<P%S)
MWZ*VNVF0!Z2&#3](^Z".W^!43^+X*B6-_Y)CEYN@8G4P5C4G,,:-:+L_?SGM
MPP# +@'8"<"\[T[(NUQPR\M"JR/1+AO9W,"7ZM%H3K3N4%96XZI G"U75E5/
M,RRK)G/5X%$;[G?K9@&6"VE(_+$(+0JY]+ ZD<XZ4G:!] ?7MR2FGPB+&'U<
M+<C-A_]80K39>V6]5^9IX_>\?CXW^PYUW%/'GGIR@1J-LK$Z.U3J4>Y^/Y=9
M?I<G<1$^CZA->K7)-;5X3*U#)0,U=D=9=D$MZ=62:VJ3,;7D3(W2E*;C8FDO
MEKXK]E-9+@D8*_#%X#E5PTM5*6.)560-^)XKM6W%/ZC'K*5GUF*6,4J3<7-9
M;RZ[MA/1F%QVOA-1S)A+'I/+>[G\FAP=D\O/+A6EDXR>W:IP\*Q=A\1GM16M
M(1(VB(QN,W2LNZ[3!5;M_4M?*XM]PP]WV*A!NP1<WRAEWP+7//K67[X"4$L#
M!!0    ( "N*JE+A^9@:?0(  ,$&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;*U5VVZC,!#]%0OM0RMMRQV:BB#ETKT\5*H:=??9@4E !9NUG:3[
M]QT;PM(LC?I010J^S#D^<\P,R8&+9UD */)25TQ.K4*IYM:V959 3>4U;X#A
MSH:+FBJ<BJTM&P$T-Z"ZLCW'B>R:ELQ*$[/V(-*$[U15,G@01.[JFHJ_<ZCX
M86JYUG'AL=P62B_8:=+0+:Q /34/ F=VSY*7-3!9<D8$;*;6S+U=Q#K>!/PJ
MX2 '8Z(S67/^K"<_\ZGE:$%00:8T \7''A9059H(9?SI.*W^2 T<CH_LWTSN
MF,N:2ECPZG>9JV)JW5@DAPW=5>J1'WY ET^H^3)>2?-/#FUL$%DDVTG%ZPZ,
M"NJ2M4_ZTODP "#/.,#K -XI('@'X'< WR3:*C-I+:FB:2+X@0@=C6QZ8+PQ
M:,RF9/H65TK@;HDXE:X4SY[GZ$-.%KS&=T-28^_%$A0M*TF"2W)%GE9+<O'E
M,K$5'JF!=M;1SUMZ[QUZG]QSI@I)[E@.^5N\C5)[O=Y1[]P[2WA/Q37QW:_$
M<SQW1,_BXW#GC!R_M\\W?,$Y^Z[6QK]LX-^84RU39)AT<>W3()@XDYO$W@\3
M& F+\#?IP]X(#7JAP5FACR"!BJP@,Y:3)>RQ?!LL1D7N7K1H..-%V!\1?IH7
M+5,X2-(+0_?&/?%B)&SBNVXT[D74"XW."OT.# 2MC!6S'(NJE$I0W4X^X$;<
M'Q)_FAOQ?U?N3OR)&Y^X,1(6NZ'OG[AA#[I!#6)KFJ1$$3NFVD+K5_L^/#/M
MYV1]COVY;:?_:-KFCF6T+9DD%6R0TKF.\8I$VS#;B>*-Z3EKKK"#F6&!WQ@0
M.@#W-YRKXT0?T'^UTE=02P,$%     @ *XJJ4CVBUQ[?!   #A(  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&ULM5A;C^(V%/XK%FJE&6F7Q"$)L&*0
M.LRLNI6VBX9.^U#UP22&6)/$K.W S+_OL1.20"Z@[O0%DG#.=SZ?>Y@=N'B1
M$:4*O29Q*N\&D5*[3Y8E@X@F1 [YCJ;PRX:+A"BX%5M+[@0EH5%*8LNQ;=]*
M"$L'\YEYMA3S&<]4S%*Z%$AF24+$VSV-^>%N@ ?'!T]L&RG]P)K/=F1+5U0]
M[Y8"[JP2)60)327C*1)T<S?X!7]Z=(R"D?B3T8.L72-]E#7G+_KF2W@WL#4C
M&M- :0@"7WNZH'&LD8#']P)T4-K4BO7K(_IG<W@XS)I(NN#Q7RQ4T=U@,D A
MW9 L5D_\\"LM#N1IO(#'TGRB0R[KN0,49%+QI% &!@E+\V_R6CBBIH!''0I.
MH>"<*4SL#H51H3 ZM]!%R2T4W&L5O$+!'-W*SVX<]T 4F<\$/R"AI0%-7QCO
M&VWP%TMUHJR4@%\9Z*GY2O'@Y1X\':(%3R#])#$!O'F@BK!8HM^)$$0'\Q9]
M1,^K!W3ST^W,4F!: UA!8>8^-^-TF/E*WA!V/R#'=NP6[<4E;3%$(VS4<8OZ
MP_7J;=8?^]6_!6J('$^KX_&IN@7>+EWNE"YW#)[;@:=AD/$[^I(&--7.1<N8
MI#W8HQ)[U(MM8#^N33R#6CS;?)XC^09)]Y/]W,43/'5FUK[NVQ8QS_9]MQ0[
M(>J61-U^HA$1%-%7*@(F*=H)%M"VM,I1)C7KWA"WF_9*TUZO:<CS!#)<F@A(
MS4-"RY-4[,%I(96!8+LNG_4C_Q%1E&;)F@K$-PUHZ.J(29D1"#HZ$(E(!M4-
MX0E('+\AE@;0Z77@UE KMO/!<^TC!M#]C:09=')4I#$B:2DXG4XZ!;$1/+ X
M+@V<V:VK:-J4!)'^!F4'J4CP;!OIF[$VI]I.2+]G)$:*(SRT?];/M139;@7=
M$E67AT$E%?!AZ;8DO#%]AZ1O.E^KN!!Y!&))0D,&0, 59F% C?H#7!C8$1[V
MU(U?YH1_.1TA(GOH>60=4Q.LK2"I0ED:@AG-Q!1NLU#SS,CQO5JB.KX_L>WV
M7!V7O,:7ZQGQ73Y4#T2$\NBYA(=LPVC85C7C)AE[-/8ZR$Q*,I/_7CC:89M,
M95#5QR1O:[63!C.@97>Y:5HRF_8R>Z)200=1P"/WV'/*E$0W3ZMG>8O^_FI2
MY9^>/,%V-2_M=^NP!91_$@?7\\\Z;(M8AS]P;:SC:SV2QZM6>ZU4<2,PV/,G
M#:I-L2ZJU3C$_?.P074/#UKS>E$@76.^FIBX?V0^)KN8OU%:9,ZWEMY_BER-
M.'QAQAG ^T:JP-C3UQ2*)R;ZV- Z'U?+9>N)W49N8$@A^SPN+6*CZ<3K<$XU
M*G'_1'LLF-9](Z\JJ*KSXO[6^SEO&H5/9.MZUVRNV'$ZNP:NNBN^HKU>6\SC
M%A>[[O0\$DVQ+II5W\7]C?<L19>9""(]R/4LNBH851_%_8WT1W:C"]#OMQQY
M^(,SOK0;@9 [G?[87F16(9FM)6PXL*?7]J2+JY ]],I52'$%#^O+3T/O?UZ#
MG&J\.?WC[3UF?&'BI%SM[B'O5$/-N334]%\?M>WQ=%_KX;1P6N:;/QKC<TY6
M[55:_U,"[XY;!BTOIAM0M(=C0!#YGP_YC>([\W:]Y@JRQUQ&E,#*J 7@]PWG
MZGBC7]C+OX#F_P)02P,$%     @ *XJJ4@PVF'/H!0  ]Q(  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&ULK5AM;]LV$/XK!Z\9$L"Q)?HUG6,@+]U6
MH.V")MT^#/M 2Y1%A!)5DHKK83]^1TJ6',=FO6!!8%LB[^ZY%SYWTFPEU:-.
M&3/P+1.YONRDQA1O^WT=I2RCNB<+EN-*(E5&#5ZJ95\7BM'8"66B3X)@W,\H
MSSOSF;MWI^8S61K!<W:G0)=91M7ZF@FYNNR$G<V-SWR9&GNC/Y\5=,GNF?E2
MW"F\ZC=:8IZQ7'.9@V+)9><J?'M+B!5P.W[G;*6W?H-U92'EH[UX'U]V HN(
M"189JX+BUQ.[84)838CC:ZVTT]BT@MN_-]I_=LZC,PNJV8T4?_#8I)>=:0=B
MEM!2F,]R]2NK'1I9?9$4VGW"JMX;=" JM9%9+8P(,IY7W_1;'8AC!$@M0'8$
MPN$!@4$M,#A68%@+#%UD*E=<'&ZIH?.9DBM0=C=JLS]<,)TTNL]SF_=[HW"5
MHYR9WY<+S;Z6+#?P[@D_-9S>,D.YT/")*D5M5L[@'+[<W\+IF[-9WZ!1*]J/
M:@/7E0%RP$ ('V5N4@WO\IC%S^7["+9!3#:(KXE7X56A>A!,NT "$N[!<^,7
M_TA1?! >%+_UB]^RJ!$//-X,FO@/G+[A 7V?RFS!%,@$=$H5T\"U+G?C5/E5
M*1HY1?8X/\U#0J:3Z<5XUG_:]F#/QH!<7$P):38^PSILL Z]6&]DEN%1Q9J,
M'I_#[<(3%27;A[I2.=Y!/=V!O&=7, B"_7A'#=Z1%^]N;<.?'YF-]E^>O(T;
MW6-_WI"2(ZI3*)2,&(OUOI,Q?N'5**C^]CLV:8Q/O,8?F,I 2)KOM3IY896,
M?%:GC=6IU^HMTY'BA:-KK%=C07Q $/LP^#4]I RPF J:K[&  %/#C6 Q&(G4
M]LB YZB<:7,N<[&&@JXSQTS8Y<"D7)GUN>;?('.\T@6\6Q96%M=QR3%]O0@\
M@8@IY+,<(IG'W(+7@)4+&3,]L$ >-GYHI%XA$($I<1V=-+B:\,2D0/,<>5!I
M[(S.]=1B1&540%*BVGP),34,]\65D@6CJG$#*/Z#LANP'%$&L6*?M9I.Z9G3
MML2>;2H>..5G<*>PM\)G*W%*M>UC&,$8%;K-%BQ<H0BS<3FS 3CE*#7HD=%)
M%PI1(HLOSF#4FP0G/;B**[^I$.NN4[")O>N^6W$GO<E)ZU\-WN%&$)@&NA!V
MX?R1YWCD5RF/4LL#Z"^-(E56VQ3/(UZ@ERX%8MV#WU"?@H19NL@C4<:X$<)>
M< ()C;C@9FT7FXB7ME&X\@::R3(WZ!+EL8UB)*2VP;9QIIB;W"; BB8P[(T:
M["]50&S1&;?J$FR-NI1A\#!7@B-"GCR+#LY1Z+-V]ZRJJEPVJRFM5F1U(#"$
MU?YFN\LZ;C0VE8D4.&%9Z%51*5L5+XO*R=5.8H YEIY!9.A+I=SFNPJDHOG2
MJDN4S"" 'W^8DC#\"<B)FX)B&\Q5RJJ(;LFN9"EP,8I*Y2'!BX81+EY'L/ /
MW"7\;Z:Z\#['AKEU_P./<&ID;?T>P\IAT(XS@;]'U16"91BAYYA5UZCVSBV5
MINEVTQGV!N%^E@RW)JK0"^%+@4FI\K37;'BH*QPP3%K#Y'^:):YK3=LSPF!X
M,0S&!S"TXTSHGV=VFL2&?&/VA(\8A<NW/;P1CA),199 ,RZ09F2.Y.@&T+UP
M_49W^@D56N(SR=>2JRUR:^TT#067JC+%!N*>05*.&!S(UV'OUIW(GOXE%OC2
M,4P";P:#H!?8[0(#XROT=A8+_</8:\[>.PP)\MXO2![F/Q[ =N8*_4/7:X;$
MZUKG\6>B'=-"_YSF"],#Q@&?HV%P5 3:X2ST3V='C8:UCNT#./&[W(YIX7>F
M*^]T6 N/C@YUVPS"UW>#3:B/"#1IN9[XN=[O:"W\[#'(ZREI&9[X&?X83\E1
MOK;<3OS<_AU?R9'GI[_UI@!);.G>N&BD-)R1JI<&S=WFK<Z5>Y?1;[=7KX3P
M01HG$ V")2@:]"88:56]9:DNC"S<>X>%-$9F[F?*:,R4W8#KB91F<V$--.^Z
MYO\"4$L#!!0    ( "N*JE( =$*&)@,   P3   -    >&PO<W1Y;&5S+GAM
M;-U846_:,!#^*Y$[39TT-4!&2E9 VI J3=JF2NW#WBI#'+#DV)EC.NBOGR\.
M"5 ?8GW88(D@]GV^[S[[+MAB6)JU8/<+QDRPRH4L1V1A3/$Q#,O9@N6TO%(%
MDQ;)E,ZIL5T]#\M",YJ6X)2+L-?IQ&%.N23CH5SFM[DI@YE:2C,B_<84N,>7
M=$2Z\0<2.+J)2MF(/%Z^_;E4YN9-X)X7[R\N.H_O;O;MEQ7PCH1>TOX1I%>=
M#DX,($8>'T=^B!NCOCZ*^@ S1CS8)6Z)=AS#.F7C8:9DF[F(.(-EICD+GJ@8
MD0D5?*HY>&4TYV+MS#TPS)10.C"V9&RH+EC*9P=W70^JJ>;)N52ZBNTBN.]I
M/7P/V/1 (!>B$=@CSC >%M08IN6M[52#*^,+**C;#^O"*IQKNN[V^J1UJ!XV
MR%3IE.DF3)=L3..A8!G(T7R^@*=110B@,2JWC933N9*TTK#QJ!N6=L:$N(=7
M[4>VP[W*MG+6@8S)IFD%U4U'XSK O\WFN+=I>Z_B#0K^I,SGI9V.K/I09.Q.
MLXROJOXJ:P1@[%V<G1:%6'\2?"YSYB9_=,#QD&[\@H72_-E&@U*960/3)'AB
MVO#9MN67IL4#6YE-.:TR7'/O##7_W76>,\DT%=NB;>V?\BJ_6G%T_:\D5[\J
M^X*]&NO]\]1%]L]!9'P.(L^B)@>G+S)*3E)C6._?6X>$G2-"8PW@*#8BW^%0
M)]J@P73)A>&R[BUXFC+YXJ1@Z0V=VJ/^#K\=G[*,+H5Y:, 1:=O?6,J7>=*,
MNH.%J$>U[:\PO6[<G -M+"Y3MF+II.[J^;1J!K9AH]87..PCM]7E1S ?A_D1
MP+ XF +,QWEA<?ZG^0S0^3@,TS;P(@/49X#Z."\?,JEN+([?)[&7?Z9)$D5Q
MC*WH9.)5,,'6+8[AXV?#M($'%@<B_=E:X]G&*^1P'6 Y/50AV$SQ2L1FBJ\U
M(/YU X\D\6<;BP,>6!:PVH'X_CA04WZ?*(*L8MJP-QA'D@1#H!;]-1K'R.K$
M</OS@[TE490D?@0POX(HPA!X&W$$4P :,"2*JGUP;S\*-_M4V/[_-?X-4$L#
M!!0    ( "N*JE*7BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,
M0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BD
MMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G
M<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^
M=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"
MR0_L?@!02P,$%     @ *XJJ4M\3?T<5 P  PA4   \   !X;"]W;W)K8F]O
M:RYX;6S%F%M/VS 4@/^*E9>QARV->^$BBC0*;$@(JG7B=7*3D\;"EV([9?#K
M<5+*'%:.]N+RE,9VG<_7S\?'#]K<S;6^(W^D4':<5,XMC]+4YA5(9K_J)2B?
M4VHCF?.O9I':I0%6V K 29'27F^42L95<G*\J6MJTO!%.\@=U\HG-@FW'![L
MW_SFE:RXY7,NN'L<)^UO 0F17'')GZ 8)[V$V$H__-"&/VGEF)CE1@LQ3K)U
MQBT8Q_-_DF<-Y"\VMVV*8_.?S(.,DU'/5UAR8UU;HJV?><85^,+KM]KI"RX<
MF#/FX+O1]9*K15.-;T4:-*/MA\USW8E'YG^Z49<ES^%,Y[4$Y=;]:$ T@,I6
M?&D3HIB$<3+1*S!->_P'+HMUVYR'"GK*''&?82Z+%B\FBBI 62C(*1-,Y4#:
M_K,!'47HZ,?0D;TI,Z "R#X"V=\5Y*PA:$I;HDMRLP3C2P>0 P1R\#&0DXJI
M!83#/40@AQ\$R6Q%+D0 .4(@1W$A;\R"*?[49@1$^PC1?ERB62TE,X]-3\WX
M0G'_-Z8<^9;GNE:="7B 0![$A;SV]5YI:\D4#)EH*;7RB]FOX@#O$,$[C#WU
MI.2NG7'AQMS#=N9>Y&%U.K^KM"C V$_D_+[V+@W94&M$UD;+]N64-6O5=YVO
MR;Y=$!GFC2RR.&;UW,)][0N1\]7;0<5<D466!;I6?],0$[-%%ET7K\N![/D3
ME #[.63#))%%ML1[<^\%-,3$-)%%]@0^TOT0$W-'%ED>[^[+9.\,' LQ,7MD
MD?71F9 -&!?=&8FY(]N=/%[A2!;B44PD-+)(MN+1#A[F$AH]!-F"U^_@H2%(
M]!AD"]Z@@X<)A4://K;@73/3A!XKZ&!B0J&1A1(>9E[.,B%NB(FYA>["+=O4
MLD8-,3&WT-ANP3 [IPB*N87&#DQ0S%"!%',+C>P6'',08F*6H9$M@V,.P\L0
MS#;]780M[V*.0DS,.OW8$<S;"*&[>X:8F'WZK7W2S9UA 2574%S[3UB?GC.1
M3PUI'NN0:#!L#BIE+<3$I]VH*\V*S17DYOKTY!E02P,$%     @ *XJJ4HH3
M@V1C 0  MQ,  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W8S8Z"
M,!2&X5LAO0#+.574B;B:C=N)-T"P@)&_T$Y&[WX(+O CLYB-Z5F1EG#Z)B1/
M"(<O6V?^VK6NNO8NNC=UZU)5>=]_:.WRRC:96W6];<<[13<TF1^70ZG[++]E
MI=4<QXD>7F>HX^%U9G1^]/8_$[NBN.;VL\N_&]OZ/P;KGVZXN<I:KZ)S-I36
MITK?ZWG;Z>E"JW&RBDZ75 VG"RD=.H@AB,,'&0@RX8/6$+0.'[2!H$WXH 2"
MDO!!6PC:A@_:0= N?- >@O;A@RA&&6,!20NL!6A-R#4)\)H0;!(@-B'9),!L
M0K1)@-J$;), MPGA)@%R$])- NPFQ)L$Z,VH-PO0FU%O%J W+SZV!>C-J#<+
MT)M1;Q:@-Z/>+$!O1KU9@-Z,>K, O1GU9@%Z,^K- O0VJ+<1H+=!O8T O0WJ
M;=ZIM_./VKJYY[G&\]])M1^?M?/QT_*YN7@O$\X:_M,=?P%02P,$%     @
M*XJJ4E4IDH^) 0  7A0  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS9C-;L(P
M$(1?)<H5$6.GI3\"+FVO+8>^@)MLB$426[:A\/9UPH_4BD8@*G4NL1+OSHR]
MTG?(Y'UKR$6;NFK<-"Z]-X^,N:RD6KI$&VK"3J%M+7UXM0MF9+:4"V)B-!JS
M3#>>&C_TK48\FSQ3(5>5CUXVX;-3NIG&EBH71T^[PM9K&DMC*I5)'_;9NLE_
MN SW#DGH[&I<J8P;A(*8G71H=WXWV/>]K<E:E5,TE]:_RCI4L4W%G-]6Y))^
MB1,9=5&HC'*=K>K0DCAC2>:N)/)UE>Q$!_W./MPP[9[\:O].IL\P5,ZM-BY,
MS-+E=H>1M-U#$X3(>M5_Q*-CD+[Z?-1..Z?\3.]PO9_:+KMY.-8MU]_Q]QD?
M]2_,(4!RI" Y;D!RW(+D&(/DN /)<0^2XP$D!Q^A!$$A*D=!*D=A*D>!*D>A
M*D?!*D?A*D<!*T<AJT AJT AJT AJT AJT AJT AJT AJT AJT AJT A:XI"
MUA2%K.E_DO5#Z^5?__%JUZ26JCGXL^ZWXNP+4$L! A0#%     @ *XJJ4@=!
M36*!    L0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q0
M2P$"% ,4    "  KBJI2->'I)^X    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  KBJI2F5R<(Q &  "<)P
M$P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( "N*JE* D4!66@4  ( 6   8              " @0T(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  KBJI2'AIFWF$%  "X%
M&               @(&=#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ *XJJ4F$0C^RJ @  5@D  !@              ("!-!,  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "N*JE)Q-(FW\P,
M &P-   8              " @106  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    "  KBJI27#'+PV4%  #J%@  &               @($]
M&@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ *XJJ4JRG
MB_$.!@  ?1<  !@              ("!V!\  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( "N*JE(SK,H1X@,  )$(   8
M  " @1PF  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  K
MBJI2&-[^JGP)  !_&   &               @($T*@  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ *XJJ4G6B_N1  P  U <  !@
M         ("!YC,  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( "N*JE)FL=RE"P@  "87   9              " @5PW  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ *XJJ4N/L^N\;!0  5@P
M !D              ("!GC\  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    "  KBJI2L1S?>94)  #(&P  &0              @('P1
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( "N*JE(^#M,/
M, L  /(>   9              " @;Q.  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ *XJJ4CDFM^O0"0  :!H  !D
M ("!(UH  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  K
MBJI2&_1]CJ($  "J#   &0              @($J9   >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "N*JE(SO8*2Q 0  %(,   9
M          " @0-I  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#
M%     @ *XJJ4JEIJ442 P  _@@  !D              ("!_FT  'AL+W=O
M<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  KBJI2:9O0P*0"  "/
M!P  &0              @(%'<0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM
M;%!+ 0(4 Q0    ( "N*JE+AVRQV4@,  .,*   9              " @2)T
M  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ *XJJ4I+4
M1A/W @  ; H  !D              ("!JW<  'AL+W=O<FMS:&5E=',O<VAE
M970R,"YX;6Q02P$"% ,4    "  KBJI2$9U@,D0"  "/!@  &0
M    @('9>@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M "N*JE)DEQ[A8 (  %\&   9              " @51]  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ *XJJ4J=CNU=D @  308  !D
M             ("!ZW\  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    "  KBJI2%JDP%(D#   2#   &0              @(&&@@  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "N*JE(_^TC)P@,
M 'X,   9              " @4:&  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ *XJJ4KJ[C7"E P  "0T  !D              ("!
M/XH  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  KBJI2
M-8#YIM("   !"   &0              @($;C@  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( "N*JE)[2VG7S (  (4)   9
M      " @221  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ *XJJ4LMFN6U$ @  !@8  !D              ("!)Y0  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  KBJI2X?F8&GT"  #!!@
M&0              @(&BE@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( "N*JE(]HM<>WP0   X2   9              " @5:9  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ *XJJ4@PVF'/H
M!0  ]Q(  !D              ("!;)X  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    "  KBJI2 '1"AB8#   ,$P  #0
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:+GAM;%!+!08     *  H ,\*  !<KP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>82</ContextCount>
  <ElementCount>289</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000004 - Statement - Condensed Statements of Operations (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited</Role>
      <ShortName>Condensed Statements of Operations (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000005 - Statement - Condensed Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000006 - Statement - Condensed Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000007 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000009 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://celcuity.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/Commitments</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/StockBasedCompensation</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - Net Loss Per Common Share (Details Narative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/NetLossPerCommonShareDetailsNarative</Role>
      <ShortName>Net Loss Per Common Share (Details Narative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/NetLossPerCommonShare</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/CommitmentsTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - Commitments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CommitmentsDetails1</Role>
      <ShortName>Commitments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/CommitmentsTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - Commitments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CommitmentsDetails2</Role>
      <ShortName>Commitments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/CommitmentsTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - Commitments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CommitmentsDetails3</Role>
      <ShortName>Commitments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/CommitmentsTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - Commitments (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CommitmentsDetails4</Role>
      <ShortName>Commitments (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/CommitmentsTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - Commitments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CommitmentsDetailsNarrative</Role>
      <ShortName>Commitments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/CommitmentsTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - Stockholders Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000026 - Disclosure - StockBased Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockbasedCompensationDetails</Role>
      <ShortName>StockBased Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000027 - Disclosure - StockBased Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockbasedCompensationDetails1</Role>
      <ShortName>StockBased Compensation (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000028 - Disclosure - StockBased Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockbasedCompensationDetails2</Role>
      <ShortName>StockBased Compensation (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000029 - Disclosure - StockBased Compensation (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockbasedCompensationDetails3</Role>
      <ShortName>StockBased Compensation (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000030 - Disclosure - StockBased Compensation (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockbasedCompensationDetails4</Role>
      <ShortName>StockBased Compensation (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000031 - Disclosure - StockBased Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockbasedCompensationDetailsNarrative</Role>
      <ShortName>StockBased Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="celc_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000032 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/SubsequentEvents</ParentRole>
      <Position>32</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="celc_10q.htm">celc_10q.htm</File>
    <File>celc-20210331.xsd</File>
    <File>celc-20210331_cal.xml</File>
    <File>celc-20210331_def.xml</File>
    <File>celc-20210331_lab.xml</File>
    <File>celc-20210331_pre.xml</File>
    <File>celc_ex311.htm</File>
    <File>celc_ex312.htm</File>
    <File>celc_ex321.htm</File>
    <File>celc_ex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>celc_10qimg10.jpg</File>
    <File>celc_10qimg11.jpg</File>
    <File>celc_10qimg12.jpg</File>
    <File>celc_10qimg7.jpg</File>
    <File>celc_10qimg8.jpg</File>
    <File>celc_10qimg9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>56
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "celc_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "contextCount": 82,
   "dts": {
    "calculationLink": {
     "local": [
      "celc-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "celc-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "celc_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "celc-20210331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "celc-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "celc-20210331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 317,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 9,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 14
   },
   "keyCustom": 54,
   "keyStandard": 235,
   "memberCustom": 23,
   "memberStandard": 9,
   "nsprefix": "celc",
   "nsuri": "http://celcuity.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000001 - Document - Cover",
     "role": "http://celcuity.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000010 - Disclosure - Commitments",
     "role": "http://celcuity.com/role/Commitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000011 - Disclosure - Stockholders' Equity",
     "role": "http://celcuity.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000012 - Disclosure - Stock-Based Compensation",
     "role": "http://celcuity.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000013 - Disclosure - Subsequent Events",
     "role": "http://celcuity.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000014 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000015 - Disclosure - Commitments (Tables)",
     "role": "http://celcuity.com/role/CommitmentsTables",
     "shortName": "Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000016 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://celcuity.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-02-01to2021-02-26",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "celc:IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000017 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "role": "http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "celc:FollowOnOfferingPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31_celc_RestrictedStocksMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000018 - Disclosure - Net Loss Per Common Share (Details Narative)",
     "role": "http://celcuity.com/role/NetLossPerCommonShareDetailsNarative",
     "shortName": "Net Loss Per Common Share (Details Narative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31_celc_RestrictedStocksMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000019 - Disclosure - Commitments (Details)",
     "role": "http://celcuity.com/role/CommitmentsDetails",
     "shortName": "Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "celc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2021-03-31_celc_SupplementalBalanceSheetInformationMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000002 - Statement - Condensed Balance Sheets",
     "role": "http://celcuity.com/role/CondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepositsAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2021-03-31_celc_OperatingLeasesMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000020 - Disclosure - Commitments (Details 1)",
     "role": "http://celcuity.com/role/CommitmentsDetails1",
     "shortName": "Commitments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2021-03-31_celc_OperatingLeasesMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "celc:ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celc:OperatingLeaseWeightedAverageRemainingLeasesTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000021 - Disclosure - Commitments (Details 2)",
     "role": "http://celcuity.com/role/CommitmentsDetails2",
     "shortName": "Commitments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "celc:ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celc:OperatingLeaseWeightedAverageRemainingLeasesTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000022 - Disclosure - Commitments (Details 3)",
     "role": "http://celcuity.com/role/CommitmentsDetails3",
     "shortName": "Commitments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "celc:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000023 - Disclosure - Commitments (Details 4)",
     "role": "http://celcuity.com/role/CommitmentsDetails4",
     "shortName": "Commitments (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "celc:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInOperatingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000024 - Disclosure - Commitments (Details Narrative)",
     "role": "http://celcuity.com/role/CommitmentsDetailsNarrative",
     "shortName": "Commitments (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInOperatingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2021-02-26",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "celc:PublicOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000025 - Disclosure - Stockholders Equity (Details Narrative)",
     "role": "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "Stockholders Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2021-02-26",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "celc:PublicOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "celc:SharesOptionsOutstandingBeginning",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000026 - Disclosure - StockBased Compensation (Details)",
     "role": "http://celcuity.com/role/StockbasedCompensationDetails",
     "shortName": "StockBased Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "celc:SharesOptionsOutstandingBeginning",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2021-03-31_celc_EmployeeStockOptionsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000027 - Disclosure - StockBased Compensation (Details 1)",
     "role": "http://celcuity.com/role/StockbasedCompensationDetails1",
     "shortName": "StockBased Compensation (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2021-03-31_celc_EmployeeStockOptionsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000028 - Disclosure - StockBased Compensation (Details 2)",
     "role": "http://celcuity.com/role/StockbasedCompensationDetails2",
     "shortName": "StockBased Compensation (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31_celc_EmployeeStockOptionsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000029 - Disclosure - StockBased Compensation (Details 3)",
     "role": "http://celcuity.com/role/StockbasedCompensationDetails3",
     "shortName": "StockBased Compensation (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "celc:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "role": "http://celcuity.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000030 - Disclosure - StockBased Compensation (Details 4)",
     "role": "http://celcuity.com/role/StockbasedCompensationDetails4",
     "shortName": "StockBased Compensation (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31_celc_StockIncentivePlanMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "celc:StockBasedCompensationRelatedToRestrictedStockTotal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000031 - Disclosure - StockBased Compensation (Details Narrative)",
     "role": "http://celcuity.com/role/StockbasedCompensationDetailsNarrative",
     "shortName": "StockBased Compensation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31_celc_StockIncentivePlanMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "celc:StockBasedCompensationRelatedToRestrictedStockTotal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000032 - Disclosure - Subsequent Events (Details Narrative)",
     "role": "http://celcuity.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "Subsequent Events (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-03-09to2021-04-08_us-gaap_SubsequentEventMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000004 - Statement - Condensed Statements of Operations (unaudited)",
     "role": "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited",
     "shortName": "Condensed Statements of Operations (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000005 - Statement - Condensed Statements of Changes in Stockholders' Equity",
     "role": "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity",
     "shortName": "Condensed Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000006 - Statement - Condensed Statements of Cash Flows (unaudited)",
     "role": "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited",
     "shortName": "Condensed Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000007 - Disclosure - Organization",
     "role": "http://celcuity.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000008 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://celcuity.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000009 - Disclosure - Net Loss Per Common Share",
     "role": "http://celcuity.com/role/NetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celc_10q.htm",
      "contextRef": "From2021-01-01to2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 32,
   "tag": {
    "celc_AgreementWithBiopharmaceuticalCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement with biopharmaceutical company [Member]"
       }
      }
     },
     "localname": "AgreementWithBiopharmaceuticalCompanyMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_AgreementWithBiopharmaceuticalCompanyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement with biopharmaceutical company 1 [Member]"
       }
      }
     },
     "localname": "AgreementWithBiopharmaceuticalCompanyOneMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_AgreementWithBiopharmaceuticalCompanyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement with biopharmaceutical company 2 [Member]"
       }
      }
     },
     "localname": "AgreementWithBiopharmaceuticalCompanyTwoMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Application of New or Revised Accounting Standards"
       }
      }
     },
     "localname": "ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celc_AtmAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATM Agreement [Member]"
       }
      }
     },
     "localname": "AtmAgreementMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_AverageSellingPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Average selling price per share"
       }
      }
     },
     "localname": "AverageSellingPricePerShare",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "celc_CashPaidForOperatingAndFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Total cash paid for amounts included in operating and finance leases"
       }
      }
     },
     "localname": "CashPaidForOperatingAndFinanceLeases",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_CashPaidForOperatingAndFinanceLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for amounts included in operating and finance leases:"
       }
      }
     },
     "localname": "CashPaidForOperatingAndFinanceLeasesAbstract",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "celc_ClosingPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Closing price per share"
       }
      }
     },
     "localname": "ClosingPricePerShare",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "celc_CommonStockSharesReservedDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares reserved description"
       }
      }
     },
     "localname": "CommonStockSharesReservedDescription",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "celc_DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes all significant commitments and obligations resulting from franchise agreements, including a description of the services that the franchisor has agreed to provide for agreements that have not yet been substantially performed.",
        "label": "Description of certain development and commercial milestone events"
       }
      }
     },
     "localname": "DescriptionOfCertainDevelopmentAndCommercialMilestoneEvents",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "2020"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "2024"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[2023]",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[2022]",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[2021]",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_EmployeeStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option",
        "verboseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionsMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails",
      "http://celcuity.com/role/StockbasedCompensationDetails1",
      "http://celcuity.com/role/StockbasedCompensationDetails2",
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_EquityGrantAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Grant Agreement [Member]"
       }
      }
     },
     "localname": "EquityGrantAgreementMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_EstimatedRemainingAmountOfPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated remaining amount of payments"
       }
      }
     },
     "localname": "EstimatedRemainingAmountOfPayments",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_ExerciseOfCommonStockWarrantsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock warrants, amount"
       }
      }
     },
     "localname": "ExerciseOfCommonStockWarrantsAmount",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_ExerciseOfCommonStockWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock warrants, shares"
       }
      }
     },
     "localname": "ExerciseOfCommonStockWarrantsShares",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "celc_ExpenseStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Stock Options [Member]"
       }
      }
     },
     "localname": "ExpenseStockOptionsMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_FinanceLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease cost:"
       }
      }
     },
     "localname": "FinanceLeaseCostsAbstract",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "celc_FinanceLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance lease liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilities",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_FinanceLeaseWeightedAverageRemainingLeasesTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance lease, weighted average remaining lease term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeasesTerm1",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "celc_FinanceLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeasesMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_FollowOnOfferingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation,",
        "label": "Follow-on Offering"
       }
      }
     },
     "localname": "FollowOnOfferingPolicyTextBlock",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celc_FutureExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Future expenses"
       }
      }
     },
     "localname": "FutureExpenses",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_FuturePaymentsRequiredUponCertainMilestonesBeingMet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Future payments required upon certain milestones being met"
       }
      }
     },
     "localname": "FuturePaymentsRequiredUponCertainMilestonesBeingMet",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_GrossProceedsFromAnAtmOffering": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from an ATM offering"
       }
      }
     },
     "localname": "GrossProceedsFromAnAtmOffering",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_IncreaseDecreaseInNonCashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash operating lease, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInNonCashOperatingLeaseExpense",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_IssuanceCostsAssociatedWithAtmOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance costs associated with ATM offering"
       }
      }
     },
     "localname": "IssuanceCostsAssociatedWithAtmOffering",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon closing of follow-on offering, net shares",
        "verboseLabel": "Issuance of common stock upon closing of follow-on offering, net shares"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
      "http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "celc_IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon closing of follow-on offering, including shares of common stock",
        "verboseLabel": "Issuance of common stock upon closing of follow-on offering, including shares of common stock"
       }
      }
     },
     "localname": "IssuanceofcommonstockuponclosingoffollowonofferingincludingsharesofcommonStock",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
      "http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "celc_JanuaryTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 2021 [Member]"
       }
      }
     },
     "localname": "JanuaryTwoThousandTwentyOneMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_LessAmountRepresentingServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts to be paid by lessee to lessor for maintenance, insurance, and tax expenses related to the leased asset.",
        "label": "[Less amount representing services]",
        "negatedLabel": "Less amount representing services"
       }
      }
     },
     "localname": "LessAmountRepresentingServices",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_LessPresentValueDiscount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Less: present value discount"
       }
      }
     },
     "localname": "LessPresentValueDiscount",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_LesseeOperatingLeaseLiabilityAmountRepresentingServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Less amount representing services"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityAmountRepresentingServices",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_LongTermOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Long term portion"
       }
      }
     },
     "localname": "LongTermOperatingLeaseLiability",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_LossOnSaleOfFixedAssets": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "[Loss on sale of fixed assets]",
        "negatedLabel": "Loss on sale of fixed assets"
       }
      }
     },
     "localname": "LossOnSaleOfFixedAssets",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_MarchTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 2021 [Member]"
       }
      }
     },
     "localname": "MarchTwoThousandTwentyOneMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_NetOfUnderwritingDiscountsAndOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distribut",
        "label": "Net of underwriting discounts and offering costs"
       }
      }
     },
     "localname": "NetOfUnderwritingDiscountsAndOfferingCosts",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering and registration statement costs included in accounts payable"
       }
      }
     },
     "localname": "OfferingAndRegistrationStatementCostsIncludedInAccountsPayable",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_OfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.",
        "label": "Offering expenses",
        "verboseLabel": "Offering expenses"
       }
      }
     },
     "localname": "OfferingExpenses",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
      "http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_OperatingLeaseWeightedAverageRemainingLeasesTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating lease, weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeasesTerm1",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "celc_OperatingLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeasesMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_OptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Options outstanding, weighted average exercise price"
       }
      }
     },
     "localname": "OptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "celc_PaymentsForFinanceLeases": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Payments for finance leases]",
        "negatedLabel": "Payments for finance leases"
       }
      }
     },
     "localname": "PaymentsForFinanceLeases",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_PaymentsForRegistrationStatementCosts": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Payments for secondary registration statement costs]",
        "negatedLabel": "Payments for secondary registration statement costs"
       }
      }
     },
     "localname": "PaymentsForRegistrationStatementCosts",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_PfizerIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pfizer, Inc. [Member]"
       }
      }
     },
     "localname": "PfizerIncMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_PlacementSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Shares [Member]"
       }
      }
     },
     "localname": "PlacementSharesMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from follow-on offering, net of underwriting discounts and offering costs"
       }
      }
     },
     "localname": "ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_PublicOfferingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering price"
       }
      }
     },
     "localname": "PublicOfferingPrice",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "celc_RemainingSharesAvailableForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining shares available for issuance"
       }
      }
     },
     "localname": "RemainingSharesAvailableForIssuance",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "celc_RestrictedStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStocksMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of supplemental balance sheet information related to leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celc_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of supplemental cash flow information related to leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celc_ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted average discount rate"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageDiscountRateAndRemainingLeaseTermTableTextBlock",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celc_SecondTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche 2 [Member]"
       }
      }
     },
     "localname": "SecondTrancheMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_ShareExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share exercise price"
       }
      }
     },
     "localname": "ShareExercisePrice",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "celc_SharesExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, exercised"
       }
      }
     },
     "localname": "SharesExercised",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "celc_SharesOptionsExercisables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Shares, options exercisable"
       }
      }
     },
     "localname": "SharesOptionsExercisables",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "celc_SharesOptionsOutstandingBeginning": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares options outstanding, beginning"
       }
      }
     },
     "localname": "SharesOptionsOutstandingBeginning",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "celc_SharesOptionsOutstandingEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares options outstanding, ending"
       }
      }
     },
     "localname": "SharesOptionsOutstandingEnding",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "celc_StockBasedCompensationExpenseRelatedToEspp": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based compensation expense related to ESPP"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseRelatedToEspp",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_StockBasedCompensationRelatedToRestrictedStockTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "[Stock-based compensation]",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockBasedCompensationRelatedToRestrictedStockTotal",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2017 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_StockOptionAwardsSharesModified": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option awards shares modified"
       }
      }
     },
     "localname": "StockOptionAwardsSharesModified",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "celc_StockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option [Member]"
       }
      }
     },
     "localname": "StockOptionsMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_SupplementalBalanceSheetInformationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental balance sheet information [Member]"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_ThirdTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche 3 [Member]"
       }
      }
     },
     "localname": "ThirdTrancheMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_TrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche [Member]"
       }
      }
     },
     "localname": "TrancheMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_UpfrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront fee"
       }
      }
     },
     "localname": "UpfrontFee",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celc_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarative"
     ],
     "xbrltype": "domainItemType"
    },
    "celc_WeightedAverageExercisePriceBeginning": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, beginning"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceBeginning",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "celc_WeightedAverageExercisePriceEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, ending"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceEnding",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "celc_WeightedAverageExercisePriceOptionsExercisables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted average exercise price, options exercisable"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOptionsExercisables",
     "nsuri": "http://celcuity.com/20210331",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line 1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line 2"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Member"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum Member"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Axis"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [],
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.",
        "label": "Public offering price per share"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesInitialPricePaidPerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used for operations:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarative",
      "http://celcuity.com/role/StockbasedCompensationDetails",
      "http://celcuity.com/role/StockbasedCompensationDetails1",
      "http://celcuity.com/role/StockbasedCompensationDetails2",
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarative",
      "http://celcuity.com/role/StockbasedCompensationDetails",
      "http://celcuity.com/role/StockbasedCompensationDetails1",
      "http://celcuity.com/role/StockbasedCompensationDetails2",
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r69",
      "r159",
      "r166"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "[Assets]",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r26"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "[Assets, Current]",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by securities or other assets sold under repurchase agreements. Repurchase agreements are agreements under which the transferor (repo party) transfers a security to a transferee (repo counterparty or reverse party) in exchange for cash and concurrently agrees to reacquire that security at a future date for an amount equal to the cash exchanged plus a stipulated interest factor.",
        "label": "Securities or Other Assets Sold under Agreements to Repurchase [Axis]"
       }
      }
     },
     "localname": "AssetsSoldUnderAgreementsToRepurchaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsSoldUnderAgreementsToRepurchaseTypeDomain": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is the type of such assets (for example, US Treasury Obligations, US Government agency obligations and loans, and so forth). This item may be presented as an element in the table that is disclosed when the carrying amount (or market value, if higher than the carrying amount) of securities or other assets sold under repurchase agreements exceed 10 percent of total assets, as of the most recent balance sheet date."
       }
      }
     },
     "localname": "AssetsSoldUnderAgreementsToRepurchaseTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r88",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r88",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type Axis"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r114",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeasedAssetsGross": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of leased physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Furniture and equipment"
       }
      }
     },
     "localname": "CapitalLeasedAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total gross amount less the charge for the use of the long-lived depreciable assets subject to a lease meeting the criteria for capitalization.",
        "label": "Net book value of property and equipment under finance lease"
       }
      }
     },
     "localname": "CapitalLeasesBalanceSheetAssetsByMajorClassNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total charge for the use of long-lived depreciable assets subject to a lease meeting the criteria for capitalization.",
        "label": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalUnitsOutstanding": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of capital units or capital shares outstanding. This element is relevant to issuers of face-amount certificates and registered investment companies.",
        "label": "Restricted stock outstanding"
       }
      }
     },
     "localname": "CapitalUnitsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r16",
      "r45"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "End of period",
        "periodStartLabel": "Beginning of period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets",
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "[Cash and Cash Equivalents, Period Increase (Decrease)]",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Note 4. Commitments"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common stock shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par or stated value per share",
        "verboseLabel": "Common stock par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheetsParenthetical",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheetsParenthetical",
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r10",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value: 25,000,000 shares authorized; 12,287,896 and 10,299,822 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively",
        "verboseLabel": "Common stock shares issued, value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets",
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r60",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.",
        "label": "Deferred transaction costs"
       }
      }
     },
     "localname": "DeferredCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r43",
      "r74"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r115",
      "r116",
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument Risk Axis"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Note 6. Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Note 3. Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Total estimated compensation cost to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentQuotedMarketValue": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.",
        "label": "Aggregate offering price, common stock shares"
       }
      }
     },
     "localname": "EquityMethodInvestmentQuotedMarketValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r128",
      "r132",
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Interest"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r130",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Operating cash outflow from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r127",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "[Finance Lease, Liability]",
        "verboseLabel": "Present value of net minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "[Finance Lease, Liability, Noncurrent]",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "[Finance Lease, Liability, Payment, Due]",
        "verboseLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.",
        "label": "[Finance Lease, Liability, Payments, Due Next Twelve Months]",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.",
        "label": "[Finance Lease, Liability, Payments, Due Year Three]",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.",
        "label": "[Finance Lease, Liability, Payments, Due Year Two]",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r129",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Financing cash outflow from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r128",
      "r132",
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r136",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance lease, weighted average discount rate, percent"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r43",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "[Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property]",
        "verboseLabel": "Loss on sale of fixed assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r30",
      "r53",
      "r157",
      "r162",
      "r172"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statements of Operations (unaudited)"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location Axis"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r50",
      "r68",
      "r112"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income tax benefits"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "[Increase (Decrease) in Accounts Payable]",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "[Increase (Decrease) in Accrued Liabilities]",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapital": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.",
        "label": "Increase in operating ROU asset and lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Prepaid assets and deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r29",
      "r67",
      "r120",
      "r121",
      "r164"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "[Interest Expense]",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r34",
      "r66"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r137",
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Schedule of lease costs for the period"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "[Liabilities]",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r15",
      "r161",
      "r169"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "[Liabilities and Equity]",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders' Equity:"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r46",
      "r47",
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Property and equipment included in accounts payable"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "[Liabilities, Current]",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtDescription": {
     "auth_ref": [
      "r22",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment.",
        "label": "Description of term Loan"
       }
      }
     },
     "localname": "LongTermDebtDescription",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermLoansPayable": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Term loans"
       }
      }
     },
     "localname": "LongTermLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "totalLabel": "Net cash provided by (used for) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "totalLabel": "Net cash used for investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r40",
      "r41",
      "r44"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "totalLabel": "Net cash used for operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r27",
      "r28",
      "r31",
      "r44",
      "r56",
      "r163",
      "r171"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity",
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "[Nonoperating Income (Expense)]",
        "totalLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "[Operating Expenses]",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "[Operating Income (Loss)]",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r133",
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating lease liability",
        "verboseLabel": "Present value of net minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails",
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liabilities",
        "verboseLabel": "Less: short term portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails",
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "[Operating Lease, Liability, Noncurrent]",
        "terseLabel": "Long term portions",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails",
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r131",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating cash outflow from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets",
        "verboseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails",
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r136",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating lease, weighted average discount rate, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Note 1. Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableAxis": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group of items that represent other investments not readily marketable, including description of investment, fair value, and value as measured by quoted value method.",
        "label": "Other Investment Not Readily Marketable Axis"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableNameDomain": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the investment category or actual investment title."
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Payroll tax receivable"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to acquire in process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r88",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name Axis"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par or stated value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $0.001 par value: 2,500,000 shares authorized; 0 shares issued and outstanding as of March 31, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r4",
      "r72"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r6",
      "r7",
      "r75",
      "r170"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealEstatePropertiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by ownership of the property.",
        "label": "Real Estate Property Ownership [Axis]"
       }
      }
     },
     "localname": "RealEstatePropertiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RealEstatePropertiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents categories of ownership of real estate properties."
       }
      }
     },
     "localname": "RealEstatePropertiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r84",
      "r140",
      "r141",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r111",
      "r174"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r49",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Clinical Trial Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r12",
      "r81",
      "r168"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of consideration recognized during the period for the milestone or milestones.",
        "label": "Net cash proceeds"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of stock number of shares issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SalesCommissionsAndFees": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).",
        "label": "Deducting underwriting discounts",
        "verboseLabel": "Net of underwriting commissions"
       }
      }
     },
     "localname": "SalesCommissionsAndFees",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
      "http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r86",
      "r105",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.",
        "label": "Schedule of maturity analysis under lease agreements"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r90",
      "r96",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of activity for all stock options outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of fair value of equity-based awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Schedule of unrecognized compensation cost"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "[Share-based Payment Arrangement, Noncash Expense]",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://celcuity.com/role/StockbasedCompensationDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Restricted stock vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Shares available for grant under the 2017 Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Options exercisable, weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "shares, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Shares, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted average grant date fair value for options granted during the period:"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Options outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r91",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Schedule of stock options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r85",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted average exercise price, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r101",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails2"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Options exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options outstanding, weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockbasedCompensationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r8",
      "r160",
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Less: short term portions"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Note 2. Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r24",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails",
      "http://celcuity.com/role/CommitmentsDetails1",
      "http://celcuity.com/role/CommitmentsDetailsNarrative",
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity",
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarative",
      "http://celcuity.com/role/StockbasedCompensationDetails",
      "http://celcuity.com/role/StockbasedCompensationDetails1",
      "http://celcuity.com/role/StockbasedCompensationDetails2",
      "http://celcuity.com/role/StockbasedCompensationDetails4",
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statements of Cash Flows (unaudited)"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statements of Changes in Stockholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails",
      "http://celcuity.com/role/CommitmentsDetails1",
      "http://celcuity.com/role/CommitmentsDetailsNarrative",
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity",
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarative",
      "http://celcuity.com/role/StockbasedCompensationDetails",
      "http://celcuity.com/role/StockbasedCompensationDetails1",
      "http://celcuity.com/role/StockbasedCompensationDetails2",
      "http://celcuity.com/role/StockbasedCompensationDetails4",
      "http://celcuity.com/role/StockbasedCompensationDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r79",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock in an at-the-market (\"ATM\") offering, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r9",
      "r10",
      "r79",
      "r81",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of common stock options, net of shares withheld for exercise price, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r79",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock in an at-the-market (\"ATM\") offering, amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r9",
      "r10",
      "r81",
      "r87",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r79",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of common stock options, net of shares withheld for exercise price, amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r10",
      "r13",
      "r14",
      "r70"
     ],
     "calculation": {
      "http://celcuity.com/role/CondensedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "[Stockholders' Equity Attributable to Parent]",
        "periodEndLabel": "Balance, amount",
        "periodStartLabel": "Balance, amount",
        "totalLabel": "Total Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets",
      "http://celcuity.com/role/CondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Note 5. Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Note 7. Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r58",
      "r59",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Accounting Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r134",
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://celcuity.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 2)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45014-112735"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "820",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r175": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r176": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r177": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r178": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r179": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r181": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(m)(1)(i)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001654954-21-005361-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-21-005361-xbrl.zip
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MU@7R(78HL/YS8"U$R2;6\9'X+Q2M-]QZ8W]G2?76]?CN\M$Z#QC"D#%K0=Q
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M2\I0^BX>=^\PI98B[MX'EC+= KI2HF7C:)?;0K]!'R+@$3Y'SH*H%H<(T'B
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M"NCTGDNY0M8/J!4B"V BDTMX9&7$YDW5CWZ XDLLP6,4BS>D&I5.3<(5L*I
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MK4&57#X!GC 3J'*95EL7KHO')LG^YY,?HK&PRUQ:G0"2"%L%#X?0&N"(91.
M)J,L_I>P@+%%B)ETZ.O$-&(FJHB96(R820_$3$PCYA+_\R9^B%["MIZ6*0V@
MI2DH%RL',MN0TI"L!2>$'MS$@'"81@DULF[BVSAZ]D-';#F+R W@12 R%S0U
M6MN0PQ>O!3[,+L;XR=E,8^@V2E(8_!]_)SU[\8D-X(<K+A<]%4K;L,,3K@4Y
MC 5@'E/'*:+Z+F($!4BI_JPI<)LC4A&L7?K-@OGGB-,(RJ;SC6E,S3!YE!_<
M/D6AV#'7)-$STR+1\MFN_V[!C M$JL\Z)0.4SMP)]QXY^QC#;SS9//AIP%O?
M31(],R\2+9_Y^N\6S+Q I/K,YV0 TP%*:&#F'V)(+A7O7[>;B->7VN]ZYIPK
M5#[AE1\MF&V>//6ISF@ (S*XP#]\<YZP8$CP )M/IG>A\T2L+_8RC040D(@E
M7/0YK=D'V-=ABDA2 /\97<$49A'8D@L"/KG>VQ>9R/5K%QZM!8A1$$]XT5+P
MD!AHF$?-'P^A'$$>3#:T&_OD_!'"'8,1"M(D_TL=3]F?_TZ/M^2>^<;[Z(<P
M='QL 47LOEF0YJ,;Z^EQUJ<K!'-=^,@$_WTRFX[',X,P["]Q,\%(Z**0Y%%[
M#P.20XP\'T/I ,&3QT/R(DFP)"W@JQ/I@QE?O#*@JA1T(M;CY0HA"Z CDZWQ
M()W2V@.)3&TJ(:-!JQL@ F&;.*D1TBF93]:3\=H:N$A%%#U49ZP_VP"?2Y@\
M780N^9\/_]C[SS#  B87Z26,XU=LY/\5!ONZ;=V15Q^\.G6F##<E1J815N/%
M:&P!_'J(W( CYF59/<D_T*$5&X!YA79DVTXJRTPP%@):?<"3"EL&&I>0SM+8
MFTUGC@7 4A"Q$9"9L=B!&P]AD=W+*&F'#8]4)VK$HE9!TZ1C$[(<KQ8VF$[M
M$C8APS@ R=N6D!-@% *'L-L HIOT"<5WR$%8(VX"E'Q!J1Q*,@9]@&H7NPPK
M,36=.F\RG:]L.-*IREF'V"U\Q6T'((7?0%RPVP"OVQCMH.]^^+8C!TTYL@2T
M^D E%;:,)RXAG:(-&GOKJ0504A"Q@2+& F#+B4_7J:GUM$2[,UV.9K.1IA%/
M2[F<VX]*5?D:=PND+>!D!Z6V03=TS%;IIK%CM1I K#M!%U+5$?$[(SO+7<,#
M9/P=0H-'.Q2GK[=8U!0?P\@1;$?<CGAS$NH>&8M.?=XN>E6MB^F9)W6]1%9X
M9-0E;2IYQDE/PRAG.P,ALN(FX@8+!TD*H4\()HC6RKCQOB:(K@R1U23GT6B4
MJ@A?L4ME#'0>5XO9?+:T '$=1*U#KF % >$%M&;*>>2=[_%_&#<VQ)L([=5L
MZKCNQ"[SHBH8WZZPS6TO[9!^"Z)EUL>Z9KS=:#C((S 7K+ 2/OEPXP=^ZJ,$
M;T<T!<)3%+@H3LC6E+ZV7->HL^L#2M<NE:&DRDLG=[E>PKD-5D4_J1N!D8=6
MJ)%1;N=[P%JRXD*H)*C:I:*,P0@N%:X7Q=39IKV8.S8H.U4Y11>-)7XKP'7A
M..05=7(+7XDOKN4X+2#6N"M*Q:WLDEQ*-DF3!5S8<&.H(F,CSB'C 3O&9 .(
M6%P/HB9W#O!7.93D+/H I2)Z&58R>CIQ"W>$/!MN@-0EK4,LX\R.0<%!8]F
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M[QDM^)U26V%M%D)]\D-$72UM/2T1&D!)0TPN4@HJ%MKK+CTKZDFUR2=!#.$
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M/C)S:ZO0@*>\&;!Y!3^0EO"&^2,H&@.'UJQPO0HZSXI #Q#A)VW(.*H5NJF
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ME9^^_^1$RT_LEY\N(BJ/=)Y9M^>8>'__@37*>"ZI^<C_LM,H?7^A<IGXRY>
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M/Z0S\NE9&.4>64[V][J[2&_D:D0UC-Y+Y7",YTE"2=R.9K<=<K$E6:UNE8I
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MZF9ZDR2KKJS,^R!5UPT#C)TS!AOW@ *X=E,W2WYA2PZ\4L<L)"%]Z#59AQ;
M'9V23Z3[.2K0&3F&C*4*PE/E;!?$ .[W5.JQBAR?G$[(PJXF ;F/-2@W&Y$"
MN/%3F6;;J=G0 6'-,!0@>4,C<&\/)8!K0!VK0#<!*Y\=MC4W,!B_X. \K(.Z
MO4(TJ>-@@S99>.O(>A0FWT*\<OUT.US9>Z U>@^V@\TB;[8=;O;CJAAP.A\"
MJ_:Z))LIMKL-&CH@US"Q-:5ZL\F 6%\5%"BBT=B%HG$-"XB#MXWBM:NM'1H
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MJ(+>4P9I<A]8@[E0%"O*JU?3R2Z\:ZK9X."?!-=Q<3UH_S&199C&'*Y7J=
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MI+[1MY3$<,W)6QSGDEEG5LJ=S<K-<'^9EWNVC6F[JG2"-V<EB=@JD!M5 [%
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MN1N2#=GQH-QQ.A[3.]&F8/XXF87LPW>KV'FFH%H7;TLO9%L.T8&4BAGJ..3
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M^#I7QH?CO4 9JQ%EK :T"?V/)^9ZCM'S@M*C;Y;AN4_/WXZ*1E.W=L5:=J9
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MM'=2E9UK&TF+KQ<HE"N-XZ)7+OL/3)?E^ED"T2Z)LI/HO-(.HV::-&3?;<5
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MW>/UKWB7T\6UIA;^R;E[^D[86YS%]5[W>G:,E,P:[N([;/A#VA9[/UD#R72
MS(CP3Q^L2.:8XR<VLAWO@H@#>K]>&+!1H/"ONK9M=JEIVB#7N#AJU,K5C_,4
M(__\UGSJW#U]^8,\W3VVGSKD\=O3\[?F0X=TV@1XNP,,+#9:*Y'V$]$J[_3W
MX@_M>]+Y^QV)"( )\S=O.J1]'WRO42HOV\U]0&)7<N;>=H@W8.2OD!)$V#L$
MK':F9\=NC_RM=\(5F*'SE8ZN';QXH-/QF($Y8%U<\]Y&I*0I!%\;PZ%QK"F%
MCIO^W[!6;WW[*6/VW($HR4[<.A1<>HR?;,+JY456[SPU'YY;R- 'X?4CPUC(
MWMYD^T/^[L-KQ:RR^C?Q[&Q?>(KR%B-4AHO!+7)O@ ?Q8%]N+V3ON*.+[X-W
M\"@>N,>%4KVHUO8F.F<<HJ[M@*]4 #NJ!T;LE?IQ[OV1'3)9WPO>6<"?KZCO
MV>$?'.-E$/Q%>%55<*I(CYGFB.HZO/K7"S7J9(7C#QC_HE;ALFRI$_63RO\A
M6M29VCD$5AJY&6'AB;WPV^PL#WO 7%S?W'VY^=;J_$%:#S>7B0S>J!^Z;%OW
ML%GO[G[0GL?71^P^<2;K(M0E[HCU,.2C$\,BAN>2WH!;,>^7+66I>[PC#VHK
MSOB/[WI&?YR<.>J5W3*'&*5<^?GC*S9'Z5$SF*EGC_;#.=DP!]X9YX 1PKL*
M\,S"C>U;GC.^L76V:)CPCC CQW[%]Z!Q>LM,^D8QA+1*MG+437<WC K]/+-3
MV\O=N6'D)V*&&J]#?[2"L*]H A.JOWJQ4*Q72Y5J-0&-U@BY\.\'VJYW'* H
M^XPH;.-$W(Q SAQ9AUI_ZPG,='$'@T-FR8W6T^:R7@H3?B^"KJGK#G/=X#]?
M#(MI%]=:M:162*GJ#4CSE5D^VJ".-UCTM'8VB>+%];-O *@U54UHGQ['1M_
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M)"4$E^JFM' $!%!BPGP9H3VPP;%D$PB&%')0W,3^E<!F%F(_<(> 8QC%"84
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M_@"JPD2/H<N $BP,\WCT!Z\"ENLX^SFRXPJWH1Y?39,H4!06T>!WL-&B8?G
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M_3FR5G!-.A'WI.^Z/B?+<IEH3,'DL^<Y@O (+9AYV"MD<MB.CC"+JT1/WK7
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MAGIV?/Y3!EPF.ARSM"X_\97+2RZ=^3VX"KHI;H(.O;(GZK&FI8LBQ%!<X#'
MO#3_P.7:T:8!LDQMS545AYEFNAM& @&8V7Q"_B(!@XF_QK>8.9V# 'LH_A?+
MF@@H<0B H(@B*T\"G- N[_FX1:@;""J'_+3%YK.,_IO,WU\@AZ&:/8Q"^S$8
M:XDA4RY74QDRL_[,G#$S:[VX*!NT&8.RX++>E>X[>#LDV(R7VKS=Q>\R=26A
MS0GD&%8X$2L#H:O=V!4V["-S>OR(_=17:#W<1[R%1]]AL""8/+R^ '*T?+E!
MX?4FSMK/\N838@74O80]\0XGGC8^_[S0U6@[X53,A=,!A=/*$UBK AF9BB9M
M'Z)I720B&P)F<S?ZE^"F8-=S^170_$I@<1VVN.=[=]T2R,IV"0TU;;L$OJ0;
M6-'9!EH.F)23V/D2:^)%UX4A[,. / J@;^R([3_4LA=]LR/=<O!+6,_$1U[:
MR7G>3T9IO]KF.>1I\6A.9@>&2"6U7IGUF%#!I$VME"M*N;2!(7)H !^Z%?FL
M'X7PO9(!OWL8)9>1>X+8C-_>'&+?R/^*)F>'AL#>@):%<"VF%:Y1CV_NYNDH
M-5(GLY5R>7VC>6FXX= "=X8;6FA',SE,AN/AA%(6G!!N_=V/$;/<] ?0RL<#
M_4,K@G]1Q^"! 2ELY?4EL(<</B-6*:=EE9!66QOD6D.I5[<\RW9HQMGWI:!R
M5OG%>(_[*>&K5+:.5Z;N=515:K4M*_5DJ\IK:%M6Y46;C=]0=W!OVF^11N-/
MC%\JUK&/HUWNJ?-[[E,?KQ=Q<1WE-=(#9B-]X#9B3-F-.(+?B&<+PVJ#;%,.
M2(G7DILH"[;Q\>:U9 3*=#,K%[N58F+&:"N0$35T+J H/S+G@BCKF3X**,,B
M]B2=@O=@SMQ[Z4;CTD?E]BXIK.3"W/8]+L_[\+;(Z@,Y?FCI>;!$4BV;1%+8
MBB6U]5]7*K4C"O!(%=M<A?19SI8!Y\<3_4Q]UTE<]#/@D+:U_6'+(^(3J32"
M((OD?'(6P=*-3RO&<=:C P:-,:+FMLH'\VIYW%0>(7Y\<=/JQO4X/-"'9OHC
M6.GWMC/1X4U+GSDDG;I+MZJH";+%4L939:HM#AW43^B_A>_BX(#-MQT>&+KB
MM[B9AL4NKF_@/X@F\L1<Q@-!SYZO&_Q>(GC#]:P_F^'V;O<J,OF_85U<MRSR
ME8Y)4=5J"H]OW=A#F/R8<+>=>Y">#9[C],HZ\F: STY)+UR^$R[?=EZH%=:A
MP+> 3W2_Y\4^Z\)6C2\#\G4BXPZI/FTT@FU(Z&CDV#\ _!XSQ^1O*U@S=35'
MJ%8Z=K/WEV\X8,H].G:/N6Y(6N#56_;*3'LTW.+^SF*MHJCJ8NJ#>^:K5A:?
MG5<C*U,+6O& *]-4-7YEAL5#HWR%.$T%(3!B\"F,.5;6KCPVV:K5"FHE6+G6
M..S*J\M6/G(,#!G;?-DATINZ;N#'P H3C+\9IDFZC.@^PRL?>Z"D*&P;L#$X
M$[8%;$P=1H;,XYLU8277\(*/J*XS_9)ST9#^X/UZ1" HN%+2Y8\LC&NX! ;@
MC,4#W3"%Y+R6Z/ >5WUWX1B3\T^BL5.[OZTU5U1*Y26;;X.JY^*L9_N.R\*[
M-2="[#(;E9&94.:"N-WS["[,&T!=WU 8=PU[-*"PB3WF<Q,'%BZ^BI@! 8QF
MAC,5OR(JFTQ(9R.>JUHL9$+V%4UCFN&Z?H=E?9Y?4S"'ML7B^\G@-;,XKD_-
M=A?LN:U*\&J)V#J6H3=26@GZ/*7;%7$<D=_ .KUACDM"_=O(MFZ$F/DZD3*?
M&;#F5Y9>!6C%^!U++-\NA?$X=VUOIEQZUO=":^J&AW?.[F+HS*Y_!FE^RWJ<
M'P.S1V)QCGU (V:!L-C$=H5FVR41DB2EZ,]*R'7>[,,*N=HR@V-#(2>-X;'@
M#?Z# E<X8XZ!XT/M5C@MUQ-<IA/L#R"Q,[!]%U;6>8.!IOIW S@?6&$K14U5
MJB>-9E&@LS&6O3=[*9H-7/V1X#G!E1Q\ATX"S95R77X#=%D!:2UU"O+9LWO?
M![8)IJQ[!QOLC1]LC_>=,&T7=G]YF6A6 =/*)8E.XG]^JA>UVD<B)B-I%/3B
MNFV1>]9UA+*K*C%" OG=9!@=H0!*T[3?"L!>=K\/M+->R-L 1$AW3 P/K7"=
M++=_BDN3!L4(<8N%8G6&>UJNZZ.(:?=A1D/;XIO,F0<H"S-H]^_YK-I6.YC3
M _.>@353Y1*"+P(C-6J:HL4QDLL?01'4XQ,""L",R#M1;H1[LF(/ED9G$^V!
MW1=#\A%]V(.>V .@!M\#VPKI,IF,F&WX1;YY6VQ+L5+;:%- P,!R+2;V06@5
MP%;?!UG$?C"G9TS#4CRI\.887H1[[%$81A_Y(*'I;!!/#/J>4-0Q([]K@C"9
M ',$HH6_>X5JF.]7,E4-"R1XY*\/(?:(+U_>P@9D\>,$2>7+V @*Z$@^?Z$$
MZ0LHEQ?09>3%L5T79F_W&--=D:W'[7&I\!:#G8:=Y3NYP)$*F0(QYGNPCX@E
M#_<T<U(HY U42V+-O/R\P#)NF,2U@^W!;TP%!%#E%3L,F:"4-XAF%RH+EZR(
MYD-53%9<+MX!ATK3Q*5T&0P *I6AG8,;/MDX_"6\!FHS<Z6QL8B8Z$"8M(M"
MTG!=>*>+J5666 JNV@5MU2:@&3CA.B8./6ZXY*7G+E=*Q9 9@X.662Q4O2PN
M7:AD5C[7W?_P+48J2H+H2M-#-^ [\TC(+X3CA4RL6O(.OX_L7E0_-CM?IY_P
MOVD?WPL!_OF2/('1.";WGY\4TK)ZE[/??(E\XY(\SLF;F1?/3IG+#HR)P:,<
M4!Q:+@,!):0@[ 5_#?Q70:%O(&MQL:0L4T #^BJ*?B,2=E%%^"-\[RH?(OXF
M*+6@5@MJ1;@'$[$C)/^,Y^ -)VN.C]H+,Q$L_X&MMZQ7,,GQV7_Z8,3J@F[\
M]JCTF4ET"F(= P6\*B>X[V+5#L3?LY;=#D2LNT?JM)UG#]-E?-6/S.%O3*9P
M5="WBS>N317N#%HG4R;BZR%P$9F.[;\(>X5C6CK^1[MA?O[D#;@>W.P7PQ7\
MSS427\0SZ_FHF9#G>SPKJC5*)06=02 $GN11%JR#)_XB4?5!.$7X6/#+/>"0
M/!=*Y-T]" /R8%^24JE4*!9KY6H5MN]M8(";CRQM.P9,F9J@ _KPJ#XU Y_O
M;O!5SVSD!4%B?H9(JW/&!UJ;%)? @%]YJIR GQ'Y7I@I+"N19&&77]$"-A2F
MUWV78Q;\W&#8P&J*7Y821#0BWW8GAZ3@>R!Q<#UB$?:L\+T,I&E@0 4B+;"=
MW!F9! 8:Z$9KK$QH8[A+QN3$#$5BEXD021<CB6/TU$%6P"[!HY/,M17BFGI\
M'D,A\D.)%Z ;2:ZS/M\5V)$G'P8H:Q6<Q- W7W@J?!/<2,<9M[X3FK\>'K$A
M_(B-&WM>;58'K?9AR_7$YP<RD(B(J':?2\0''Q^ 7_AK4(,S4!,=AUJNF.,6
M/EU)4>LQ5L\2A3HO(>;T.;IBH&M%VT^NNY/Z8O4$Z9%4V\EMQ: 1Z;.8$'??
M-M,J6O&RNEB(/O7B9&.!F<!.*82Z\,?_XUMS#OF\O(IS*Q>HS:4A:)DA2'<O
ME *[J6U<'35,75X]C0_RZ!*Z$=&#YGB^W^4 ^ Q:19\44RV))9(@7LKTIA>F
M4KN]?J64892Q&D09"WQ&)#II:6.,G4F<@@ME47S@#^$1>)4K2I)0OX,!+,[O
M@<$OA(TP[ET\NN!ZH)SQ^^$1Y!6"/<N&MZO[W:8NMHST/)C@*TI,3N2V6'XS
MV!S9^QV<_!U$.VFC6]W'<6,$HB37P^2TW)Z6J@RT/&3WXU,$SU[Z#@AS5M9;
MC'(*;T_A^9O7R%V8W.%>3T[ZTR5]SMRG3N$C96X9S]!?7+=CO$OJD2Z#)_C=
MBG:?WS4DR7T_AQMY]S<--3:,J]X-1Z8]9BSJ)L=$_81 ##YO3\G\.23Q%F'3
M>KFA-!*<HS\KI"1K\I/N5N\,\591$W=ZW@AO<]=>A<*9R^8(YI+$FQN7I5*.
M+3E&WCT>E]0%SIYMEDO^5>H5I:A5<HP>H_S3XJ^=W19O&<H_K7Q9VN#R!QD-
MV4/>8OJ;0X&ZNJ1L<4*BN]Q(?&8A*2M-<D2QF:&F Z1]X0G8S^.%Y&3SC3IZ
M\%:. ;=EB<ZBOV%=\39E G6EU%BLJY* QN<X\AY,Y,0W/&2.:W<C8*]2.@EU
M3>6RN,'-;N> KU-&=C'^V,$6QH^<$KM24RHQ!;\2T/@<1]Z#41]_F\D^<+UW
MB:U>:D?N'>PMS!WC'80[GOL'>_ /$E<GI@CM3 BYS9G.AM)HR,=,9SKR'@S[
MQ)=>[5U-A'#.4%/4XT[?2D#G<QPY*VP7)%C+.8Y\,O0[FC#NO>WTF2%=('=]
MT_Y#@S+#OO[O5JC2Q'W0]QU)"(#C.U-=NM41L6)M?>AWY8T!FV3"WN=(/PC2
M5P ]/E\H@\T8@_3MK<;:977Q2.1&>#\'>^ <>62%-M#B/7T)XLK9:@--4^K%
MQ88PN3HX,:BO0'J2JQA.2!UHZF5U\[NZ#Z$/=AR"WJ:N?:8[=[DR5^K.#Z5>
M7'^F)N]-1+W):=Y<V4DH =3$5[UG4K!XQ_^]3;5VI:*HM=RFRP[F698V[@>R
MNSECL$J[A+!-5O!=75],F\,SE\)1.RR^]G!79>-;2^%J257J]2WOGLQA?LQ2
M6-O-28>LI#!VZ]W2M971TM_W?:GGP*-KLF&GMMQS'#DG\<F/G)/XY$<^)Q++
M68(:=EH([AG@C>HB$;XK&79NH_O8#PW>O5SS7E$3MS=,[U[>32&QS5F'LEI5
M2J7-XWNE,_4LI3^AK&9^K'*MGQB+R(3I(0G/*LLP<BY*P[!'?/ YTTA=1J*T
M6"LKQ>IZ/.>B]$A$J9;Y><?=B=)$61"IC>H\U)9[</G(.8GSD7,2G]W(YT1B
M.4-M"QUB^=%[<HL7W]U3PR'\1C5^BT9XN\:+Z!5%].FM22->."E97"['\^EN
M]+'X4FKFI_EWTSMFSCGC'Z(,0!$0W"29,+*EYI$M24;.A5$NC&8#._''3R4X
M<+03852]K,C7;IM;@1^":[$^\#NXKA<NP5MZ*5Y&]P3\QW<]HS_^.#.]U?>!
MX7KYRC.^_VMRY<*H.W"F\UEM,,_8Q7,!^:X)QG2D&''V' GN1-R%"9J6:,PI
M*7X9 3(+78?1[P7:AY=<$6J^T;'[RW42DS]X&QM>?Z)DX"!T?^JT;RZN^:5M
M>)/ #3(J,,6G#Q1>A \NQT^&( 7D!=<2THGTB%Y-&'-I(6.-DJIFP"MK+OY#
M7.&<J$D,2Z0K<(:T:_L>67X!(%[2NZ200%QSN;_K_Q*?BLY:OOZ+N2A/+?WN
M!]X:S/2.C7^*U&KSSR:;=!17!RX1 %/6CU>9D3M8M')6A]567<(25K-$=EN&
M^]@.,>"&]^NDN%9'4_=)T@C+R$#2=!IS X;9RZ5%F_)+?D=5QCQTF*NIGMB0
M&OP>)31]T%[W0=-_,?J975.5C&0I]_G@^[?D/N==C7\<-XGE#)J:P,V7%X>]
M8!Z@!>QH6"[8LMS[SFE]<K3>U)[)J7R,5#[2VR!SBI^/#-\V27[PZ+\VFUC)
MB+ )+JF8:['4=-O]PR47(Z[;@R\&V$$K%BF3/^<P\JI4E5;</%>U&"HM[O8V
MH>YZ:'?70WLN3S5Q8"/^:X<YP^(,^ LNZUWIOH,W!6/CR+JVF/XY.('E&3G[
M7&H:@,8)W$H6 I=7QJ]%5HH6=%(6QDLU\@Z0M?2MFR&K*JDJG]B001)^8Y4.
M +VXKBA:K:&HFGRY^3,=>1^0KLD$Z4B48VOK-.E!XK-"U/$H\;JDN,RD!VU^
MR/A8+8!&YK#<PN.)P'+6 M#2F@!%I53D9H!T^$Q4GK>7<KPLBJF0WM0:$X?U
M[!<+7J&+.JD")S5 ; H'PG[@S^*DQUPQ59_\;3E6*QM>#\;QVK(P5&F\LD>3
M6G'GU/&A!4GZQ$S*:Y>>F LXQ#HF_F#']A!PZ;!8UNJ*UEA4X+QN;-6ZXR,4
M2XMII5MW156JU?+BNA$ >*;'&SB,D2$L<> 29ND F-FZ.;Y#N$P% .9B71DL
MS!Q?DI8%3XZ#C[P(#H>V;O0->!'^D87)AQ$J-0*;NW2SJ_/AH$ @P@97"EIY
MTPT6<HV+.%>HRZ_!Q+9I@Z"6E%IEL>O[##,1R@<EGKT26DN;/U0BT-ITY3C/
M%'9$Y5);7)0@:\^T7:S7 +'SG7E3.N)G#]35Z5_DAHX, "DB!Q^Q!3*T,D>0
M>DD>;*(;()X\/%\&_^OWX1U.N$UOS&$3T%P2%&FLWX>G\45+)=D;=5?N[J:=
M8H1@7-=98W^<JY64<GE1=:X56)M>-R+;NF-X:WM9E1!3-EAU?"1G4J7D,N<5
M 2_./I(WPS1)EQ$Z&CGV#UB#!^]?08_JD@!B"AK<^WA_1?!LFE8N E;%HJ+&
M7'YYF75Y]':O(I/_&Y:P<CYCQ7_AN3>P3?B.$+0%%$9<-MDZ,[E(\)&H('@!
MD9PZG)Q]/.+ZRH^X@IG#_O(-;QS0/Y1!AC<0CTXJT]\"YZQ @SPZ. 3^,+"6
M$D RBX+SV6U(4GP>?P=+DN+SWH#IOLG:_7CO-8I.] N$>S'=DCT5DXN]*>!3
M5]3W[/ /W-T2?Q'>1+V2JMS\+ L;DA\_.U"% \)6UF*&G+Z9T%>5E;X9=W0(
MR^VWG^B3X7XO]%'_&+B=H/&( QI/*F1&8#0;[-D$C(>HM"EE5IKPI^MX?WX%
M:W+H#S..*$^.RD;T,*+B'D#1"C#Q!)!8[@,^@DD)E $JP'P*P.OJ9;6T8!S^
M3 K+W?9*.;-;G\16T1_'L57:I9:L7FF3"/36//ESSO^9\']\P#/%*?KCXG_M
MLK184;*&_S-K.'!L_%^-NQ1&'OZ7\T+[\' R>;5-H)X)OKBDF4,YBC.RZ0I2
M2AP8V%L^/(XE0W#\:X*-#9FR5KU<?U-3JMSPSQ+@Y*01FOD=8)(BM'2Y:&%G
MB5 Y6Q!.Q+YI]!EYAX71[GM9P+W+8,?:*OA29E>0)C0UTU2)K&(%+'_75I2_
M5R[5^>H*#-$OWY#,;GE(:%#N>T.JD?YYT_, 4K#"V3)A?->>W?E[^V?"RF9,
MN&DB^?B8,.9,SN$Y07*G33=>#9U9.AD;S-2)##MVZG9Q?'A%5L_M-@#(IG'G
M[:[7S1TYB0";^<TR.6 WKUJ6KX+'L$:^-RV=F2WH>0U+2H):'@>K=+ ND%I4
MT/9_?JH7M=I'E[BP848?-L_RHC4YE]C? M]M1ZM1)]\"@\PSJ$E&?M<$0\?N
M]QDVMA<UCJ*H<<1 [2)^L$JH9P^'8:T8KRS2F0<6A6&!$NR.8X?HV@ U(NJ*
MX*L.PP2&>+>[\$K7!O5I6/CQ*]8IA1."=3S[71>6CU\.%K/5Y(WYN?MNV-$_
M56TG?LAO!R Z3%P4USGQN6B7X(0F.\)+ZW"QB(%OE\_P78=1%RPR J:9[\ B
M\2L>?U 7NQ(,Q0NTP)##A\;\,W>N" ]V#*89;!B;B38$;YR?].Q#L$TS$W4-
MD$NBD'G(O('-J45[/=O1J07;-"D9>[Z[(<\>[?=)$S[UL7'J"_GLFR:#G\B#
M#135U!JO3=0T=6[H:1 <)Q!6K450-#" B@Z*BIEG(ZU188]&#*C?XW#$'?0&
ML&+<>8$7V!SZ2@V3EV#!E.#!KF$%9;3A*N;!# /V?%[?&1T7T )+[S)<XN3E
MGD-UK-R5N82P:9HS!7QAG>!DF7,(F:L9!!%;8(&>FAR9P!U^819SJ F[ "K/
M!5JQ$*SXOH41XV[8P&K%X-4N+ZOG '[E[!\IJQ<<+( /O\*D#)"F.*IO<LC1
M%^ _E)2ND N^]<H;PDX&-& V3!<(L"S6FP7 ].ODS?9!.($6M+'6M8=P!S1+
M1^&+ZP<;"WV#VN- W$6KRF,N,4E>1"PX-=S^ =57Y$"KQ95GN0(#YL^Y0NEO
M(-;=I^=O\=9.('GY0Y'SV5N<7M J2K6^F![A*UZQ-FUE";,D:XL[D\$_0DY9
M ,E,ZVC^2*)*<F7=5B7/LJ7:MM0&\!VO>6Y9,);/>;P-O.!T!M2:Z1T=]N;?
M&QT"";41?X((763/30^_+2)BY?FW:O)RL(T(N^_3%0#H<F6)!%BU_.35,%(O
M?Q>'2V33B5&N"/P&$_D#3[+@@0>PHGDH%A&_XMQ*;"\'K5;0U$*QDNQ$VD38
M<V^$/QW(?2$LGH(YW=N..-S2 @,%C8TMQ$^MHL:>;XD(H1GG",EO!,/"V_3@
M ! NE32' @=(>$0A-X;Y,LADU0273=[A=]!T+JH?^5?QK_QW[>/[R^5!]NJ&
MJ;]$9P CVSV[S[?,[3D&E_<")A;OBX%[$NS.!"4SVX+>+YZL0'^CQ]$$7@ Z
M;L*=U-2B4BFKDQVVR#^HY5-PZ@3GJ'P#@P<;C?K2!P6+\2-6X0!SXT:_PH_R
M4&!0^"]\N8@<;/LO _RE%KKH"RN<>(G:I?HS_EV8OF$#Q>GS40MABIV0L68P
M) P([J</ATPWA#\Z0O^??_T6?N"O+6F7"SF8O]MO8.L[RHJ(PI B_^I^3S@I
M=(A.YF3(<*?0.X69C2@&EL"E<0CF.826]%!H1D^UB05-O4*DMW!^ICPP/YD)
ML.,M)D3)"@V2H ='4GF2V@H2?6""$TYN,UP]R!]^^] VYX*K5:4N_[$Z8'N.
M!-^*V$LS-E+/QM"-T+W()K-- I _%RRGF;B%QUW&R-NI&YRI<[.\@86L/@67
MV%I;?@KN6V2+HC"[@0UZL /76IPN/_ZC;X<L#!)GNZ3(C>R^=4PV&9;RRFC#
MC#$P2:Z(<\SQHA/P_*\(GA?A[OW!8*20'40+3!TEZ;V!*9$_,*&>]D"RHI:*
M2K&X/I^29^(#=BE*RBZGE,0LK^RTO',6^]WP!H;5>;.1M=(?]E>T<DW1*AO4
MF\K(6_M4125)$'[2O!7?YV?/O(7QGJVXJU9O*/5CYZU]ZJVR) @_:=Y:V;!Z
M3[QU;_O.5JQ5;&A*L7;DK+5/M561!.#).E%(P',9],I(P(PK>WSOBQF-U^WT
MG*8I56W]H;J5Y6XR\N>>5)^ #/K+/+!SJ59&WK3SB8C'3>-GB\&X^8C:ZBM(
M96'Y$C"4;OM=DZ6K>5P73EDW7$8,O+*C^7SP,"D/S\0.D?[K&#DMYY9 B185
M35M_1\0\\Y8.Q;SKZEL_S%U=GNDT5D=JET=FM[SA.NR9,>H.G.E\TE_UV\7*
MVHA*(YV[?W<*K8?;NX>..!H5UV0#FYDDNLX^W/!?1O2%%;H.H]\+M \ON2+4
M?*-C]Y?K)!(Y>!O>>4\).&, VI\Z[9N+:QY.%\DV"\OIW$\?*+P('UR.DVPO
M=H\BC(L#_,.?C#5*JKHU\A<KH],4L41R-%@'."E.%#F9_Y^]=VUNVTK:1?\*
M*A//ELZ M$CJ:L],E2S;B=[$L;?LF9Q]OIP"25!"# (,+I*97[_[Z5XW7$A1
MMB23-M^J=V*1Q,*Z].KKT]VS,AM=(2HX0[QN*;;EL%Z'_,L33); .E3]2H/N
M>)7/9I^MF #,TA+J7PYF.:RW _CR_(3'6N_ /SEN\O)[JH^Z%#,B >2EB)%Z
MGE(;8J2RE>\4C:X'<(2X]U+@R *@R+)[MP3X<?0EY3@6;]Q7P7\<P%:_#?Y!
M/]H_.?DRZ >C/7*;'&&A(+>B/?:Z!P;MH6C9P7<TGGL(I(=(&/G?]0%]W)&D
M/P?Z<;0<&WUG^C8=^)HPCOO@ X<#_ZBE&/H#@M_OO<'$ IU"".)6S<(B-AZK
MS/%JI8U7;D&Q&-2QDH5V2FL?\;_>3JP-)L!H6&?Y1D,]ME6./Z<*[N%C5,'E
MD)3W1F[9*]RRY;Z>K^U3VY+2.A=4WA;,_K;/=P,+9C]"+.S];=H-:<SI+,P"
M3IE4'RIHZM?WI==\W<NJYWYKH?'MIJ]UL.R1@MFU8!DB9?!>L*T!#\&8S.8X
MG0'1OPY;N$&8X8/5J[0[*7R\\Z?)^*7==^71O$MJQF?#0 X._-YQ;^U@(&OU
MYK4EN-7+@J\/P9T,_-X*6(>U9M5?!]< 5OV3%,-@3AV,IU$2D88:(,BP7G=G
M"T^2&]I><7F92% G3!?TM'*^CWA'>W1'3WJW-[U>!SS2EMC7A]C;(V[+Q-$Z
M$/M1SS\8W Z$70=BWQ![@A%7:WU%OQ'LW,I5O!_V"NWOG_A[)\<; 8';$N-#
M$>/*U:P?F!@/]_W#EK;.ZTB,7Q^/N2@4?+QR2>3&:1KTR"L4V%L8RO74FL+Q
M::'0?R?'P[!_? _[K'WX1Y5*GS*?JD]_C>I&O$V\TUD6Q=ZQ8#XJT!6/PQ-<
M6K!(O<"+HY$@"71)P4J!G%_5MZ?Z6UTH1VH1OIO0Y#(?)7:ZWHYZ1C[4/_0!
M2@'2@]'Q=!U&E1J67C#BXK%C+_PTBLL<97IVHH3^J>N]T5,R(KTSS>(Q7:T0
MR"*9. ?QF:?P+S/EE?"U]]%'5=IR0E>WS$(I"0>44)B-(N)'?Z$HY#@H2(/-
MHR%][<U2P%A][X;X7H<^1_0A' .#1YR-?D-O&P.G%"57T3 J&'.!DJ6T_2%-
MX=WYX!=^R?3#VPO?8C*R,"BF// X"BZ3-(^D0,<LX^*1JC1H$,?T?0ZT$$KD
M.ON&01IG43U7&C&E3;G42-.2?FJ7RA#!($\3WC!2Y]),=DSM$\\F#\./]+-+
M%-E,L[D4;;VFU6(=M,J81D!96=2Q3<?EJ$"$!G- Q3"NMZ1*7A)U35H'XDD6
M :K;^ES2LW(6>4G$<>O0E8EP"5NICTK#3X,_:*92(;?K5A]9H]OI GYF0316
MU$VTMP0'6Z_3;7%9^YV]8V,%U5BFZNG J"UY"UU4]T-%4H:B6A!<_YE-B,D5
MK\-5@5J=@YH@U96X#RO=92QHDW8LQFI+>9,W"4/Z-X<!PU&I[T;K#0 ]5!E,
MD'A2/]'C,D'N95$E50T_6;K?"W%P7[3?,C6>V8(];X'3<C'TA][\"IZRM<:P
M@ZT4S&(#B:DV>"G"\+#>W.Y1*+EE5P5#>,Y3_@((XH LEOV]!54:L1-.;>;A
M7%IR0+#]2*=A-I^^6$*+>U]CQP2=+"7'WZ'4^+LPXS4O+KM/Y/;.(#/WNX-F
M+,BO%#)7%<Q)[-EBZ+=1WJT%SRN*3W>15GK86UAU:M#9.]%:Z4/OKP/R?CLY
M(\N)!*,33#E-8,<H^?@FBD/:@B04Y;-6.S*7"M"J$C\SN6GP,02%R5,D:N92
M,-KR/V:RP>@JHE<R-T7!19F%&[RM*4W.F*R[Y#X-I%BO+<Z'-);!8,\2>=T:
MZ7JGXW$D<AO%>EU5AK'E-&$]T2)BC35+YT',9>=!#D$LS,I1X* :S&B6-*O@
M$A#Y(+D$I9%<F?(+XO2&MR8:=XJ03L=7"BD W$/6*O\(1X6H15!"N) :E)_P
MTRS*3 EWTF0BMI&C*0TA<.^<]$*+S(ZR<0= [[G6KT5UX0KD1(B,=BEX]5W2
M<&@EN4=Z:QSA85T[?.PO$'J\/3PC)2A5%7UGAM D9;OF6BN4O@O< $!],6.8
M;&4X$(3'A?&S>6<X[ZA_HL0]T9AY&?@9<_Z=8-?K]1G(KI'(NCBP[@DPB3+2
MU1SZP<FQU*AI>_RW>J'O[0QW%ZW+ZI5T,O2:P-@.4FZ_,A(?7^55]/?.:-?.
MD5=E#9.*O4!*M,\3]J61@XS&"\B\:#HC+=K,;=EZ5)GV)"423"YIG"B9H(PR
MC3LL"V,G:&-,UT)7.G"+YA^X1"A,5#U,1D7 E>W9*MH$+?@*5MZ5,N/8VM%7
M8,$%P':-D)N;1"'G0^ $3_;H..>Y$AN0+O2KFRPJ:#-HXPL:I:L9"NX[?51[
M4;#H!5WO580:W!4F13]Q1KMMRI'(MI2'$<X0H=$)^F30-:1K@>1,A9QARE%_
MTZ\PTU$)#GC#50*DY<6,Q#!WO,!7ZBYS2X) \57?"[]XUFZ# Y"X>6F4Y&E,
M'X_F2@K0)]?TB;[]SD+7KJ[F*8E*OZ$L+/>2I)!N;"*/I*W) G\)?K? 67*>
M)&0#%V5.&ST)O?<CIBWZ*Y3,IM<D/+QSW_OU':[WRS!&=P3PA"E;P-A+DA[Y
M530SKA8SI/6V0.4D/@RJ0G3_4@MP/F"D@Q"CCB/I-9%X.MW"ZW5[^$D6%FF;
MQ\:\B%\0J)%\OKJ\$U;ET!H$:(OW+:^U^=%4994%.H9D%,TP7Y,Z)3K%,K5X
M8;[_[6I;W2[XE9@R>A#B^/)WP1Q.DGNPN/I+32Z7;O!RC]_N5*)>LVL#^@2=
M*C5=Y/JR UI84655O?H#B4$BT$<]L][2,RMD1EXZ(C:0R1VJFAR5_%Q6K4BQ
M#$D#8]\A-,LLN!$]BWA)BINIQUR:^;VWL"CSJKOYGE_W-?;T%K?/8BO$F!K$
M=ZQ3>!J&A98SM/=3Y)6BS>4LC2"(4&O<"K[7IV<?.MR(@O_5)XTI2KA%4P&Q
MJ^LDCT*RPYCO)$[1Y(2,RE&0LUHW(B;'@QO_XS+_47N+VCO;E_4#NH"P+4.5
MZH:7&KOP#3>^JOY@]7HD2X]O;]GY&>/*I*>RG%1*?IM!'XJ#SK81N\NE8=MJ
MU3MS\L4<"&];SRO#(K3]V@3&LEYP@]@:HZ.J/_B.DX<'K7>$-?1[OR<+FRI\
MCA_F]M/Z*O?G:.EAWLO]63==P>JZ%>/.!U%P"9186IK1!ZA&X_U/F825\@)H
MS1>K?&9<^"!)(D3@P.MU-*"B:ZMP4@( @E(>^[9KA%M!H$W;A%\!MS@7)8PT
MV;&;9E]]E1@%J[O+L>B@T?JQT@.13*=R&GHWC,-"%0]:!NGN35]IV[ML=Q1\
M>]!!CS\\1.:P]O$H$\.X;U"KS/E5>X4$<;_48S#5K7"5V#/>_1P_OL ZC"HK
M.(6'ZW[Z?=>"&FQK02VO!75_:)"%X82%]0Z^3-W3RL7+<%@T*L(XSG] "(K8
M,<)U9]=.FN!*:]^_\(@H*^:T^D^J2(0/Y5@X)E !\PZ?M:X@$5GM .9#I)J+
MH-UO6(CB9HU7T=VX]:OI33N))L55&__6C7(GRJYD9ZPI+3,,@\PVJ&4.RNUH
M#=O,I2T6/-#2#C0T3NEH%_V%B9^B3S3] DUU)]Q15SM4*TQLEUW"$3TUZ/8/
MGOC>+";!!0?T0?=H[\FR2 7+,6??^]VC)W9]3G==N$UFHAW2%YV/$0+7XELA
M<8"&IZ-15LK/C'SB(T#-)^X B,!XKI0X^J%T19H0E^-NKXB:ZQTON>J'^*Q8
MQ/F"-*!=U *%@11T-M 1^=&)M^_4W6D.P>$-U9RWTML7FZ=C%U%%0$&4T)IS
M%7I!D:4VMZ\TK,$6RN_-S_G4T4T51UD-+HCSH86H^#FU2%\U3)7HD0PN[MVP
M'AS:8QG6ZSWW^D]L/]^;JS!15J9Y5ASY;/\W0EKKIH5]:%%=<M$;)1P=2*?=
ML*CK,6C0K31Y;8Z9GK@W:?:1C0@5?)V5V2S5$2XPD5)9"W4]1?7?]89H:HV0
MEPI7,F\2VJC-%CR5. ^I4V6. E,94$PS@+P2B;OD*LZ.?E+2D)ICE<11 XY,
M.A$].\0HR*Y%)11 F+I2.5^'A&-49@BW=E\<T73'[/P5MPW=/-#C31A?FXH[
MF1@0:T<+Y\U.PAQ?F%2]>I:7-]!E;G"9H1[XAU7T WT,%9WP=_G,N#7YFNLJ
M54%K-:];U6DC OH.QVK3ZL5DC<-KS,JL3#,WQF+8#O&DZ6:C*%<]VC5SUM1?
M:3=.C,A*FHU6W[7@:\%EW/>[NMYKM43E]Q2G@N/-05P_;CN,%4^A]I#>49$5
MQF/DK'AMCVT!T=+7PB;UK=+ !;WRL0K@!_D58PHD;,^R/C._8AU$-V#$VWI[
M_\S+V;^+JW\^Q7_;Q&HPF\712"K1.>K: B!86^-.N4[,<M3L67%UIJ2=3"20
MTE'$3+=VHEB$R]&57CK+4@3BQ>$5C%%;3=3= ,*.H[G$[71$7KU=^4RV-8H?
MS"[=W]JE]R*Y=0["/U'J1!]N4 27)B]G'.6S.)@_(QHGC23\@2W3J$]"_\.K
M-S*3?M>M:?DF2()+$Z)F=O8RRDE#8N<-+N(IW:4YF ?MVVNC%IUI"U#WV2UC
M41W?2ID>4LB(A] T_[VFR1&5',,]LO90UOG_I"5Q+M;KB?B$"5ES8US=F,#9
MF+3,*CJCNSF9W9S4; YQK<N0;3E6P/!\F03E.))V I@6:]EF3&YDK)B9\<&+
M0IJD#(B?S<CXPCS%6WE./Y?=XJ:[[X*L\,Z%B].<_W=)?X<9R9N+$"P3XH*D
M\I1$0.=_0V^CWRC%K?Y3&Y=^GTY#:^.*=UPZ("2"[!<KFX9:N'69PY?#. ]O
M@#PPC]5?[48NW!?R'JKBR) 'V$X4/I6]X@S@\%( 8/C*F!WX%M6DV'*W>ZU.
MS'?L@31#X?].G*9L\3BGP5D? GF!;SO_F"NWM1)*XI:O4-9U1 3IJ,87])3W
M.A@5::;58[UCLH>8]&F20-EM'M<O1O4 ^$X5^G1JVOJJ>#2-\^H3YZIX)R?=
M?;U/9PA?DPRN#7S<^<6G+8D5UHC'?__JK!'FECV\]>0D<<2E Z(;!9N#'2Z+
ME\T<\3:- N2M 'YG3X0#@!'#[S1:BMY@XB;Z5V-VD W5WC$\+XZL?K_D,&N4
MN\+M[WHN.]V<:K-:EKR]1E55>G*3^/3OH@$&)CS9R8'S]881L<+159+&Z247
M@6:+%<E,K$^G=-F+4''/F#1;45 1:@-"C6XJ:("H!+ G\8VQ[^XR,UU>@@0$
MH%*WBFCD[9R]_+2K67(6S,*2/[V@#PW?8:J.0[$I<KEUKW[-Z4"BP*/GP:L*
M<+.N\SE0MDGT9PF;(%#!;R:ZOV3N>L)>44X!4B3MD.]'A)VB,^;=1/K^K'65
M<?01(W.?FB2<$%.0:\3I:Z%>C0K)LV,9DX!Q7YTZ^U]G?,6#\77@A)+Q?CJW
M:!18]'000Z[J-#"\IN5];\NLLIEF'X&RYH2V(N(L,3,3H[O(C@&3*(F ')^S
M&P0"8=)P]@F,L:,0L[Y;KDQE +)C&H8C$6&'=2ZPE&'H?M!<A9PY9_N)I1N0
MJ%1G,,Y@5#5V<@1J4Y/J>D3BPS!&3%\8JD.'^#%K79_LUBAW^Z=HBHUA@4S$
M"HQSA=@TH;'+55FC)B61[-)DS/FT GNM4LRZA99;&0-(!T9@%H4%C%:[<N?*
MFDV(E-L9OH9Z@N08F%C#2FX4P[DQV2ETKB6[.O4&&1JDR\G<9L&U=""[([K8
M"928F'_'E> 9-T$D!2)A%M087YV+U@)KM*>X#>A33I9(IZC=X;(Z(\,3;JY2
M$KD\\5R5LL]GJ?AR@\:+?,;[TE_:?3#WV#P,.)<U2LL<G,N:\-,T#J7:_;04
MGVW7>S$WTQ!'<I5)528D@R?ND/ CXT3U@ RAOPKHSC0W%F@+3@L(H#N,KOB,
MJDL2=A.Q D%4HQR<DM_KM]Q64AWU*4BFJ6)RCA]D988W4FH8QE9; C8"(S@7
MW&YZ3>H][+YEF\2+K_"9W/*Q6)\H)U>#,YJKSSK>53G%JF;T?MX[DAXW]+$H
M9PSYF>$?_4X"M"XG:/_\ZJ*_ZWM3..)'5W-ZJD//T]KBB$%#I(.+):0&V1EU
MWKSZL,N1QAE-?$;$&HWG),93^F$:>P-$Q)#V[.T@A7JW]8PVAQFUL%X00C3F
M"(6C ;/P9"4FA7!@[Z!&;IF+8YD8[8!6W%N_-JK"A'0.G##T%\V+)/$:N-,D
MF)%58ESD]?N$$"2'6+AE18,3,<UUO?^PKL3R5;\MU_GL^8+IL;(A<S1I0O.$
MMGG4N+$1$&L?D_2&^UCP:["E0<R!/>9V*A$HE&]I@^-H$NI<(23]D(I['<2T
M9W(S<'FUE.?0W@CPJ9%B%^[P:F3V 5^1O@]Q +ZMF0D[$O6T*B_VB0>34,$Y
M:UZ$)*5YKB<[)@,Z LJKN>LB99"NPK+I)@P^LHC*G!B4;)D=K39U.\7;) ER
M#-H."8R05I2$$I!-5;XJZ\10A6.ZE;:(@:NZ%B1\<J9C;(#H+YR\H)CTG/A%
M0(?"9I5SZFVSC\2-[;*\)9*6]"8<9U";#!TV"?/".8KFFV0;(.01T0W<M9G(
M4KLD5OJ<4]%@(]C3[]J-SMJ[OH4M2KS5@^OJ/* C8H^S(=(0;3X;U'0K8K&^
M52[054!G,&).SMXR-JO"7%WF&^4ED?9!;?8&8RT<Q13-4A5BM6^ JIF"[=T$
MK.Z'=/]+G=\43DCY"D9S!;"<A(6.;^2AH\,3[=F7YQKA8=_[@7]O!#%>J3*T
ML!_QO )<9L0L:_-X:)R5ES8>@Z>TT&=;C\6Q>RU!Q1M!51],G U+Q!491PP.
M42JT8KOBP>.*'=R:*E^U_$H^!51!;4R]!(MO"ICJE*V,]*&$55%%77*,W$'-
MU&K!B&=LR/5H)BFD--]Y6\,EF-)KH7S)(_B2:"28SD=$(SLH\;++&7?B&I,D
M,EJPY@=.29O+.!W2E!=G54=_"9>TI6S<O&;Q[;85ZVF6X8'^8:!'-$]WG!N&
M%]'-XV@G(V]O0G8\ETSD1.]%.9Y+CG,&95YVHU4;0T@OKAQMU>KD)T\U1Q=2
M7J <!=+"J'3U%->@,Y9],$S+PKK!L;5TJ^5HV;>KSV^A1T,6.$D%I$*DX>Z/
M(BEZ[(K>1[L#]TUL1NTHA^^X36318&)9"[M;MF^AX4MCY7J8$F\MQ,XGSAQR
M[BK?I'R>A!E,4=97TNF0"4NB!Y+CTK+0G^R2C-32:#L#[7=ID?;Z,@NFXD^8
MI*.RQ4U >V"-#X:/P'-(6HPU$6;0YME >'7Q#]+V8288J\'70F8,C6A*!PL/
M+.D RM@1L>J"[9;.-5<A[9D!X)EYJXUA_:"8S\*:MS[PKHCF^ 7V&&EI5R0S
M?*/:A<F8M!@6*[XVPL1^R5)V'>L)WS=W_KZ#Q@?;H/%#R>CW597/O5-</V"A
MX[/A:X(26+FU/CN6J\+<1#A;^#U *5X"%"D:JL,[KX-#>,!ZT*6*6=-S#LU.
M*IFUN9OE_AL%4U<$:..4+^:*J:JLJ(:GO^H54B]U11,FP)S:G87$SI:ZARWK
ML>8<[P$66_$&L4ZAO<)*GS(Q F&YJ?9:3=G?)-Y&Y+L@X)5..B,\,^'2:  M
M!UD\[[#D@0VIHRCN@3KJ+D3V92JUVV 2Q@&<:1_#.5%='.J(V;2,BV@6NP*#
MG5\!X[I<Z* LO_UM0/QJQ2.7&BZBH$>9+HQ'MI[!+BI1X*M=N??VAK>SXOKX
M(B>*9V)ORF<"+ZM\Q$/J3^JM!@'AZ%Q5'OI"WEZI4[M?;8USEQ*W^XWZKO7"
MSU7<"O J[F&HW<_GTV$:\^N.!\\-8*3YUM:7_2H1-9L W*(F.BQ'N]TX)K0@
M@@9,&^-B[]I%;[7-^_I[)KZZ%J.Z$C9LB1(ZH0!QA<@MK@F$;W7;7EK3)N =
M:HT<J/R%AE T^_FM;L\;"3PZ-W$8#"4;A>MR%:QKM)4!Y709+MG6&LNRHG03
ME"W/_#^T+.B2]IJ]K!G\N';OM &CU,FU=^Z\99B;)-P$\5QW^>8"5,:&;8VD
MY@B7-CT#6@]4*0;F<]B+WCNQQ*SGX .&:5$YE9(&M>HFY=7DY; C!A_17\7X
MK-U,I8?=$FS!K^&C$S>RXUEAT[$HQU#I\BO4E,-X3-UT(P30W3OHJ/SC91,Q
M++<:ON2-:/$QY'3?V"^8:L^$.#)(">.W& .\^A;E)#^%UBUH*5\Y)*MSJ\X&
M.&_9X;'\CCW>26ULSK]AW^TP7"PX& B!%)T.+ZU%->:01W419CK&B9J. P%)
M\ 2ETS6?B"JB[/H,E$?X=F^P.J*V247UU9HI&;]PBYFSF(P?+BOH2Y!B5<N<
M+WT%/L9:J; !E;I1B[,T19_>:6SA.)R%S%"\4>=-6+31-6=AF1IBCF>3MM*3
M'7$>T]2^Z'*[@:$[W5FZL)W^P>=>VH6K$^\38(8=_BPP=.->^,8Z=:3!S+J\
MO&1\!S,O]F42OV.LU\HSEGP1Y*0Z][,*!PB416SJ&CIS8T;/RS3.]WS-,MT6
M2C!)-;H#Y;(']QZISO'R>B! B8::F-LB!S..3%DQ.E:9AXEBD1S)TK"B*5<P
M88BM@ZZQ9T]2;1$ D-=JSU2<V1J<HB/5$N!E\E-SE^=,!'LC0E6_B\@0VE<>
M=1,#A$!1RZ0O.:6\IJ.\@:.CT\K=V3WL_/*=\'QQ6/"%36@^*@V6;U>5&MF/
M 0"[#;V'#'UR4@Y>_?3ZXBG184^\Z_R_ ]]C?(W@&)F.DG0<>LNB%5S4EGTH
M%6N8:6FJ?/I$8!L3T];0A''=KYD:Y;7EZM? 573% 9K7-5,Y7L2_=:!9@=$T
M#>=="-'B<Q>$%M^:-GF!(UN@[E5!YB(,)A%GW]6D0<!/@PD 5+32Y&I O]N$
MP*ML^**=_:M)_L9>15)[_;V]/=((IPS(X-P$XG["9:IS\24S $X]O3VYQVF+
MS'T"[P#U#8@(.SR*AO.H<@I<OT#7QD0NOR TZZ:D&.>Y/5).5\ K.&79W;8R
M(09*IZO2W)TB6DUK/V\C'^,S52]C?;O-J>S7%,9%]*C37H5?B?OT*HQG"[$4
M.G;:ZI16:2^2NVZB>LYRF$6-4(TBE-((-H2FE_2[+MO!-\WD1BA:7S@M"=MR
M7=)AJOJY(V.HIJO3S!G/Q9=P,_@.EUWG:E$N*;%C&I2L.(H;)!<&4CM\]X2U
MU:6H0$#!(0.H*LBOB]/WKK(H2WU9#29,JK_26>TFPPFR[>+T]=,WKWYY^NKB
M%R- GI[^\N$I  XZ,(JTJ!PA7]:599Z8EC<@G7E?#%T *M2<NP#FM-,",T&U
M'TAC0_$,^/L%&^-TT\'4K4*DYZ$I\>?T!HY@<2%8Y"UK78&JW!Z0PG69RT!V
MW_1(S&_XZ$@+HM.%*A;/&=D4C4C*Z_!3%8ZS"$0-^E]\/$H,.&S(7#3F6QIT
MQO3A LSXV(-E(Y-NAHH<.)YIP"0(U%4HB53PC"#L ZW10K;,#B L1-=;.73T
M7NM97H2(RYJ>2E+L%_3NH"<P%P<W*L&A*6+HS,DMTE4'BY;M$=B^@R(7C+DI
M8;X .^)FS.1EI+L?)?36RUBT-U$./BG'Y*VG).:HB]QOB!57.HZ"F0X6,U]E
M8V$S8%MO 42M*4Q\GV@ [(SPIMQJ5ZRB6O699"0NC\HI-&#VN@KLFEE-3+L"
MYBS7C96/Z;.T8C TT8TK'&6MM.+O&_5QN$5]/-05=QH"F-S?&F0;5+_,M=&\
MLLP&!'OE]I"K#^PJ,U)4K@HL5N-;M_V-\NQ"LP207#)RXQ*:B\%@?8S&23B7
M"TWT-AZ'F54[3G7&#1* DVLH+)>Z.YQ"WY+,LUC=X#J(8IUH:1+W\O"6F;(3
MVFY ')2)M \!.-,Q' 02STD714 &&]?=XJ(LDN_!O/83*I+=J"8J JI4)4ET
MZ,2(8%?W<-Z#R3:FZ(A-O(RULP;>U&!MHDHW0#<*PG+>27K2O'&6SK2>:1#/
M;$:TX&P4ZKQJ ;#.A,;="7+N? -C_0U'742J.M>[<AJHVJ[<667BPK[K%L0R
M)S^+*#L!FK9NJ; 8(03R6^3S3T(]:HWNI2H.8V8LO%Q9.+F;.ML"P^+56;IK
M->0,I>J34/F^HI8YN5[ WC<-30G)1-GMV6E-0:[RBW(E9FMNIS:16N;M62@,
MQ:@X3<7!(5=&Q7?<K7"929J,@#Q%EG#+&Q,)V/&M1M9)37^/$E7M4OI'*J_?
M2NYSYH3R%!_4(@> 5W$RLB)N?$GN%5[II<U,/U7>?D&XT+_=Q<2>2O.KZM%U
M5^48NJY&%50B%&[O67B+:X"U2,8%BZK>!ODU&+"6"VK*5'#B&?("],437PAW
M5GEY:K$'C'5LN5>;H; [:K8!0BMK_ME74$JW^+='1]W\C 9W,Q*@7+2-QCC:
M?VX*MQ$?#K,_PB)H?MG4\@0'NAS]^0K6$-\4G3:#N\;<Q,#^V5PFC>8FD7PO
M1Z1S1LH'-_<ITYGW5@4S8DC+M18.R _BM?_H?JMPJO]&?S%^M_U<_]\@_IAF
MT2KGN@*H5[^+<ZZ"!*B,2CZ5?2%^4?/Y^W**^K@KV4?UL[;'S*?>/.NJ!RU)
MDX[D>C$N$YJ_<883$;#TL_'.1FF!_)LE#K),,^@T[<3Q&VHN)9_NB3CTNUJ/
MWKWH6E'W3G]RIU'Y#:OO+]P*/9I2U%O8O_3(5.+.]-9W,]=9M%G?*KWI#<*Q
MO@[R.!V'GYB:7EW\X^F=*4J/X'N!3<5L22 ;H]@--Y9S2>@4*N?_1T)E%'SS
M^RU;W)$M7D5";X)C2E"QNO;8>16P=Z8U_@\F"/A.5<,I&[#U#\J">B_)X.\T
M6\"V?=!!3:>FV=H!;&4K5%.RZM*QKE?:>?'*<5P8?<H8SZQ_?=#&T =M#*WA
M>BM6S&#0/3J8%:8(08L[Z+?WIR_>,=<QJUXUC[^Y3:R&^)[1F+T=8B1Y4?Y%
M,FFXZZK+WLZ,;J7Z0O2?T54X32TB_7. H)+S+$O*0?-<DEA*09$84JJSK5QN
M'99IID,Q[#C2*K;V[2A7FR\13IWPBN)&J'FO@/?ES%K3>50@D2Q,4)7!187Y
M*M,]D8P::WX'1:"GSM4< EYD'LZ"3,"25>^="UFR^^WNL"Y7*0G8)%<3N D8
M'R740"> @)Y.)U@)%MZL"V'>8S>.!S>53(HK6\.Z\EM#-FJHCBZ[@EFBTHD$
MP60,N#GX!8S14/EM"\ZC'(&;3<I8[7\]G=JW'0UYR# 9<RM#]F2H$QJY+]>+
MXRHIN'MT''2$":=/2\G><)B52(DRG6TSY [2__2// M"9;)@-V@$"BP4SA%O
M4"R*7R0.36?RF>KM[2!A:>,YG@UP;68"B>(B5WY+H2:R*2XCJ?^@"&;<]5[H
MPN[\&UO8;R8)!AIWD#LOK<\G%]CYA*G!+84W\<[>_O?\9:=W4@M;*+ ,0P:B
MJ:XC*JQ/XU#0.5(^$7P3?=3G Y'6*;KV:!5'G !2J/I!<"=>QR.L_>P6"\K^
M]8JM*SBQ9&$^@$E6IUTWT+1QN[O77XKR6E03;=V:-K>+$1G^%$42TIE3L4=N
M!YU(D9*(416-5+.',$YOUA.&WQ89U3I3N\+P7JW[P8JXWLD!J+XG??;9W_;X
M_YQ L/J2RYLL_GJ8%D4Z7?P]_(,MW]Z/>U"%LB_.?_KYPS-OX5L.;W4"KEZ&
M]YWJ7ON6>QJ0350]R58GY,'G3T E<GQ8$B1+PA0=%+CY!',=\?T9OD'\TC5*
M5@M@U%,='%ZV<KC^*Y[2>TC)I^]%95MPU^XPFC2P6'1I5Q_HE583OGBD\UJ@
M_#2;/BPAVBD(G%[XG<<]YMP [2*3X*X+/=A?V?6]TS]D'T?_F*ALU[OKFZ"F
M2K5 %>7B>GE*;P^]G?GLP][3#R21YK/?]NX^_.E9YX/W#V+_QHRAO]X9TZ5V
MF];<(: :<J]H!<.1N-0 GG\#YB][2T'JO\.Z474KS^1V.!B(0 $@SL\]N$CB
ML!, "5EUK!1Z.U<QGBN["Y[O&Q_ICD#RDNC>+>.613Z$F=QB]BZU>OD0@-&(
M$6!6V^!S@F(C5M(6QU(-!Q!UYK=_4MAN(U@K1;4:XK0]B9?-9&UA?X9]3!M$
MO&@5L(&8'U?SF0"IK\-*]F_#"FFSN-DH5A7'T*I!=P2L6];RA+*OC0W80A;6
M +R3D5<S[73/"&.\JX0#U2+G :R]"G4N,/WN>C)!XVSJ".86P[!*,;<9AH;F
M'0M1<J25=5@M5*]R:MP,"'.EW%*$*GE)T!>VXJS <AA>UL1W,'&MMD,:]#X)
M;\*LKKCJ1!<NZ%X!_1$WL]4$X19@[TWU'0[P;Q,$S'=C$C>TAZU)O#6)/V\"
M]V@5K\K1MW;Q1MG%9CQ/_V"]#.46O4D#J.^Z _VC.Q#TK72\/O;S;]J4P15/
M2&DF/:4(/H4QF=%G039,9USVG_XROWP\F_K[S@$ZVN8 W:]G9;"R9X4!?$[X
M4VQ<F^V_P4B#\\3[GR!Q0J$H%9HD:<F%J(-: DD;5WT?9,$5V&I"GUSH1)QS
M,N&BHBP0\]75W>,0V"5FSL(8==J.RI#@;6;PF_/0,$I;L?&H7-_J\*G.6"5/
MIK,PZ=#,B9&9'SKQZ97:(-RD>HIM+1TT8M3;&0<TP\@XA&[!CWH[HRSZ*[4_
M;R(*JTF_7'1E[!8(7RG(L,S;M*1F2]?[#]?6YR88NJJ^7SUTWD)V3'V)7TH7
M<_A2YY0<D<P)/JJY/9H*;+?%EE[NJS* 1V?K%R,MV07 L]!.J97WW/%*"<QM
M43'X%=Q2#I=:W3-U1W\4?GD+%S#,<R6DPDHX!*_7QY>] ^U;DGX-JM*F,>,M
MF*/II^KU._9QY9JR>8O.K+@<U"7/0>A;RKREJFJ6\.@_I;DK%@96>D<O5\L5
MK][K^R8"29CZ8E>8N5Q14LGZYR_597MD=]A=6:,DD.E2.[HVB=#VC%M-5)ID
MJ$*-DILGW35PPL,X'7T,>,*MZ?;.(9C[QUTK3,)(RP_@C7-/$SBB81@FU988
MC"2+IERG<QS&6R?<>CGA&HKFU@GW<$ZX;\GY9O$H9(%*X:^JW\TTO#%<>!:7
MN5$MVS7'%<5*KOQ-J@GFZB+E"UUS6Y?<=^22NT5M=.W".[OH!F[FS3)%H.F?
M>UJC[+N^V_ 'ZYF37(V+5V?G[S]XO6Z/FVN2/GMGUV.;->-M(+!E__Z +6M?
M*=YUM[P,1R%78T/AN\_PM[PA61",KDJD,>0,^4*3H)_3?!85RHAKRRD,UL>3
M<A<LC<FMVYF4,5A;1LHW?^>FO:E1;O>47%CTR,[/S1YL]US-O-UW<LL!+O>F
MB'F[V*.B._CYJE .?O^?LU]/O?^A,7*4#:,SS\*K4"J@-*,A>."_ >8]C.*B
M<YYPX[OJ[ZI3'*4=-4.=#V^JND2*D3.R(+(%!WE6"=>B>X]><:;"S$'/^^WL
MO/.2>TKQZ2V9+SIOY1_UJ3@E)'$?G>Y*MC**=.H=VSITVE?#-\;U&55037S$
M=X(T,3JFUD#J-O#2$F?12@@FHN<Z.7^!S^#N>*8[>HV67X-U=1A51_@,GU'#
M2[2ME'>?4;+C;93LP927+_9GWBN#NG]7IBEZT.+)=#/T37M4C?%UBO(J&[V>
MN?\5/:#-3;\/-^C;B4J+Y,H19L[<MAN-P)R*X,Y>JF)Y]&8NH$7?L(44H1?C
MB,&%[%HUVV=7Q?TS]2&(%U8Y7/F6-4LEF*)>"YRMZF,<@TM9.J6^5M[=XB(J
M2NG6';N![MB&X;EUQV[=L7?&0B[UR(*':&G"'EG#,>YBHM;Y=A48>:L\W/IA
MMW[85?VP,,:,#69<2%_H<FU40GHX6.1#.ES;2CUMH+_U<%5_JZY:9DQP<8:?
M&_^'IH\&(LZX2#;)'_N&0PZ?"7Y[\]([A:\L3Y/5@&Y.2;C50&Z+_+EM+MNG
MJSMMG][=;5NCBR90S52LVQD%LVG%C;N<7!;X?]<1^.8<^!)/[4.!VPSUN*Y*
MMQQALQ''O4+:%KM)/__54CYPD2/@.X+1.:2UKM[/^X'+-7V@WP52SA;T;/$O
MJ8NT1<IMD7+?L6NFH:-N73-;U\S]NF: &M&,F%TSCM=_"Y;;.FG6V4GC&IO-
M)D!WW87_<).7_>-O$R9G+KE;_WV;JOHH0?B3;1#^ =O5D2WU1YF,+%\HFFVR
M6KINL96H7!;AQRI_N:T_,?$)LGGB<5L_L0?O3O2?[ONN]SI-Q21]B<H2I^,I
M?<=*/79A!_9R?^_YZY>G_*_>\]T5^AFI_F]GU8V '2$6K?0X4.TPG6I-RH,&
M<]8@(&NEQ1Z\[=K=>Z[9!M75MB-J7KKIE74CZ G#MX.V13H-MK4'7,.>526>
M6Q)E:^@)_@S:F2V:QA])TR;P2R_:;<FYMAW6GWN1\PO[N33T3L8IB9 DU&XI
M_'KQSZNS>"X%TZYWI078;4.[W8OAXN)^P*9=!G=1J\_=)^'Y";)4L8/*5^R!
MP5G6WP[370EEXV/HTJ4P_0[Y-;XSKM.#SEU%!F<#[I@^;+:0TZ1SF5:\CT+&
MZV8L2W#CIW <%"2=\FCH\8WI/2<UR>,N"M@+9AAGM/P(M;*9^Z_E.MZ2"GD=
MA3?K.,-64>1N_,Z[UYV]@WZO/SC>WV4_HNI,"(<8+4P\WN.2_58ZCL3>/-/N
M!$:7@E QG;(?_,/;BZ[GONB&[I13(=WV21_.O=_G(3349-PNAVX8J\Q]0]W&
M3,H1&A5>,.(J]6,92/DVB0OE,KLX(@T'SBX5M&%+GWG[I3-!+J&G1J:[=#K+
MHEAY.4^=JR62HS?4)>T-%ZY%^4T[F<6V)]8ETDG=W_Y>[U!B-^4P#_\L%:-G
M_RS]HC<X=EK/O&LZE;4[FWD/-S;-P==)-\@;#EI=@J:6#CX)KDF:X<S)IHXC
MDM9P!FA'<A:BO:?(5UQ*77<PK&U+K9NV7J2OS6W62\)P/(26:L8@UNN;F%C_
MZ: >QG/VVCVX-BDV"^)A.HIH  %^!4F3ZU=:H-;.3.E&[/I>>'[*23Z),OKL
M*H@GRB_>7T]^^X(V&PU5N=6G]T*6<F8[(9^I]HNFW4R^]NDYFJ.]J)Z+N)"F
M:2XQAR#&LNRAW:2T.J*TT8@VH]#M,@9[3UCE1/PG)$,YU+V7>7-Z _Y6/C+Q
MH#'MU%6N":&2&"%N]-]TY6FUSS9!3@>(QL)-JY4W^T=[/OR(TOXXERA2C7EP
MV_AA:'K'CENGH=C*B>@1U;?L]_DEBT(&_()Q%&K6H:('JA6U&:5WPG-E)?1H
M[XEODTCL[*&O5'ILU6.%&T!CK\%4Q]%D$O(M:;@1I=%W54=WHD[B'ZFW[.6S
M1U=?M(<1$R.&Y,,F*JV9_9#$S!&PX6ZNI\.T++#5#:*0UYM-YE2BT17N@[:>
MKODT19.'[3E# =]D-.]Z+T/D;]C8$%.3B8.IWKBLX#O\<,%Y>CO3%V>[)"VF
M9 GB_L H*$6L*"KR3:..<!PI5'' X6G2I6#][;Q]ORND!/5;6H@S"7.#X@X^
ML#_6;5OZ!T^V>1GWZA+J[VU=0H_$4?C A=6WV.I5QE+F;B-'>PTE-E'M5GK)
MZ$",!HV>=.A<*G]RJMN//1( 41Q#<Q+UF&U9EAGKW"I'[Z%V^(-B7FD-KS-D
ME;:H%75S?MH5U>:]:=E(S'::CHDSLWV]4P13DG"3,-GUG;Z.]"/=R+&9UHIV
M7#3C(N#T26.J[YR>Y[OBG,I!E5%^A?Y4!3T09.-<E(HL-'J)\,6?K?7PXDQ4
MB=%52G8,2?SB)I20>@[W^R7M5Z+#[#H[DAY2S#W7BCW$$\]R7&8F.T)"_TW-
MV#)^,E%N@"92."F<CD?*SPS[:Q1WJ/F+1R,+(\Q)$LH(&*WS,4EODHHS3993
M6-43?;>@6'=B.Y3R6=E]@B"\CO(1HU_II3G"*J+W:35&&9+.M)R\%>#].*27
M5A)?)D$4EQEI.CH8VOIPA,$G')@,<BZT/<.=*S/3C(T- Y2?$_&U9,/I0RUX
M06@:J($U5JP,.)T4CH=&<S:H.23#1$ \[QG$H\PX9_+0*'#$.[U=(9_ +"(=
M$:MQD48M2S%U@UL\=3O]14.J%?7ZSC*<%G#+!J7U[ S,N&W;59DV,4+&'27N
MIAF299@3>ZF1A+1X\S: !;X/67<B36I$JXWRJ0B+)F*Q2<..MU94_'E.' 5<
M4#&(*8*;,]A"=$9IPC=*F0/$#'4JUDXP##/%5>APZ1NKK_JLVG7L!TJU':4=
M!5DS+M,Q,85.]?WTJRSD)^E78+,QL%.09.ZO;&Q>Z=?,)]C]SU81XR%'\Q$4
MB$S^TJJC;W+GU6S4D&$^(FY@44HF_4VC&7D4FENLHQ*;0"JNM#Q[^<O^TT-'
M5%6E9-=[F_"QT\VQI(6MJ>;]U>\.\^B\94<YS#2'2Z>C[8["^Q@E;"#N\S$<
M>CLRJUV]\5J3T;_CW';W/ T;2*4IYS@B><#'H6#OS%4:$U&+G[%&5.0V#9$9
MA/Z]NA4R:^]EKR./=2Z&BF=]0@?*,G>!<3!VIO"2@8O=;=]$SHNOC;WX=IE!
MIA"#XW($9;""+!P3BV6E3?!ZSI9L!%'2IGI52I2&GB)SHH1.!JO6'M*#KO>J
MA>8"%5ED]M :V */;! ]JP#LHYRJ>(]Q.AKUA"4.QU0S':]KHWI2 NBNI$;K
M.4]88)*".$ZGM%%CGSA<2>RX0UI@T@C)^M7N.3\W?9%+J^W7$U_K'M PXL >
MR=DL_2L53NBHL%6T996^2$9DH:BUXE@3D]V]>A,8Z=9V?_>:C/=92,K.F&5/
M!;^+3-\(.^U.L>W$;INR.1*TZ&U]P\)'@USUE_+(6F5WNO 9I^_KV$6551&S
MJ8X]+-1X?T^S>'P#.9$'L1A<UGBC^_"1K;L&-6J/C1@$[+()QPY*W:&/"C'X
M<F-^/.Q::Z[J^*L%QR^S] ;__;&WW]VO/M(_;)U^K9:VUISK2_#-J49#=@F>
M#S-,D5C(T?YS/<^#QDOW-LW8K(5DZ\+S5!C!G02HPY462E!^K6V3ZPJ;B)M9
MD\Q@_Z+6S5AQ4>H2*B5#IN#T5< -SKPA BG3NE\W97H&ZE^X48W]B*?!K*5H
MDVESND;9$+?%"M1IJ;LF:YV 3.9X#K,K+X=E$C%U8YF(0$Y(KQ2*#1!=_&5P
M=MKU7CL7N<P7L/L@GH4<'^)=8N:/03M__]O)_L%S)YAI;B/>$/V9!7.A500:
M3=I.6R),A!2TN;ID@ Q4 >N+Y4DE[L3 ?+698#J!6J;9*#XF?$,41=978;E;
MH^EQ_3(^ E=S=\QW>!PV*4WH'[13';-[JW R!!V+.E/G%H+5?<D5,ZG&-'X<
M$"O9\Z8UYK()>I#+71 _7\)=WM,><1 AU6>N42*^2&@\KCD HUGB/)6L"B<D
M@<_OHJ(2!;PB6XZXQ;24JF")5YVH<)OHMH+LK61PJ\+3JB)\"J?PJR6A5)8[
MKTS1K#R_@K_)W,1AF(23J&@=T=$2ONCZG)XOOC>-UI(P.,VT_0I+.IT@>L[=
M^QI,B<,A6A)73Z+]<AP/>O7+T3M9M\LAT6J80N=*MHW8\2_%(QF#X<),L R)
MKFX, .>T5:P_;=Q:N;!3\3&H)"B/Z<C!]5V5]$8= /25WX.A8:(^M\E>ULQ$
M02D3<<:R99WI=$6>0H W3XQ_XX.J# B'D0V.JP4(/?NX$X@-TG4$]R#M0N @
MHS2&*PC [G(J*BGR4WTI+"A363N86NO9,>V-4AW'!PN-HUDT5BX*S\ !K?NI
M8*O>=5B->:_%D2':6I:.P$E<_*3H:C-PA4DHWC7?\5N-YD6:?PS)Q %6-KLD
M)OZ7^A&V]S(N1ZQ:$"?+<8VZWAD"3-XY$YOX"--*,2C7!:Z3%/G8YY*DAS!U
M.J;M IW!^(+#78HN&1UN9];K[8F.1<2@_GWH_/OX.1.?_O,(B%_F8VJ'TFQ.
M@QP?F#$.G'_:D>4'A_8'1WK<O=ZNUB3APQK!K4,3XW.SCL)*QBPQ5>QUAS9W
M0AJTJ45%1F():RRWU:F*>89JE,8CY7L_=9#-%T9)9Y26LYB=D^IQ97NQ[)V[
MD8_43$L]:]]T$6S&/5 9V^+XR,G@"PR869E& K]6CC(/U)T4G#XMGE-SVH[?
MVM(^T&&D)MP$F4IHUF@Q>X1QFLY0T.Q:I6Q5&*I3)6R2&2B=#GG0I12V.>5P
M-[$R7@>:WL2<D^I])*+/X#BPM2 J?C6G7*K [>P5B/*49BZ0NY%SY?!V"?4*
M')W=*$6H5B07%64AM,XOWKR*M]H;NE@]#NG!2:\7,3?.;,1\,1?H\;-(_\7>
M<PV73]C#<!TQME-GJ(N]E@.V#P0A) !0>P4=2IA+YG7%RN&M-C>^N0G8_R0$
M:T/\2>M]RO[$]HGAHTJ6 MI94_*QHJ<05N;&7)R^YV4NO)+/*[,Z;)N5VOI<
MWL_[@QS=0#$T$R6*T]Q(N'$X(UN-_C^;QV#T@2Y9 "OHPZO?GMLROX;5M6_(
M571Y!5RGA$1$1L1A^3$EELX F^ CLR@4"!G3Q 0X(Y@ WD.EY2D=KJ%)7X53
M@"/1:[!"X%WO9:D[ ]O(#O%*(X;B=*05A,#<;^%B4447$SR81BXHF<@77=1;
M+>Z@= 3)W!-PE '0M8HV0'SI$VW^VPT62\,Z.M1.V)MI%.TM].<^H3^]+?3G
MH:2G&"ZYF.#(E-0>(E*0TTS'+#LM)4O$H0@$O8G5"@>IV $22N*W-,9@W>Z2
M"Y!X0]*\:XY##A9\<C^1$40^<M4</>\0#SJRG"\X;K;U*OJ*V?OUVRXP=Q%K
M7<_L!UY O/PI8'\I-Z!7&I+B[@"((TZ<@^--[8X9GZ&(!KTO)%$4V#'7,R$-
M?625LZ0D"P4TY5O?!1UKP+".2"(X$Y6T)XD+$6G^]+>9%T!;TV%,C/*9+$-K
M/#UO!W^?]7:MK:J_ZZOO^KNR]K,>EW](+B4SS_R.Y/9-FGT4WXS1F(PRQ"J0
M+"0%9Z:CYQ(RC"$5E(;5C 04@,KJ8Y_E,N<#Q_,&4H ]<#KXZ1S;=6A(@945
M^I7:XW)6.P^KS[)E>_K+!\/.27?ZL^3WZD7*3CA.:OS<$;9",#^]_V6@=7Y.
M%='B@O0_LG;F9&+.<YU6+59---,0:&4?F8BN(?81FN):4TH"QUZ@,K)\?3C.
M-L+?DFLI.HY@TM+4M>(&=4R68\27/7RZG]KH$,71$!;1-+"R%EOAN]@DXLLT
M"/,0'3C7$%Y;-M?,D%>@O:G$)9RW.,JS7@4\"6F96Y,6QVR%OUZ0%>]&/^&/
M ^\2"9ZNZ2CB>1/B.>"1$5&"R4?E$BS0]**1*@BMR;?JG,&1ZHTSGUD2L1;-
M!I5SB::77IZ-_O4#78[1_]_;^Y,^..K^,;O\ 79#V\=/URPUY <3F)/3@C5M
M'=IOC*,;]1.-:YLS7\2'?F[C;YN2^ (*+F=5Y])BLB5>/DW!$>L) (6H^ Y_
M>74A/)XV:::8AV9H.DC-##@:LA.L$BUP\64NPM+:LUHGL-XLFE<4\^#UJ.1Y
M48M@U.M"T0BI".^Z7]A82>"\\&8!$IBC(XEBS6U!#E]!O,2S)2$7+U-Y/*&Q
M86MP"S;";C2,E(VM#2"?BJA;2#>^%'$7?S$)?>VZ4BJI+X(-YZ,(S,:NC0S1
M&"KWOB&)D/%<51W#P)[H!+HV'9BHW 1PM$-"%=*L9(6:>EHA_L-85Z5-,U#V
M4YBDI/Q."E5(3"BGY40-,34Q0U.Z2Z8,OE&A(Z*KD7C\QL%,5T=9%D]KN1YT
ME96/*1=-)/'>G+T^JD_;VS&8_Z>.RR0I=MN6XF9+MJ9'NM"86*5WJGR=MFEI
M2QSIZ08'H$-A]"R06"@U<YW&Y30TH-_^GC>&"8/KDL'W4-B-T!J=Y/@6J4H>
M(KV(E%1D(VNX]Z3,I$*!?A(7LN2*."<R_M8-<+]N@/[6#? 55*_C=M7K>)U5
MKU,$[E&.BN^XF_W/1IH(D%8AK3$.FR TV6HPSD@.$BQ1N3B>8%V54&44AZU"
M+,%_IRHV433K K$7M>9Q;=E$YH9\NTTJV,_I#; %OMMG34&1V'[AJK<0CW16
MH?'J*TRKTR#'XQYUC? T*=5Q'":7+*RY9C5=V3C4]A--36;,,C$8LI*GN#T;
ME,J#WL2VW7 1U80$2(9I+@P(*1_(*$MS$K7Q1[>,C551]!M)^1,?BG&HA0GS
ME:JH=M%]DG2K\'S3X _:X:LR&SNZ8.VLW'6X9V/V3#9&;P8</J,K+AR;S@H6
MG$C<ZZAM-]UR-, [5QT"@^M4M-22E"#,^E,T$GW+ 9CIL+T^IE"TE_ 3$292
MJ:[FBVF)PSV,.D,)*17M(1G,R6N5,C/&U\%DJHNF QZ@0:<;H0[?5L)7*J,@
MAHF3=[4J+J<UYKSIEEJ4K<A)@?7)+;$#<P5F@VI4Q9A8!9,0BMR*Q?R&9BRX
M#ZZ^!/7:E*PT82YQ6L5SJ;\THOLCM=LOW:M3<2\W_="<CL4%F99"R-18J.2S
M69;1:<Z0!*1B<#$331?.H1LL=)E$?Y9A=1L"&\=E]_HUZ>\EL^>I-=4GV!OM
M3PX<X0EIV0*AD]$JI2\7\&J^TP"WLA\DYO)B@ O2=U</46_A3M5X^4^XSVB]
MS\0++9_=B!;H?L1#ZD_J'=9AT'6N*@_=3[U=&:7_I%(*],MWJ;4(:?_6&J2?
MJY'1 225,=1#^7PZ3&.>V?& 9H;?M59);9^70J&^50:P= *NW'O3*@[YF,)4
M5/B;B"(<@9W62YIUW:*P=S(W[N]<-F/,[<:H,5W[0@J7!4E' VXTW*)*9D*+
M\/$G09).4X;>0?:.+#CE-@#;D8H_.2@/C?A1L" 'ZB%P+T#9J]B?0&KJ6X6^
M#02D<A,E+JG@5"V@(%^Y<5D5G"ELD,W(;>*S&-D2)1\Y!4NE69[R[M5V"W>8
M\QNES(3)4@!&B-VCJJ:P:)U2%4ZMXXJ4]LNKNL6B-TJ[D*7&D-%^&#>)7#^W
M_8"%@0#].LQ2+K\P2V>.R]L@M#G?&V"1Y>RF%N2+"JN;VQ)GLNW&AXSRG$E8
M60>KTD/X)"8Y-/6YTNPE76Y<@0BQ[LS:D,&'-3?). Z="%(ED17%J6QA2;.;
M05[11L=IJ+RR?'HJRU5Y!I,)2H I*U U=C 4"X^$4EUX_>SIO ,77Z="S5N-
MXYO5.&9!%HQA[VK;L^JU%R;"08%:)*CKE(K?2M.MFK'"F*>V)JHC&A4L@GN=
M:4&B'4>^RXQ]_= R/ ''D R(1M?"4'_2J^@!I#URY -U3:HBJX;(5>&LJA?*
MA;M/TIA4($@ 6]JH'C$=PHU#)B_7M%2= XS+K16\[6MA8X.G['"3+FG5 &H>
M 7X:)"%LXJJ,K960W0J4K4!Y,('R(BRXP)%Q? _G-572Y U;!RD75=O*D:T<
M^4)SM5JOQ+@(R0;:.?_OKN Y;\+P8\S5P>!+9-6_<\--(*28D2Z/B<_R#A=;
M2N2O#MDDOB2X8FQIJL@V2"8&J/MZ8_K1BS@=Q&*HG'" U*E%3";U %6EFR,U
MZ'48P"WKW?7>9IQ78D=N'91C#&1SD7U)_'<N HTM%"D<S=:@ZX-')3EEN:@I
M<:(KPA1<J*[U,JO(5#&?J7D:^&/ V1B06C#[ZN8D,H<B-G7'*5?;4Z9YSMY4
MDW,QCG*%7;"IDFY@3,=F&($UB?3)Z1*-L-2DR'WN(2M#9>LB=-BHQ:)SDB3L
M-.):1[P0>AO+_2ASPU'P#4A=5Z1 LP.?*%.R7'0]@J[W8F[(I**[H$PA@E1_
M ?%=P&_"%2T2 7XK-"PCC1%QBH-\&E2*LK316LUB])UZ1PQ<1O\OM5N^"G0!
M"*)[BE3>#I0Q%A&IWI5JV)J298(7ZQ9X^.'?Y[?8T]6M4]O)]&[KYS-6AJ_)
MH@C@[[R+G(4:T+5EXK,_K7N'&C9^M2Q)$F09TX&5C[==<M]9AD)@3_5BF*^I
MRP-E<!@@0I47:'=C+FG+53+ELA!@!()_%*HJ& F7&# Q$YEAK[>G*W\TU^6K
M*A:^!0.K8I4F:LH.(^CP4IQ^X,VBZ[0PE>GE>2[H7^==@?<3"H;2([0[^XCR
M<.:O>&1,7]E46L\!QAY.(^XT.CAY4N%%IM-'S7G5/ZS^SC(CMT1([9(K#M+;
M&W1TZA]S.-LTP&&'A5O?OU:3G_>\8NYP<LI1;>[FD,;5[:BNFM/"I0,@'6-O
M[\G"Q:R36? M8[\&6^S7O:&C3(?45S66Y6B&&P.".F6(U_\$I/)D<Z_7\[E5
MBN_M'QS5RO:X:"2M[JD"1K4N'DP'C19<JC6[B_$EY5*XDOLVW^OU3T0X:MQ%
MG3E)VII;^$T8(3=XJK=,DEJ,4Z5W#/K'KEK8OH %S;0XF*' 'U)NSN/6S]<M
M;W5Z0=WOZQ*I,*;! W#"F(U=\W91"ZHE.:X!_@&IPZH1V[,2W3;A6OGAWTIP
M>:^Y5G*4='[F/,GW13F>>Z[C8+V7J\#M%O"N^^30G2,U,.G$P3!$*)"D> ?%
M:U5P;**6K=)#<UXVE\S%)>C():C15:VRI*[&5(45?N#<0"F/G9IVH'#@!5E!
M^ZWT!GDA%"/N".\VNLB#20@E7RRVH9O^$7R*IN74L>58.=EY\^'E[M+)5]5E
MQX(.5,$#B\1A(SM*)J74<WC/"MF\D^._J^R O9686UZ'V>M: #1E7KU9^EA!
MO'H'^][TTCO_;V6>.XGW+V\?6:'O30LH&BO@U,;*(-K-2]-(IU-D[8QUYR39
MK9%N$&/CD?3FWO%>\[4;<>%/"[VAJL89D)@JN&H53=TK2RFXV'[T/)I55%!6
M4;F./Q&JT2I-5Y^*CHX*_J]R.A"MM][Z>^V/4!5K!]WCBC)L*TYSH7JG.HD)
M/:L:2W014,.'6Z]-XF ZM?4 \P*M!B)4 =LYZO:>[/K.,9_^^L%\*I Q\\U[
M^F:?)D3K^2UM60HME2F9U[H/'?W PY7@C>:%F4G"&01,,FB-O0#K1D6>^?_/
M$QE#MX?;B[-ZA_L+U1-MQVF4MKLY N5<VLWYMN6=;D07U'O<L4R91 (:<,P^
M-%5KV(L<WF'.+I4$=-%+MY-J)1^)R_F/Q\*>5,TRD1S2(L/R5S=KB3O 5\K[
M-KYUDYJ6M'I;U-ZM*\X84X83OZ%1P<SA;&2(KH@5.O[+2(&Y5==KB)0E#?I:
MNO"M%\G<FAM]A?K!2S/-?/=$_$::&3>E*D1N<3*$C0C"#0S0N\!1W)Q47\57
MV<'T]V Z>X[LO!9XLL=M"!HU:RU*6S77HJ<C%[KHXFXV.W7[I#U_Z&1=\X<>
M6'F@LR^DI[3;17/U5IWL<W6[[%5MIBVB>AN.-N%H[Z[QZ,&!0Y&@M(H:>Y,J
MWZRUZKBC:[TWN2-U79-*X"05RPM:<3TM&&)X83'MV^5Q6U]MXZ-?; 2)-;(D
M%NI:*1L;4*ZPI,&W''I?#KM84SA(;V^PY/YQ[LRDM:?RSJGOO?"],]][N5OU
M;T2FVS*GN2_)QV=5M7Z3*HKMK;]VU:J9;I82>'G)'3@RQSVC*CV%WL[;BUV_
M$JN]BE >@R6:KJQ$KPU,L3_N7%)=R4Y#Y6Y4." [\S3^'%?FW;G-W-NYI6'(
M+D?.3G%R<G"L ?HMLZOYBIC]0G40=E4[P8HC15[@O;R'4>\.^.AZ;YM'76.\
MTH?V0G_[2O74IM>=B>G"P<?W[.GZ()ZNZUY7VOM>O#H[?_^!_^YZV_#;PX??
M]K?AMV]7&3[<=&58 )!__]O)X='!<YF'^[]N1M_C:0CR1O#@TV=V!O#?2>6;
M6K^X)*VW.U'-8_,YZ:-3E+.S+3J;'5:T->@8CGE8% PV>MW2G;/2F5:UF;2/
MZCZ6.[I DD&8)0'Q]-T&[F&K!G^?:O":W[P7M]T\U217IZ7?K'P)%UXWU4_>
M7&?]@')4S]E/Z.3_25/<#K\>3:X^YYYNK^/V.F["=3Q[H.NH@*;M%U(L4Y-I
MU'8KMW=R>R>_USOYLG8GKX)KA<YW6HK5;DA[![2&&T35%&)T 7P/C#.^I'DE
M"^_,@]R\M85C+H@0.7%\"[G1$=N*C[".,KDK:IH3]K5C#8DO^-6H+-+)!'^'
M[=!*9'"$XV?;0-,VT/2Y@:97&HU1H6]4E6!_-G*9+XG_7!(-/MMZ=KY7S\Y"
MH?EXHO)P[TE;V )@4,0N+G:?>0<#S4*/CU4@%*14:=:I6R!RV9,HFW(^D%<F
M]D]N%,$]3.05[.=^=^'M[!_;AWSOP'UHMU[F9*MC?H\ZYAI<DZ.#)\VNMG))
MSE[@DAP>?M8EH0N *J<!IL\/:,\DQ$5_7\)/VV(_6QWE 724%R';+<*.I;;5
ME&BO5!E 3@S2YVQTZ>VL-''K<!A=!9ET+_7&*?<IBJ4WA>H!J1(\1>F>**8_
MI@N4Z,[8 Y)!MK$/]P2$HHYA=A\K_/FXF,'>7CMH4']>1PU^_J3L_T=)^P2-
MF;Z]_IM\_>]Z^]\Y1K@!M(FMLK5(MA;)UU.U7B\RE'W^N#75'34S&$4,S_I/
M*M^(QI%_]IW\FW :9I=2 =+))5)='.'(,VT?;?Y-->L(DT%1^MQ)X.&^@*C>
MF*GR&F9"D&UNWI3).'(3BXXY@R@)RR)#BF$4T$=[_%%0DCKH[9#Z27]-Z/>7
M):F<A\?X<SS/P\NPS/'S_4-\<IVJ?H([^P>2D\39_CO[/-@X"K+L"L,-]OGO
MT)3/G,W" K5+=@9]?,,]<M5$\,G6#-N:8>O.&Z!DZLQ!7,?]6R]]ON#*]FM7
M5M(,W<MY>(1;XM[@/GTB'5&#_(K^W./$/^<9KILL18JE<K*M"=MH>]7UWMNA
M@2I$6=E,VH;21)E-U1)G/6"ZTVA,UNDT+>D3-,D*!1/*+$HU@[HEHW)AF129
MA<F:]/K]RAX]7U9LI/YLM61)M]*^AC&4;BF22,J3N ^LDS7\+6,B#[:8R*V>
MNM53E\DB+F-O53N-2+^Y2BT8O5X[8,:A2IULY#^JT')E%MZWTX=VMPE28JN!
M;C70=;CUMRDK6[+=DNT:DFV_7Q,-BFA52UPEK&Y-%K.]-:3<$)=H]KW>$8B>
MI-Y4ZHYQ;=E4%T&RX'K&,Z7<5BV0?-MY&&R;66P=W _MX!XBU(5F;W >&) #
MIUV")D,T$PJDD9"*6EG,F9 ,%^581\>X0VM_E'D13>9JV Y([UE0%JG^(&,B
MXD_D2$_Z=Z6^YVA+@#I/R;@S2N,T>_:WT2@,)Y,V^_/#VW?/O+_M\?^YYF?-
M/&W^XGXAH&X%^?NH,*E&VVE&^7=KKZJ1Z9=NB^(9!]7K?N\!2[US_QQFWM-_
M[_SVK_[^-[6P%V9AO?XWM; S>V)'W]3"7MJ%';0N;+'*V,*P)OQ_RQQF#\*)
M5)6J?*6#63Z3^][GWJ\UL/-]OP#5GSJ_!7__6W]P0EK$VBR\_^L_'F/ER3JN
M_.G@44Z=]"E5)?B[6OOY=!J.(^DO\;!ODH0O[/5G\L/%"MR#\L.W2ATW%3(N
M *>L9@L]I*ZV/#'IJQ#F\?Z3M9G+T<&3?^;EK&J=S=*<BV8_8Q=P=!T^)UOK
M66?0/9@5)$:,B88'UT>\#09W7DI_39=RN'?GI0P6+643E"93"O:%PEP_,I-8
M0V6-C/;M7%KFLG_\9'T.Z>CPR;?NU&QXF5J\G/?G>/KA5G]?K]MP)#X[:H(S
M?OBWIVK6]/=TRD9_?U'*1C57HVLQ]G= 8[3.MG^GV;YXYIWHR?;Z=\XO<?.P
M@+X_JOS"]_JU7^S>XT('=UKHF;/0_M$C+/3>UKE_IW6^)#YS8!9Z\,4+[>W7
M5MI;Y4@?AB=M4PF^XTB+6^UD@@**>9E=1T3=WLZ[U^]WMS&7;<SEBU1T71#B
M&P^Y#'K?U,*<D,O@FUJ8#;D,OJU8TLO;8DF;X#UX Q=LXI'@>2B7P90>N,IW
MO9V3@R?>V?DZ^@O^?ED\[Y\\K ]ZY[>T\/Y/6'@7$.OA>'=M5M_K=1]Z[8/N
MD>_]=K$^:S[H]AY\R?N^=]0]6)\U]P;=_@,O^@2)\+W#[M'NX[EV'J#^UGGB
MQ=S_4UF?;C6N3+7:,D!LU-J'QY63\BN%ME1]K9M0=1>23LS2VLHGK9]KRN##
M21B.(1'L&*]?GOJF^57_Z:#>ZE@UVP V\39 8KU6/9I$->JT+>E)93H.5BNM
M57O2Z)('*#.,]N\3;%U_K]]?MV92K>?]N[3NEL,H<VE,<O;J5VYV'TCOK0#E
M?]#"I !0#KC^,)ZAKP'(P&US7R^>#TNNOEEC.DIN&M_UWI:9])9"FU6@05')
M<AR2U)3FW]S=2A6=T,-C0K2&ZS1&]H3M.#4-V+J\CI!OZY&]B*#'M>3>FE;C
M=(97Z1C#1-@$LLQ4LRHY?4Z=BZ./B,IR8Q0)*C!EUCK"=[W?V0*-:/'.=F&#
M<J],HC]+#!(F;#>6W"1F5F9Y&;H[4.^V-6'731[&(;<6U1W!9^FLC-43W"K!
MO*[Q4[I8'>ZSR!U?D,:!_NNPI6G_O4M$VCEW6?K4(_4DRC\R))TF)]5"G0E*
M53(O)@JB2SLLB^6SXQHA=.-G,>"[2& Q9?ODZL>U"ZO?HYJBX_*JOO0TW9GT
MS8DDZZ1&D:<5BE1)CK.TX D%20<_>LK=R6S51AQLM3':C3U"^B>*F)B3R\M(
M,3AN@DHW37'#=*C[^="LTF&A^A)GX25V(47-0FYY#W:%A[./8:4W:O?QZP9^
MRUF(A]LLQ'L@J"]LT=GWWD4QJ?BUSIRX_)"C_WCZ[OR7P=GI/SP'Y+8A[3E1
M^.&7E,@E\<Y$@DG'ZI^XF:UMW6WT%6_&6U'3619UW12FIUNDD_S(2%:6?Y73
M8.@-HY3D0T3<U]OY.<SP(:WU:/\Y-YFMZ2S5?5ZDJ^3(PLAM&3$$$9Q2MWPA
MG(0,E=0!/ZU.S1 X$=[F%1 +A5./5E6W5<W&:CL@&8XC<>*^#$?A=$COZN_U
M3E1O7/2\F=H^I>()UCJA*%>]PY;:KTBSLAYBU8WY/9W7:5*D291Z+V0']/'-
MIP!$E-/://I[IE.HVRIHX8D<>]/+IQ^Y@S/HO(<]YMY <1IP@U9)WU0]AA/O
MT/X>Z?IS;R#5VW:E8Y-+%#O2B<C7S:C/_[M;[?--.NPLC7! J%_;*,\([=D6
MS"*>5"DW G45_80\4J'*:5BMY=6[=_'T$"6"62,(A$1JY7K?CHH4!SK8XW*]
M]+]))(W#7.(AA0A2'^?;+#Q)I//VX@*/'!P^40U3T72L$GJKUN-C98LLHC"I
MOZFX*AUR,@&[^EMQOZI#^LK:TIF\"^H+TNN.>T](@:I4:[M[0;;<5F2K%V0S
M,9MKRSAVV&U$U"2D1"KG37&UJ_8J:RZ/?S\POR=.H:) NYO4WU6[J['7&I=X
MSZ&,KU=SKK>@YEQO/3O5&I6E!Y;P_Y@NSR+@1#81UY.^"J:4$3&[P\$3-F4"
M'C8.9T5*@HEN1@@C- R9>4L6?3A>-Q.^4J]OD;XR+C/3XK":7<D $5>(*IUD
MC#!KA5\PEY 0:]<[-572Z^S5Y<%^96@N4447?1JP?I,F6DWH>J\KW+22(FVF
M*PWUQF0OPY!47,>)'E>^#Y)J#0+,5I?YTF6MY %F3*-HAA:-1!61#,7UN1(#
MKJ!E@P9*,=[A%H'">YFJ6@U_EA$TOC<7YQZ)XTN6]6H>=!G)FH=RD:6TIU-8
MPLI_D*1)QQZ&KI%PD]*DV8"D*=,^Q- P2($Z%2X,0L W>I<[O,W2Z(-C%_*#
MI'G,4$7W'!V1%(7>7K<G.@J=#ANI9-@*!+U'^H8*5;";+([QD7WZ*A6XDQ&;
M26M5Z.9A>V0DTH%-N8A:;5'XMZXIJ,1T$URELY#U2Y3@"O(K([ARW0/=3(3T
MG8%:$*_G4/WQ<,K-@\79G*O\09_Q(I%S[Z&AKR:+^@MD4?^A9-'W[40YVCI1
M[EDVVQM\/B4RDD)N;_][_K)#]BZN,TG %V@!2\SQ?F//#VMZX=!^)D6)F[F-
MR<SFRK#JB-9^]A]4Y()$7\$1#Q(:5W8UJLXM_+KH,4W2.YV'*'V-2$<<P7V"
MGY&4CH,AG&$DO-F)7*3I1X_][!"(OM0=%(,I<*I6<XN:(*.1R'Z -]NH56E9
M\&WBJ$*8!.Q@SZ++-$.#8C4O%0CA2E*8H)F$M);7S=LSSO&@D2?1").7DJ)L
M1M**.(Z"/_)T! N-5"O26$:JYU&1TN)RKJ0JQB+I)Q_Q7Y[_%2G*2K^ CFTV
M"/4Z"GC[D[2@PS!=Y6=7)-K)8HWGVD$CEBQ-G.,A84:#\;9$&;\).YW/PH1G
MRPV:8[\ZZX)>2HI%4:)&R54X^IAKCT^(CL[)*.10"[9G0MQ;X@>^1[2 @- U
M=!VV4:'%T1/T)VU E*#6(BMAI4P$K#^4TY:8DD28\H\\>GWY4(^F95ZTKUG.
MU(38M*YK*J;DH3W9DKZ+)0*GF06IJF/N]48:.IX5#0LS(\)#T*L(/M*IE)EX
M%D8J3)1[ERAHD;!.&)0TY4QB*4I_]=@*5V7'N*<JAVYLYW0Y0F4-<($,=M%Q
M?&O)#?&;5V3=;*B%C*WJOE:Q-K,2[.M],;K6*3RXTRQ0+B7-=1HTYCM$0]O@
MDHVYA41\23D-F3')42?@(+A*(8*R?%,T/>.R9'--]H&BINLH*YEF /'-U47W
MAH$*;X+&LD@(V?< /@#))=YE !*G\>G3/\L G>0A/]&0*XR)-&G%'3*X1J#M
ML2'%H9*R]*NR&).%FW<5#OV4*=[<1]AO$NYGXFZXKUTZ\'6\$*"#&-R US=2
M+G-^'OZ#Q D$J%B!FM:,%@([-*8AKFG!T:42)WP/4<,67NT4D6MFYS.RQZ>T
MMI+QU?"FS]!-E4] OZ$FF+ @MKXD KM0#U&H"O:G,[L 98EI5;W+[$HA:[UD
M"YSN]8M -<@;DSD[-TTHG:&JM:WY=:3II.R'K&QPKFUHJ9FHZ9&V.2'K3K%/
M'230.!0+&3D]^]#I\73YGWT]J' QGA[-5-@K+&]NY>8QSCPCR@5:0P1#E(C;
MDL>O&LELH2JK$F-D74\HZ?2V'::K2.*!"PW1P=&^D@U.U)/YFH=KH0DOE3FQ
M K";2\UL0>T@&%Q LW7$"(AV4CHJ/9=W#LTL)6$%D&DCJTB=O*98GB+M9F4O
MX4)S5YW4YLP[&?W%F +2AIAWY!!B4!+F82'5CKMN3LCZ2X@+DM9!-A)U\:6#
M>]D4#?CWJR@.7?5HKAD5PT+@OR%>RRH6$0D07'RA[\+8I<:;D(725$ _6D/1
M]*(T+=( 1ZI OGYKE0F*LJ4NP3706TH--RJ'X(@<;;AE':;1(Q'@F"%H1+\<
M1C5.(\5[6H3B36C69&2@,B&8-9.I/8JT&NQ@:TA.PE=*[\U<NG'Q4B0Z)Q,]
M48GTU%7[@MMFPSV)L^YZ/Z<W""#RY"M(O4E*G!E_B$DS"CA<RX@HM66TE;.H
M %^$28)G-=Q&B^20JR[H$:WLB@J]/HVQ J:)8SE%E /6-&&%4BV3M^N*9L'1
M8?B6P^R:S!%?MD>_U6X0"+@R'$.V$$S&[M^D94P#S6=*L[;:M(JLL5>0SA Y
M8E!,1H(@BQC41<27DSD#;C^.V$82";WP4!3<C8Y4LZ=S.)C'D8"<%))-/V[*
MX!HN/PW#0M04H^+08D]):8J PCK-V?8R "L5F#:\9>?T].QBUY="C)K=XH?Z
M=)0S4\T-Q)^7PVDD4IDM*V5MF14:@588BT.F*"\)1J-P5J"_GN;JM";VN"M"
MT,_SKV=I7M"5D4@^[?0?93*JUH#4DU9O\7* OLO8[N<&<$JP^U\CLI7HV.>;
MPMY/Z=ZGY26? K136)1$6V#0Q=PMS"R^=ZM16-U%U:,&^5@U1KDGM#XS*=D
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M#(NJ;?(3FV="0:=5_.RFF"?N$FH08'-FD'81NH(;M1K91@V=:+G^4]/ E)\
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M,!\4:GBBPFN(;3)E1K:;(,0E_2BD(U0'6!*CI$6QX$W8=P2K)2$YRU(ZAW5
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M@SI0P4A77HBR43D%HQGI5#S#0)P'Y$#L/DN^2CJ26G6R2"X%Q?F%0UVLSSZ
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MHO^VT$KQ\L[%!ZL/P8:XVM63FM[Q7&VX5"TF57$4<DM['C\,KAEB&$*#XP9
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M!M5,7<"SMBZ8G8=>"=U1R*/=>)(&6ZW4&XS;9D._ 1C^Z?>\\$:"S[&)!_\
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M<6EM9S$P+FIP9\RY950<4; N.@1W27"70'!WA^!.""X)@P\PN,,@P1T22(!
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M^Y_ _@]<BP L1(1_SD/$!T@"'CFB/OQY\U]4I#+R4T(OL-ITJMITJUS!@IG
M2L/42C]%N'/W4]YN\M0LM#3\'#?LA)\S8A5O=J,ZV,A$:.6Y1&^IR;.;2 *7
M:>=J7XIRE'"##!(>P&1B(%MX$.UOGW*F;S#*8]?C/Y[J9[KYV=*^8@_7CYO"
MYU-X4 #MO&TJHEK[M*%MN6/VC_<S"PL3X(D_L:0_CX"@G0_.P9A^_6)_49MG
M"><B6T4M/5VM/2OTNUQM<;/$.)VR-^,?CYH&*.+\#\=;V3<T"#FC^);*;>M9
MU7 63JVAU:DZMF1K;@G/F<+*39=.2+UO]#G6>;S*5GR[7_C2>S,_I'>+^(_&
M5I0Z.-VB^!:I>A)+:#/P+"7X#60<(_3@-9H9 F[.I %QTF7'LMI35]'$[3.<
MQT?LG\AWFQ*!<N.(;(J$\(?"L!<:$Y5-I:,R=U%:UU)INJ[G@EH%\204+#H4
MRP]'_;[,-K W16*N]25>UKT=9S%>9)":\4W1#ER3\M'MV*L)MCG9P22NI6B2
MD0ACKN$OQX\+.X&BQX*FD^[1T3_YRF7(I^RKZ\*(EO\HMB2$4>#I902#[%HM
MGU K3;S67@@.'00H&;<KZ^YS TWQMSH3133(D>YQ7$2L)5HQAB<"R+R:;6>I
M\63!.+\D<D&N[I9@GT/2S]!,X8;0KL6Q<PH"%81+BJ@OOOUVQ=[N#H4+X[[>
M/$9+TN0J;'%.15$\^IF="&:BAGL2;-#SAMC< RT[GC4#_25#:7?J7S1AX%KE
M=L^?\K.AI-^APARETW&^DIAWN+UID![.=S:&B<F/*I^J019*%4F*AF8T, N3
M$H$P<W3V%'$-OF8!2HV/?Y_4_G@EH5O]=?=U4**EM;A@P (R6#A2RBNH7I>^
M FQ"*ZEFK&1%/B3F8 F6)$DQN ,2G/SC\[U6^D/\0,5LS?FP^$*CL1L!D4^V
M.X>C/'UO:\5&ECYC;@=^%@8XCC-@A(UOC,?P[2$/VS:0Q54*AAW7+50X<IIT
M^+\;,=%0V\BQ!&1@%=(C32&N%E4P;8Q%EGE!NA)M?:80G2E'>V!([58#:;HV
M<T*(H31?G+B#^CRF S_D1 '^.Y29->,<I=PSO^UG?: QW\YG[B,/*]:W/.N5
MB&SO7)]/A$L"J.;X_3_I)*W>C *#@%8&1*3TJP@F-=AKW??VG%I56QE_495L
MW3@RMV4(+QBY,K+: G$@ADWZS>2*KX!%-3;33^G]0R?8\3]\HQ;_2\D EVVF
MU;_45K!VN8YHO,!HW/\F>,ASJ>=-;XXZ+OV(_^C+(+Q00&]3^YZ[_SGK';1/
MPD9N0!TR<3;?1:O4>#B.N<8_WY]K6SWL^:%6 02S_BER@F7PV2CD+Y?<P)[S
MJ$$<;):W651?\QC]1PSN=S=JZ<6T*MZQ$PDZNVX5Q458O\:/BA\:6;X1>:K+
M\ET9A8.770E2PD@X.')*H'.1S1=2AIJSY9\CW# .#J2/2O0R?X06%<W6+/!P
M9#)1Y'PH&CQJ8<"T16:\:STIZ=-G-6K+^D>EQD>Q %= @5J(,V("[[$JCJCQ
M>3[L1VE#(O8W'F.TG+''V++Q#_[Y;QU-WA6.>'6*"_'+OA XN/3+GSGL%!9]
MU'X@67T<NEBU94CX(U4DDTQE'*RE@IL:S /ZF[FZJC3I$2?P"^%S0A';GVO
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M0]))P1BG!JXS45YG6WGRCKWENY(Y5S*]:.CGV%S8YBZ+0&*FG)RMZY\:VU?
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M<*$.U>_RPE_(!)9O'R5?)NVNQ-^.KA7=/V)EV?L=C4D<P"OKO8_^=63.'J^
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M9N^"-GY>^?H;';NF@U(2Z9= M/8P=/N*Y3A4B)8Q2C(8_0REI"$ ,TJ<<X1
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M,B*-QT4ZH"_]+D1P%+1].]L?:4L?,R(-PR:\!-)5N->701.=(8KF92-]W4?
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MRZX:Y6DU(QR 2$?\0G:">9"?("U@53]I^M?PM%Y\NQ/\XQTM8/:;E[$U9\U
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MBA7^_%Q;6AQP_S4)73A^CQ1VJ:DJX(08NMY?0N#3<5CXB\RAMC+^5S@'N5(
MKXGRS<\H+%ASD+!JE+S@D]13PXT?/*YR/Y&\<%>-YF]O9B53UVE?=5F1N/C@
M]#G#M2VY9MSZ>$L5XJJX8\,I\7WGC"1D/Y;A^HWL[RM0 VSD8#>!SP: ]5>Z
MRKHHXG@4PT;SZ4*/%66_VY16?8S4)%_NVR:P]0T?#EC_:IO@A=J6OU3NR@3%
M54K(/VK\%1 Z*:S],,,,LW1]1Q;,E1$I&9[-QPMC<$ 0O(:Q4+DRH7R4,[>&
MF60JO;5)]K#LLSXW@;1'=MT76ZY+=XHF '%K:U5G:6?EC?V,3(-SS$0@<U1!
MUHE?PEL&V,*:KU-:8!E2H<B@3DD!&_.58JC,Z+%GP&5[M</OC!KHX4N&FQ_[
MEAZ%YQ1HJ;14:>^::QQ^WHIVWZC=_2A#&-\70&_GXZN_KB?SE /T 6]LX#4?
M!K:X%H,5(N,WT_F-@VKA!G]49D];Y191]Y1JR-HH]%A[<A%Z?+9G]L)F :3S
M=!.+ND<2[V. M+R)Y\;W^GVD=)8U+>'*8!9H& JXM()'== <I"(G8"MPT-<T
MT1H+-GG&KC"FS=MJN^T&S6"29_IPVQIH*><I)0?DD&/(58OBNXX=HB:UC&SI
M)K8W$HPG-E;AL54(8):Z23]*B&(N<,=52O^4$/=D;IE]?7V.5>3RRCG(./@6
MU3@2F5?"[0?F+(UDS/0GGFL;IFV1UOD"!]T:IQ\HXZ;7*2M0)J[YZ69R >-=
MO:6K7Q0D(U)>>+8>J;!O0.F 4=8ZO22&U\\U6BW<Y)FI[SA[V5X9_H!?<,.@
M8T&,5L#>>D;FS.O,FQ\778[)-,-%G#]PA0ZTC@PO)(1[X%8GRM/$M*?DZ]'C
M7*+(/E1"S/2?D&?7*' SNF^TK5$T ^[3R4O@=OK?TS(NLU_T($C3.?NW;-GN
M#6IP 5O9D&\_6\W7#RUG,9"9(D"8X,5H;X,/($-T>2R6NA\#M#%F"W!>KUQ)
M:.86K=J9(=#TO:CS6D-OT^J=4OHZ;$.9KOU%:\ K5[8RO/T/?KG2=*W5ZV)&
M+5NMM2AFKE#A#F!U>V W/&]VP)]@C<J$B9G)@"#&O&2,BORRL+![KPBM%B8;
MX 4;25S^VLI[-T,XXW1'H]R5><.N7:E*%_Q7KY!;06ZO:52A1'@[ SU";,PG
M+A<M:_(]AUE2K\+T8&18,S<14-:WW>2).Q+Q7<-H+]6G&@;&'2G;4:FK-%UF
MA,\L[DE+O[V\0E38'?."P F_:]I^#LXC!,6Q/M*N@?E_*1Z&B8V$!8"Y;FXN
MBD8&<K/6<=M!)$A^$^ZP+["PAE9]@/ZI, ;]H'.V<L;*NZ;4&$5V3]1H?4%5
MSXE06H[VGHA/C@X&T0]FQ*@9UV)ROK@>,Z!81MX@\YS269M16:3"@ LXG],-
M8%W-S>E,)<P:+A9#(Q+U4V'CFW24" DW[C+:6]E^;<XILSAYXTC"T[[[W&LK
MX.?(!>X*O>.?TW!OU>C#3@68AE]R=?&@G1,E<0!P=9;=3QKE ;=J2J,4NFZ&
MW[IJ9D];763O?6*.J)53WL-\DC6M!B?4)LLG9 >,;2:WY^$*3A:<,GSO6RMP
M>M(B)]S/7QE!%5[/NHJ,RP"U7#>[X+8,[T]S,?05<)V\BX5V0]ZXZ=B*A&R$
M&E>*I)\L,A\'!*+@8?M$4(F]YHRC/M/NILW 8"GCCD*A2JS+D ERC1]TE6,%
M8SNE+L#T=S*BQ1ZZW7G".%((D<.F\#=KHJG588P9Q1>>W(HL;8]4=989(5AO
M,BK-*=+:B3)RC909PD.J@64-'\* 7QR2X389F65=Q)8'XGK]E*G"N#"0P0&3
M-]P"9%-TU'>EHSGWH1TW*[6+V)_W>=VEOTX$%9P*).L-S^[>P+V6_ENVS ;]
MMIL?790V]P:@D5KOD+?$;N1ZNAA:*(8N!QV#2VMXLI**BR-0.R:A>2G *30:
M):&U_@EX8&P%@W35R)[W\(A"Q$LC^Z"-*OVAKQY^"&-0]FXYTNT,/.MT4;LA
MW];Y1GK=704KC2Q;WHU1M/<ZD)B0I!K:CRC!O2>Y((D?!KJ[=C@=;50SX1K+
M5ZF-5,X6M9VYM<6KILO)GYE_A+!4N&QO]C%#JV6 A$6,BS;V,FO/.$7.[W8*
M8VW(8*!V?AD3P *$20L4VM4AO?>!UN:\1\<MHOF@[<NOW%BHT)\D"'G8,DX?
M;DX_GJ,5L+7ISVR9=6L W=69V-SKQ6V9A;;*<V\UX4)Z(XV[R,)P1!:E\R0.
MG_ZP'KA3_!"14X>..WPIDJ]&&5%":]X14=_]+N3LYX &GYXO0B_'-3&;D=(G
MC=*?-MV*$1WTX07F^[/3J<@B/QW+K,<:$O5TX]:D>BI4(\.]N$YT H@IMWK?
MTB/P+._1&X0;7V2QX5>;3MX];4B5DR>OV?/05^=%Q<U/^H>5[E[E>XT%R;4;
M<[W89N4N*!D?W^?N"P2N?3!*?XP,O,UR=,I@9ZDP&RO1)0:KXY"HJ$A5EZ@^
M:0G[7T^?OXZ7I-,WXZG1KA.S#77#7=LR_&2-)C46*10$I=[QI%"ZX;IETUAW
M9WW>:>"Z3.AO?\N7L(VY@KG#:25SUO.!<K+'8G/O95WATOH^8]M673@MO765
MRAS.9O7I&VR]-2N7[2R9>621K?.+*[.K_S19,G,N:\5,]8&-7S<5/Z2UO?<Y
MSB@YOSX\7'KU)8W#5,%60-=LS]Q;Q@B_I_S2U.-+_OZN/]//;UE^T7Y:I+7M
M68;A ;(?1*N'6X8H'"Z-/]U6#/'\Q- %Q*&JMH<EAIXG2X^&47D)>;C\0KH-
MYH1VXIHOR"$]W80)>WZ]<9T8HI'Z+5 F4TV0+G+['2#Z:-[8_=D_:XEMV$ 2
MS!TG<>7']/2%Y\D3)M!F(L\5XZ; 3 8Z0NG3 .%S QD-!>0/-Q\;Q)PO_(90
MV[[M+E1)=A?^!G<\L4[LV"4Q=! O*./-@T[\+*I IB ?$T-_([K&"/6F&/*V
MF=: 5,$3;T%\X71$2OP]/\N4%=/^I4FI?^H1&M CZE (YH 4N5'&9,30"Z2>
M(B-\#AIH@/MP8@A0MQ3(B/ 2'<6/R>H+ \S8>N83\A*%(9GQ5>S*A1F@?0^L
M"W.^)!&-06&BXS!S'!W!]:D3N-SX ;3YPAST2ZJ@[S;*[$/:]0:0'RX@?:$_
ME4/HTQC%LO$39);>.]"&+Y8F?+M)##6_Q9B8Z3_;OPSNW3+ZH7TBEQ<SV;X?
M*NA+!@1+7@SYH!GF4^-O1%C=  'R./?G K/O0V3ZC0,'T ZXO$Z?G\Q%-MN+
MH0/R BI/$>H?-5A_G^9[F^I4T)!TQS;']*#_E0\#U/O]N#?(YCXV&N(UB"[U
M@9<OW&M^I"BD:L.]W?-NS=%]O0D>$FUI"?K\66V9 EP?BU"K<.- CMZU&?!0
M;/I=7J'*-(-F3;T1 '//I''A;BER@<GY1ZV?V[B1C$/;9'\/+M4O_Q@0[KI8
M^MZ5A,0LX4'<8LHX )NZ[87F0<))H1C[PJ[E]HEQ_452%_]BEB?,T%BUB)I[
MNN4^?5_XG4_K)Y(V95CLZR[2"I** 0EU30^N"RS6>N-W,,O,  ^6#F7;V#\V
M[PJ4)LU'2C=[+O [65NZ*NJ*]+#H#*7PO?$CKKYQH]Y\996A9M/L'*TO*^+^
M7N[9RS%8<J#RTNWLK_&?SZ\K;8S[VEP1T !6X[> (CU&O^@,030O1Q['J#OM
MB@4BX]<SNP5E9\^UCE#2S%<]&@^=OC+J^?"F9>4U?N5BZ))I/[8T]IZZX$C0
MM@MFO2>V%(U\[D]U[TF^G&;]X$$S4'L[GIQS#N3O#K?][/"JQA<G*=R*H0YD
MBGD"9,@12JAGNH1Z3N"DN4;]9LP;>1GF@<N?T:)=KNV^LNO528+?6$T(*AU@
MU8G^?4^/,9*Q8(F[/LNQAB3WX-Y)!D/ST<"F52I:GY)']MP]^AI)N[%X<>I>
M@\K6O(D<N(3&\HC'<=@TOH$=CDK@K;@'?:]8#Q5L2?)0)'SM.I,ZY.#X-F.T
M]4#1A[H$P:ZA;<7CF38]I<_AZ04S<[1,>_;FS3KDN8)':%2LO.V>S3;I)FY8
MN3<R+:MQJ&@#4D'@^HLA8K 8,BMS+*"Q[/1&^9TP6SX3U^,JC!5#(10.'V8'
MK/\,DLAJ%VO -("W;_-CCL$YV*K E=A,N!0P9]42F&57<'!RI\4GN8O(<=*0
M%&7N-)^[B/8^X;Z>E'9T8_#H4($-)D"^<BJN=JADL0R>X!C]0ZCN16X<<(\[
M60"_]Z/LAYNI3'WA+5HP3(_(PBXV/6-J85;Z1-#W,V1PEP^YF\33S9J-M"@1
M1;/2!_]$2ZX]QE9R5HI2D%X<HPHK:A-#QUOV=,OPMI!ED);[P&'/M. %%D@Y
MW$46!>%$R8YF5^'>$8.?"]W$QGHR4TU2Z::Q'(7_K'3+8*:XGRK=Y[Y7NKTE
ME6Z;J4KWVF^5[OA9XX7(7AQ(=16;FL30<"H6YC"&CP#K."Z&QN4!"&R/+M0M
M0UC6N22!FQA*:BZHZ3DGO"U"19=[) 7J# ;N74BR\,-G N/HD(]D0RK:G]&
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MWJG)?:L$?1,Q%(@DZ&.')%B<:E6'T$!',WX%0QGL!4XR*1Q70)R0&9.%\,(
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M3"2"/$5:692#]ZOA2I&"5, 2<M! &.I^207RPI8L_'4KZC6,G.N4;5)(.E3
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M-DFZPSZ5K5LZK,\;;C7?:7"1O%K'G,*X6RQ>-NYM:FKP$1WWOK;=HL#?>FD
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MED)_B_JO\8+OH!7X^C_Y!=N_=^KO_P502P,$%     @ *XJJ4L,*&"<L/P
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M=P_%X!Z?DSC[=3N]U]'F1*(33LFN--2R+LW$H*\VV3BUM,$:<Y#A0NQAFX+
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M%>)6%>Q,@>:GW2K'0 0H4$,FDL@I0=2B175ZPY(O;4N8WS?2#&$H4$P[9IF
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M!OF 2TT';58Y-#:8EK/U*[<!8Y/EG\YN62]:7DKE_"QP%'*2G#7F)(GE[Z!
M_V@FXEC!^Z[>7Q1/W]$_6K?;.UG6L9X"'7<,)NTUH=IM[0\%;S@M$:AX\= ;
MS/2$CXKMRQU#+3:R,Q0('SP.+R R-QZKG+-"J!B?:4;]_+BG%SORP[\ @CD
MV.DN.O=_Q[1.P:A1(SRIQ<C11C,W]WG-P>RF@KS)\B3Q]NB&U1#R*CQ^YA6O
M5G=YAMK.=_M*/P1 2E!B#P5*1LXFDI](MOA]5H\IO**E'M:DROOMEP(2BU@'
M"<HWS^XG3'&N^9.2FRG01WA9\W@W6<F4 MG"+R%-ZG-.R>QKF=$Y]\KO.5AW
M!YT<RVF/6SO+OVK1TW/Q(W?ECO>WJ^F%[-8M#+.[[RA8=S_],=-+Z_-VY<+N
M0@'G[IS;34$.U@VU4WT)EYKNO2K6R[;LKF,L%]5P"M7K?GGSWF.B7P9)4;>A
M;T=8!9N]0%FQBV#@9"&@T5L:^*:<7RCO*\0??\MP1,4J7<-2]"O^!.MGOI7[
M:)68]8^LLF[O;6IMJDN];2R*=[FKJ0NL=@?3@"-YJNQ@9O^S\*.]/8[6NWH5
M-/J^[(V%%1VN"%Q[>N1+@0SKRO/ U!B%.WSHLF(18MZ@POET*??FT_EWA]6M
M3)^)G4"_K#4-<&%_G?@="2VDQ;U?7I7\*@MB%2#,AZ_J?FK'H+4'^SRD8K>'
ME>^RQUSYS!$O0Q%(.:NE3X-P<OY45G&C]? 1^(;:WNXHQW?F,YV5T]]ZWK+D
M>GZM/ZKJL>@G62HK=65(]MD73^^>5(?A\CU9V=F,-V6J]>TS3%OWW[X!#=,U
M9TY75>HGYGJ9>[\*/1^N;J9A'R1B=.M-O?JNHP7?=_0V>RB%_I:\N@$:MH2V
MR#T^O $[1.;C[PXHH!SF/[Q!'9D=B1*9]V Z,!9XT'V/98QXZS'C@VBK-VB+
MIU_4Q$6^6#_-;G8WK?J'^<3$["GA*E7'6ZDYE=/'Q3.R\D(==^?D78V<$ D9
M"7.-,;ETCJE?TF:0.7667X]T!A3TJ:SFX?RBS!R]VWGAQ[W$CDV(2(V&>0G<
M'1 I.=' 2S?IXX>OM25\K#[I/6@2%?O%2$4H1=O 8WNUCYQK #^KT1:$@LOM
M_/WQQ)2NV\]U]@8M3'#<V<;V(-:F:HMQU9,JS=B*#C\/I0L!NOZ@K]D>&)]Q
MNZR69%BF2,?X^EQ;) ,/J4)%J-@\@!"J9K3 &[,+#Y>S*(OK.<96"'0<]/1'
MLVH@0V7N^>5JD3O=H^=<VN)MA:M^'XBV_CHCW>W]YX!H"' ]:C7$R8)QM)Z[
M[=>'/U#][8B]S];@JNWI1T #LUFOCL:GJ0_6^F*Q2(6H:UV[),.["W*U2%.-
MQ6)3D8D^9.%)YWK_;5&7L[G^,9,L<#JRKSOX_OET-IN /CEED;9CU5GG=]8W
MV&K,W_6\J=WT4^P367:LU>$=BM^S<56@+)+5T?W;8*]US,C,H9WV(96<(A"*
M\1K2VVDF:R#:TIAP*#%)+RO)<^R 8M7NSQ B8&<'T7#0ZDJ%\(Z\O'9Q<VE<
M[OY##.X&PTS,!8CKIW9__CJV-R^8VS',N$51/[FSTZ*YN_Q+J)AQ[@XHYEV>
MC.L'5&&;D["]5,M5"N08G=X(I"F:&W9N(%.@?T_H8_N_ &2JHWZ1'47:&[./
M"I+] ".I3](3_5#C)ZC2E&\$P]D9HTG5CEAZ#!"/SU!C\1&_3P#$R>L;B\\H
MW%&"W#I3/$WP!Q,ODFB(#0,5^6[!1<8D>*X6+PN(J^-CLK/!)C6D?N%PD'-E
MPGR3(J<$;TK99Z@-\4G]YKLI3=;&+2O]8W>%K$O<^1'?7W[QY]N?GQ,1RXDM
MJ-Y$Z@,OB>6?%(C*JV6?*YH-'M;8^L U!NL0VYR828"?#F.S Q>37QG<U%8V
M.6TZ;6 0>X>X<X_J^BLA^#&))V4\9K?AVFC.X:<FJ-X\L[  >^&7DTH?CIW0
MTEY*-W@IWQ)\$&T?2/V7/>OWW-))>\O1ZSFOYE8\'>ZC?)%R"ZDGOT6-%']!
M*UCC)&H*M_9P_*BIRI8QW!69M;5CU9,&W E)UMA6SF5 P<_PTLG^491<M?]!
M4$[ ;=BUA*A_!:7'WG=^^[9$=W:;TZ!WS+['=JI[ZO+*MKX)2YO[[^[>"I#T
MZF1G7A2RT,B>^YEHU7TXP,&:+>CD,'Z_J>W2]N'>D!$OPQ,-0@]. B2P'-^3
M&ET4F%]F;OV\O(A;EI71T.AV83'ZF2Y;TO-LF5W;?HP$_Z/;T8*O<&;HBGZ9
M%K!:U#K%^/K^RJPDGD\F%(TS>BC#^V'^W.OTVKPB(\7QI/G*CA\YG*M3P9N'
M>-43RL?Q]>_G?[:99;WH.7B&;<#JUD&M"QZAID&G&6SK+4A]>_&]1<GY4<:?
MSI=6KQ4W)NY6)I\8VS[&U[5P6&X\Y>@@FE/J9?30E/U^&]<8JX^9D^\>5?Y,
M0-=5*>KL<KV(]YI857Z[]ZVX3E=I9OCG8QQ7WUR/^N%QYM"H5GA5'R]=CY91
ME0_)^"TQO\LRD&-B5&^'RK/=CO\P[;CB SU7$UF0;6FD^\TN#U3\^M[.&[9?
MCU^HU^G_#"30GZ_?< PS:7&5P:U%V^G>-MQEE:!SK3>3GUY^-<1($UO1SU3K
M\B@Q*WK!@;^@N(G'@+W*-]#].DO5D;>D=<D,@ISO0PK$1WPP=JHU)THR]=VU
M,W37MQ\_@4B3?/:%*(&+4C+4:H,S'^U/E]WW1)=;7?26Q\-[^")W55XUM]/3
M;]N)9N61=YXMU#S:>GS'NV>W[W;>#A#CAX1^,.!/,R"=1V4YN1PQE]IG?RY:
M'40_S&'7)W\/O2G(53,6_TA8 %\7[/TP^>'4+O]G0TZ1-^:?&XI#"(@=>N,N
MV$&?[F@MI%&>'ST<(])R3S^->>ZVZ\D!N@:EJ2BNNF]Y?)TUSY9>QQ;H.I"V
MHH@:A?1@/J!(81=L2'OZ.:E_UX,"A9H;S9)VV\,+<N:H93P<B")OJT6M[CH6
MNT9$5192H'[J0V>Y];@5W9X@7S)W@R\%6J!'$IE?P*7Z> I$]C"C0'3<>?U$
ME7O H&4S/#M ^X8U&X"HMP4 $["/27?7EX'4PTPCOQ4//X3Q_[BBJD@>:N0M
M>\S'=_H^452UD\H*\N>NY6;959=U;;N$\&(%7"IP!\A?^S  , ABA_I [U%-
M?-];NT=V@X&''H7+;-<;O7P:H51GJ=%](EZ;M5_,0KFS]<)[OB*N+C7<.F^#
M_$G-$#H?5%-+\ N7*QUEJP<^W6I.*:-_KII_$_GM%>?33,[,GMCI6@Y]> 2'
MRE>:A(GG"U$ OVHY2<QH0KI&J%*P;F=5QD?56Q2H5 U'@58Y]."!,W @$A]"
MA,F/PY'$;;%#5_63]2-V['SY;L7;P6;%(:GWZ\]S:%QS&)D;Q4D]62P#5(F'
M9'EHJCR2N?7G54>O<J>8Z_336A[W\R9:R0R7$5J7>^$D&A$\$$P2=T<"(!_Q
M)3-($%OEE$7Q*T_@\KFRV412H<2R;Q%DI:4/__GI:G_=T<@4SQ<!\!_I2_T.
M)<!>3Q;JWRC[<^^0Q?]@X0EVLG^]11,(WF ]N <SHM_LZ%]&O@+FS%S96PH4
M\01D]A;V::&RE"G"Z-/:8[()3\O4J5U7=3!_&6KZC]N@D^WLOD6#P>'#1K:3
MCD@#-VR=N?"EGV]JQ 4)D_*R86Z#:(Z*1*.:O=CK3T..'G5+9H*$'J#YC@F+
M-NIT[;%Z4+6;R>[!DX6E8W2U-?BN>LVSWZ5W2+W*V7XFP'.]L2_6^]'.A, [
M*8[.4V?R=?AU#\L6I-PQ9STGK_04#!G5-V-D%7N:PV@@9?Q!5A8$ 4A_I;HS
M%.<3KUK3$IB7<_RC0;P)QERRV^R)C?=.Y;>P@\O'R8@NG[B]HJ%SJD^/0J+[
M/7B@I !VSWI#)0MY,@OQSK1.AX! A ,38Z12\)?K^FS;N$Z56AVT]9LQ)?![
MCAE1L[=^G1HW\OCRQ[\JQSCJGY^V.?WL"ZD::Z(*!5/9QL?;%8[3F2'O!FX_
M23]'>G_$ZX)5@TK%737\6%F?C6_7H%R^,5-=JI3VY?A+]JX_9;S*KE=9H_D:
M07FJ_I%BZ;\3D7O/KH\#?RYLP-+07TG8G-R "J\/?2GFG-9,HJNUC>GDZVK_
M'U)G,F#Q6^ G_H<791EB1!N5.^G(W9\J=X%:Z.[S.#Z>@B6>)_W;2G%_]\)=
M>FT_0(Z?!/^5!!1.#$#).N(@"K\;5>DAN^]_,+)E>O,D02\"[&#KZS>6X4@'
MLCL/R0+^Z[XW6R]('NG7:SXTMLW (CR"1_!YR,64*CQ3YOCO!U74:]H([4TZ
MVR=>D*>1>KSKH*I0J]2NE2?E/R?IA]GEY^I/50_K6NFWYUM')QZ;-C6SN6LM
M6"OCM0<MTT XCI#H:61,S^BB0 TIF.6O<3_ML?-3 NOX \[[MG#^UW^,[92"
MQ[JDUP9T[).PIDWIUC\7,@OS? 1"]_$QW;I^1,"SI[UDZMK>')_1+@V7I^%Z
M-[73@O)T$$EBN>^7=GPU+Y85R/?VSFO^&:T_Z(5/6W",#^G=\N$DD\+%._8_
M'PW)IY]=$THGK0*5YLI:YWNZR6HD*[)?[;./X5F9[GS#=YD'G+U%7-^LZ=1I
MB2/-LH!NU\/.>JK]F(;'VL&>KBYH[T#\6F@M*6!6%OW)1#XE7CK#G]G]\]/
M!\F&+'B[9N+DR4"_<?L8M]3*ZB[U^\';<XY^X1;PV7V>#<R>9DM6##OQ@=-8
MC!4"'6[YBE\_.O5R9AKVT3]#H0H\I]64<-)\JH,:I=@?2TOM+:764D^O-S/H
ML]^\D$MG*":RQ7%5U_;W1VOW7VRY-V-MG7I/:GHL[WI+#>^%U/U"/SS#B.TO
MCS K5UE2(.4,N']+\.]H)X^_/_)G[,-_QY[>G\"49?L>XZ^ Y"QS$P\7D+O\
M(5M87[3[::FW1'0O?*&ZB60EG)QBT$F!;G<J*EMT&2FZM)^-?MF]1>Y4MVZM
MR$Q)@[5D1F'C0^,+$X<6A42_S>"V57YNV%+P0?@#RPYH]<KT@A1_\R#;1V/1
M>I;4P3G34'D^@V/DR>='$%FRHYS5C?_FYM^=)[Y[OLTMJ(/L=H,"%3/^FQ1M
M'YT=VLP3%8Q>7M_O(^Q.<?W[)E/'H)',: Z-*2'E>J=6CXQZ>X32R_OOPR4\
M9%H[U/6=?<(2)L-+.ZZV3,\.L NJVG)7O_55\3JYUHB(41^:\FF-RP@NZW*U
M,]GA7CN&]MS^-/>YYA,%P^4[=W?4.7.\W!.3'*<W^>QFB%0/B[S.Z9?L;S_!
M)[T+Y7"=8C''&Q^.:OCHO-+\P+4;DV\8='XZYN7G#Q\\KT)OKM,U:C4RD__+
MC+SY;S+UAE6[^U3(4:F4@]_>>UR%T!V"NJ_['&>F+IY/RY+F[%)-''3MJQA5
MO/)94/1<J>*67O\!0=O(A1HQ=:VX$)6/6U+>W]SFLK,Z!Y_N8V6P-Q-/CJ97
M*:B5,13]V7/8UK-254CEK4:97)7.YWRYR$>OY72^K$@OW9X7M0DQXKOQ9N$Z
MI]#IM+#?O1GO$VL:WYD:$WN+,3K_9LKA<V*G8W+I_9H3Q$__JD;>?U. 5MW]
M_+_*VI6F4\(.:8Z10VJ$\XUF3??>RUWPJC?O?*<B=IA!9K\7D]T<OYB';<AE
M(J:*B^BOG>V=:>CB8AA[Y-CNY?.?*Y\VO.P.](6_V84%O>XPM,6MLTX:)J<M
M&.X8SK\<P;DG7^:5VJGRH%-?IR:N=$^<U(P>PAA,9#?V'K/DT10\D*;E?.A4
M/2*>3;,DHKFO[WBOH$R<\P</"^?__?^AAB']>#$13H9+M3Y.&7"D"H?L?4<V
M4V15^<)FK]K?Z1NI$M+/-W'L,B)(SM-]C]%!I 6AD@)]2;GWX<MYN>KTUQFL
M\O1*>4-B17IA)2AN,9\]GXG>MFWLQ7;\4@%CEGP*SD Y0#L7O^WOX91L(7$.
M5MNX3J,KM"T.W)NQ.A]J?CCU@,C6(%^.U)+Q77[?6\B"I%/-*:HQ$8.UFL>[
M]*X)=_VH&>G.K_KR4'_'2OV.+P'"+W\N:-U7=%_#S0;*;KV@?JA0KUG_?6>.
M=^(+[XOL D*"(VJ(H"))M0MXW^#IQ0*-=;7*NF.'OZ<L??NN?:UW?DR,"( 2
M?6%A=;^4T%>")<J'?-!KQNI,]]7,C.)]UZP=JF_?8']L+EE9V8?,8^ XT$ 2
MA;G9Y;B,'?_I4]L6J'-"?/>AJ^6N(_([3CS8,K9]-G*1W%J4U.-PY)B"@C^2
M8R);+M0IAW^I255R3.'5U2VPC$%O\MVX!]J?M%1YV?_\6Z[_W47I_+\ 4$L#
M!!0    ( "N*JE+2\Z7V_C<  '0Z   0    8V5L8U\Q,'%I;6<W+FIP9Z6[
M!5#<3[<M.H00" 0([A(D. 1W"\$3W-W=W35 <'=W=W=G<-?!W8(,.NA<_M_W
MSCWGWGJOWGWO]%1/U=2OJZO7]-ZKU]HS#5V&;@$^2XE)B@%@8&  >F\O '05
M( * >__68/]Y_P ']P$!&0$!'A[A,]*GC\@8GS$QT#^CHV/B$.%A8A-BHZ/C
MD^,3$I-\^?(%$X^"BH+T*Q'I%])_)H&!^_ ! 1X!%0$!E10+'8OT_W.#]@#0
M$&#083[#PI !WJ'!P*+!0 < )   #!S,OQK@_VHP[V#?PWV 1_B(B/0VH/$S
MX!T,+.R[M_6_ 7A[ZOWV'/ >#0[]"[/P!PQY?7@R>TP6_]A<!/+OM;U8"C.7
M%*P&#@$?$;%Q</'P*;]24=/0LK%S<')Q\XC\$!43EY"44E125E%54]<P-#(V
M,34SMW!T<G9Q=7/W"/P=%!SR)S0L+CXA,2DY)34M+[^@L*BXI+2LKKZAL:FY
MI;6MKW]@< @X/#(Z.S>_L+BTO +:WMG=VS\X/#H^ 5]=W]S>W4,>'O_!!0.
MA?F/]G^+"^T-U[NW;7D/_P\NF'>N_PQ >P_WA?D#NK \O+X]!AF+/P+F]]C<
MVMZ/Y*P*EU@&#C.(V!1LVY3@?Z#]"]G_&;" _U_(_B>P_\0% GR"A7G;/%@T
M@"#@B3&,.N?=_V,'9T<2,X*9@FT:E"Y?;L_J1HQ+M<>;Y/K),=[+U[&&"K^
MDB@#G@><JCP'LBC!1<F"8=5ZX/V!T&*( I$#[G; 6L_7Y G%AI1[W*&>L?AL
M!3/8(P^ZWH;L<)ZFU%R.RATN#>GR2/._MI5?C8,%47.0:G4-ZD=:I9J>/__,
M5$*\3P-0YX7]O_36*6SQTHDM:Q<BG/'7><^/BTLCWM$'*:LFB[OP+M_,8//R
M.HB!XN#; 8YO$EWD5P4S)L&[$YUQFW^78,>-G/3MSL\G:B6\MO2"Y1/+3K>A
M@'#LYFDHP'C3PI+DCO9[M7-):JW;8AWV6M6 X03=]96(%>S^!!R)D+P.*D/R
M0+F[RLGFKZ6+!M'4M/Y?V2IHZQ79K8!UJ>J6P5AN *LAN=T08*ASIHN%([.$
M(_YK/78NUD8A!V7[%T9R8V=_S(9QGF]TC7)TM'NF:8!'J;!2BSJ&!"2.GP'L
MR.WQ&8XJ1Q3_@=/0J8"(GXY<:['2B9]6^K2HCPI&7,5P1KS3G?UPP!9=:WS*
MEH(CUG1?-$( OM6FN]!A<6 NOZ"9ZW3G>-HEZ;!F34U]?3A.>Z77;K2J;'8(
MMZRF'R:VASR =QXY[Y@^FL#<Q2KZ':@N!0<9\28BPB&0"FDN;<>+ 8QQMB1_
M#)JE4.1>)3SN8_Z+\-?[4;6(1LN(F$Y#.5>%;\:DP;*OP3UG7#,21S3M]"P9
MGS^B/D2=[YAANL885V4$;Y@0=EF)Q:V[_]M:NCM[N#TI%ZF D*#\H)TN&I\\
MJXY B"ES%#7X+EDQ8.70=!JE<:1_N]/"TM)]NWZ=<-5E>XF6X#P);S1P.6V[
M/"(N/H+<D]C;RRF?$]&^LUG /\S,YHMZKCW9M]&ZC "!1L-.-UO_9W&.Z I@
M\00-!R?3?B+5G[5+7 _'WFJ'DYPE'>*V2F(C%_U:M&H4X_P3:H%\S-;A*EM=
ML%CZ-@2KJH"!#@HH#^)V?>9%==0R?68(%9B# DCM]WR7?+,?#,)2PIPVZ;/R
MLV@C.<=H+#PZ\79JV4@^F[^2UN.H,-JA+(EMQW8B5.:X5>934CK7SN#1,)JU
MY][(B\H+BV+*P?QO_0-V;;GFT1VRH]U4Q)FH<)+)#4DL-Q_@(Q]B3QUXL'$T
MO)2AMW:]\9SA7,4>IQUF=3YB]U@!<C6YX\W"^R>?11S]%Z'?I[_H8DK<=_#5
M.11WU0)S2TK!JU)U$1W+$4-@I.7BZV[71B5:_ZO#S,T^>'Y+;LDBE]G"CXH'
MIR>>-:3^4:(\';/ (1W9%;9V9G/ZFKX_<(.]DE0P/H\E"M\ST#^>< \Z/S)6
MI#66C^RS8?Q8_>I_J<$QY!&%0!J :F>1$,]]*"6WMI871AL1I3DD0%U[:1ID
M<[LN0A_C5SM0C,P6$B1\*Q@S<J9+=^J++?#5PC5F$UEF5ZJYC7ZQ1AW8B">B
M%T2!#N'#.-4)?9*V4##L;^.I16-..P::D"-V)VE>5Y'WJFYP=%[^Z@K?YHTU
MI;7 $+\KD+N*O'PH)UFGA#%;_82 Q\6^)/51)#,_[R/UVC$?*GA78\[YQZR7
M6]'.?(U8QU5':^54>0FLW>T6VH6NY.J:B/-[QUZR$<PP(FT9Y82( %1[762W
M,;%Y-MW/8FT-]XX;.B 13[H-&O7FX59C._=A/7&!Q',HH+X[?&^>C7?JH\ZP
MCC4G.BB)6T"$$ L*\&L^ZI\-:TAFXA/E*G<DU]Q)RID]Q4ZS:#[?"I_4/QFW
M$Q1^7&(V:*,]#F4?C-Q_V4Q1WHF29<#T_3BLN%2LL0*)Q1#?Q38YID!0O269
MS=QZ.JZL^&&W.D+#&5&^+T.N:O+[N;J7"D:2^/;*F?_Q2N&YRBM1UA>-DFGT
MD,;[4\SF%(%Z9RIR+&Q\VS=WP&%6XM\NU,55E<L$Q?&5ED#FG[(*JMT[S#J*
M.]38#%(T21])I<O=SK&,$@M\4QQ;T^,<N*OJMSO2*YQ3-(3*OG]6VWHG@GI9
M'!(?)$Z\TS\R5[+5MOD\B?AX(MW^E#XB8)HE%I.ME;%DU<9_EP2VD'8N8;N+
M86B]JA2ASQ\;[IU$1/G=S(W5RV:5GL?]J55WP%XGB-[#R[YQ*;&DK[Q-+.CO
MOA(POH;1,<+FH5Z1R&;ST,"PFBWKM8GOWM'03I!33KS2\SEMST4 -5JCA=>O
M29UY/53>'Q*O*WA=3P362=P]+JB]S K*/S2GK22% NP!KZ8W9?WS3MO<[CA!
M9<=]!<D_NJX#YIG.&[UE-$]7FF5Y'61%B?SNL.KM\X[B0%HC12=U'8O3'1%Q
MU,;>$3 &_>?!PR">!5GD 55E;<E*C0,"#H69<L#XN4N.UJ6F_21_N<A 6@*+
MAEC-WSC)6LS9*2O#5I>(K7HN7EPCPZB=O(]<W%.*7*(\#J7\FA005Z^[K&_!
MFRYD;2J1R;6D-HJ//HWGAH$Z<%MN&K8$YF7=/6=?'N'8+S8'=:+@FG\]9A6I
MK>9=K'EC*DK#*4CV$$UXB%>PNF)F>I\&+G:8C7UIGE4B*O[@ND=R+W[+'I%%
MO90D!P78L/C6C+;+'FO/7[*;$EMWRF)7F8ME/+#[6!HN"FZQ-?KGG**=JNCX
M;#(:\QK]/#2_NV//!&,,)&>A0[S++-N\[!H76B+)60]'_W2$DZ1 #@W.U[P3
ME@ASJ26'-/,7"Q78#8KAG2:'PA[N52#^U<<'R(A+@VU!Z\\>.\L;VOVY0(HL
M30U)-@.$>+M8M;R8=9<L;TO#?A]Z,/ />W@XOZ-2P^7">:BA*<-!4M/1E<X8
MO8!A1BTOAB U4GS,"I]!P?)=&]TAZH=G/3 ],5[;$I\T\F3E>Q4-[_$ ::4&
M3Y<,"1W;>%*07R Z6L8A><32M,L]VKJ&B#T2'9 67E5L#8&<-'!-3M+A39.@
M2 ^F+0S%%AM,6V?)_26L.OL3IIZ"<@@+(&81<ZO"!JJER\T:M=5WJYTSD7D)
MLTV/W?DI4OC\12[.6D>5UX8"0MEX(PUEF ?)@/2>339'HZ/*"5DK\-5<I,0>
MJGB66YF.SI$-T>P='#DE<2;^ 0'M+.\8U0,.W^^64LW6)9Z[3CLM\&O\/%0]
MFSG!<:U\#;.I_+*"L>F=8:-6@\*1V1/W;=3#<RG?C7CRE9]%<VP_1M(N]JLQ
MKCL'(U+L$(LDL :^TQ8NJD^3SJT'>_4'(L)3!?S85,M['^6R,NP,?9LB97O"
MXT$Z:PBZO*A<2UM3X]7S<1)';!,I5;*5*<"5BXA.).%2$&0JZ]U%N) H*6I>
MF?&(CI7\P.YNVZ\M3W][&LGAO,1(UAU!"S*;K6.;A1UZ*4#WPYY$J"X0H##W
MO4QS0[^7EIA=B#!W-V=?699FE(01N"2U<Q ,Z_I1,\]N#:NJ.2%PX,TKWT2?
M]^-!AT58A226K/,37Z*4#5WN'.:#E:LN9D-"0U;?U08U.A\;2V%E?-[W]>\C
MW*[HP^Y'0-P""+DW9?3@.J_).RT1-A8;ZWR;OA6JY1)VG2=9L&DH'Z>U<YFT
M)U=S3;:*Y5-X2!K>]GLXV?.",)$(^WG$^DM-26OQ'3;78/YI\[L+UC@NN. %
MDM+G<M5G3H+D.RM/IFB")TFK1LJVAB2U'%T.7H-)@(%=;VU Z^Z\21T?N3<%
MYZPZP\)+VSH+T^,GBW$9^R0*0IBLO$[*L\J]1DN5(+Y@[2! #_EL"]W%I],T
M_K5D?,RY!AG$ _A5:MWS;-V^+E6,WZ4R%@7.%X8'8#=UL;IR..?%U=0NVK =
M?B7W2UU2@CSUJKUK?.W*^X0M/4_/Q8L JW.5OH-CZS/*L.V(7W<)##'YY,2K
M-;*S=0Q\K#O(&L>:<M?;T8)LS?22L,L8<9:S# SZM?5AL^LN@^AG\F($2+2)
M1)+E7_2_73MG2M(Q)O/U#X"T)[/+T\-C"AFCTW0H^VSX:F";V3WN=6:+9A8G
M5Q67L']<J_^L*/BIAIHX+.AD>,M^A)/DTGQ7:>F..('AK'AZPH_LF'WI?_3J
M @4('(Y-/7;V/^RR*]MAD7\]!HT[U[ ;*B@$53+U['8(YJ]9M 4TV!7$"(E(
M4%*0.]X[<!\T\SD35O(WKC75]G:NBR>3<QG#?+\]LN-!/&>@/ZM@4 '-8@53
M'I4_3Y66>1S$I4TFW 4%2*! ,J  )-1C4*.;@!9OV*(8%""_US^*MBBK"X$G
MVM;EF.P[?U1G=#H*"(]N9$.B1Z>-R;$FIZR30>"NT'9XL&V$4]-86QW$C2*I
M)Z<P,JHEY22GR%@(@@)^YXNDK XMV57Y+EBS_( "_$?3&@L@LO+SYSXSO@0:
MFJPV!OV6@E[49SJNE)*%4LRN?!M2\1'F8HPOORZ"09XB?&D#B[/#==\:?P^U
M-QU29MS#^K'J)%J7J:W3GK7 C!O\BK[ZIF#W$3XVCBXU7+:A65G3;*)%._LD
MI9276\Y^7F&$Z#Y!N3#J3,CDZGP7N?7>YF?-'AP_G"=FS74^'%;I#:X5F]F<
M?.NJ+Y9]%]M"1[K3W-FF55S$L+A<5G;T32X315 JF64ZCHE19.CUMJEORG#/
M%8#4?\ICKW%LL&N)D3$WUOC/MJ'ST>@'%KKYGMF[1/[]IN+DM(5$1(YHD O=
M\1U#B4YAA@/%SYZ8B3G_:<.X-RX_8]068(N3+J% C2R+<MVZ!PF1*J]_N;EK
MX*@FHQRS7:/\:<OUP"%XJ7>MWKR$@X-1VK)L&NI5['SZE3=^[6FIHIA[H6Z&
M_(!2)H.ZE-_H&0J S;NDKVAK'!?LNSPG7^.$ G3:0[<#KC:D/?^HF&E+\=GD
M)O9N!:"^5R79TE2Y9F+Z\V!'KNLX#P5(Q>N  X595\QS-42W#_B"!/Q<V0\-
M:$8[7?$M:R_TP&C]^OFTU9V1TJ@($%7)*]6?EP>9!E_2SYA?LA8PC-JE+G )
M.1;)!7Z'M;IO3\ JSI\U\DN+UG9T-;Z%CR-_&U^L;]N D6IJ4VVY)%4**+'7
M5OX+[C.<\RL&F')P#PI8:9[J^M6>'W-KY0R_4=3TH9#:<>..K=^DH7Q>Z>_"
M'3OEI>_O XG*HLN-9 IY$:(V<HTORJ$?J?T,STNI8'-&;JM"E0V%_N0JBP%@
M 8AQ8==3=O\V6_DF2@KC/=1X%#?O_.C61>[2U;^L-_X9;;Y7<T#=LE=.5FC6
ME#A,;9(:W6PE;&<);%5RIM"[I,W<J$PT;M"+O<+??]3+U9N)BB/.0.R5+@5!
M)&VO@/9UM@VCV7S%8Z G)2B@C"H0@A^^*9&4O[;4L9#N41&/Q.OB+ /CGJDM
MH(#IB(>\%CA;_^9'5,QVGS"&0[O<)9*VAD-@ZN_==6UN*3C _<':4U^G(^E#
M'%N(6-9__=(42U;'7V'X(]I!9LA*$Z=P1NJ.6ZNP;I\5N*P*LSL5Y&$;?F M
M,V0\YQRA7[B:<@C\M>4*!9CY<%>+YK61GWOQH/Q]F"7Y[8O>->S$L9 3*&[.
MV6#P$$$!!7B.P<9#5.O<Z'K3? ,:6/5-#CQ#U?@GQC[A:1ZOB.MK\V,5%.WG
M<-KEE>I8R*U,('?'\R_L/3!KK'Y]($0I)@3DD]-+$,[YS%1" =/%)5# YK(@
M9-^$[ 5+Y Q_Z071(^3E)1 *B%(T7&#VQHK*+5XW3V8U'=%,U*[_S/*]+:Y@
M-\.(Q (PDQ=&#<@+RW<O%;=TQ,IPN<=IKJ<Q:FS\=85%B,U-2GL8$??![-V=
M;"66^!G^X7].*W]XZGM#<R)X?X?ZRJWHO*8J>D+'0R2O\>+T=$I0R7'F;[;;
M)A_J=UH[GVC &W$(JA:E5_P*,5+'L=<J'1ZF0(-\%M]68KX=./V<XNP^] WW
M0C>W"E1RPF/%\UN/FX;L98FHLRMQ*:BL5.9J)4O,-##I:S2]#\5YE ._^:51
M2V.89</W6FTXT(G$D R71:ZE)?_^J*9FKKMN#DEI9>+E^-.K94G?8Q!WI:?V
MU\4)$9%.4SF7210B2=SAFZJ1Q4(IIA6+J>S<) /:"5J0J(>6\5VA91Y$!S0E
M'>_4C)0)H5WFJX]QQSO+/M:*[&#@'[#+J\?60QFD%SJWHY,>0)=XK%%O:@>B
M4Z5&9PG!J_)/_,KOMRNI8VB?9%3*6&V5)!.U[2 HIC D BO*WK.Y[X.E%6E/
M5U6<# L,\ZYJI:XF%PSC=B8?3$()+$5)5\FN(W8A(;,%T^K) ]B4 O=I\-L;
MN0MI>.S2H5^2Q]4)6\>-$>,7)/@'+2$"@U4=0LUPOJY6A2-O478)?RT8Q"TU
M3TDC$,) [;B3CTMG.3=R[O'GB,8LK\OM:>MM<]]E+JQW%GS7#'UOIBZ'L1[:
M0Y+IR)F6,/>SE*5M% ^A08R@<M72D1G^4T@4G:F&9<D9^1-]*!X+8'^)^R>A
M_Y'W*2*N D(2V]JJD/;D:LKN?-8OQ/3T*XX E9;ELY6.5L:P]J+9V)(!N1HM
MGS/?WPIK^7P4P-=:E)O'J,UHV:&BO#8E)>586?G8X;J!.JIU_5C9,NQR]L[!
M 44I2C'OZ3PF6E0*/<\%,-$('K;C[KK0JTGFH%U>RL6^;U64A/>>%NI4(6_)
M\)XB;H.\*$!IVJ@Y!,A3X4JI<K"S\:&186%;3J3LA3!._$GZ)W@H>8=!\2_)
M,HLD24S\R!?)--9VLY7(BFX!QV87)>*<L+A[V;IY XD+ZX$\CHW(N$H"C_)W
MB-EV%M5WE-UO7'W2#6')A@+"2A(8ST4BAQM6ND@%ZJ*]+=E<J!2A (6)CV1K
MQ;P9+BI[ )85()&E*M!!! I .-'P/CT-3U&9@-]D"<4*1+T7HL@6LD3OEY+,
M;V4YT:C';$UB?U/&$<^TK0#O"ZGIQEEZ^O/(-?L1AAGM+.^!*39_;UAN"E3]
M,$SZ"SOY>B+*KA)CA[0"VJ"HF;N?6]ZN<P)3Y;[3&B3/L%# W]/O8=/U60OT
M'=KDZIDDVO6_*U8RIDRO&MSV])@I#G'W#!<;GYDH[-V*M9I;]9B*/DOC\;G'
M(/0]=_7>'TXW=VJ4)8.LHPIJPX?YAD*;Q4X&B5E/*@JPGI&IRFJRR@:U7<7
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M"2B0[D^J&FJ19GT77KYNSI/P%6E,\I/"D&]0D'=V@1NPYY5XQEBS&_^8Q>]
MY:J*,_;*WS^C'B/BE>M,E]:M70$*" H$ZUR=2OK[+52C(QGI7W^6$*5:NZVL
MN2V7D@59&]+>F%5O5[6Y5XN<7@2 /,V[X?C8D1@7TSZTDD(!<^(F)+E81^RJ
MLK4ATK-6-^UV[SGL*-M@CLIP'I7+=N,/XF./OO/5RO]C%R7U)3P49HD38):
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MC$Q !&G?F>HYM+DES]'1V![<_YR](D)M5*:<7$8&O@A#+P#PT]9VO>J8\/=
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M"RW)<3<5]LED;N-JJ#&T)LVY<)"<RXXS+XI +OG^Z+&+@M'P4+6)(6N1H;/
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MY-":[UAN2N2" :X^Q8P>#)GS>_86.EK1_=2=S*7:[O8C_.OU)<9C#G6/6VG
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M;AC!LRE,8$UKRZ399>\#]]6=LU>6L7?<S#2+SB'JP1IST;^J.S_T;9=L7Y"
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MI67V17JOQ?<C^3(UV,245\2V\7*O!B>F&V#GSWB:SU(KF>:2?K,CQ9PA @D
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M3 SX<815K$0FW7U# QPR7W+3_=\?]B&B#1YAK5D,=3J18]R '!!77^^P9Q/
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MB)O9:OAQK#6P:QLD+/J^2,F%@]V%!B$B$\ZZ%#X%E(P6F<';C)AQ<<XL%;B
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M1W:2-547\2C[[$R$&)V2DIN_=# 2$+HPU#5)#9@X\TIT2G?;?$/>T!8EXVM
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MQN,,=O:(ZL]-0T&$N,B+7,MB,.KR.,QK[^5NY_X+4$L#!!0    ( "N*JE(
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MN01[2NV7W'FK=]*(XQ$# "DO/VFJ2SR-:PU[1OO*;'MF&2*KZBHJ6G0,,$F
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M\,1RWF]Z!5@8,_HNHM_JGCZ"7N!S7@&=HM#QVO#FIEQWR4?&D*5;^T<4B5?
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MC\RR?\ YVX=IG<]18DR ?OY>MGV?='<''$]&I'X/D#JT:^KY<!<Z4+5!VF-
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MZ_S!<P(TW=X#8;,JT'FFF=R=3D!<IMIPIO0]2'-<:WR,RI);P/E]IZS ,NH
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MNY/W<)[)E65-)HI8S:QE>:8,>85BV^@A%J%Q]!&9-G8ADMP-N$P2F65"O$"
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M8FD44C>E]*FT$39HQL)W!I+>,4S3 ;8YP;2 C6;E8]C!=[OP/7I;^ H6R@0
M(:PM 5$!=B&.X;0T+I.0LH&5T",37V4!= )TI=NO +"2(MT8F"&XDQLHM<1S
M 27S:&FX3"!)<84D,@4!@%@#:6XYX^SQN8E8J/34S!&>BCMI;,JQ$*?.W&Y8
M62D!U<R->6+M#JO;Q>HW_Y.<.UP!PM?__'>C_MV)*=!;4#@*93H,)9H.(A[C
MJ7!@!+CD2 D"#1/P@)&2)B)Q$HL1QBF44SN0QE?:9)A' 3[5*D?E.-6^"-!M
MV#Y & B@.D=:]\&/>'(G6 >Q<Y I2-2/>+5^O"_>N:GUXR!OY4U)S#?)O8'T
M,PJP)2?)04NV;+Q0N+)0B(5HGX]=!Q)$6YJKB,('$=,=Y_U,SOOM'\YY]_F[
M;3O7N3 HU@$S1QD^[0,58C,^S\SF4XA6C 3P7*R4$Q6=I5" "#Z1QN4%2(G$
MZ:%R;)E1REDI%8H[!RF8RA+DE2)CT:!$=H$M1BL9N-<+DXV,#"1/)6U YGS*
MY<F$-&6&.(Z+)\81(I=%M!$PR")KT:0Q*+[T,\4I^6%;SH@E5\*,G'F5"2/^
M-Q(DB/R$^2+8Y:/MYJ/]T1O[P\81^XE;;![K-_8.>-1$!@1Z;G3"*:EQ X<A
M^D^>P--@CDKXB>0CJ:CF!)5:MRSYJ .PPV;N7BNBI?+!Y<Z'8D/C+!W#-XRC
M?KZOT\ 9X J).Y& T2FX"$;$F'R/1% DY6X 'Y5CI*^=(VS9$?RM.T)WPE7F
MHB>A1(0A6+V<X'[-&G:^(&4;9(.\N9ZP.]QC(B*YR<N"D<[L\Q9LDJ_X0EI0
MS1-^NL1EHWDUY5Q9Y"<!>TY(^0ZZVX5NL/T8GJ/B*;KHP:9@TFZD#.%_F=?$
M;&(HVO>SE-!3H@,K^F)M+'KHQ1M:C \5O^9/A6S_B7 (Z"."/I(KS$1E+-S+
M$CTZ)=G"EG>Y)1$W"[Y$L=>YB@A<4G*[+Q+&C"EY+U3QS/1(OO(%![+&,7;5
MQ5_M1?UX*R]1GU>MNU?U8.ZWE64$IH10]J-E,"9_> 4_>U(Q+$SCJ!JL3LV"
M$KD.J(QC::T0+Z2[D0;IHO% PCZG9!\^A^QB*'OA7ZI=YL%!_)I)F._"09;X
M[N'KW:XHWQ7ECU5V%.@WR@$)%Z$'''H*\J4 I@O^M"B.IX+?$R'*Z;BC1*Z0
M<-\YS%]77^4I11V;/Y^MR1L\P$0C%FGC6:\JR@],@6N@2JCDK,R DIDLCE&,
M_R;<9HKDO/8=>L>X_A)5<P?$*DP1-RN CW"A'@!T7S452*WD3$4F$ZTF@NA*
MPN^*;\S2(CN(>*ST3&!T&ND\)? 5/P!NUS"W!>0VQOC!GR;FKD37)R'RBZ/A
M<>VE<'A.Y5V3W? 9#*BP1JU1_S0P/C-.+O]DLM<^G;VL_'B]]L41G?:'P_X-
M=@Z%[IEOPW4/S6'Y%R O&E%OO"*5_(&1Z76A8*2MU?&&Q_/LT?R?G<-9)$7(
M+A:!HY]SU2\YD^W&F+*YCS*5VT#9 OIY'OU6CW[^]SM02P,$%     @ *XJJ
M4MZ_CZ+W P  ?@X   X   !C96QC7V5X,S(Q+FAT;>57WV_;-A!^'[#_X9:A
M10)8MF4O0VNK!F19<00XEBLI_;&7@98HBQA%J1+=6/WK=Y1E)T8:KUF3[F$/
M%DSR[N/Q[KN/DI'(E(^,A))H9$@F.1V%E(=_TDV_I[=QT>AL9XU?-&V2A>N4
M"@EA08FD$:Q+)E9@3Z:F=T5*20M-&QF=+=@RBRHH9<7IFQ-)-U(CG*W$@--8
M#N-,2*UD7^A [^;-,"8IX]4  I;2$N;T!KPL)>)D9"QV,!?N/-!\YP][ +4?
MU!,7YI4S^S@ 63L*="R4XQ "^T.@F3-G.A] P58).ER9WM3!83??(+ ?>.Y\
M.K(W"5LR"?U>6S<ZS:3168Q^_NG9]GXIEF4^?,)-0JP++1XXH65[@7/A6&;@
MN'-87'O^M3D/('!!?P77;;]MM<&WK7I5[Y]W6V#Z8$[<16!/GB,C1X.]&]XN
MJ-?=W\&]@.#2!M_TQN;<]C7WP\S^"*85J)5>M]O[89$^2?$.$!T!828$#27+
M!-PPF8!,*,2,JP;+XGKT=DT*#(97X-$\*R2@Z456I+B=]A;BK*BM/FVM@(H(
M._2*%&$"?;V%&>KI<*HL7O[ZJM?K#K<@]4 ?GL&R @L[?\UD!8X(VW"ZMUNQ
M4A9$[&U;X+1@7#""^R-QUIRSST2TZNVMA-$8[ T-UY)]IN#&,0LQG.8,5I;F
M1%0M3&PA68Q_\G51KA$<9 9^DP!5[L;!)\62"%IJ[H;3"LQ0JA55[M9=\C:.
M6_+*A-1PRG])R]HCK> OD=UP&JWHX"E+=T"&P!S/[..H[TS/078/0&#I"!_"
M>V<27"J3[HO&Y+WM3"_O6&R!@H\S^W;N+DEK386QZTUL3_,7IN7,IQC=$&;.
MW-8N#]!.,/.<+T@4(;/>=#%H%;:WBWEGK)^KLZFER6ZIB;/_XN0@=P\DP^@$
MDP?\A_!.Z9%ESG8'D%E^!%1O?QWP<2@!DJ'IFQ@96V'#I3EG6-E]NQ7TTYH5
M5%UQI>+,+:M.R1E@?^GGI]'9GIE(\8))A6!OPH2(%=W14W_=_ZT%I 22UFTX
M!"*B_2'PX8W^*>N/R_%#U@U/G/G$5I3K/QK@GO4S!/_OZME[,E8P$:O6J$N-
M*BP)$ZB<3-15WE&&,"6\>4%+Q8Z66B:< [I1%$*.W"ESI$O9:H1;$!&J>02,
M6 V-%%!6:[XE5Y;3HMZSW!'J5FC;A^G&A]*5_T*R#L3IGL)\MYB<=X^IR42]
M9 [P#JLP@.T-]J32<OMC^)XYKHZ#GW\=?9^6L1L$[A6>%@'+C+/H&_?ME)W[
ME^G14/3>(S3X!ZK-X]I[F4F9I=]:G.,)^I]EPTI0CK"O:TUYX(WK>Q+T?()C
M=-1WH?I(5-^=?P-02P,$%     @ *XJJ4HV!C$OI P  7PX   X   !C96QC
M7V5X,S(R+FAT;>5748_:.!!^/ZG_86Y/K78E @2.4PLI4H# 1F()3;+;[KV<
M3.(0J\:AB=&2_OH;A\""NM#NE;U[N <B;,]\'L]\\SDQ8KG@72.F).P:DDE.
MNP'EP5]TW6PTJKAHU#:SQJ^:-DB"U8(*"4%*B:0AK#(FYF -1J9[0S))4TWK
M&K4-V"P)<\ADSNG["TG74B.<S46;TTAVHD1(+6-?:5NO+\MA1!:,YVWPV8)F
M,*$/X"8+(BZZQG0+,W0FON;9?UIM*/R@F!B:-_;XO@VR<!3HF"K'#OC6)U\S
MQ_9HTH:4S6-TN#'=D8W#^G*-P)[O.I-1UUK';,8D-!O5AE$K)XW:M/OJEQ?;
M^XV89<O.&3<)L"XT/7+"ON7Z]M#NF[[M3&!ZZWJWYL0'WP']+=Q6O6J_"I[5
M+U;U9JM> =,#<^!,?6OP$ADY&>Q^>-N@WM7_ &<(_K4%GNGVS(GE:<ZGL74/
M9M]7*XUZ_45J]V2D9RG> :(M($B$H(%DB8 ')F.0,86(<=5@252,/JQ(BL'P
M'%RZ3%():#I,T@5NIWV *$D+JR\;*Z BQ Z](6D00U.O8(8:.EPJBS>_O6TT
MZIT-2#'0.U<PRZ&/G;]B,@=;!%6XW-G-6293(G:V%; K<,>"SSE<DUC02K%Q
M/V8T@B$31 2,<'"BB 482!E]/UDLB<@KF-)4L@C_+%=IMD)8D EXY=%5H4L'
MCZ0S(FBF.6M.<S #J594H2O[M"T=-[25,2G@E/^,9H7'(H?/(GG@-)S3]CF+
M=D #W^R-K=.H=Z9K(Z_;(+!HA'?@HSWPKY5)_75I\M&R1]=[%AL@_WYL/<[M
MT[-04^@Y[L!R-6]J]NW)"*/KP-B>6-KU =H%9I[S*0E#Y-3[.@:MPG:W,6^-
M]98ZFUH:;)?*.)NO+PYR=R091LT?'/'OP)U2HKXYWAY )LL3H'KU:<#GH?A(
MAK)CHA7']@F0BIQA97>-EM(O*Y92=;EEBC./K+HD5X"=I;<NPZL=,VFP2IE4
M"-8ZB(F8TRT]]7?-WRM ,B"+H@$[0$2X.P0^W.[WLOZ\'!^S+GEB3P:6HESS
MV0#?6+] \/^LGHVSL8*)2+5&46K47TF80,UDHJCREC*$*<E=IC13[*BH9<(Y
MH!M-E<[APA+IDE5*R=[J'P*&K(!&"BBK%=^0*UG2M-@SVQ+J46*KA^G&A]*5
M_T*R#L3I&X7Y:3%IU4^IR4"]7K;Q]LHQ@,W==59I>?PQ?,/LY:?!6T^C[]+2
M<WS?N<'3(F"6<!;^X+ZUK+9_C9X,0F\\0WW_19UY7F//$BF3Q0^FYVAJ_F=Y
M./)B]3,Y>3E=,6KJPT]]!:H/R[\!4$L! A0#%     @ *XJJ4A/,($SK#0
MW8T  !$              ( !     &-E;&,M,C R,3 S,S$N>'-D4$L! A0#
M%     @ *XJJ4N'90<.%"P  F(4  !4              ( !&@X  &-E;&,M
M,C R,3 S,S%?8V%L+GAM;%!+ 0(4 Q0    ( "N*JE*I;(FROQ@  "B5 0 5
M              "  =(9  !C96QC+3(P,C$P,S,Q7V1E9BYX;6Q02P$"% ,4
M    "  KBJI2XIH%>9=)  "AEP, %0              @ '$,@  8V5L8RTR
M,#(Q,#,S,5]L86(N>&UL4$L! A0#%     @ *XJJ4I](5#PA-   M=D" !4
M             ( !CGP  &-E;&,M,C R,3 S,S%?<')E+GAM;%!+ 0(4 Q0
M   ( "N*JE(UFU#4F>P  %*K"0 ,              "  >*P  !C96QC7S$P
M<2YH=&U02P$"% ,4    "  KBJI2*MM=+7AT  "CA0  $0
M@ &EG0$ 8V5L8U\Q,'%I;6<Q,"YJ<&=02P$"% ,4    "  KBJI2XBBS#^4X
M  "X/@  $0              @ %,$@( 8V5L8U\Q,'%I;6<Q,2YJ<&=02P$"
M% ,4    "  KBJI2PPH8)RP_   22P  $0              @ %@2P( 8V5L
M8U\Q,'%I;6<Q,BYJ<&=02P$"% ,4    "  KBJI2TO.E]OXW  !T.@  $
M            @ &[B@( 8V5L8U\Q,'%I;6<W+FIP9U!+ 0(4 Q0    ( "N*
MJE+.-!1HB&   +UK   0              "  >?" @!C96QC7S$P<6EM9S@N
M:G!G4$L! A0#%     @ *XJJ4@"JJ<QT/0  @4   !               ( !
MG2,# &-E;&-?,3!Q:6UG.2YJ<&=02P$"% ,4    "  KBJI2TP4VH&\'  "'
M*   #@              @ $_80, 8V5L8U]E>#,Q,2YH=&U02P$"% ,4
M"  KBJI2)1JNOVH'   %*   #@              @ ':: , 8V5L8U]E>#,Q
M,BYH=&U02P$"% ,4    "  KBJI2WK^/HO<#  !^#@  #@
M@ %P< , 8V5L8U]E>#,R,2YH=&U02P$"% ,4    "  KBJI2C8&,2^D#  !?
M#@  #@              @ &3= , 8V5L8U]E>#,R,BYH=&U02P4&     !
,$ #L P  J'@#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
